MetLife (MET) 10-Q 1 Nov 24 2024 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2024	Oct. 28, 2024
Entity Information [Line Items]
Document Type	10-Q
Entity Registrant Name	MetLife, Inc.
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Entity File Number	001-15787
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-4075851
Entity Address, Address Line One	200 Park Avenue,
Entity Address, City or Town	New York,
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10166-0188
City Area Code	212
Local Phone Number	578-9500
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Central Index Key	0001099219
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		692,420,423
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Common Stock
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.01
Trading Symbol	MET
Security Exchange Name	NYSE
Floating Rate Non-Cumulative Preferred Stock, Series A, par value $0.01
Entity Information [Line Items]
Title of 12(b) Security	Floating Rate Non-Cumulative Preferred Stock, Series A, par value $0.01
Trading Symbol	MET PRA
Security Exchange Name	NYSE
Depositary Shares, each representing a 1/1,000th interest in a share of 5.625% Non-Cumulative Preferred Stock, Series E
Entity Information [Line Items]
Title of 12(b) Security	Depositary Shares, each representing a 1/1,000th interest in a share of 5.625% Non-Cumulative Preferred Stock, Series E
Trading Symbol	MET PRE
Security Exchange Name	NYSE
Depositary Shares, each representing a 1/1,000th interest in a share of 4.75% Non-Cumulative Preferred Stock, Series F
Entity Information [Line Items]
Title of 12(b) Security	Depositary Shares, each representing a 1/1,000th interest ina share of 4.75% Non-Cumulative Preferred Stock, Series F
Trading Symbol	MET PRF
Security Exchange Name	NYSE

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Investments:
Fixed maturity securities available-for-sale, at estimated fair value (net of allowance for credit loss of $162 and $184, respectively); and amortized cost: $309,406 and $300,555, respectively	$ 293,779	$ 281,412
Equity securities	746	757
Contractholder-directed equity securities and fair value option securities, at estimated fair value	9,289	10,331
Mortgage loans (net of allowance for credit loss of $847 and $721, respectively)	90,415	92,506
Policy loans	8,822	8,788
Real estate and real estate joint ventures (includes $380 and $317, respectively, under the fair value option; $59 and $0, respectively, of real estate held-for-sale; $230 and $0, respectively, relating to variable interest entities)	13,731	13,332
Other limited partnership interests	14,186	14,764
Short-term investments, principally at estimated fair value	4,609	6,045
Other invested assets (includes $1,949 and $1,993, respectively, of leveraged and direct financing leases; $472 and $333, respectively, relating to variable interest entities)	19,706	18,202
Total investments	455,283	446,137
Cash and cash equivalents, principally at estimated fair value	21,765	20,639
Accrued investment income	3,722	3,589
Premiums, reinsurance and other receivables	31,443	28,971
Market risk benefits, at estimated fair value	310	286
Deferred policy acquisition costs and value of business acquired	20,401	20,151
Current income tax recoverable	304	190
Deferred income tax asset	2,469	2,612
Goodwill	9,155	9,236
Other assets	11,315	11,139
Separate account assets	148,809	144,634
Total assets	704,976	687,584
Liabilities
Future policy benefits	201,340	196,406
Policyholder account balances	224,609	219,269
Market risk benefits, at estimated fair value	3,117	3,179
Other policy-related balances	19,932	19,736
Policyholder dividends payable	381	386
Payables for collateral under securities loaned and other transactions	17,132	17,524
Short-term debt (includes $132 and $0, respectively, relating to variable interest entities)	404	119
Long-term debt	15,278	15,548
Collateral financing arrangement	529	637
Junior subordinated debt securities	3,163	3,161
Deferred income tax liability	956	927
Other liabilities (includes $25 and $0, respectively, relating to variable interest entities)	38,162	35,805
Separate account liabilities	148,809	144,634
Total liabilities	673,812	657,331
Contingencies, Commitments and Guarantees (Note 19)
MetLife, Inc.’s stockholders’ equity:
Preferred stock, par value $0.01 per share; $3,905 aggregate liquidation preference	0	0
Common stock, par value $0.01 per share; 3,000,000,000 shares authorized; 1,194,027,818 and 1,191,823,651 shares issued, respectively; 693,651,782 and 730,821,111 shares outstanding, respectively	12	12
Additional paid-in capital	33,766	33,690
Retained earnings	41,765	40,146
Treasury stock, at cost; 500,376,036 and 461,002,540 shares, respectively	(27,418)	(24,591)
Accumulated other comprehensive income (loss)	(17,240)	(19,242)
Total MetLife, Inc.’s stockholders’ equity	30,885	30,015
Noncontrolling interests	279	238
Total equity	31,164	30,253
Total liabilities and equity	$ 704,976	$ 687,584

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Assets
Amortized cost of fixed maturity securities valuation allowances	$ 162	$ 184
Amortized Cost	309,406	300,555
Mortgage loans valuation allowances	847	721
Real estate and real estate joint ventures - FVO	13,731	13,332
Real Estate Held-for-sale	59	0
Other Invested Assets - Leveraged and Direct Financing Leases	1,949	1,993
Other invested assets, at estimated fair value (2)	19,706	18,202
Liabilities
Short-term Debt	404	119
Other liabilities (includes $25 and $0, respectively, relating to variable interest entities)	$ 38,162	$ 35,805
MetLife, Inc.’s stockholders’ equity:
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, Liquidation Preference, Value	$ 3,905	$ 3,905
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	1,194,027,818	1,191,823,651
Common stock, shares outstanding	693,651,782	730,821,111
Treasury stock, shares	500,376,036	461,002,540
Residential mortgage loans - FVO
Assets
Real estate and real estate joint ventures - FVO	$ 380	$ 317
Variable interest entities
Assets
Real estate and real estate joint ventures - FVO	230	0
Other invested assets, at estimated fair value (2)	472	333
Liabilities
Short-term Debt	132	0
Other liabilities (includes $25 and $0, respectively, relating to variable interest entities)	$ 25	$ 0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues
Premiums	$ 10,647	$ 11,230	$ 32,328	$ 32,497
Universal life and investment-type product policy fees	1,228	1,334	3,757	3,911
Net investment income	5,227	4,825	15,868	14,542
Other revenues	648	606	1,960	1,866
Net investment gains (losses)	(77)	(927)	(873)	(2,650)
Net derivative gains (losses)	767	(1,202)	(720)	(2,289)
Total revenues	18,440	15,866	52,320	47,877
Expenses
Policyholder benefits and claims	10,597	11,130	32,156	32,811
Policyholder liability remeasurement (gains) losses	(132)	(17)	(164)	(42)
Market risk benefit remeasurement (gains) losses	531	(796)	(345)	(1,425)
Interest credited to policyholder account balances	2,037	1,658	6,327	5,455
Policyholder dividends	150	153	445	463
Other expenses	3,263	3,204	9,660	9,394
Total expenses	16,446	15,332	48,079	46,656
Income (loss) before provision for income tax	1,994	534	4,241	1,221
Provision for income tax expense (benefit)	653	39	1,072	233
Net income (loss)	1,341	495	3,169	988
Less: Net income (loss) attributable to noncontrolling interests	(1)	6	14	17
Net income (loss) attributable to MetLife, Inc.	1,342	489	3,155	971
Dividends, Preferred Stock	67	67	168	165
Net income (loss) available to MetLife, Inc.’s common shareholders	1,275	422	2,987	806
Comprehensive income (loss)	4,838	(3,373)	5,174	(661)
Less: Comprehensive income (loss) attributable to noncontrolling interests, net of income tax	0	6	17	1
Comprehensive income (loss) attributable to MetLife, Inc.	$ 4,838	$ (3,379)	$ 5,157	$ (662)
Net income (loss) available to MetLife, Inc.’s common shareholders per common share:
Basic	$ 1.82	$ 0.56	$ 4.20	$ 1.05
Diluted	$ 1.81	$ 0.56	$ 4.17	$ 1.05

Consolidated Statements of Equi

Consolidated Statements of Equity (Unaudited) - USD ($) $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment	Preferred Stock	Common Stock	Additional Paid-in Capital	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Treasury Stock, Common	Accumulated Other Comprehensive Income (Loss)	Total MetLife, Inc.'s Stockholders' Equity	Total MetLife, Inc.'s Stockholders' Equity Cumulative Effect, Period of Adoption, Adjustment	Noncontrolling Interests
Beginning Balance at Dec. 31, 2022	$ 30,125		$ 0	$ 12	$ 33,616	$ 40,332		$ (21,458)	$ (22,621)	$ 29,881		$ 244
Treasury stock acquired in connection with share repurchases	(1,465)							(1,465)		(1,465)
Share Repurchase Program, Excise Tax	13
Stock-based compensation	14				14					14
Dividends on preferred stock	(98)					(98)				(98)
Dividends on common stock	$ (788)					(788)				(788)
Dividend Per Share	$ 1.020
Change in equity of noncontrolling interests	$ (8)									0		(8)
Net income (loss)	493					482				482		11
Other comprehensive income (loss), net of income tax	2,219								2,235	2,235		(16)
Ending Balance at Jun. 30, 2023	30,492		0	12	33,630	39,928		(22,923)	(20,386)	30,261		231
Beginning Balance at Dec. 31, 2022	30,125		0	12	33,616	40,332		(21,458)	(22,621)	29,881		244
Dividends on preferred stock	(165)
Net income (loss)	988
Ending Balance at Sep. 30, 2023	25,895		0	12	33,666	39,958		(23,724)	(24,254)	25,658		237
Beginning Balance at Jun. 30, 2023	30,492		0	12	33,630	39,928		(22,923)	(20,386)	30,261		231
Treasury stock acquired in connection with share repurchases	(801)							(801)		(801)
Share Repurchase Program, Excise Tax	9
Stock-based compensation	36				36					36
Dividends on preferred stock	(67)					(67)				(67)
Dividends on common stock	$ (392)					(392)				(392)
Dividend Per Share	$ 0.520
Net income (loss)	$ 495					489				489		6
Other comprehensive income (loss), net of income tax	(3,868)								(3,868)	(3,868)		0
Ending Balance at Sep. 30, 2023	25,895		0	12	33,666	39,958		(23,724)	(24,254)	25,658		237
Beginning Balance at Dec. 31, 2023	30,253	$ (219)	0	12	33,690	40,146	$ (219)	(24,591)	(19,242)	30,015	$ (219)	238
Treasury stock acquired in connection with share repurchases	(2,046)							(2,046)		(2,046)
Share Repurchase Program, Excise Tax	19
Stock-based compensation	50				50					50
Dividends on preferred stock	(101)					(101)				(101)
Dividends on common stock	$ (766)					(766)				(766)
Dividend Per Share	$ 1.065
Change in equity of noncontrolling interests	$ 33									0		33
Net income (loss)	1,828					1,813				1,813		15
Other comprehensive income (loss), net of income tax	(1,492)								(1,494)	(1,494)		2
Ending Balance at Jun. 30, 2024	27,540		0	12	33,740	40,873		(26,637)	(20,736)	27,252		288
Beginning Balance at Dec. 31, 2023	30,253	$ (219)	0	12	33,690	40,146	$ (219)	(24,591)	(19,242)	30,015	$ (219)	238
Dividends on preferred stock	(168)
Net income (loss)	3,169
Ending Balance at Sep. 30, 2024	31,164		0	12	33,766	41,765		(27,418)	(17,240)	30,885		279
Beginning Balance at Jun. 30, 2024	27,540		0	12	33,740	40,873		(26,637)	(20,736)	27,252		288
Treasury stock acquired in connection with share repurchases	(781)							(781)		(781)
Share Repurchase Program, Excise Tax	7
Stock-based compensation	26				26					26
Dividends on preferred stock	(67)					(67)				(67)
Dividends on common stock	$ (383)					(383)				(383)
Dividend Per Share	$ 0.545
Change in equity of noncontrolling interests	$ (9)									0		(9)
Net income (loss)	1,341					1,342				1,342		(1)
Other comprehensive income (loss), net of income tax	3,497								3,496	3,496		1
Ending Balance at Sep. 30, 2024	$ 31,164		$ 0	$ 12	$ 33,766	$ 41,765		$ (27,418)	$ (17,240)	$ 30,885		$ 279

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Statement of Cash Flows [Abstract]
Net cash provided by (used in) operating activities	$ 9,987	$ 8,539
Cash flows from investing activities
Sales, maturities and repayments of fixed maturity securities available-for-sale	41,355	45,512
Sales, maturities and repayments of equity securities	89	1,007
Sales, maturities and repayments of mortgage loans	7,203	6,571
Sales, maturities and repayments of real estate and real estate joint ventures	562	123
Sales, maturities and repayments of other limited partnership interests	842	698
Sales, maturities and repayments of short-term investments	9,743	10,680
Purchases of fixed maturity securities available-for-sale	(48,197)	(50,578)
Purchases of equity securities	(80)	(121)
Purchases of mortgage loans	(6,008)	(6,617)
Purchases of real estate and real estate joint ventures	(850)	(906)
Purchases of other limited partnership interests	(930)	(1,284)
Purchases of short-term investments	(8,100)	(12,491)
Cash received in connection with freestanding derivatives	1,725	1,960
Cash paid in connection with freestanding derivatives	(2,783)	(4,216)
Net change in policy loans	(59)	42
Net change in other invested assets	(457)	(1,077)
Other, net	(184)	(125)
Net cash provided by (used in) investing activities	(6,129)	(10,822)
Cash flows from financing activities
Policyholder account balances - deposits	74,869	74,327
Policyholder account balances - withdrawals	(72,334)	(70,834)
Net change in payables for collateral under securities loaned and other transactions	(394)	(2,927)
Long-term debt issued	1,547	2,003
Long-term debt repaid	(1,742)	(1,027)
Collateral financing arrangement repaid	(108)	(65)
Derivatives with certain financing elements and other derivative-related transactions, net	(41)	(170)
Proceeds from mortgage loan secured financing	147	340
Repayments of mortgage loan secured financing	(578)	(725)
Treasury stock acquired in connection with share repurchases	(2,801)	(2,244)
Dividends on preferred stock	(168)	(165)
Dividends on common stock	(1,149)	(1,180)
Other, net	140	(97)
Net cash provided by (used in) financing activities	(2,612)	(2,764)
Effect of change in foreign currency exchange rates on cash and cash equivalents balances	(120)	(236)
Change in cash and cash equivalents	1,126	(5,283)
Cash and cash equivalents, beginning of period	20,639	20,195
Cash and cash equivalents, end of period	21,765	14,912
Supplemental disclosures of cash flow information
Net cash paid for Interest	750	678
Net cash paid (received) for Income tax	1,273	1,352
Non-cash transactions:
Fixed maturity securities available-for-sale received in connection with pension risk transfer transactions	2,342	1,691
Real estate and real estate joint ventures acquired in satisfaction of debt	342	11
Other invested assets received in connection with the sale of other limited partnership interests	375	0
Increase of real estate and real estate joint ventures	134	0
Increase of short-term debt	$ 113	$ 0

Business, Basis of Presentation

Business, Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business, Basis of Presentation and Summary of Significant Accounting Policies	1. Business, Basis of Presentation and Summary of Significant Accounting Policies Business “MetLife” and the “Company” refer to MetLife, Inc., a Delaware corporation incorporated in 1999, its subsidiaries and affiliates. MetLife is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management. MetLife is organized into six segments: Group Benefits; Retirement and Income Solutions (“RIS”); Asia; Latin America; Europe, the Middle East and Africa (“EMEA”); and MetLife Holdings. Basis of Presentation The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the interim condensed consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates. The accompanying interim condensed consolidated financial statements are unaudited and reflect all adjustments (including normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Interim results are not necessarily indicative of full year performance. The December 31, 2023 consolidated balance sheet data was derived from audited consolidated financial statements included in MetLife, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”), which include all disclosures required by GAAP. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company included in the 2023 Annual Report. Consolidation The accompanying interim condensed consolidated financial statements include the accounts of MetLife, Inc. and its subsidiaries, as well as partnerships and joint ventures in which the Company has a controlling financial interest, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions have been eliminated. The Company uses the equity method of accounting, unless the fair value option (“FVO”) is applied, for real estate joint ventures and other limited partnership interests (“investee”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations. The Company generally recognizes its share of the investee’s earnings in net investment income on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period. Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (each, an “ASU”) to the FASB Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The following tables provide a description of ASUs recently issued by the FASB and the impact of their adoption on the Company’s consolidated financial statements. Adopted Accounting Pronouncements The table below describes the impacts of ASUs adopted by the Company. Standard Description Effective Date and Impact on Financial Statements ASU 2023-02, Investments—Equity Method and Joint Ventures (Topic 323): Accounting for Investments in Tax Credit Structures Using the Proportional Amortization Method The amendments in this update permit reporting entities to elect to account for their tax equity investments, regardless of the tax credit program from which the income tax credits are received, using the proportional amortization method if certain conditions are met. In addition, disclosures describing the nature of the investments and related income tax credits and benefits will be required. January 1, 2024. The Company adopted this update, applying a modified retrospective basis. The Company has elected to use the proportional amortization method to account for its tax equity investments that meet the required criteria. The adoption of this update resulted in a decrease to retained earnings of $219 million, net of income tax, primarily related to the Company’s tax equity investments reported within other invested assets, as of January 1, 2024. Future Adoption of Accounting Pronouncements ASUs not listed below were assessed and either determined to be not applicable or are not expected to have a material impact on the Company’s consolidated financial statements or disclosures. ASUs issued but not yet adopted as of September 30, 2024 that are currently being assessed and may or may not have a material impact on the Company’s consolidated financial statements or disclosures are summarized in the table below. Standard Description Effective Date and Impact on Financial Statements ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures Among other things, the amendments in this update require that public business entities, on an annual basis: (i) disclose specific categories in the rate reconciliation; and (ii) provide additional information for reconciling items that meet a quantitative threshold. In addition, the amendments in this update require that all entities disclose on an annual basis the following information about income taxes paid: (i) the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes; and (ii) the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than five percent of total income taxes paid (net of refunds received). Effective for annual periods beginning January 1, 2025, to be applied prospectively with an option for retrospective application (with early adoption permitted). The Company is currently evaluating the impact of the guidance on its annual disclosures to be included in its 2025 consolidated financial statements. ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures The amendments in this update are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The key amendments include: (i) disclosures on significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss on an annual and interim basis; (ii) disclosures on an amount for other segment items by reportable segment and a description of its composition on an annual and interim basis. The other segment items category is the difference between segment revenue less the significant expenses disclosed and each reported measure of segment profit or loss; (iii) providing all annual disclosures on a reportable segment’s profit or loss and assets currently required by FASB ASC Topic 280, Segment Reporting in interim periods; and (iv) specifying the title and position of the CODM. Effective for annual periods beginning January 1, 2024 and interim periods beginning January 1, 2025, to be applied on a retrospective basis unless it is impracticable (with early adoption permitted). The Company will include the applicable enhanced disclosures in its 2024 annual consolidated financial statements.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Segment Information	2. Segment Information In the fourth quarter of 2023, MetLife reorganized from five segments into the following six segments to reflect changes in management’s responsibilities: Group Benefits, RIS, Asia, Latin America, EMEA and MetLife Holdings. The Group Benefits and RIS businesses were previously reported as the U.S. segment. These changes were applied retrospectively and did not have an impact on prior period total consolidated net income (loss) or adjusted earnings. In addition, the Company continues to report certain of its results of operations in Corporate & Other. Group Benefits The Group Benefits segment, based in the U.S., offers a broad range of products to corporations and their respective employees, other institutions and their respective members, as well as individuals. These products include term, variable and universal life insurance, dental, group and individual disability, vision and accident & health insurance. RIS The RIS segment, based in the U.S., offers a broad range of life and annuity-based insurance and investment products to corporations and their respective employees, other institutions and their respective members, as well as individuals. These products include stable value and pension risk transfer products, institutional income annuities, structured settlements, longevity reinsurance solutions, benefit funding solutions and capital markets investment products. Asia The Asia segment offers a broad range of products and services to both individuals and corporations, as well as to other institutions, and their respective employees, which include life insurance, accident & health insurance and retirement and savings. Latin America The Latin America segment offers a broad range of products to both individuals and corporations, as well as to other institutions, and their respective employees, which include life insurance, retirement and savings, accident & health insurance and credit insurance. EMEA The EMEA segment offers products to individuals, corporations, other institutions, and their respective employees, which include life insurance, retirement and savings, accident & health insurance and credit insurance. MetLife Holdings The MetLife Holdings segment consists of operations relating to products and businesses that the Company no longer actively markets in the U.S. These include variable, universal, term and whole life insurance, variable, fixed and index-linked annuities and long-term care insurance. It also includes an in-force block of assumed variable annuity guarantees from a third party. Corporate & Other Corporate & Other contains various start-up, developing and run-off businesses. Also included in Corporate & Other are: the excess capital, as well as certain charges and activities, not allocated to the segments (including external integration and disposition costs, internal resource costs for associates committed to acquisitions and dispositions and enterprise-wide strategic initiatives), interest expense related to the majority of the Company’s outstanding debt, expenses associated with certain legal proceedings and income tax audit issues, the elimination of intersegment amounts (which generally relate to investment expenses and intersegment loans bearing interest rates commensurate with related borrowings), and the Company’s investment management business (through which the Company provides public fixed income, private capital and real estate investment solutions to institutional investors worldwide). Financial Measures and Segment Accounting Policies Adjusted earnings is used by management to evaluate performance and allocate resources. Consistent with GAAP guidance for segment reporting, adjusted earnings is also the Company’s GAAP measure of segment performance and is reported below. Adjusted earnings should not be viewed as a substitute for net income (loss). The Company believes the presentation of adjusted earnings, as the Company measures it for management purposes, enhances the understanding of its performance by highlighting the results of operations and the underlying profitability drivers of the business. Adjusted earnings is defined as adjusted revenues less adjusted expenses, net of income tax. These financial measures focus on the Company’s primary businesses principally by excluding the impact of (i) market volatility which could distort trends, (ii) asymmetrical and non-economic accounting, and (iii) revenues and costs related to divested businesses, non-core products and certain entities required to be consolidated under GAAP. Also, these measures exclude results of discontinued operations under GAAP. Market volatility can have a significant impact on the Company’s financial results. Adjusted earnings excludes net investment gains (losses), net derivative gains (losses), market risk benefits (“MRBs”) remeasurement gains (losses) and goodwill impairments. Further, policyholder benefits and claims exclude (i) changes in the discount rate on certain annuitization guarantees accounted for as additional liabilities, and (ii) market value adjustments. Asymmetrical and non-economic accounting adjustments are made to the line items indicated in calculating adjusted earnings: • Net investment income includes earned income on derivatives and amortization of premium on derivatives that are hedges of investments or that are used to replicate certain investments, but do not qualify for hedge accounting treatment. • Other revenues include settlements of foreign currency earnings hedges and exclude asymmetrical accounting associated with in-force reinsurance. • Policyholder benefits and claims excludes (i) amortization of basis adjustments associated with de-designated fair value hedges of future policy benefits (“FPBs”), (ii) inflation-indexed benefit adjustments associated with contracts backed by inflation-indexed investments, (iii) asymmetrical accounting associated with in-force reinsurance, and (iv) non-economic losses incurred at contract inception for certain single premium annuity business. These losses are amortized into adjusted earnings within policyholder benefits and claims over the estimated lives of the contracts. • Interest credited to policyholder account balances (“PABs”) excludes amounts associated with periodic crediting rate adjustments based on the total return of a contractually referenced pool of assets and other pass-through adjustments and asymmetrical accounting associated with in-force reinsurance. Divested businesses are those that have been or will be sold or exited by MetLife but do not meet the discontinued operations criteria under GAAP. Divested businesses also include the net impact of transactions with exited businesses that have been eliminated in consolidation under GAAP and costs relating to businesses that have been or will be sold or exited by MetLife that do not meet the criteria to be included in results of discontinued operations under GAAP. Other adjustments are made to the line items indicated in calculating adjusted earnings: • Net investment income and interest credited to PABs excludes certain amounts related to contractholder-directed equity securities. • Other revenues include fee revenue on synthetic guaranteed interest contracts (“GICs”) accounted for as freestanding derivatives. • Other revenues exclude and other expenses include fees received in connection with services provided under transition service agreements. • Other expenses exclude (i) implementation of new insurance regulatory requirements and other costs, and (ii) acquisition, integration and other related costs. Other expenses include (i) deductions for net income attributable to noncontrolling interests, and (ii) benefits accrued on synthetic GICs accounted for as freestanding derivatives. Adjusted earnings also excludes the recognition of certain contingent assets and liabilities that could not be recognized at acquisition or adjusted for during the measurement period under GAAP business combination accounting guidance. The tax impact of the adjustments mentioned above are calculated net of the U.S. or foreign statutory tax rate, which could differ from the Company’s effective tax rate. Additionally, the provision for income tax (expense) benefit also includes the impact related to the timing of certain tax credits, as well as certain tax reforms. Set forth in the tables below is certain financial information with respect to the Company’s segments, as well as Corporate & Other, for the three months and nine months ended September 30, 2024 and 2023. The segment accounting policies are the same as those used to prepare the Company’s interim condensed consolidated financial statements, except for adjusted earnings adjustments as defined above. In addition, segment accounting policies include the method of capital allocation described below. Economic capital is an internally developed risk capital model, the purpose of which is to measure the risk in the business and to provide a basis upon which capital is deployed. The economic capital model accounts for the unique and specific nature of the risks inherent in the Company’s business. The Company’s economic capital model, coupled with considerations of local capital requirements, aligns segment allocated equity with emerging standards and consistent risk principles. The model applies statistics-based risk evaluation principles to the material risks to which the Company is exposed. These consistent risk principles include calibrating required economic capital shock factors to a specific confidence level and time horizon while applying an industry standard method for the inclusion of diversification benefits among risk types. The Company’s management is responsible for the ongoing production and enhancement of the economic capital model and reviews its approach periodically to ensure that it remains consistent with emerging industry practice standards. Segment net investment income is credited or charged based on the level of allocated equity; however, changes in allocated equity do not impact the Company’s consolidated net investment income, net income (loss) or adjusted earnings. Net investment income is based upon the actual results of each segment’s specifically identifiable investment portfolios adjusted for allocated equity. Other costs are allocated to each of the segments based upon: (i) a review of the nature of such costs; (ii) time studies analyzing the amount of employee compensation costs incurred by each segment; and (iii) cost estimates included in the Company’s product pricing. Three Months Ended September 30, 2024 Group Benefits RIS Asia Latin EMEA MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 5,538 $ 1,451 $ 1,272 $ 1,141 $ 562 $ 673 $ (6) $ 10,631 $ 16 $ 10,647 Universal life and investment-type product policy fees 231 67 420 346 84 80 — 1,228 — 1,228 Net investment income 311 2,133 1,132 435 55 981 96 5,143 84 5,227 Other revenues 377 61 18 9 9 40 98 612 36 648 Net investment gains (losses) — — — — — — — — (77) (77) Net derivative gains (losses) — — — — — — — — 767 767 Total revenues 6,457 3,712 2,842 1,931 710 1,774 188 17,614 826 18,440 Expenses Policyholder benefits and claims and policyholder dividends 4,927 2,247 1,035 1,091 276 1,221 — 10,797 (50) 10,747 Policyholder liability remeasurement (gains) losses — (148) 60 (18) 9 (35) — (132) — (132) MRB remeasurement (gains) losses — — — — — — — — 531 531 Interest credited to PABs 49 874 683 108 17 84 — 1,815 222 2,037 Capitalization of deferred policy acquisition costs (“DAC”) (4) (53) (336) (174) (119) (4) (1) (691) — (691) Amortization of DAC and value of business acquired (“VOBA”) 6 14 217 126 92 58 3 516 — 516 Amortization of negative VOBA — — (6) — (1) — — (7) — (7) Interest expense on debt — 4 — 4 — 4 245 257 — 257 Other expenses 1,007 183 758 485 342 220 164 3,159 29 3,188 Total expenses 5,985 3,121 2,411 1,622 616 1,548 411 15,714 732 16,446 Provision for income tax expense (benefit) 99 119 125 88 24 44 (41) 458 195 653 Adjusted earnings $ 373 $ 472 $ 306 $ 221 $ 70 $ 182 $ (182) 1,442 Adjustments to: Total revenues 826 Total expenses (732) Provision for income tax (expense) benefit (195) Net income (loss) $ 1,341 $ 1,341 Three Months Ended September 30, 2023 Group Benefits RIS Asia Latin EMEA MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 5,276 $ 2,330 $ 1,312 $ 1,116 $ 502 $ 685 $ 9 $ 11,230 $ — $ 11,230 Universal life and investment-type product policy fees 219 82 411 359 79 184 — 1,334 — 1,334 Net investment income 330 2,009 1,023 365 51 1,153 125 5,056 (231) 4,825 Other revenues 371 66 20 9 7 41 103 617 (11) 606 Net investment gains (losses) — — — — — — — — (927) (927) Net derivative gains (losses) — — — — — — — — (1,202) (1,202) Total revenues 6,196 4,487 2,766 1,849 639 2,063 237 18,237 (2,371) 15,866 Expenses Policyholder benefits and claims and policyholder dividends 4,592 3,100 1,095 1,020 230 1,311 4 11,352 (69) 11,283 Policyholder liability remeasurement (gains) losses (29) (76) 108 (4) (9) (7) — (17) — (17) MRB remeasurement (gains) losses — — — — — — — — (796) (796) Interest credited to PABs 50 756 576 106 19 198 — 1,705 (47) 1,658 Capitalization of DAC (5) (41) (404) (171) (114) (5) (2) (742) — (742) Amortization of DAC and VOBA 6 13 204 121 87 65 3 499 — 499 Amortization of negative VOBA — — (6) — (1) — — (7) — (7) Interest expense on debt — 3 — 2 — 4 256 265 — 265 Other expenses 937 138 788 493 315 238 250 3,159 30 3,189 Total expenses 5,551 3,893 2,361 1,567 527 1,804 511 16,214 (882) 15,332 Provision for income tax expense (benefit) 135 124 130 83 24 51 (79) 468 (429) 39 Adjusted earnings $ 510 $ 470 $ 275 $ 199 $ 88 $ 208 $ (195) 1,555 Adjustments to: Total revenues (2,371) Total expenses 882 Provision for income tax (expense) benefit 429 Net income (loss) $ 495 $ 495 Nine Months Ended September 30, 2024 Group Benefits RIS Asia Latin EMEA MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 16,848 $ 4,574 $ 3,785 $ 3,378 $ 1,634 $ 2,078 $ 15 $ 32,312 $ 16 $ 32,328 Universal life and investment-type product policy fees 682 215 1,280 1,089 238 252 1 3,757 — 3,757 Net investment income 939 6,339 3,407 1,219 163 3,007 297 15,371 497 15,868 Other revenues 1,156 185 57 31 24 127 293 1,873 87 1,960 Net investment gains (losses) — — — — — — — — (873) (873) Net derivative gains (losses) — — — — — — — — (720) (720) Total revenues 19,625 11,313 8,529 5,717 2,059 5,464 606 53,313 (993) 52,320 Expenses Policyholder benefits and claims and policyholder dividends 14,943 6,966 3,090 3,092 799 3,724 17 32,631 (30) 32,601 Policyholder liability remeasurement (gains) losses (1) (170) 24 (29) 10 2 — (164) — (164) MRB remeasurement (gains) losses — — — — — — — — (345) (345) Interest credited to PABs 145 2,508 1,987 337 53 293 — 5,323 1,004 6,327 Capitalization of DAC (13) (160) (1,032) (527) (362) (13) (7) (2,114) — (2,114) Amortization of DAC and VOBA 19 45 634 380 265 174 6 1,523 — 1,523 Amortization of negative VOBA — — (16) — (3) — — (19) — (19) Interest expense on debt 1 11 — 11 — 11 744 778 — 778 Other expenses 3,026 500 2,204 1,502 1,002 663 546 9,443 49 9,492 Total expenses 18,120 9,700 6,891 4,766 1,764 4,854 1,306 47,401 678 48,079 Provision for income tax expense (benefit) 315 332 460 271 71 116 (158) 1,407 (335) 1,072 Adjusted earnings $ 1,190 $ 1,281 $ 1,178 $ 680 $ 224 $ 494 $ (542) 4,505 Adjustments to: Total revenues (993) Total expenses (678) Provision for income tax (expense) benefit 335 Net income (loss) $ 3,169 $ 3,169 Nine Months Ended September 30, 2023 Group Benefits RIS Asia Latin EMEA MetLife Corporate Total Adjustments Total Consolidated (In millions) Revenues Premiums $ 16,154 $ 5,512 $ 3,999 $ 3,164 $ 1,497 $ 2,127 $ 44 $ 32,497 $ — $ 32,497 Universal life and investment-type product policy fees 660 232 1,204 1,046 231 537 1 3,911 — 3,911 Net investment income 967 5,771 2,954 1,162 143 3,450 255 14,702 (160) 14,542 Other revenues 1,114 205 61 31 23 143 310 1,887 (21) 1,866 Net investment gains (losses) — — — — — — — — (2,650) (2,650) Net derivative gains (losses) — — — — — — — — (2,289) (2,289) Total revenues 18,895 11,720 8,218 5,403 1,894 6,257 610 52,997 (5,120) 47,877 Expenses Policyholder benefits and claims and policyholder dividends 14,452 7,766 3,282 2,962 728 4,021 32 33,243 31 33,274 Policyholder liability remeasurement (gains) losses (31) (116) 92 (5) (10) 28 — (42) — (42) MRB remeasurement (gains) losses — — — — — — — — (1,425) (1,425) Interest credited to PABs 144 2,104 1,682 310 54 595 — 4,889 566 5,455 Capitalization of DAC (16) (136) (1,202) (470) (341) (17) (7) (2,189) — (2,189) Amortization of DAC and VOBA 19 36 587 344 257 197 8 1,448 — 1,448 Amortization of negative VOBA — — (17) — (3) — — (20) — (20) Interest expense on debt 1 10 — 8 — 10 747 776 — 776 Other expenses 2,819 430 2,373 1,388 929 707 656 9,302 77 9,379 Total expenses 17,388 10,094 6,797 4,537 1,614 5,541 1,436 47,407 (751) 46,656 Provision for income tax expense (benefit) 318 339 435 233 62 139 (265) 1,261 (1,028) 233 Adjusted earnings $ 1,189 $ 1,287 $ 986 $ 633 $ 218 $ 577 $ (561) 4,329 Adjustments to: Total revenues (5,120) Total expenses 751 Provision for income tax (expense) benefit 1,028 Net income (loss) $ 988 $ 988 The following table presents total assets with respect to the Company’s segments, as well as Corporate & Other, at: September 30, 2024 December 31, 2023 (In millions) Group Benefits $ 36,894 $ 36,715 RIS 229,709 218,587 Asia 162,531 157,206 Latin America 73,419 69,177 EMEA 19,653 18,596 MetLife Holdings 146,403 148,524 Corporate & Other 36,367 38,779 Total $ 704,976 $ 687,584

Disposition

Disposition	9 Months Ended
	Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]
Disposition	3. Disposition Pending Disposition of MetLife Malaysia In October 2023, the Company entered into an agreement to sell its ownership interests in AmMetLife Insurance Berhad (Malaysia) and AmMetLife Takaful Berhad (Malaysia) (collectively, “MetLife Malaysia”). The transaction is expected to close in the first half of 2025 and is subject to regulatory approvals and satisfaction of other closing conditions. See Note 3 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for further information.

Future Policy Benefits

Future Policy Benefits	9 Months Ended
	Sep. 30, 2024
Insurance [Abstract]
Liability for Future Policy Benefits and Unpaid Claims Disclosure	4. Future Policy Benefits The Company establishes liabilities for amounts payable under insurance policies. These liabilities are comprised of traditional and limited-payment contracts and associated deferred profit liability (“DPL”), additional insurance liabilities, participating life and short-duration contracts. The Company’s FPBs on the interim condensed consolidated balance sheets was as follows at: September 30, 2024 December 31, 2023 (In millions) Traditional and Limited-Payment Contracts: RIS - Annuities $ 67,645 $ 64,324 Asia: Whole and term life & endowments 12,661 12,874 Accident & health 10,598 10,712 Latin America - Fixed annuities 10,906 9,637 MetLife Holdings - Long-term care 15,657 15,240 Deferred Profit Liabilities: RIS - Annuities 3,754 3,697 Asia: Whole and term life & endowments 785 654 Accident & health 913 830 Latin America - Fixed annuities 549 562 Additional Insurance Liabilities: Asia: Variable life 1,227 1,258 Universal and variable universal life 399 424 MetLife Holdings - Universal and variable universal life 2,471 2,362 MetLife Holdings - Participating life 48,629 49,543 Other long-duration (1) 11,340 11,099 Short-duration and other 13,806 13,190 Total $ 201,340 $ 196,406 __________________ (1) This balance represents liabilities for various smaller product lines across multiple segments, as well as Corporate & Other. Rollforwards - Traditional and Limited-Payment Contracts The following information about the direct and assumed liability for FPBs includes disaggregated rollforwards of expected future net premiums and expected future benefits. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. The adjusted balance in each disaggregated rollforward reflects the remeasurement (gains) losses. All amounts presented in the rollforwards and accompanying financial information do not include a reduction for amounts ceded to reinsurers, except with respect to ending net liability for FPB balances where applicable. RIS - Annuities The RIS segment’s annuity products include pension risk transfers, certain structured settlements and certain institutional income annuities, which are mainly single premium spread-based products. The Company reinsures portions of certain newly issued pension risk transfers on a modified coinsurance basis. Information regarding these products was as follows: Nine Months 2024 2023 (Dollars in millions) Present Value of Expected Net Premiums Balance, beginning of period, at current discount rate at balance sheet date $ — $ — Balance, beginning of period, at original discount rate $ — $ — Effect of changes in cash flow assumptions (1) — — Effect of actual variances from expected experience (2) (32) (89) Adjusted balance (32) (89) Issuances 5,042 4,422 Net premiums collected (5,010) (4,333) Ending balance at original discount rate — — Balance, end of period, at current discount rate at balance sheet date $ — $ — Present Value of Expected FPBs Balance, beginning of period, at current discount rate at balance sheet date $ 64,515 $ 58,695 Balance, beginning of period, at original discount rate $ 64,737 $ 61,426 Effect of changes in cash flow assumptions (1) (195) (284) Effect of actual variances from expected experience (2) (99) (222) Adjusted balance 64,443 60,920 Issuances 5,168 4,420 Interest accrual 2,326 2,145 Benefit payments (4,479) (4,121) Ending balance at original discount rate 67,458 63,364 Effect of changes in discount rate assumptions 338 (5,438) Balance, end of period, at current discount rate at balance sheet date 67,796 57,926 Cumulative amount of fair value hedging adjustments (151) (430) Net liability for FPBs 67,645 57,496 Less: Reinsurance recoverables 2,041 — Net liability for FPBs, net of reinsurance $ 65,604 $ 57,496 Undiscounted - Expected future benefit payments $ 123,186 $ 119,270 Discounted - Expected future benefit payments (at current discount rate at balance sheet date) $ 67,796 $ 57,926 Weighted-average duration of the liability 9 years 9 years Weighted-average interest accretion (original locked-in) rate 4.8 % 4.7 % Weighted-average current discount rate at balance sheet date 5.0 % 6.1 % _________________ (1) For the nine months ended September 30, 2024, the net effect of changes in cash flow assumptions was partially offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $62 million. For the nine months ended September 30, 2023, the net effect of changes in cash flow assumptions was largely offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $211 million. For the nine months ended September 30, 2024 and 2023, the net effect of changes in cash flow assumptions was primarily driven by updates in assumptions related to mortality. (2) For the nine months ended September 30, 2024, the net effect of actual variances from expected experience was partially offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $29 million. For the nine months ended September 30, 2023, the net effect of actual variances from expected experience was largely offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $95 million. For the nine months ended September 30, 2023, the net effect of actual variances from expected experience was primarily driven by favorable mortality. Significant Methodologies and Assumptions The principal inputs used in the establishment of the FPB for the RIS segment’s annuity products include actual premiums, actual benefits, in-force data, locked-in claim-related expense, the locked-in interest accretion rate, the current upper-medium grade discount rate at the balance sheet date and best estimate mortality assumptions. When single premium annuity contracts are issued, the FPB reserve is required to be measured at an upper-medium grade discount rate. Due to differences between the upper-medium grade discount rate and pricing assumptions used to determine the contractual premium, the initial FPB reserve at issue for a particular cohort may be greater than the contractual premium received, and the difference must be recognized as an immediate loss at issue. On these cohorts, future experience that differs from expected experience and changes in cash flow assumptions result in the recognition of remeasurement gains and losses with net remeasurement gains limited to the amount of the original loss at issue, after which any favorable experience is deferred and recorded within the DPL. For the nine months ended September 30, 2024, the Company incurred a loss at issue of $129 million. Substantially all the loss at issue was offset by a deferred gain on ceded reinsurance, which will be amortized over the life of the reinsurance agreement. Additionally, for the nine months ended September 30, 2024, the Company recognized a net remeasurement gain related to the net effect of changes in cash flow assumptions. Asia Whole and Term Life & Endowments The Asia segment’s whole and term life & endowment products in Japan and Korea offer various life insurance coverages to customers. Information regarding these products was as follows: Nine Months 2024 2023 (Dollars in millions) Present Value of Expected Net Premiums Balance, beginning of period, at current discount rate at balance sheet date $ 4,561 $ 4,682 Balance, beginning of period, at original discount rate $ 4,793 $ 4,943 Effect of changes in cash flow assumptions (1) 58 11 Effect of actual variances from expected experience (43) (41) Adjusted balance 4,808 4,913 Issuances 386 614 Interest accrual 52 43 Net premiums collected (456) (457) Effect of foreign currency translation (77) (518) Ending balance at original discount rate 4,713 4,595 Effect of changes in discount rate assumptions (236) (319) Effect of foreign currency translation on the effect of changes in discount rate assumptions 3 23 Balance, end of period, at current discount rate at balance sheet date $ 4,480 $ 4,299 Present Value of Expected FPBs Balance, beginning of period, at current discount rate at balance sheet date $ 17,435 $ 17,463 Balance, beginning of period, at original discount rate $ 17,198 $ 18,209 Effect of changes in cash flow assumptions (1) 36 58 Effect of actual variances from expected experience (39) (14) Adjusted balance 17,195 18,253 Issuances 386 614 Interest accrual 276 278 Benefit payments (726) (895) Effect of foreign currency translation (263) (1,847) Ending balance at original discount rate 16,868 16,403 Effect of changes in discount rate assumptions 272 (742) Effect of foreign currency translation on the effect of changes in discount rate assumptions 1 40 Balance, end of period, at current discount rate at balance sheet date 17,141 15,701 Cumulative impact of flooring the future policyholder benefits reserve — 2 Net liability for FPBs 12,661 11,404 Less: Amount due to reinsurer (2) (1) Net liability for FPBs, net of reinsurance $ 12,663 $ 11,405 Undiscounted: Expected future gross premiums $ 9,393 $ 8,911 Expected future benefit payments $ 28,008 $ 26,785 Discounted (at current discount rate at balance sheet date): Expected future gross premiums $ 8,042 $ 7,582 Expected future benefit payments $ 17,141 $ 15,701 Weighted-average duration of the liability 17 years 17 years Weighted -average interest accretion (original locked-in) rate 2.5 % 2.5 % Weighted-average current discount rate at balance sheet date 2.6 % 2.9 % _________________ (1) For the nine months ended September 30, 2024, the net effect of changes in cash flow assumptions was more than offset by the corresponding impact in DPL associated with the Asia segment’s whole and term life products of $28 million. Accident & Health The Asia segment’s accident & health products in Japan and Korea offer various hospitalization, cancer, critical illness, disability, income protection and personal accident coverage. Information regarding these products was as follows: Nine Months 2024 2023 (Dollars in millions) Present Value of Expected Net Premiums Balance, beginning of period, at current discount rate at balance sheet date $ 19,835 $ 21,181 Balance, beginning of period, at original discount rate $ 21,232 $ 22,594 Effect of changes in cash flow assumptions (1) 439 867 Effect of actual variances from expected experience — (75) Adjusted balance 21,671 23,386 Issuances 842 813 Interest accrual 168 179 Net premiums collected (1,394) (1,546) Effect of foreign currency translation and other - net (149) (2,474) Ending balance at original discount rate 21,138 20,358 Effect of changes in discount rate assumptions (1,481) (1,803) Effect of foreign currency translation on the effect of changes in discount rate assumptions 12 136 Balance, end of period, at current discount rate at balance sheet date $ 19,669 $ 18,691 Present Value of Expected FPBs Balance, beginning of period, at current discount rate at balance sheet date $ 30,480 $ 30,879 Balance, beginning of period, at original discount rate $ 36,010 $ 37,189 Effect of changes in cash flow assumptions (1) 439 898 Effect of actual variances from expected experience 4 (99) Adjusted balance 36,453 37,988 Issuances 841 812 Interest accrual 353 367 Benefit payments (939) (958) Effect of foreign currency translation and other - net (323) (4,061) Ending balance at original discount rate 36,385 34,148 Effect of changes in discount rate assumptions (6,207) (6,866) Effect of foreign currency translation on the effect of changes in discount rate assumptions 43 595 Balance, end of period, at current discount rate at balance sheet date 30,221 27,877 Cumulative impact of flooring the future policyholder benefits reserve 46 143 Net liability for FPBs 10,598 9,329 Less: Reinsurance recoverables 164 136 Net liability for FPBs, net of reinsurance $ 10,434 $ 9,193 Undiscounted: Expected future gross premiums $ 41,446 $ 39,891 Expected future benefit payments $ 47,705 $ 44,612 Discounted (at current discount rate at balance sheet date): Expected future gross premiums $ 33,666 $ 32,286 Expected future benefit payments $ 30,221 $ 27,877 Weighted-average duration of the liability 24 years 25 years Weighted-average interest accretion (original locked-in) rate 1.7 % 1.8 % Weighted-average current discount rate at balance sheet date 2.7 % 2.8 % _________________ (1) For the nine months ended September 30, 2024, the net effect of changes in cash flow assumptions was primarily driven by updates in assumptions related to morbidity, substantially offset by policyholder behavior assumptions related to lapses. For the nine months ended September 30, 2023, the net effect of changes in cash flow assumptions was primarily driven by updates in policyholder behavior assumptions related to lapses, partially offset by updates in assumptions associated with mortality and morbidity. Significant Methodologies and Assumptions The principal inputs used in the establishment of the FPB reserve for the Asia segment’s accident & health products include actual premiums, actual benefits, in-force data, locked-in claim-related expense, the locked-in interest accretion rate, current upper-medium grade discount rate at the balance sheet date and best estimate assumptions. The best estimate assumptions include mortality, lapse, and morbidity. Latin America - Fixed Annuities The Latin America segment’s fixed annuity products in Chile and Mexico offer fixed income annuities that provide for asset distribution needs. Information regarding these products was as follows: Nine Months 2024 2023 (Dollars in millions) Present Value of Expected Net Premiums Balance, beginning of period, at current discount rate at balance sheet date $ — $ — Balance, at beginning of period, at original discount rate $ — $ — Effect of changes in cash flow assumptions (1) — — Effect of actual variances from expected experience (2) — (2) Adjusted balance — (2) Issuances 760 785 Interest accrual 13 16 Net premiums collected (773) (799) Ending balance at original discount rate — — Balance, end of period, at current discount rate at balance sheet date $ — $ — Present Value of Expected FPBs Balance, beginning of period, at current discount rate at balance sheet date $ 9,637 $ 9,265 Balance, beginning of period, at original discount rate $ 9,249 $ 8,240 Effect of changes in cash flow assumptions (1) (4) (5) Effect of actual variances from expected experience (2) (21) (13) Adjusted balance 9,224 8,222 Issuances 789 869 Interest accrual 253 258 Benefit payments (519) (504) Inflation adjustment 270 273 Effect of foreign currency translation (258) (403) Ending balance at original discount rate 9,759 8,715 Effect of changes in discount rate assumptions 1,126 (59) Effect of foreign currency translation on the effect of changes in discount rate assumptions 21 6 Balance, end of period, at current discount rate at balance sheet date 10,906 8,662 Net liability for FPBs $ 10,906 $ 8,662 Undiscounted - Expected future benefit payments $ 14,663 $ 13,204 Discounted - Expected future benefit payments (at current discount rate at balance sheet date) $ 10,906 $ 8,662 Weighted-average duration of the liability 11 years 10 years Weighted-average interest accretion (original locked-in) rate 3.4 % 3.9 % Weighted-average current discount rate at balance sheet date 2.5 % 3.7 % __________________ (1) For the nine months ended September 30, 2024 and 2023, the net effect of changes in cash flow assumptions was largely offset by the corresponding impact in DPL associated with the Latin America segment’s fixed annuity products of $3 million and $4 million, respectively. (2) For the nine months ended September 30, 2024, the net effect of actual variances from expected experience was not offset by the corresponding impact in DPL associated with the Latin America segment’s fixed annuity products primarily due to the variance related to cohorts with no DPL. For the nine months ended September 30, 2023, the net effect of actual variances from expected experience was partially offset by the corresponding impact in DPL associated with the Latin America segment’s fixed annuity products of $2 million. MetLife Holdings - Long-term Care The MetLife Holdings segment’s long-term care products offer protection against potentially high costs of long-term health care services. Information regarding these products was as follows: Nine Months 2024 2023 (Dollars in millions) Present Value of Expected Net Premiums Balance, beginning of period, at current discount rate at balance sheet date $ 5,687 $ 5,775 Balance, beginning of period, at original discount rate $ 5,566 $ 5,807 Effect of changes in cash flow assumptions (1) 212 (152) Effect of actual variances from expected experience 34 173 Adjusted balance 5,812 5,828 Interest accrual 213 222 Net premiums collected (424) (438) Ending balance at original discount rate 5,601 5,612 Effect of changes in discount rate assumptions 159 (258) Balance, end of period, at current discount rate at balance sheet date $ 5,760 $ 5,354 Present Value of Expected FPBs Balance, beginning of period, at current discount rate at balance sheet date $ 20,927 $ 19,619 Balance, beginning of period, at original discount rate $ 20,494 $ 20,165 Effect of changes in cash flow assumptions (1) 205 (190) Effect of actual variances from expected experience 45 194 Adjusted balance 20,744 20,169 Interest accrual 812 801 Benefit payments (638) (579) Ending balance at original discount rate 20,918 20,391 Effect of changes in discount rate assumptions 499 (2,012) Balance, end of period, at current discount rate at balance sheet date 21,417 18,379 Net liability for FPBs $ 15,657 $ 13,025 Undiscounted: Expected future gross premiums $ 10,735 $ 10,713 Expected future benefit payments $ 45,098 $ 45,152 Discounted (at current discount rate at balance sheet date): Expected future gross premiums $ 7,319 $ 6,714 Expected future benefit payments $ 21,417 $ 18,379 Weighted-average duration of the liability 14 years 14 years Weighted-average interest accretion (original locked-in) rate 5.4 % 5.5 % Weighted-average current discount rate at balance sheet date 5.2 % 6.3 % __________________ (1) For the nine months ended September 30, 2023, the net effect of changes in cash flow assumptions was primarily driven by updates in policyholder behavior assumptions related to claim utilization experience, which lowered the expected cost of care. This was partially offset by updates in morbidity assumptions associated with an increase in incidence rates. Significant Methodologies and Assumptions The principal inputs used in the establishment of the FPB reserve for long-term care products include actual premiums, actual benefits, in-force data, locked-in claim-related expense, the locked-in interest accretion rate, current upper-medium grade discount rate at the balance sheet date and best estimate assumptions. The best estimate assumptions include mortality, lapse, incidence, claim utilization, claim cost inflation, claim continuance, and premium rate increases. Rollforwards - Additional Insurance Liabilities The Company establishes additional insurance liabilities for annuitization, death or other insurance benefits for variable life, universal life, and variable universal life contract features where the Company guarantees to the contractholder either a secondary guarantee or a guaranteed paid-up benefit. The policy can remain in force, even if the base policy account value is zero, as long as contractual secondary guarantee requirements have been met. The following information about the direct liability for additional insurance liabilities includes disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. The adjusted balance in each disaggregated rollforward reflects the remeasurement (gains) losses. All amounts presented in these rollforwards and accompanying financial information do not include a reduction for amounts ceded to reinsurers. Asia The Asia segment’s variable life, universal life, and variable universal life products in Japan offer a contract feature where the Company guarantees to the contractholder a secondary guarantee. Information regarding these additional insurance liabilities was as follows: Nine Months 2024 2023 2024 2023 Variable Life Universal and Variable Universal Life (Dollars in millions) Balance, beginning of period $ 1,258 $ 1,381 $ 424 $ 455 Less: Accumulated other comprehensive income (loss) (“AOCI”) adjustment — — (14) (33) Balance, beginning of period, before AOCI adjustment 1,258 1,381 438 488 Effect of changes in cash flow assumptions 17 (4) (23) (2) Effect of actual variances from expected experience (8) (9) (14) (32) Adjusted balance 1,267 1,368 401 454 Assessments accrual (3) (3) — — Interest accrual 13 15 4 5 Excess benefits paid (30) (29) — — Effect of foreign currency translation and other, net (20) (158) (6) (55) Balance, end of period, before AOCI adjustment 1,227 1,193 399 404 Add: AOCI adjustment — — — (18) Balance, end of period $ 1,227 $ 1,193 $ 399 $ 386 Weighted-average duration of the liability 16 years 16 years 42 years 43 years Weighted-average interest accretion rate 1.4 % 1.5 % 1.4 % 1.5 % MetLife Holdings The MetLife Holdings segment’s universal life and variable universal life products offer a contract feature where the Company guarantees to the contractholder a secondary guarantee or a guaranteed paid-up benefit. Information regarding these additional insurance liabilities was as follows: Nine Months 2024 2023 Universal and Variable Universal Life (Dollars in millions) Balance, beginning of period $ 2,362 $ 2,156 Less: AOCI adjustment (14) (63) Balance, beginning of period, before AOCI adjustment 2,376 2,219 Effect of changes in cash flow assumptions (2) 38 Effect of actual variances from expected experience 36 (10) Adjusted balance 2,410 2,247 Assessments accrual 78 80 Interest accrual 98 92 Excess benefits paid (104) (81) Balance, end of period, before AOCI adjustment 2,482 2,338 Add: AOCI adjustment (11) (65) Balance, end of period 2,471 2,273 Less: Reinsurance recoverables 2,147 766 Balance, end of period, net of reinsurance $ 324 $ 1,507 Weighted-average duration of the liability 15 years 16 years Weighted-average interest accretion rate 5.5 % 5.5 % The Company’s gross premiums or assessments and interest expense recognized in the interim condensed consolidated statements of operations and comprehensive income (loss) for long-duration contracts, excluding MetLife Holdings’ participating life contracts, were as follows: Nine Months 2024 2023 Gross Premiums or Interest Expense (2) Gross Premiums or Interest Expense (2) (In millions) Traditional and Limited-Payment Contracts: RIS - Annuities $ 5,098 $ 2,326 $ 4,433 $ 2,145 Asia: Whole and term life & endowments 850 224 841 235 Accident & health 2,324 185 2,580 188 Latin America - Fixed annuities 773 240 799 242 MetLife Holdings - Long-term care 543 599 547 579 Deferred Profit Liabilities: RIS - Annuities N/A 133 N/A 124 Asia: Whole and term life & endowments N/A 27 N/A 22 Accident & health N/A 15 N/A 13 Latin America - Fixed annuities N/A 15 N/A 17 Additional Insurance Liabilities: Asia: Variable life 85 13 60 15 Universal and variable universal life (32) 4 (20) 5 MetLife Holdings - Universal and variable universal life 492 98 559 92 Other long-duration 3,469 362 3,194 341 Total $ 13,602 $ 4,241 $ 12,993 $ 4,018 __________________ (1) Gross premiums are related to traditional and limited-payment contracts and are included in premiums. Assessments are related to additional insurance liabilities and are included in universal life and investment-type product policy fees and net investment income. (2) Interest expense is included in policyholder benefits and claims. Liabilities for Unpaid Claims and Claim Expenses Rollforward of Claims and Claim Adjustment Expenses Information regarding the liabilities for unpaid claims and claim adjustment expenses was as follows: Nine Months 2024 2023 (In millions) Balance, beginning of period $ 16,468 $ 16,098 Less: Reinsurance recoverables 2,592 2,452 Net balance, beginning of period 13,876 13,646 Incurred related to: Current period 20,532 19,983 Prior periods (1) 80 327 Total incurred 20,612 20,310 Paid related to: Current period (14,470) (13,991) Prior periods (5,773) (5,883) Total paid (20,243) (19,874) Net balance, end of period 14,245 14,082 Add: Reinsurance recoverables 2,757 2,523 Balance, end of period (included in FPBs and other policy-related balances) $ 17,002 $ 16,605 __________________ (1) For the nine months ended September 30, 2024 and 2023, incurred claims and claim adjustment expenses associated with prior periods increased due to events incurred in prior periods but reported in the respective current period.

Policyholder Account Balances

Policyholder Account Balances	9 Months Ended
	Sep. 30, 2024
Insurance [Abstract]
Policyholder Account Balances	5. Policyholder Account Balances The Company establishes liabilities for PABs, which are generally equal to the account value, and which includes accrued interest credited, but excludes the impact of any applicable charge that may be incurred upon surrender. The Company’s PABs on the interim condensed consolidated balance sheets were as follows at: September 30, 2024 December 31, 2023 (In millions) Group Benefits - Group life $ 7,676 $ 7,692 RIS: Capital markets investment products and stable value GICs 65,330 64,140 Annuities and risk solutions 19,572 17,711 Asia: Universal and variable universal life 51,756 49,739 Fixed annuities 38,742 36,863 EMEA - Variable annuities 2,617 2,720 MetLife Holdings: Annuities 10,437 11,537 Life and other 11,284 11,641 Other 17,195 17,226 Total $ 224,609 $ 219,269 Rollforwards The following information about the direct and assumed liability for PABs includes year-to-date disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. Policy charges presented in each disaggregated rollforward reflect a premium and/or assessment based on the account balance. Group Benefits Group Life The Group Benefits segment’s group life PABs predominantly consist of retained asset accounts, universal life products, and the fixed account of variable life insurance products. Information regarding this liability was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 7,692 $ 8,028 Deposits 2,857 2,529 Policy charges (493) (475) Surrenders and withdrawals (2,512) (2,432) Benefit payments (9) (9) Net transfers from (to) separate accounts (3) 1 Interest credited 144 143 Balance, end of period $ 7,676 $ 7,785 Weighted-average annual crediting rate 2.5 % 2.4 % At period end: Cash surrender value $ 7,614 $ 7,721 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 265,266 $ 250,611 The Group Benefits segment’s group life product account values by range of guaranteed minimum crediting rates (“GMCR”) and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ 456 $ 72 $ 877 $ 4,141 $ 5,546 Equal to or greater than 2% but less than 4% 1,266 8 59 1 1,334 Equal to or greater than 4% 684 — 39 36 759 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 37 Total $ 2,406 $ 80 $ 975 $ 4,178 $ 7,676 September 30, 2023 Equal to or greater than 0% but less than 2% $ — $ 82 $ 887 $ 4,595 $ 5,564 Equal to or greater than 2% but less than 4% 1,223 10 62 2 1,297 Equal to or greater than 4% 733 1 42 34 810 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 114 Total $ 1,956 $ 93 $ 991 $ 4,631 $ 7,785 RIS Capital Markets Investment Products and Stable Value GICs The RIS segment’s capital markets investment products and stable value GICs in PABs are investment-type products, mainly funding agreements. Information regarding this liability was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 64,140 $ 63,723 Deposits 56,170 54,674 Surrenders and withdrawals (57,068) (56,873) Interest credited 1,811 1,524 Effect of foreign currency translation and other, net 277 369 Balance, end of period $ 65,330 $ 63,417 Weighted-average annual crediting rate 3.8 % 3.2 % Cash surrender value at period end $ 1,953 $ 2,110 The RIS segment’s capital markets investment products and stable value GICs account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ — $ 2,754 $ 2,754 Equal to or greater than 2% but less than 4% — — — 148 148 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 62,428 Total $ — $ — $ — $ 2,902 $ 65,330 September 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 1 $ 2,620 $ 2,621 Equal to or greater than 2% but less than 4% — — — — — Products with either a fixed rate or no GMCR N/A N/A N/A N/A 60,796 Total $ — $ — $ 1 $ 2,620 $ 63,417 Annuities and Risk Solutions The RIS segment’s annuity and risk solutions PABs include certain structured settlements and institutional income annuities, and benefit funding solutions that include postretirement benefits and company-, bank- or trust-owned life insurance used to finance nonqualified benefit programs for executives. Information regarding this liability was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 17,711 $ 15,549 Deposits 2,367 2,007 Policy charges (122) (133) Surrenders and withdrawals (239) (134) Benefit payments (731) (615) Net transfers from (to) separate accounts 20 54 Interest credited 556 469 Other 10 (133) Balance, end of period $ 19,572 $ 17,064 Weighted-average annual crediting rate 4.0 % 3.9 % At period end: Cash surrender value $ 8,476 $ 7,693 Net amount at risk, excluding offsets from ceded reinsurance: In the event of death $ 44,437 $ 42,043 The RIS segment’s annuity and risk solutions account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ 19 $ 2,403 $ 2,422 Equal to or greater than 2% but less than 4% 198 35 109 417 759 Equal to or greater than 4% 4,131 — 472 6 4,609 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 11,782 Total $ 4,329 $ 35 $ 600 $ 2,826 $ 19,572 September 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 22 $ 1,525 $ 1,547 Equal to or greater than 2% but less than 4% 260 33 94 437 824 Equal to or greater than 4% 4,363 — 277 6 4,646 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 10,047 Total $ 4,623 $ 33 $ 393 $ 1,968 $ 17,064 Asia Universal and Variable Universal Life The Asia segment’s universal and variable universal life PABs in Japan primarily include interest sensitive whole life products. Information regarding this liability was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 49,739 $ 46,417 Deposits 4,694 5,439 Policy charges (812) (888) Surrenders and withdrawals (2,483) (2,018) Benefit payments (345) (393) Interest credited 1,153 979 Effect of foreign currency translation and other, net (190) (1,906) Balance, end of period $ 51,756 $ 47,630 Weighted-average annual crediting rate 3.1 % 2.8 % At period end: Cash surrender value $ 46,366 $ 40,663 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 89,793 $ 91,861 The Asia segment’s universal and variable universal life account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ 10,681 $ 18 $ 235 $ 1,449 $ 12,383 Equal to or greater than 2% but less than 4% 7,829 15,730 5,397 9,650 38,606 Equal to or greater than 4% 241 — — — 241 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 526 Total $ 18,751 $ 15,748 $ 5,632 $ 11,099 $ 51,756 September 30, 2023 Equal to or greater than 0% but less than 2% $ 9,986 $ 25 $ 233 $ 729 $ 10,973 Equal to or greater than 2% but less than 4% 5,742 17,923 5,628 6,633 35,926 Equal to or greater than 4% 256 — — — 256 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 475 Total $ 15,984 $ 17,948 $ 5,861 $ 7,362 $ 47,630 Fixed Annuities Information regarding the Asia segment’s fixed annuity PAB liability in Japan was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 36,863 $ 32,454 Deposits 5,002 6,230 Policy charges (2) (2) Surrenders and withdrawals (2,248) (1,665) Benefit payments (1,718) (1,614) Interest credited 784 629 Effect of foreign currency translation and other, net 61 (552) Balance, end of period $ 38,742 $ 35,480 Weighted-average annual crediting rate 2.8 % 2.5 % At period end: Cash surrender value $ 35,005 $ 30,289 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 8 $ — The Asia segment’s fixed annuity account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ 385 $ 460 $ 5,250 $ 31,353 $ 37,448 Equal to or greater than 2% but less than 4% — 5 — — 5 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 1,289 Total $ 385 $ 465 $ 5,250 $ 31,353 $ 38,742 September 30, 2023 Equal to or greater than 0% but less than 2% $ 315 $ 574 $ 6,494 $ 26,811 $ 34,194 Equal to or greater than 2% but less than 4% — 6 — — 6 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 1,280 Total $ 315 $ 580 $ 6,494 $ 26,811 $ 35,480 EMEA Variable Annuities Information regarding the EMEA segment’s variable annuity PABs in the United Kingdom was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 2,720 $ 2,802 Deposits 2 3 Policy charges (44) (48) Surrenders and withdrawals (214) (206) Benefit payments (95) (95) Interest credited (1) 117 69 Effect of foreign currency translation and other, net 131 46 Balance, end of period $ 2,617 $ 2,571 Weighted-average annual crediting rate 6.0 % 3.5 % At period end: Cash surrender value $ 2,617 $ 2,571 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 426 $ 577 At annuitization or exercise of other living benefits $ 550 $ 725 __________________ (1) Interest credited on EMEA’s variable annuity products represents gains or losses which are passed through to the policyholder based on the underlying unit-linked investment fund returns, which may be positive or negative depending on market conditions. There are no GMCR on these products. MetLife Holdings Annuities The MetLife Holdings segment’s annuity PABs primarily include fixed deferred annuities, the fixed account portion of variable annuities, certain income annuities, and embedded derivatives related to equity-indexed annuities. Information regarding this liability was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 11,537 $ 13,286 Deposits 121 115 Policy charges (10) (12) Surrenders and withdrawals (1,292) (1,425) Benefit payments (298) (320) Net transfers from (to) separate accounts 105 48 Interest credited 265 299 Other 9 15 Balance, end of period $ 10,437 $ 12,006 Weighted-average annual crediting rate 3.3 % 3.2 % At period end: Cash surrender value $ 9,866 $ 11,263 Net amount at risk, excluding offsets from ceded reinsurance (1): In the event of death $ 2,238 $ 3,970 At annuitization or exercise of other living benefits $ 657 $ 923 __________________ (1) Includes amounts for certain variable annuities recorded as PABs with the related guarantees recorded as MRBs which are disclosed in “MetLife Holdings – Annuities” in Note 6. The MetLife Holdings segment’s annuity account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than 0% but less than 0.50% above GMCR Equal to or greater than 0.50% but less than 1.50% above GMCR Equal to or greater than 1.50% above GMCR Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ 3 $ 166 $ 444 $ 52 $ 665 Equal to or greater than 2% but less than 4% 1,378 6,188 501 153 8,220 Equal to or greater than 4% 745 404 17 — 1,166 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 386 Total $ 2,126 $ 6,758 $ 962 $ 205 $ 10,437 September 30, 2023 Equal to or greater than 0% but less than 2% $ 235 $ 245 $ 292 $ 227 $ 999 Equal to or greater than 2% but less than 4% 2,887 5,828 457 130 9,302 Equal to or greater than 4% 965 274 26 — 1,265 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 440 Total $ 4,087 $ 6,347 $ 775 $ 357 $ 12,006 Life and Other The MetLife Holdings segment’s life and other PABs include retained asset accounts, universal life products, the fixed account of variable life insurance products and funding agreements. Information regarding this liability was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 11,641 $ 12,402 Deposits 549 617 Policy charges (519) (529) Surrenders and withdrawals (744) (892) Benefit payments (114) (120) Net transfers from (to) separate accounts 26 29 Interest credited 318 336 Other 127 1 Balance, end of period $ 11,284 $ 11,844 Weighted-average annual crediting rate 3.8 % 3.8 % At period end: Cash surrender value $ 10,722 $ 11,360 Net amount at risk, excluding offsets from ceded reinsurance: In the event of death (1) $ 64,816 $ 68,972 __________________ (1) Including offsets from ceded reinsurance, the net amount at risk at both September 30, 2024 and December 31, 2023, would be reduced by 99%. The MetLife Holdings segment’s life and other products account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than 0% but less than 0.50% above GMCR Equal to or greater than 0.50% but less than 1.50% above GMCR Equal to or greater than 1.50% above GMCR Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ 17 $ 58 $ 75 Equal to or greater than 2% but less than 4% 4,159 171 265 536 5,131 Equal to or greater than 4% 4,911 122 405 9 5,447 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 631 Total $ 9,070 $ 293 $ 687 $ 603 $ 11,284 September 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 19 $ 54 $ 73 Equal to or greater than 2% but less than 4% 4,595 172 285 554 5,606 Equal to or greater than 4% 5,109 126 414 15 5,664 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 501 Total $ 9,704 $ 298 $ 718 $ 623 $ 11,844 6. Market Risk Benefits The Company establishes liabilities for certain retirement assurance and variable annuity contract features which include a minimum benefit guarantee that provides to the contractholder a minimum return based on their initial deposit less withdrawals. In some cases, the benefit base may be increased by additional deposits, bonus amounts, accruals or optional market value resets. The Company’s MRB assets and MRB liabilities on the interim condensed consolidated balance sheets were as follows at: September 30, 2024 December 31, 2023 Asset Liability Net Asset Liability Net (In millions) Asia - Retirement Assurance $ — $ 197 $ 197 $ — $ 203 $ 203 MetLife Holdings - Annuities 179 2,787 2,608 156 2,878 2,722 Other 131 133 2 130 98 (32) Total $ 310 $ 3,117 $ 2,807 $ 286 $ 3,179 $ 2,893 Rollforwards The following information about the direct and assumed liability for MRBs includes disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. Asia - Retirement Assurance The Asia segment’s retirement assurance product in Japan offers a contract feature whereby the Company guarantees the greater of the account value or a return of premium accumulated at a guaranteed rate upon maturity. Information regarding this liability was as follows: Nine Months 2024 2023 (In millions) Balance, beginning of period $ 203 $ 226 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ 205 $ 233 Attributed fees collected 3 2 Benefit payments (9) (9) Effect of changes in interest rates 4 2 Actual policyholder behavior different from expected behavior (2) (1) Effect of changes in future expected policyholder behavior and other assumptions — (1) Effect of foreign currency translation and other, net (3) (30) Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk 198 196 Cumulative effect of changes in the instrument-specific credit risk (1) (3) Balance, end of period $ 197 $ 193 At period end: Net amount at risk, excluding offsets from hedging: At annuitization or exercise of other living benefits $ 122 $ 116 Weighted-average attained age of contractholders: At annuitization or exercise of other living benefits 58 years 58 years Significant Methodologies and Assumptions The Company issues certain retirement assurance products with guarantees that meet the definition of MRBs, which are measured, in aggregate, as one compound MRB, at estimated fair value, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in other comprehensive income (loss) (“OCI”). The Company calculates the fair value of these MRBs, which is estimated as the present value of projected future benefits minus the present value of projected attributed fees, using actuarial and capital market assumptions including expectations concerning policyholder behavior. The calculation is based on in-force business, projecting future cash flows from the MRB over multiple risk neutral stochastic scenarios using observable risk-free rates. Capital market assumptions, such as risk-free rates and implied volatilities, are based on market prices for publicly traded instruments to the extent that prices for such instruments are observable. Implied volatilities beyond the observable period are extrapolated based on observable implied volatilities and historical volatilities. Actuarial assumptions, including mortality, lapse, withdrawal and utilization, are unobservable and are reviewed at least annually based on actuarial studies of historical experience. See Note 12 for additional information on significant unobservable inputs. The valuation of these MRBs includes a nonperformance risk adjustment and adjustments for a risk margin related to non-capital market inputs. The nonperformance adjustment is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries as compared to MetLife, Inc. Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties of such actuarial assumptions at annuitization, premium persistency, partial withdrawal and surrenders. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees. These guarantees may be more costly than expected in volatile or declining equity markets. Market conditions including, changes in interest rates, equity indices, market volatility and foreign currency exchange rates; and variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, impact the estimated fair value of the guarantees and affect net income, and changes in nonperformance risk of the Company affect OCI. MetLife Holdings - Annuities The MetLife Holdings segment’s variable annuity products offer contract features where the Company guarantees to the contractholder a minimum benefit, which includes guaranteed minimum death benefits (“GMDBs”) and living benefit guarantees. The GMDB contract features include return of premium, which provides a return of the purchase payment upon death, annual step-up and roll-up and step-up combinations. The living benefit guarantees contract features primarily include guaranteed minimum income benefits (“GMIBs”), which provide a minimum accumulation of purchase payments that can be annuitized to receive a monthly income stream, and guaranteed minimum withdrawal benefits (“GMWBs”), which provide a series of withdrawals, provided that withdrawals in a contract year do not exceed a contractual limit. This segment also includes an in-force block of assumed variable annuity guarantees from a third party. Information regarding MetLife Holdings annuity products (including assumed reinsurance) was as follows: Nine Months 2024 2023 (In millions) Balance, beginning of period $ 2,722 $ 3,225 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ 2,772 $ 3,360 Attributed fees collected 266 286 Benefit payments (67) (36) Effect of changes in interest rates (70) (881) Effect of changes in capital markets (527) (542) Effect of changes in equity index volatility 37 (84) Actual policyholder behavior different from expected behavior 176 95 Effect of changes in future expected policyholder behavior and other assumptions 12 9 Effect of foreign currency translation and other, net (1) 34 118 Effect of changes in risk margin (7) (46) Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk 2,626 2,279 Cumulative effect of changes in the instrument-specific credit risk (19) (16) Effect of foreign currency translation on the cumulative instrument-specific credit risk 1 5 Balance, end of period $ 2,608 $ 2,268 At period end: Net amount at risk, excluding offsets from hedging (2): In the event of death $ 2,243 $ 3,979 At annuitization or exercise of other living benefits $ 643 $ 921 Weighted-average attained age of contractholders: In the event of death 71 years 70 years At annuitization or exercise of other living benefits 68 years 70 years __________________ (1) Included is the covariance impact from aggregating the market observable inputs, mostly driven by interest rate and capital market volatility. (2) Includes amounts for certain variable annuity guarantees recorded as MRBs on contracts also recorded as PABs which are disclosed in “MetLife Holdings – Annuities” in Note 5. Significant Methodologies and Assumptions The Company issues GMDBs, GMWBs, guaranteed minimum accumulation benefits (“GMABs”) and GMIBs that typically meet the definition of MRBs, which are measured, in aggregate, as one compound MRB, at estimated fair value separately from the variable annuity contract, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in OCI. The Company calculates the fair value of these MRBs, which is estimated as the present value of projected future benefits minus the present value of projected attributed fees, using actuarial and capital market assumptions including expectations concerning policyholder behavior. The calculation is based on in-force business, projecting future cash flows from the MRB over multiple risk neutral stochastic scenarios using observable risk-free rates. Capital market assumptions, such as risk-free rates and implied volatilities, are based on market prices for publicly traded instruments to the extent that prices for such instruments are observable. Implied volatilities beyond the observable period are extrapolated based on observable implied volatilities and historical volatilities. Actuarial assumptions, including mortality, lapse, withdrawal and utilization, are unobservable and are reviewed at least annually based on actuarial studies of historical experience. See Note 12 for additional information on significant unobservable inputs. The valuation of these MRBs includes a nonperformance risk adjustment and adjustments for a risk margin related to non-capital market inputs. The nonperformance adjustment is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries as compared to MetLife, Inc. Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties of such actuarial assumptions at annuitization, premium persistency, partial withdrawal and surrenders. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees. These guarantees may be more costly than expected in volatile or declining equity markets. Market conditions, including changes in interest rates, equity indices, market volatility and foreign currency exchange rates; and variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, impact the estimated fair value of the guarantees and affect net income, and changes in nonperformance risk of the Company affect OCI. Other In addition to the disaggregated MRB product rollforwards above, the Company offers other products with guaranteed minimum benefit features across various segments. These MRBs are measured at estimated fair value, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in OCI. See Note 12 for additional information on significant unobservable inputs used in the fair value measurement of MRBs. Information regarding these product liabilities was as follows: Nine Months 2024 2023 (In millions) Balance, beginning of period $ (32) $ 32 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ (50) $ 24 Attributed fees collected 38 23 Benefit payments (5) (23) Effect of changes in interest rates (12) (98) Effect of changes in capital markets (8) (15) Effect of changes in equity index volatility — (4) Actual policyholder behavior different from expected behavior 6 (21) Effect of changes in future expected policyholder behavior and other assumptions (2) 2 Effect of foreign currency translation and other, net 22 37 Effect of changes in risk margin (1) (2) Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk (12) (77) Cumulative effect of changes in the instrument-specific credit risk 13 20 Effect of foreign currency translation on the cumulative instrument-specific credit risk 1 — Balance, end of period 2 (57) Less: Reinsurance recoverable 16 18 Balance, end of period, net of reinsurance $ (14) $ (75)

Market Risk Benefits

Market Risk Benefits	9 Months Ended
	Sep. 30, 2024
Insurance [Abstract]
Market Risk Benefits	5. Policyholder Account Balances The Company establishes liabilities for PABs, which are generally equal to the account value, and which includes accrued interest credited, but excludes the impact of any applicable charge that may be incurred upon surrender. The Company’s PABs on the interim condensed consolidated balance sheets were as follows at: September 30, 2024 December 31, 2023 (In millions) Group Benefits - Group life $ 7,676 $ 7,692 RIS: Capital markets investment products and stable value GICs 65,330 64,140 Annuities and risk solutions 19,572 17,711 Asia: Universal and variable universal life 51,756 49,739 Fixed annuities 38,742 36,863 EMEA - Variable annuities 2,617 2,720 MetLife Holdings: Annuities 10,437 11,537 Life and other 11,284 11,641 Other 17,195 17,226 Total $ 224,609 $ 219,269 Rollforwards The following information about the direct and assumed liability for PABs includes year-to-date disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. Policy charges presented in each disaggregated rollforward reflect a premium and/or assessment based on the account balance. Group Benefits Group Life The Group Benefits segment’s group life PABs predominantly consist of retained asset accounts, universal life products, and the fixed account of variable life insurance products. Information regarding this liability was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 7,692 $ 8,028 Deposits 2,857 2,529 Policy charges (493) (475) Surrenders and withdrawals (2,512) (2,432) Benefit payments (9) (9) Net transfers from (to) separate accounts (3) 1 Interest credited 144 143 Balance, end of period $ 7,676 $ 7,785 Weighted-average annual crediting rate 2.5 % 2.4 % At period end: Cash surrender value $ 7,614 $ 7,721 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 265,266 $ 250,611 The Group Benefits segment’s group life product account values by range of guaranteed minimum crediting rates (“GMCR”) and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ 456 $ 72 $ 877 $ 4,141 $ 5,546 Equal to or greater than 2% but less than 4% 1,266 8 59 1 1,334 Equal to or greater than 4% 684 — 39 36 759 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 37 Total $ 2,406 $ 80 $ 975 $ 4,178 $ 7,676 September 30, 2023 Equal to or greater than 0% but less than 2% $ — $ 82 $ 887 $ 4,595 $ 5,564 Equal to or greater than 2% but less than 4% 1,223 10 62 2 1,297 Equal to or greater than 4% 733 1 42 34 810 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 114 Total $ 1,956 $ 93 $ 991 $ 4,631 $ 7,785 RIS Capital Markets Investment Products and Stable Value GICs The RIS segment’s capital markets investment products and stable value GICs in PABs are investment-type products, mainly funding agreements. Information regarding this liability was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 64,140 $ 63,723 Deposits 56,170 54,674 Surrenders and withdrawals (57,068) (56,873) Interest credited 1,811 1,524 Effect of foreign currency translation and other, net 277 369 Balance, end of period $ 65,330 $ 63,417 Weighted-average annual crediting rate 3.8 % 3.2 % Cash surrender value at period end $ 1,953 $ 2,110 The RIS segment’s capital markets investment products and stable value GICs account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ — $ 2,754 $ 2,754 Equal to or greater than 2% but less than 4% — — — 148 148 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 62,428 Total $ — $ — $ — $ 2,902 $ 65,330 September 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 1 $ 2,620 $ 2,621 Equal to or greater than 2% but less than 4% — — — — — Products with either a fixed rate or no GMCR N/A N/A N/A N/A 60,796 Total $ — $ — $ 1 $ 2,620 $ 63,417 Annuities and Risk Solutions The RIS segment’s annuity and risk solutions PABs include certain structured settlements and institutional income annuities, and benefit funding solutions that include postretirement benefits and company-, bank- or trust-owned life insurance used to finance nonqualified benefit programs for executives. Information regarding this liability was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 17,711 $ 15,549 Deposits 2,367 2,007 Policy charges (122) (133) Surrenders and withdrawals (239) (134) Benefit payments (731) (615) Net transfers from (to) separate accounts 20 54 Interest credited 556 469 Other 10 (133) Balance, end of period $ 19,572 $ 17,064 Weighted-average annual crediting rate 4.0 % 3.9 % At period end: Cash surrender value $ 8,476 $ 7,693 Net amount at risk, excluding offsets from ceded reinsurance: In the event of death $ 44,437 $ 42,043 The RIS segment’s annuity and risk solutions account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ 19 $ 2,403 $ 2,422 Equal to or greater than 2% but less than 4% 198 35 109 417 759 Equal to or greater than 4% 4,131 — 472 6 4,609 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 11,782 Total $ 4,329 $ 35 $ 600 $ 2,826 $ 19,572 September 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 22 $ 1,525 $ 1,547 Equal to or greater than 2% but less than 4% 260 33 94 437 824 Equal to or greater than 4% 4,363 — 277 6 4,646 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 10,047 Total $ 4,623 $ 33 $ 393 $ 1,968 $ 17,064 Asia Universal and Variable Universal Life The Asia segment’s universal and variable universal life PABs in Japan primarily include interest sensitive whole life products. Information regarding this liability was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 49,739 $ 46,417 Deposits 4,694 5,439 Policy charges (812) (888) Surrenders and withdrawals (2,483) (2,018) Benefit payments (345) (393) Interest credited 1,153 979 Effect of foreign currency translation and other, net (190) (1,906) Balance, end of period $ 51,756 $ 47,630 Weighted-average annual crediting rate 3.1 % 2.8 % At period end: Cash surrender value $ 46,366 $ 40,663 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 89,793 $ 91,861 The Asia segment’s universal and variable universal life account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ 10,681 $ 18 $ 235 $ 1,449 $ 12,383 Equal to or greater than 2% but less than 4% 7,829 15,730 5,397 9,650 38,606 Equal to or greater than 4% 241 — — — 241 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 526 Total $ 18,751 $ 15,748 $ 5,632 $ 11,099 $ 51,756 September 30, 2023 Equal to or greater than 0% but less than 2% $ 9,986 $ 25 $ 233 $ 729 $ 10,973 Equal to or greater than 2% but less than 4% 5,742 17,923 5,628 6,633 35,926 Equal to or greater than 4% 256 — — — 256 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 475 Total $ 15,984 $ 17,948 $ 5,861 $ 7,362 $ 47,630 Fixed Annuities Information regarding the Asia segment’s fixed annuity PAB liability in Japan was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 36,863 $ 32,454 Deposits 5,002 6,230 Policy charges (2) (2) Surrenders and withdrawals (2,248) (1,665) Benefit payments (1,718) (1,614) Interest credited 784 629 Effect of foreign currency translation and other, net 61 (552) Balance, end of period $ 38,742 $ 35,480 Weighted-average annual crediting rate 2.8 % 2.5 % At period end: Cash surrender value $ 35,005 $ 30,289 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 8 $ — The Asia segment’s fixed annuity account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ 385 $ 460 $ 5,250 $ 31,353 $ 37,448 Equal to or greater than 2% but less than 4% — 5 — — 5 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 1,289 Total $ 385 $ 465 $ 5,250 $ 31,353 $ 38,742 September 30, 2023 Equal to or greater than 0% but less than 2% $ 315 $ 574 $ 6,494 $ 26,811 $ 34,194 Equal to or greater than 2% but less than 4% — 6 — — 6 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 1,280 Total $ 315 $ 580 $ 6,494 $ 26,811 $ 35,480 EMEA Variable Annuities Information regarding the EMEA segment’s variable annuity PABs in the United Kingdom was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 2,720 $ 2,802 Deposits 2 3 Policy charges (44) (48) Surrenders and withdrawals (214) (206) Benefit payments (95) (95) Interest credited (1) 117 69 Effect of foreign currency translation and other, net 131 46 Balance, end of period $ 2,617 $ 2,571 Weighted-average annual crediting rate 6.0 % 3.5 % At period end: Cash surrender value $ 2,617 $ 2,571 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 426 $ 577 At annuitization or exercise of other living benefits $ 550 $ 725 __________________ (1) Interest credited on EMEA’s variable annuity products represents gains or losses which are passed through to the policyholder based on the underlying unit-linked investment fund returns, which may be positive or negative depending on market conditions. There are no GMCR on these products. MetLife Holdings Annuities The MetLife Holdings segment’s annuity PABs primarily include fixed deferred annuities, the fixed account portion of variable annuities, certain income annuities, and embedded derivatives related to equity-indexed annuities. Information regarding this liability was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 11,537 $ 13,286 Deposits 121 115 Policy charges (10) (12) Surrenders and withdrawals (1,292) (1,425) Benefit payments (298) (320) Net transfers from (to) separate accounts 105 48 Interest credited 265 299 Other 9 15 Balance, end of period $ 10,437 $ 12,006 Weighted-average annual crediting rate 3.3 % 3.2 % At period end: Cash surrender value $ 9,866 $ 11,263 Net amount at risk, excluding offsets from ceded reinsurance (1): In the event of death $ 2,238 $ 3,970 At annuitization or exercise of other living benefits $ 657 $ 923 __________________ (1) Includes amounts for certain variable annuities recorded as PABs with the related guarantees recorded as MRBs which are disclosed in “MetLife Holdings – Annuities” in Note 6. The MetLife Holdings segment’s annuity account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than 0% but less than 0.50% above GMCR Equal to or greater than 0.50% but less than 1.50% above GMCR Equal to or greater than 1.50% above GMCR Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ 3 $ 166 $ 444 $ 52 $ 665 Equal to or greater than 2% but less than 4% 1,378 6,188 501 153 8,220 Equal to or greater than 4% 745 404 17 — 1,166 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 386 Total $ 2,126 $ 6,758 $ 962 $ 205 $ 10,437 September 30, 2023 Equal to or greater than 0% but less than 2% $ 235 $ 245 $ 292 $ 227 $ 999 Equal to or greater than 2% but less than 4% 2,887 5,828 457 130 9,302 Equal to or greater than 4% 965 274 26 — 1,265 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 440 Total $ 4,087 $ 6,347 $ 775 $ 357 $ 12,006 Life and Other The MetLife Holdings segment’s life and other PABs include retained asset accounts, universal life products, the fixed account of variable life insurance products and funding agreements. Information regarding this liability was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 11,641 $ 12,402 Deposits 549 617 Policy charges (519) (529) Surrenders and withdrawals (744) (892) Benefit payments (114) (120) Net transfers from (to) separate accounts 26 29 Interest credited 318 336 Other 127 1 Balance, end of period $ 11,284 $ 11,844 Weighted-average annual crediting rate 3.8 % 3.8 % At period end: Cash surrender value $ 10,722 $ 11,360 Net amount at risk, excluding offsets from ceded reinsurance: In the event of death (1) $ 64,816 $ 68,972 __________________ (1) Including offsets from ceded reinsurance, the net amount at risk at both September 30, 2024 and December 31, 2023, would be reduced by 99%. The MetLife Holdings segment’s life and other products account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than 0% but less than 0.50% above GMCR Equal to or greater than 0.50% but less than 1.50% above GMCR Equal to or greater than 1.50% above GMCR Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ 17 $ 58 $ 75 Equal to or greater than 2% but less than 4% 4,159 171 265 536 5,131 Equal to or greater than 4% 4,911 122 405 9 5,447 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 631 Total $ 9,070 $ 293 $ 687 $ 603 $ 11,284 September 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 19 $ 54 $ 73 Equal to or greater than 2% but less than 4% 4,595 172 285 554 5,606 Equal to or greater than 4% 5,109 126 414 15 5,664 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 501 Total $ 9,704 $ 298 $ 718 $ 623 $ 11,844 6. Market Risk Benefits The Company establishes liabilities for certain retirement assurance and variable annuity contract features which include a minimum benefit guarantee that provides to the contractholder a minimum return based on their initial deposit less withdrawals. In some cases, the benefit base may be increased by additional deposits, bonus amounts, accruals or optional market value resets. The Company’s MRB assets and MRB liabilities on the interim condensed consolidated balance sheets were as follows at: September 30, 2024 December 31, 2023 Asset Liability Net Asset Liability Net (In millions) Asia - Retirement Assurance $ — $ 197 $ 197 $ — $ 203 $ 203 MetLife Holdings - Annuities 179 2,787 2,608 156 2,878 2,722 Other 131 133 2 130 98 (32) Total $ 310 $ 3,117 $ 2,807 $ 286 $ 3,179 $ 2,893 Rollforwards The following information about the direct and assumed liability for MRBs includes disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. Asia - Retirement Assurance The Asia segment’s retirement assurance product in Japan offers a contract feature whereby the Company guarantees the greater of the account value or a return of premium accumulated at a guaranteed rate upon maturity. Information regarding this liability was as follows: Nine Months 2024 2023 (In millions) Balance, beginning of period $ 203 $ 226 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ 205 $ 233 Attributed fees collected 3 2 Benefit payments (9) (9) Effect of changes in interest rates 4 2 Actual policyholder behavior different from expected behavior (2) (1) Effect of changes in future expected policyholder behavior and other assumptions — (1) Effect of foreign currency translation and other, net (3) (30) Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk 198 196 Cumulative effect of changes in the instrument-specific credit risk (1) (3) Balance, end of period $ 197 $ 193 At period end: Net amount at risk, excluding offsets from hedging: At annuitization or exercise of other living benefits $ 122 $ 116 Weighted-average attained age of contractholders: At annuitization or exercise of other living benefits 58 years 58 years Significant Methodologies and Assumptions The Company issues certain retirement assurance products with guarantees that meet the definition of MRBs, which are measured, in aggregate, as one compound MRB, at estimated fair value, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in other comprehensive income (loss) (“OCI”). The Company calculates the fair value of these MRBs, which is estimated as the present value of projected future benefits minus the present value of projected attributed fees, using actuarial and capital market assumptions including expectations concerning policyholder behavior. The calculation is based on in-force business, projecting future cash flows from the MRB over multiple risk neutral stochastic scenarios using observable risk-free rates. Capital market assumptions, such as risk-free rates and implied volatilities, are based on market prices for publicly traded instruments to the extent that prices for such instruments are observable. Implied volatilities beyond the observable period are extrapolated based on observable implied volatilities and historical volatilities. Actuarial assumptions, including mortality, lapse, withdrawal and utilization, are unobservable and are reviewed at least annually based on actuarial studies of historical experience. See Note 12 for additional information on significant unobservable inputs. The valuation of these MRBs includes a nonperformance risk adjustment and adjustments for a risk margin related to non-capital market inputs. The nonperformance adjustment is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries as compared to MetLife, Inc. Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties of such actuarial assumptions at annuitization, premium persistency, partial withdrawal and surrenders. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees. These guarantees may be more costly than expected in volatile or declining equity markets. Market conditions including, changes in interest rates, equity indices, market volatility and foreign currency exchange rates; and variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, impact the estimated fair value of the guarantees and affect net income, and changes in nonperformance risk of the Company affect OCI. MetLife Holdings - Annuities The MetLife Holdings segment’s variable annuity products offer contract features where the Company guarantees to the contractholder a minimum benefit, which includes guaranteed minimum death benefits (“GMDBs”) and living benefit guarantees. The GMDB contract features include return of premium, which provides a return of the purchase payment upon death, annual step-up and roll-up and step-up combinations. The living benefit guarantees contract features primarily include guaranteed minimum income benefits (“GMIBs”), which provide a minimum accumulation of purchase payments that can be annuitized to receive a monthly income stream, and guaranteed minimum withdrawal benefits (“GMWBs”), which provide a series of withdrawals, provided that withdrawals in a contract year do not exceed a contractual limit. This segment also includes an in-force block of assumed variable annuity guarantees from a third party. Information regarding MetLife Holdings annuity products (including assumed reinsurance) was as follows: Nine Months 2024 2023 (In millions) Balance, beginning of period $ 2,722 $ 3,225 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ 2,772 $ 3,360 Attributed fees collected 266 286 Benefit payments (67) (36) Effect of changes in interest rates (70) (881) Effect of changes in capital markets (527) (542) Effect of changes in equity index volatility 37 (84) Actual policyholder behavior different from expected behavior 176 95 Effect of changes in future expected policyholder behavior and other assumptions 12 9 Effect of foreign currency translation and other, net (1) 34 118 Effect of changes in risk margin (7) (46) Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk 2,626 2,279 Cumulative effect of changes in the instrument-specific credit risk (19) (16) Effect of foreign currency translation on the cumulative instrument-specific credit risk 1 5 Balance, end of period $ 2,608 $ 2,268 At period end: Net amount at risk, excluding offsets from hedging (2): In the event of death $ 2,243 $ 3,979 At annuitization or exercise of other living benefits $ 643 $ 921 Weighted-average attained age of contractholders: In the event of death 71 years 70 years At annuitization or exercise of other living benefits 68 years 70 years __________________ (1) Included is the covariance impact from aggregating the market observable inputs, mostly driven by interest rate and capital market volatility. (2) Includes amounts for certain variable annuity guarantees recorded as MRBs on contracts also recorded as PABs which are disclosed in “MetLife Holdings – Annuities” in Note 5. Significant Methodologies and Assumptions The Company issues GMDBs, GMWBs, guaranteed minimum accumulation benefits (“GMABs”) and GMIBs that typically meet the definition of MRBs, which are measured, in aggregate, as one compound MRB, at estimated fair value separately from the variable annuity contract, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in OCI. The Company calculates the fair value of these MRBs, which is estimated as the present value of projected future benefits minus the present value of projected attributed fees, using actuarial and capital market assumptions including expectations concerning policyholder behavior. The calculation is based on in-force business, projecting future cash flows from the MRB over multiple risk neutral stochastic scenarios using observable risk-free rates. Capital market assumptions, such as risk-free rates and implied volatilities, are based on market prices for publicly traded instruments to the extent that prices for such instruments are observable. Implied volatilities beyond the observable period are extrapolated based on observable implied volatilities and historical volatilities. Actuarial assumptions, including mortality, lapse, withdrawal and utilization, are unobservable and are reviewed at least annually based on actuarial studies of historical experience. See Note 12 for additional information on significant unobservable inputs. The valuation of these MRBs includes a nonperformance risk adjustment and adjustments for a risk margin related to non-capital market inputs. The nonperformance adjustment is determined by taking into consideration publicly available information relating to spreads in the secondary market for MetLife, Inc.’s debt, including related credit default swaps. These observable spreads are then adjusted, as necessary, to reflect the priority of these liabilities and the claims paying ability of the issuing insurance subsidiaries as compared to MetLife, Inc. Risk margins are established to capture the non-capital market risks of the instrument which represent the additional compensation a market participant would require to assume the risks related to the uncertainties of such actuarial assumptions at annuitization, premium persistency, partial withdrawal and surrenders. The establishment of risk margins requires the use of significant management judgment, including assumptions of the amount and cost of capital needed to cover the guarantees. These guarantees may be more costly than expected in volatile or declining equity markets. Market conditions, including changes in interest rates, equity indices, market volatility and foreign currency exchange rates; and variations in actuarial assumptions regarding policyholder behavior, mortality and risk margins related to non-capital market inputs, impact the estimated fair value of the guarantees and affect net income, and changes in nonperformance risk of the Company affect OCI. Other In addition to the disaggregated MRB product rollforwards above, the Company offers other products with guaranteed minimum benefit features across various segments. These MRBs are measured at estimated fair value, with changes in estimated fair value reported in net income, except for changes in nonperformance risk of the Company which are recorded in OCI. See Note 12 for additional information on significant unobservable inputs used in the fair value measurement of MRBs. Information regarding these product liabilities was as follows: Nine Months 2024 2023 (In millions) Balance, beginning of period $ (32) $ 32 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ (50) $ 24 Attributed fees collected 38 23 Benefit payments (5) (23) Effect of changes in interest rates (12) (98) Effect of changes in capital markets (8) (15) Effect of changes in equity index volatility — (4) Actual policyholder behavior different from expected behavior 6 (21) Effect of changes in future expected policyholder behavior and other assumptions (2) 2 Effect of foreign currency translation and other, net 22 37 Effect of changes in risk margin (1) (2) Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk (12) (77) Cumulative effect of changes in the instrument-specific credit risk 13 20 Effect of foreign currency translation on the cumulative instrument-specific credit risk 1 — Balance, end of period 2 (57) Less: Reinsurance recoverable 16 18 Balance, end of period, net of reinsurance $ (14) $ (75)

Separate Account

Separate Account	9 Months Ended
	Sep. 30, 2024
Separate Accounts Disclosure [Abstract]
Separate Account	7. Separate Accounts Separate account assets consist of investment accounts established and maintained by the Company. The investment objectives of these assets are directed by the contractholder. An equivalent amount is reported as separate account liabilities. These accounts are reported separately from the general account assets and liabilities. Separate Account Liabilities The Company’s separate account liabilities on the interim condensed consolidated balance sheets were as follows at: September 30, 2024 December 31, 2023 (In millions) RIS: Stable Value and Risk Solutions $ 40,448 $ 41,343 Annuities 11,989 11,659 Latin America - Pensions 44,158 41,320 MetLife Holdings - Annuities 29,349 29,224 Other 22,865 21,088 Total $ 148,809 $ 144,634 Rollforwards The following information about the separate account liabilities includes disaggregated rollforwards. The products grouped within these rollforwards were selected based upon common characteristics and valuations using similar inputs, judgments, assumptions and methodologies within a particular segment of the business. The separate account liabilities are primarily comprised of the following: RIS stable value and risk solutions contracts, RIS annuities participating and non-participating group contracts, Latin America savings-oriented pension product in Chile under a mandatory privatized social security system, and MetLife Holdings variable annuities. The balances of and changes in separate account liabilities were as follows: RIS Stable Value and Risk Solutions RIS Annuities Latin America MetLife Holdings (In millions) Nine Months Ended September 30, 2024 Balance, beginning of period $ 41,343 $ 11,659 $ 41,320 $ 29,224 Premiums and deposits 1,669 34 5,082 175 Policy charges (214) (16) (198) (454) Surrenders and withdrawals (3,799) (609) (3,913) (2,798) Benefit payments (81) — (1,231) (377) Investment performance 2,152 561 4,075 3,691 Net transfers from (to) general account (21) — — (105) Effect of foreign currency translation and other, net (1) (601) 360 (977) (7) Balance, end of period $ 40,448 $ 11,989 $ 44,158 $ 29,349 Nine Months Ended September 30, 2023 Balance, beginning of period $ 48,265 $ 11,694 $ 39,428 $ 28,499 Premiums and deposits 1,857 154 6,181 190 Policy charges (223) (17) (219) (460) Surrenders and withdrawals (8,696) (636) (4,485) (2,114) Benefit payments (74) — (1,301) (350) Investment performance 711 (157) (216) 1,740 Net transfers from (to) general account (57) 3 — (49) Effect of foreign currency translation and other, net (1) (1,280) 111 (1,915) (1) Balance, end of period $ 40,503 $ 11,152 $ 37,473 $ 27,455 Cash surrender value at September 30, 2024 (2) $ 35,632 N/A $ 44,158 $ 29,210 Cash surrender value at September 30, 2023 (2) $ 36,246 N/A $ 37,473 $ 27,320 __________________ (1) The effect of foreign currency translation and other, net for RIS stable value and risk solutions primarily includes changes related to unsettled trades of mortgage-backed securities. (2) Cash surrender value represents the amount of the contractholders’ account balances distributable at the balance sheet date less policy loans and certain surrender charges. Separate Account Assets The Company’s aggregate fair value of assets, by major investment asset category, supporting separate account liabilities was as follows at: September 30, 2024 Group Benefits RIS Asia Latin America EMEA MetLife Holdings Total (In millions) Fixed maturity securities: Bonds: Foreign government $ — $ 508 $ 1,271 $ 524 $ 3,139 $ — $ 5,442 U.S. government and agency — 9,875 — 12,228 — 19 22,122 Public utilities — 1,157 239 — — 7 1,403 Municipals — 295 20 — — 13 328 Corporate bonds: Materials — 131 — — — 1 132 Communications — 807 16 — — 4 827 Consumer — 1,910 38 — — 11 1,959 Energy — 822 113 — — 3 938 Financial — 2,697 558 5,371 307 19 8,952 Industrial and other — 748 68 3,759 — 2 4,577 Technology — 531 — — — 2 533 Foreign — 1,935 — 3,227 54 12 5,228 Total corporate bonds — 9,581 793 12,357 361 54 23,146 Total bonds — 21,416 2,323 25,109 3,500 93 52,441 Mortgage-backed securities — 9,372 — — — 40 9,412 Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”) — 2,357 18 — — 13 2,388 Redeemable preferred stock — 9 — — — — 9 Total fixed maturity securities — 33,154 2,341 25,109 3,500 146 64,250 Equity securities: Common stock: Industrial, miscellaneous and all other — 2,426 2,417 2,413 807 — 8,063 Banks, trust and insurance companies — 730 333 442 378 — 1,883 Public utilities — 73 24 — 123 — 220 Non-redeemable preferred stock — — 130 — — — 130 Mutual funds 1,320 9,435 3,153 11,835 200 36,250 62,193 Total equity securities 1,320 12,664 6,057 14,690 1,508 36,250 72,489 Other invested assets — 1,372 369 4,287 98 — 6,126 Total investments 1,320 47,190 8,767 44,086 5,106 36,396 142,865 Other assets — 5,348 454 72 68 2 5,944 Total $ 1,320 $ 52,538 $ 9,221 $ 44,158 $ 5,174 $ 36,398 $ 148,809 December 31, 2023 Group RIS Asia Latin America EMEA MetLife Holdings Total (In millions) Fixed maturity securities: Bonds: Foreign government $ — $ 509 $ 1,190 $ 1,051 $ 2,638 $ — $ 5,388 U.S. government and agency — 9,673 — 9,920 — 18 19,611 Public utilities — 1,077 308 — — 4 1,389 Municipals — 380 31 — — 13 424 Corporate bonds: Materials — 144 — — — — 144 Communications — 893 8 — — 3 904 Consumer — 1,882 39 — — 8 1,929 Energy — 911 105 — — 2 1,018 Financial — 2,717 551 6,006 398 15 9,687 Industrial and other — 764 38 3,598 — 3 4,403 Technology — 547 — — — 3 550 Foreign — 1,920 — 3,095 27 13 5,055 Total corporate bonds — 9,778 741 12,699 425 47 23,690 Total bonds — 21,417 2,270 23,670 3,063 82 50,502 Mortgage-backed securities — 9,671 — — — 35 9,706 ABS & CLO — 2,557 18 — — 11 2,586 Redeemable preferred stock — 9 — — — — 9 Total fixed maturity securities — 33,654 2,288 23,670 3,063 128 62,803 Equity securities: Common stock: Industrial, miscellaneous and all other — 2,411 2,661 2,453 677 — 8,202 Banks, trust and insurance companies — 731 269 392 341 — 1,733 Public utilities — 67 19 — 72 — 158 Non-redeemable preferred stock — — 115 — — — 115 Mutual funds 1,159 8,517 2,929 10,099 109 35,418 58,231 Total equity securities 1,159 11,726 5,993 12,944 1,199 35,418 68,439 Other invested assets — 1,620 403 4,212 30 — 6,265 Total investments 1,159 47,000 8,684 40,826 4,292 35,546 137,507 Other assets — 6,093 503 494 35 2 7,127 Total $ 1,159 $ 53,093 $ 9,187 $ 41,320 $ 4,327 $ 35,548 $ 144,634

Deferred Policy Acquisition Cos

Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue	9 Months Ended
	Sep. 30, 2024
Deferred Policy Acquisition Costs and Present Value of Future Insurance Profits, Net [Abstract]
Intangible Assets and Liabilities and Unearned Revenue, excluding Goodwill [Text Block]	8. Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue DAC and VOBA Information regarding total DAC and VOBA by segment, as well as Corporate & Other, was as follows at: Group Benefits RIS Asia (1) Latin America (2) EMEA (2) MetLife Holdings (3) Corporate & Other Total (In millions) DAC: Balance at January 1, 2024 $ 258 $ 397 $ 10,864 $ 1,950 $ 1,618 $ 3,271 $ 30 $ 18,388 Capitalizations 13 160 1,032 527 362 13 7 2,114 Amortization (19) (43) (579) (348) (254) (171) (6) (1,420) Effect of foreign currency translation and other, net — — (71) (224) (5) — — (300) Balance at September 30, 2024 $ 252 $ 514 $ 11,246 $ 1,905 $ 1,721 $ 3,113 $ 31 $ 18,782 Balance at January 1, 2023 $ 265 $ 267 $ 10,270 $ 1,542 $ 1,480 $ 3,791 $ 29 $ 17,644 Capitalizations 16 136 1,202 470 341 17 7 2,189 Amortization (19) (34) (518) (306) (245) (194) (8) (1,324) Effect of foreign currency translation and other, net — — (600) 125 (27) — — (502) Balance at September 30, 2023 $ 262 $ 369 $ 10,354 $ 1,831 $ 1,549 $ 3,614 $ 28 $ 18,007 VOBA: Balance at January 1, 2024 $ — $ 16 $ 1,119 $ 497 $ 113 $ 18 $ — $ 1,763 Amortization — (2) (55) (32) (11) (3) — (103) Effect of foreign currency translation and other, net — — (19) (22) — — — (41) Balance at September 30, 2024 $ — $ 14 $ 1,045 $ 443 $ 102 $ 15 $ — $ 1,619 Balance at January 1, 2023 $ — $ 19 $ 1,290 $ 545 $ 127 $ 28 $ — $ 2,009 Amortization — (2) (69) (38) (12) (3) — (124) Effect of foreign currency translation and other, net — — (144) (10) (1) — — (155) Balance at September 30, 2023 $ — $ 17 $ 1,077 $ 497 $ 114 $ 25 $ — $ 1,730 Total DAC and VOBA: Balance at September 30, 2024 $ 20,401 Balance at September 30, 2023 $ 19,737 Balance at December 31, 2023 $ 20,151 __________________ (1) Includes DAC balances primarily related to accident & health, universal and variable universal life, variable life and fixed annuity products and VOBA balances primarily related to accident & health products. (2) Includes DAC balances primarily related to universal life and variable universal life products. (3) Includes DAC balances primarily related to universal life, variable universal life, whole life, term life and variable annuity products. Unearned Revenue Information regarding the Company’s unearned revenue primarily related to universal life and variable universal life products by segment included in other policy-related balances was as follows: Nine Months RIS Asia Latin EMEA MetLife Total (In millions) Balance, beginning of period $ 31 $ 2,850 $ 989 $ 608 $ 59 $ 4,537 Deferrals 1 424 111 72 12 620 Amortization (4) (167) (88) (51) (4) (314) Effect of foreign currency translation and other, net — (9) (124) 3 — (130) Balance, end of period $ 28 $ 3,098 $ 888 $ 632 $ 67 $ 4,713 Nine Months RIS Asia Latin EMEA MetLife Total (In millions) Balance, beginning of period $ 36 $ 2,382 $ 848 $ 559 $ 281 $ 4,106 Deferrals 2 477 108 71 41 699 Amortization (5) (129) (87) (47) (16) (284) Effect of foreign currency translation and other, net — (49) 85 4 — 40 Balance, end of period $ 33 $ 2,681 $ 954 $ 587 $ 306 $ 4,561

Closed Block

Closed Block	9 Months Ended
	Sep. 30, 2024
Closed Block Disclosure [Abstract]
Closed Block	9. Closed Block On April 7, 2000 (the “Demutualization Date”), Metropolitan Life Insurance Company (“MLIC”) converted from a mutual life insurance company to a stock life insurance company and became a wholly-owned subsidiary of MetLife, Inc. The conversion was pursuant to an order by the New York Superintendent of Insurance approving MLIC’s plan of reorganization, as amended (the “Plan of Reorganization”). On the Demutualization Date, MLIC established a closed block for the benefit of holders of certain individual life insurance policies of MLIC. See Note 10 to the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for further information on the closed block. Experience within the closed block, in particular mortality and investment yields, as well as realized and unrealized gains and losses, directly impact the policyholder dividend obligation. Amortization of the closed block DAC, which resides outside of the closed block, is based upon policy count within the closed block. Closed block assets, liabilities, revenues and expenses are combined on a line-by-line basis with the assets, liabilities, revenues and expenses outside the closed block based on the nature of the particular item. Information regarding the liabilities and assets designated to the closed block was as follows at: September 30, 2024 December 31, 2023 (In millions) Closed Block Liabilities FPBs $ 35,229 $ 36,142 Other policy-related balances 284 319 Policyholder dividends payable 178 174 Policyholder dividend obligation — — Current income tax payable 13 — Other liabilities 896 668 Total closed block liabilities 36,600 37,303 Assets Designated to the Closed Block Investments: Fixed maturity securities available-for-sale (“AFS”), at estimated fair value 19,915 19,939 Equity securities, at estimated fair value 10 10 Mortgage loans 5,856 6,151 Policy loans 3,850 3,960 Real estate and real estate joint ventures (“REJV”) 676 668 Other invested assets 418 496 Total investments 30,725 31,224 Cash and cash equivalents 957 717 Accrued investment income 382 383 Premiums, reinsurance and other receivables 36 54 Current income tax recoverable — 3 Deferred income tax asset 239 312 Total assets designated to the closed block 32,339 32,693 Excess of closed block liabilities over assets designated to the closed block 4,261 4,610 AOCI: Unrealized investment gains (losses), net of income tax (551) (820) Unrealized gains (losses) on derivatives, net of income tax 116 130 Total amounts included in AOCI (435) (690) Maximum future earnings to be recognized from closed block assets and liabilities $ 3,826 $ 3,920 Information regarding the closed block revenues and expenses was as follows: Three Months Nine Months 2024 2023 2024 2023 (In millions) Revenues Premiums $ 214 $ 219 $ 648 $ 680 Net investment income 336 345 1,021 1,024 Net investment gains (losses) 1 4 (19) 13 Net derivative gains (losses) (1) (2) 6 1 Total revenues 550 566 1,656 1,718 Expenses Policyholder benefits and claims 390 403 1,209 1,261 Policyholder dividends 90 89 266 275 Other expenses 21 21 61 65 Total expenses 501 513 1,536 1,601 Revenues, net of expenses before provision for income tax expense (benefit) 49 53 120 117 Provision for income tax expense (benefit) 11 11 26 24 Revenues, net of expenses and provision for income tax expense (benefit) $ 38 $ 42 $ 94 $ 93 MLIC charges the closed block with federal income taxes, state and local premium taxes and other state or local taxes, as well as investment management expenses relating to the closed block as provided in the Plan of Reorganization. MLIC also charges the closed block for expenses of maintaining the policies included in the closed block.

Investments

Investments	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Investments	10. Investments Fixed Maturity Securities AFS Fixed Maturity Securities AFS by Sector The following table presents fixed maturity securities AFS by sector. U.S. corporate and foreign corporate sectors include redeemable preferred stock. Residential mortgage-backed securities (“RMBS”) includes agency, prime, prime investor, non-qualified residential mortgage, alternative, reperforming and sub-prime mortgage-backed securities. ABS & CLO includes securities collateralized by consumer loans, corporate loans and broadly syndicated bank loans. Municipals includes taxable and tax-exempt revenue bonds and, to a much lesser extent, general obligations of states, municipalities and political subdivisions. Commercial mortgage-backed securities (“CMBS”) primarily includes securities collateralized by multiple commercial mortgage loans. RMBS, ABS & CLO and CMBS are, collectively, “Structured Products.” September 30, 2024 December 31, 2023 Amortized Gross Unrealized Estimated Amortized Gross Unrealized Estimated Sector Allowance for Credit Loss (“ACL”) Gains Losses ACL Gains Losses (In millions) U.S. corporate $ 88,612 $ (60) $ 2,275 $ 5,976 $ 84,851 $ 85,563 $ (68) $ 1,894 $ 6,672 $ 80,717 Foreign corporate 59,282 (15) 2,164 4,679 56,752 59,123 (2) 1,750 5,427 55,444 Foreign government 47,586 (62) 1,776 5,168 44,132 48,260 (88) 1,754 4,437 45,489 U.S. government and agency 37,727 — 589 3,640 34,676 35,374 — 590 3,712 32,252 RMBS 36,761 (1) 630 2,126 35,264 31,479 (1) 353 2,735 29,096 ABS & CLO 17,750 (10) 138 358 17,520 17,910 (7) 54 663 17,294 Municipals 11,521 — 354 1,077 10,798 11,991 — 408 1,228 11,171 CMBS 10,167 (14) 167 534 9,786 10,855 (18) 73 961 9,949 Total fixed maturity securities AFS $ 309,406 $ (162) $ 8,093 $ 23,558 $ 293,779 $ 300,555 $ (184) $ 6,876 $ 25,835 $ 281,412 Maturities of Fixed Maturity Securities AFS The amortized cost, net of ACL, and estimated fair value of fixed maturity securities AFS, by contractual maturity date, were as follows at September 30, 2024: Due in One Due After Due After Due After Structured Total Fixed Maturity Securities AFS (In millions) Amortized cost, net of ACL $ 11,313 $ 48,735 $ 54,449 $ 130,094 $ 64,653 $ 309,244 Estimated fair value $ 11,361 $ 48,895 $ 54,079 $ 116,874 $ 62,570 $ 293,779 Actual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities AFS not due at a single maturity date have been presented in the year of final contractual maturity. Structured Products are shown separately, as they are not due at a single maturity. Continuous Gross Unrealized Losses for Fixed Maturity Securities AFS by Sector The following table presents the estimated fair value and gross unrealized losses of fixed maturity securities AFS in an unrealized loss position without an ACL by sector and aggregated by length of time that the securities have been in a continuous unrealized loss position. September 30, 2024 December 31, 2023 Less than 12 Months Equal to or Greater Less than 12 Months Equal to or Greater Sector & Credit Quality Estimated Gross Estimated Gross Estimated Gross Estimated Gross (Dollars in millions) U.S. corporate $ 4,384 $ 685 $ 41,061 $ 5,258 $ 4,722 $ 420 $ 45,373 $ 6,208 Foreign corporate 2,505 181 28,069 4,477 3,210 187 32,355 5,240 Foreign government 2,828 432 19,170 4,735 3,913 246 19,715 4,187 U.S. government and agency 3,426 159 15,987 3,481 7,856 368 13,960 3,344 RMBS 1,926 73 15,673 2,053 3,465 60 17,128 2,675 ABS & CLO 2,441 17 5,833 341 1,662 31 11,438 629 Municipals 209 87 5,241 990 483 34 5,449 1,194 CMBS 433 15 5,433 517 1,034 36 6,671 917 Total fixed maturity securities AFS $ 18,152 $ 1,649 $ 136,467 $ 21,852 $ 26,345 $ 1,382 $ 152,089 $ 24,394 Investment grade $ 15,804 $ 1,577 $ 131,959 $ 21,256 $ 24,834 $ 1,287 $ 146,138 $ 23,675 Below investment grade 2,348 72 4,508 596 1,511 95 5,951 719 Total fixed maturity securities AFS $ 18,152 $ 1,649 $ 136,467 $ 21,852 $ 26,345 $ 1,382 $ 152,089 $ 24,394 Total number of securities in an unrealized loss position 2,855 11,063 2,922 13,049 Evaluation of Fixed Maturity Securities AFS for Credit Loss Evaluation and Measurement Methodologies See Note 11 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for a description of the Company’s Evaluation and Measurement Methodologies of Fixed Maturity Securities AFS for Credit Loss. Evaluation of Fixed Maturity Securities AFS in an Unrealized Loss Position Gross unrealized losses on securities without an ACL decreased $2.3 billion for the nine months ended September 30, 2024 to $23.5 billion primarily due to a decrease in interest rates. As shown in the table above, most of the gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater at September 30, 2024, relate to investment grade securities. These unrealized losses are principally due to widening credit spreads since purchase and, with respect to fixed-rate securities, rising interest rates since purchase. As of September 30, 2024, $596 million of gross unrealized losses on securities without an ACL that have been in a continuous gross unrealized loss position for 12 months or greater on below investment grade securities were concentrated in the utility, consumer, and communications sectors within corporate securities and in foreign government securities. These unrealized losses are the result of significantly wider credit spreads resulting from higher risk premiums since purchase, largely due to economic and market uncertainty and, with respect to fixed-rate securities, rising interest rates since purchase. At September 30, 2024, the Company did not intend to sell its securities in an unrealized loss position without an ACL, and it was not more likely than not that the Company would be required to sell these securities before the anticipated recovery of the remaining amortized cost. Therefore, the Company concluded that these securities had not incurred a credit loss and should not have an ACL at September 30, 2024. Future provisions for credit loss will depend primarily on economic fundamentals, issuer performance (including changes in the present value of future cash flows expected to be collected), changes in credit ratings and collateral valuation. Rollforward of ACL for Fixed Maturity Securities AFS By Sector The rollforward of ACL for fixed maturity securities AFS by sector is as follows: U.S. Foreign Foreign RMBS ABS & CLO CMBS Total (In millions) Three Months Ended September 30, 2024 Balance, at beginning of period $ 37 $ 2 $ 58 $ 1 $ 9 $ 14 $ 121 ACL not previously recorded 27 13 — — — — 40 Changes for securities with previously recorded ACL (1) — 4 — 1 — 4 Securities sold or exchanged (3) — — — — — (3) Balance, at end of period $ 60 $ 15 $ 62 $ 1 $ 10 $ 14 $ 162 Three Months Ended September 30, 2023 Balance, at beginning of period $ 69 $ 2 $ 115 $ — $ — $ 11 $ 197 ACL not previously recorded — — — 1 7 2 10 Changes for securities with previously recorded ACL — — (7) — — 3 (4) Securities sold or exchanged (2) — (19) — — — (21) Balance, at end of period $ 67 $ 2 $ 89 $ 1 $ 7 $ 16 $ 182 U.S. Foreign Foreign RMBS ABS & CLO CMBS Total (In millions) Nine Months Ended September 30, 2024 Balance, at beginning of period $ 68 $ 2 $ 88 $ 1 $ 7 $ 18 $ 184 ACL not previously recorded 41 13 — — — — 54 Changes for securities with previously recorded ACL 10 — (1) — 3 2 14 Securities sold or exchanged (59) — (25) — — (6) (90) Balance, at end of period $ 60 $ 15 $ 62 $ 1 $ 10 $ 14 $ 162 Nine Months Ended September 30, 2023 Balance, at beginning of period $ 29 $ 5 $ 130 $ — $ — $ 19 $ 183 ACL not previously recorded 36 — — 1 7 2 46 Changes for securities with previously recorded ACL 6 — (22) — — 6 (10) Securities sold or exchanged (4) (3) (19) — — (11) (37) Balance, at end of period $ 67 $ 2 $ 89 $ 1 $ 7 $ 16 $ 182 Equity Securities The following table presents equity securities by security type: September 30, 2024 December 31, 2023 Cost Net Unrealized Estimated Fair Value Cost Net Unrealized Estimated Security Type (In millions) Common stock (2) $ 453 $ 193 $ 646 $ 424 $ 239 $ 663 Non-redeemable preferred stock 100 — 100 90 4 94 Total $ 553 $ 193 $ 746 $ 514 $ 243 $ 757 ________________ (1) Represents cumulative changes in estimated fair value, recognized in earnings, and not in OCI. (2) Includes common stock, exchange traded funds, certain mutual funds and certain real estate investment trusts. Contractholder-Directed Equity Securities and FVO Securities The following table presents these investments by asset type. Unit-linked investments are primarily equity securities (including mutual funds). FVO securities include fixed maturity and equity securities to support asset and liability management strategies for certain insurance products and investments in certain separate accounts. September 30, 2024 December 31, 2023 Cost or Net Unrealized Estimated Fair Value Cost or Net Unrealized Estimated Asset Type (In millions) Unit-linked investments $ 6,263 $ 1,345 $ 7,608 $ 7,770 $ 1,112 $ 8,882 FVO securities 1,025 656 1,681 972 477 1,449 Total $ 7,288 $ 2,001 $ 9,289 $ 8,742 $ 1,589 $ 10,331 ________________ (1) Represents cumulative changes in estimated fair value, recognized in earnings, and not in OCI. Mortgage Loans Mortgage Loans by Portfolio Segment Mortgage loans are summarized as follows at: September 30, 2024 December 31, 2023 Portfolio Segment Carrying % of Carrying % of (Dollars in millions) Commercial $ 57,949 64.1 % $ 60,326 65.2 % Agricultural 19,469 21.5 19,805 21.4 Residential 13,844 15.3 13,096 14.2 Total amortized cost 91,262 100.9 93,227 100.8 ACL (847) (0.9) (721) (0.8) Total mortgage loans $ 90,415 100.0 % $ 92,506 100.0 % __________________ (1) Includes certain mortgage loans originated for third parties of $7.7 billion at amortized cost ($7.5 billion commercial and $259 million agricultural) and the related ACL of $88 million, with the corresponding mortgage loan secured financing liability of $7.7 billion included in other liabilities on the consolidated balance sheet at September 30, 2024. The consolidated balance sheet at December 31, 2023 includes certain mortgage loans originated for third parties of $8.5 billion at amortized cost ($8.2 billion commercial and $246 million agricultural) and the related ACL of $73 million, with the corresponding mortgage loan secured financing liability of $8.5 billion included in other liabilities. The investment income on the mortgage loans originated for third parties and the interest expense on the related mortgage loan secured financing liability was $87 million and $272 million for the three months and nine months ended September 30, 2024, respectively, and were recorded in investment income and investment expenses, both within net investment income. The amount of net (discounts) premiums and deferred (fees) expenses, included within total amortized cost, primarily attributable to residential mortgage loans was ($863) million and ($736) million at September 30, 2024 and December 31, 2023, respectively. The accrued interest income excluded from total amortized cost for commercial, agricultural and residential mortgage loans at September 30, 2024 was $269 million, $189 million and $104 million, respectively. The accrued interest income excluded from total amortized cost for commercial, agricultural and residential mortgage loans at December 31, 2023 was $277 million, $204 million and $95 million, respectively. Purchases of mortgage loans, consisting primarily of residential mortgage loans, were $753 million and $1.5 billion for the three months and nine months ended September 30, 2024, respectively, and $221 million and $1.2 billion for the three months and nine months ended September 30, 2023, respectively. Sales of mortgage loans, consisting primarily of commercial mortgage loans, to an equity method investee were $168 million for both the three months and nine months ended September 30, 2024. For the nine months ended September 30, 2024, the Company contributed commercial mortgage loans with an amortized cost of $218 million to REJVs which subsequently completed foreclosure on those mortgage loans. See “— Real Estate and REJV” for the carrying value of wholly-owned real estate acquired through foreclosure. Rollforward of ACL for Mortgage Loans by Portfolio Segment The rollforward of ACL for mortgage loans, by portfolio segment, is as follows: Nine Months 2024 2023 Commercial Agricultural Residential Total Commercial Agricultural Residential Total (In millions) Balance, beginning of period $ 367 $ 172 $ 182 $ 721 $ 218 $ 119 $ 190 $ 527 Provision (release) 212 40 (21) 231 147 52 2 201 Charge-offs, net of recoveries (28) (77) — (105) (10) (13) — (23) Balance, end of period $ 551 $ 135 $ 161 $ 847 $ 355 $ 158 $ 192 $ 705 ACL Methodology The Company records an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the amortized cost basis of mortgage loans that the Company does not expect to collect, resulting in mortgage loans being presented at the net amount expected to be collected. In determining the Company’s ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling mortgage loans that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of its mortgage loans adjusted for expected prepayments and any extensions, and (iii) considering past events and current and forecasted economic conditions. Each of the Company’s commercial, agricultural and residential mortgage loan portfolio segments are evaluated separately. The ACL is calculated for each mortgage loan portfolio segment based on inputs unique to each loan portfolio segment. On a quarterly basis, mortgage loans within a portfolio segment that share similar risk characteristics, such as internal risk ratings or consumer credit scores, are pooled for calculation of ACL. On an ongoing basis, mortgage loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), such as collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is reasonably possible or probable), are evaluated individually for credit loss. The ACL for loans evaluated individually are established using the same methodologies for all three portfolio segments. For example, the ACL for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost when foreclosure is probable. Accordingly, the change in the estimated fair value of collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the ACL which is recorded on a quarterly basis as a charge or credit to earnings in net investment gains (losses). Commercial and Agricultural Mortgage Loan Portfolio Segments Within each loan portfolio segment, commercial and agricultural loans are pooled by internal risk rating. Estimated lifetime loss rates, which vary by internal risk rating, are applied to the amortized cost of each loan, excluding accrued investment income, on a quarterly basis to develop the ACL. Internal risk ratings are based on an assessment of the loan’s credit quality, which can change over time. The estimated lifetime loss rates are based on several loan portfolio segment-specific factors, including (i) the Company’s experience with defaults and loss severity, (ii) expected default and loss severity over the forecast period, (iii) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, (iv) loan specific characteristics including loan-to-value (“LTV”) ratios, and (v) internal risk ratings. These evaluations are revised as conditions change and new information becomes available. The Company uses its several decades of historical default and loss severity experience which capture multiple economic cycles. The Company uses a forecast of economic assumptions for a two-year period for most of its commercial and agricultural mortgage loans, while a one-year period is used for loans originated in certain markets. After the applicable forecast period, the Company reverts to its historical loss experience using a straight-line basis over two years. For evaluations of commercial mortgage loans, in addition to historical experience, management considers factors that include the impact of a rapid change to the economy, which may not be reflected in the loan portfolio, recent loss and recovery trend experience as compared to historical loss and recovery experience, and loan specific characteristics including debt service coverage ratios (“DSCR”). In estimating expected lifetime credit loss over the term of its commercial mortgage loans, the Company adjusts for expected prepayment and extension experience during the forecast period using historical prepayment and extension experience considering the expected position in the economic cycle and the loan profile (i.e., floating rate, shorter-term fixed rate and longer-term fixed rate) and after the forecast period using long-term historical prepayment experience. For evaluations of agricultural mortgage loans, in addition to historical experience, management considers factors that include increased stress in certain sectors, which may be evidenced by higher delinquency rates, or a change in the number of higher risk loans. In estimating expected lifetime credit loss over the term of its agricultural mortgage loans, the Company’s experience is much less sensitive to the position in the economic cycle and by loan profile; accordingly, historical prepayment experience is used, while extension terms are not prevalent with the Company’s agricultural mortgage loans. Commercial mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios, DSCR and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are classified as restructured, delinquent or in foreclosure, as well as loans with higher LTV ratios and lower DSCR. Agricultural mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios and borrower creditworthiness, as well as reviews on a geographic and property-type basis. The monitoring process for agricultural mortgage loans also focuses on higher risk loans. For commercial mortgage loans, the primary credit quality indicator is the DSCR, which compares a property’s net operating income to amounts needed to service the principal and interest due under the loan. Generally, the lower the DSCR, the higher the risk of experiencing a credit loss. The Company also reviews the LTV ratio of its commercial mortgage loan portfolio. LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. Generally, the higher the LTV ratio, the higher the risk of experiencing a credit loss. The DSCR and the values utilized in calculating the ratio are updated routinely. In addition, the LTV ratio is routinely updated for all but the lowest risk loans as part of the Company’s ongoing review of its commercial mortgage loan portfolio. For agricultural mortgage loans, the Company’s primary credit quality indicator is the LTV ratio. The values utilized in calculating this ratio are developed in connection with the ongoing review of the agricultural mortgage loan portfolio and are routinely updated. After commercial and agricultural mortgage loans are approved, the Company makes commitments to lend and, typically, borrowers draw down on some or all of the commitments. The timing of mortgage loan funding is based on the commitment expiration dates. A liability for credit loss for unfunded commercial and agricultural mortgage loan commitments that is not unconditionally cancellable is recognized in earnings and is reported within net investment gains (losses). The liability is based on estimated lifetime loss rates as described above and the amount of the outstanding commitments, which for lines of credit, considers estimated utilization rates. When the commitment is funded or expires, the liability is adjusted accordingly. Residential Mortgage Loan Portfolio Segment The Company’s residential mortgage loan portfolio is comprised primarily of purchased closed end, amortizing residential mortgage loans, including both performing loans purchased within 12 months of origination and reperforming loans purchased after they have been performing for at least 12 months post-modification. Residential mortgage loans are pooled by loan type (i.e., new origination and reperforming) and pooled by similar risk profiles (including consumer credit score and LTV ratios). Estimated lifetime loss rates, which vary by loan type and risk profile, are applied to the amortized cost of each loan excluding accrued investment income on a quarterly basis to develop the ACL. The estimated lifetime loss rates are based on several factors, including (i) industry historical experience and expected results over the forecast period for defaults, (ii) loss severity, (iii) prepayment rates, (iv) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, and (v) loan pool specific characteristics including consumer credit scores, LTV ratios, payment history and home prices. These evaluations are revised as conditions change and new information becomes available. The Company uses industry historical experience which captures multiple economic cycles as the Company has purchased most of its residential mortgage loans in the last five years. The Company uses a forecast of economic assumptions for a two-year period for most of its residential mortgage loans. After the applicable forecast period, the Company reverts to industry historical loss experience using a straight-line basis over one year. For residential mortgage loans, the Company’s primary credit quality indicator is whether the loan is performing or nonperforming. The Company generally defines nonperforming residential mortgage loans as those that are 60 or more days past due and/or in nonaccrual status which is assessed monthly. Generally, nonperforming residential mortgage loans have a higher risk of experiencing a credit loss. Modifications to Borrowers Experiencing Financial Difficulty The Company may modify mortgage loans to borrowers. Each mortgage loan modification is evaluated to determine whether the borrower was experiencing financial difficulties. Disclosed below are those modifications, in materially impacted mortgage segments, where the borrower was determined to be experiencing financial difficulties and the mortgage loans were modified by any of the following means: principal forgiveness, interest rate reduction, other-than- insignificant payment delay or term extension. The amount, timing and extent of modifications granted and subsequent performance are considered in determining any ACL recorded. These mortgage loan modifications are summarized as follows: Three Months Ended September 30, 2024 2023 Maturity Extension Weighted Average Maturity Extension Weighted Average Amortized Cost Affected Loans % of Book Value Amortized Cost Affected Loans % of Book Value (Dollars in millions) Commercial $ 39 Less than one year <1% $ 145 Less than one year <1% Nine Months Ended September 30, 2024 2023 Maturity Extension Weighted Average Maturity Extension Weighted Average Amortized Cost Affected Loans % of Book Value Amortized Cost Affected Loans % of Book Value (Dollars in millions) Commercial $ 236 Less than one year <1 % $ 367 Less than one year <1 % For the three months ended September 30, 2024 and for both the three months and nine months ended September 30, 2023, all commercial mortgage loans which were modified to borrowers experiencing financial difficulties were current. For the nine months ended September 30, 2024, commercial mortgage loans with an amortized cost of $182 million which were extended over the past 12 months became delinquent and foreclosed. Credit Quality of Mortgage Loans by Portfolio Segment The amortized cost of commercial mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2024: Credit Quality Indicator 2024 2023 2022 2021 2020 Prior Revolving Total % of (Dollars in millions) LTV ratios: Less than 65% $ 2,007 $ 2,545 $ 2,668 $ 3,168 $ 1,495 $ 13,882 $ 2,398 $ 28,163 48.6 % 65% to 75% 462 374 4,012 2,267 297 4,230 — 11,642 20.1 76% to 80% 2 16 611 287 428 2,789 — 4,133 7.1 Greater than 80% 37 57 1,119 1,412 1,679 9,707 — 14,011 24.2 Total $ 2,508 $ 2,992 $ 8,410 $ 7,134 $ 3,899 $ 30,608 $ 2,398 $ 57,949 100.0 % DSCR: > 1.20x $ 2,284 $ 1,983 $ 7,448 $ 6,496 $ 3,715 $ 25,911 $ 2,398 $ 50,235 86.7 % 1.00x - 1.20x 148 603 711 490 105 2,485 — 4,542 7.8 <1.00x 76 406 251 148 79 2,212 — 3,172 5.5 Total $ 2,508 $ 2,992 $ 8,410 $ 7,134 $ 3,899 $ 30,608 $ 2,398 $ 57,949 100.0 % The amortized cost of agricultural mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2024: Credit Quality Indicator 2024 2023 2022 2021 2020 Prior Revolving Total % of (Dollars in millions) LTV ratios: Less than 65% $ 459 $ 1,177 $ 2,792 $ 2,602 $ 2,639 $ 7,090 $ 1,427 $ 18,186 93.4 % 65% to 75% 9 56 44 306 119 512 104 1,150 5.9 76% to 80% — — 24 — 3 — 3 30 0.2 Greater than 80% — — — 14 29 46 14 103 0.5 Total $ 468 $ 1,233 $ 2,860 $ 2,922 $ 2,790 $ 7,648 $ 1,548 $ 19,469 100.0 % The amortized cost of residential mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2024: Credit Quality Indicator 2024 2023 2022 2021 2020 Prior Revolving Total % of (Dollars in millions) Performance indicators: Performing $ 805 $ 927 $ 2,493 $ 1,747 $ 326 $ 7,112 $ — $ 13,410 96.9 % Nonperforming (1) 2 34 75 24 15 284 — 434 3.1 Total $ 807 $ 961 $ 2,568 $ 1,771 $ 341 $ 7,396 $ — $ 13,844 100.0 % __________________ (1) Includes residential mortgage loans in process of foreclosure of $136 million and $140 million at September 30, 2024 and December 31, 2023, respectively. Past Due and Nonaccrual Mortgage Loans The Company has a high quality, well performing mortgage loan portfolio, with 98% and 99% of all mortgage loans classified as performing at September 30, 2024 and December 31, 2023, respectively. The Company defines delinquency consistent with industry practice, when mortgage loans are past due more than two or more months, as applicable, by portfolio segment. The past due and nonaccrual mortgage loans at amortized cost, prior to ACL by portfolio segment, were as follows: Past Due Past Due Nonaccrual Portfolio Segment September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 (In millions) Commercial $ 724 $ 75 $ 16 $ 3 $ 1,072 $ 427 Agricultural 346 40 238 — 118 206 Residential 434 418 24 16 412 402 Total $ 1,504 $ 533 $ 278 $ 19 $ 1,602 $ 1,035 Real Estate and REJV The Company’s real estate investment portfolio is diversified by property type, geography and income stream, including income from operating leases, operating income and equity in earnings from equity method REJV. Real estate investments, by income type, as well as income earned, were as follows at and for the periods indicated: September 30, 2024 December 31, 2023 Three Months Nine Months 2024 2023 2024 2023 Income Type Carrying Value Income (In millions) Wholly-owned real estate: Leased real estate $ 4,536 $ 4,446 $ 88 $ 89 $ 255 $ 271 Other real estate 687 507 79 71 204 206 REJV 8,508 8,379 11 (64) (191) (218) Total real estate and REJV $ 13,731 $ 13,332 $ 178 $ 96 $ 268 $ 259 The carrying value of wholly-owned real estate acquired through foreclosure was $264 million and $190 million at September 30, 2024 and December 31, 2023, respectively. Depreciation expense on real estate investments was $32 million and $91 million for the three months and nine months ended September 30, 2024, respectively, and $26 million and $84 million for the three months and nine months ended September 30, 2023, respectively. Real estate investments were net of accumulated depreciation of $1.0 billion and $952 million at September 30, 2024 and December 31, 2023, respectively. Leased Real Estate Investments - Operating Leases The Company, as lessor, leases investment real estate, principally commercial real estate for office and retail use, through a variety of operating lease arrangements, which typically include tenant reimbursement for property operating costs and options to renew or extend the lease. In some circumstances, leases may include an option for the lessee to purchase the property. In addition, certain leases of retail space may stipulate that a portion of the income earned is contingent upon the level of the tenants’ revenues. The Company has elected a practical expedient of not separating non-lease components related to reimbursement of property operating costs from associated lease components. These property operating costs have the same timing and pattern of transfer as the related lease component, because they are incurred over the same period of time as the operating lease. Therefore, the combined component is accounted for as a single operating lease. Risk is managed through lessee credit analysis, property type diversification and geographic diversification. See Note 11 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for a summary of leased real estate investments and income earned, by property type. Tax Equity Investments The Company invests in certain tax equity investments, including low income housing tax credit partnerships and renewable energy partnerships. The carrying value of tax equity investments, reported in other invested assets on the interim condensed consolidated balance sheet, was $737 million and $1.0 billion at September 30, 2024 and December 31, 2023, respectively. Beginning January 1, 2024, tax equity investments that meet certain criteria are accounted for using the proportional amortization method, where the initial cost of the investment is amortized in proportion to the tax credits received and recognized as a component of income tax expense (benefit) in the interim condensed consolidated statements of operations. Investments which do not meet the qualification criteria for the proportional amortization method are accounted for using the equity method of accounting. For the three months and nine months ended September 30, 2024, income tax credits and other income tax benefits of $37 million and $112 million , respectively, and amortized expense of $33 million and $100 million, respectively, were recognized net as a component of income tax expense in the Company’s interim condensed consolidated statement of operations. Cash Equivalents Cash equivalents, which includes securities and other investments with an original or remaining maturity of three months or less at the time of purchase, was $12.1 billion and $10.8 billion , principally at estimated fair value, at September 30, 2024 and December 31, 2023, respectively. Concentrations of Credit Risk Investments in any counterparty that were greater than 10% of the Company’s equity, other than the U.S. government and its agencies, at estimated fair value, were in fixed income securities of the following foreign governments and their agencies: September 30, 2024 December 31, 2023 (In millions) Japan $ 21,688 $ 22,606 South Korea $ 6,654 $ 6,411 Mexico $ 3,651 $ 3,778 Securities Lending Transactions and Repurchase Agreements Securities, Collateral and Reinvestment Portfolio A summary of these transactions and agreements accounted for as secured borrowings were as follows: September 30, 2024 December 31, 2023 Securities (1) Securities (1) Agreement Type Estimated Cash Collateral Received from Counterparties (2) Reinvestment Estimated Fair Value Cash Collateral Received from Counterparties (2) Reinvestment (In millions) Securities lending $ 11,079 $ 11,257 $ 11,178 $ 10,510 $ 10,788 $ 10,553 Repurchase agreements $ 3,010 $ 2,975 $ 2,895 $ 3,029 $ 2,975 $ 2,913 __________________

Derivatives

Derivatives	9 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	11. Derivatives Accounting for Derivatives See Note 1 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for a description of the Company’s accounting policies for derivatives and Note 12 for information about the fair value hierarchy for derivatives. Derivative Strategies Types of Derivative Instruments and Derivative Strategies The Company is exposed to various risks relating to its ongoing business operations, including interest rate, foreign currency exchange rate, credit and equity market. The Company uses a variety of strategies to manage these risks, including the use of derivatives. Commonly used derivative instruments include, but are not limited to: • Interest rate derivatives: swaps, total return swaps, caps, floors, futures, swaptions, forwards and synthetic GICs; • Foreign currency exchange rate derivatives: swaps, forwards, options and exchange-traded futures; • Credit derivatives: purchased or written single name or index credit default swaps, and forwards; and • Equity derivatives: index options, variance swaps, exchange-traded futures and total return swaps. For detailed information on these contracts and the related strategies, see Note 12 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report. The following table presents the primary underlying risk exposure, gross notional amount and estimated fair value of the Company’s derivatives, excluding embedded derivatives, held at: September 30, 2024 December 31, 2023 Primary Underlying Risk Exposure Gross Estimated Fair Value Gross Estimated Fair Value Assets Liabilities Assets Liabilities (In millions) Derivatives Designated as Hedging Instruments: Fair value hedges: Interest rate swaps Interest rate $ 5,188 $ 1,134 $ 554 $ 4,550 $ 1,257 $ 535 Foreign currency swaps Foreign currency exchange rate 1,664 43 7 1,475 55 — Foreign currency forwards Foreign currency exchange rate 350 — 69 450 — 65 Subtotal 7,202 1,177 630 6,475 1,312 600 Cash flow hedges: Interest rate swaps Interest rate 4,155 — 259 4,156 1 265 Interest rate forwards Interest rate 5,090 59 923 6,115 51 938 Foreign currency swaps Foreign currency exchange rate 45,985 2,458 1,655 43,906 2,457 1,509 Subtotal 55,230 2,517 2,837 54,177 2,509 2,712 Net investment in a foreign operation hedges: Foreign currency forwards Foreign currency exchange rate 205 7 — 503 — 8 Currency options Foreign currency exchange rate 3,000 412 — 3,000 394 — Subtotal 3,205 419 — 3,503 394 8 Total qualifying hedges 65,637 4,113 3,467 64,155 4,215 3,320 Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate swaps Interest rate 29,675 1,654 1,062 29,801 1,497 1,102 Interest rate floors Interest rate 9,228 48 — 15,321 41 — Interest rate caps Interest rate 29,052 130 1 30,016 373 — Interest rate futures Interest rate 1,732 2 2 1,243 1 5 Interest rate options Interest rate 43,481 269 119 43,926 385 103 Interest rate forwards Interest rate 2,934 130 76 2,383 69 36 Synthetic GICs Interest rate 49,081 — — 49,066 — — Foreign currency swaps Foreign currency exchange rate 10,755 981 231 11,891 1,200 356 Foreign currency forwards Foreign currency exchange rate 13,511 283 961 14,128 310 806 Currency futures Foreign currency exchange rate 321 2 — 314 2 — Currency options Foreign currency exchange rate — — — 50 — — Credit default swaps — purchased Credit 2,801 4 74 2,877 3 79 Credit default swaps — written Credit 12,851 267 2 12,468 233 5 Equity futures Equity market 1,866 13 6 2,163 8 11 Equity index options Equity market 14,106 276 263 19,421 399 255 Equity variance swaps Equity market 114 — 3 99 — 2 Equity total return swaps Equity market 2,301 — 90 1,912 1 218 Longevity swaps (1) Longevity 1,000 — — — — — Total non-designated or nonqualifying derivatives 224,809 4,059 2,890 237,079 4,522 2,978 Total $ 290,446 $ 8,172 $ 6,357 $ 301,234 $ 8,737 $ 6,298 __________________ (1) Longevity swaps are used by the Company to mitigate risk associated with life expectancy and unanticipated changes in mortality rates. Included in the table above, the Company uses various over-the-counter (“OTC”) and exchange traded derivatives to hedge variable annuity guarantees. The table below presents the gross notional amount, estimated fair value and primary underlying risk exposure of the derivatives hedging variable annuity guarantees accounted for as MRBs: September 30, 2024 December 31, 2023 Primary Underlying Risk Exposure Gross Estimated Fair Value Gross Estimated Fair Value Assets Liabilities Assets Liabilities (In millions) Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate $ 9,092 $ 13 $ 603 $ 9,096 $ 13 $ 663 Foreign currency exchange rate 577 20 1 716 22 2 Equity market 4,659 94 193 5,189 77 373 $ 14,328 $ 127 $ 797 $ 15,001 $ 112 $ 1,038 The change in estimated fair values and earned income of derivatives hedging variable annuity guarantees, recorded in net derivative gains (losses), were ($395) million and ($740) million for the nine months ended September 30, 2024 and 2023, respectively. Based on gross notional amounts, a substantial portion of the Company’s derivatives was not designated or did not qualify as part of a hedging relationship a t both September 30, 2024 and December 31, 2023. The Company’s use of derivatives includes (i) derivatives that serve as macro hedges of the Company’s exposure to various risks and that generally do not qualify for hedge accounting due to the criteria required under the portfolio hedging rules, (ii) derivatives that economically hedge insurance liabilities that contain mortality or morbidity risk and that generally do not qualify for hedge accounting because the lack of these risks in the derivatives cannot support an expectation of a highly effective hedging relationship, (iii) derivatives that economically hedge MRBs that do not qualify for hedge accounting because the changes in estimated fair value of the MRBs are already recorded in net income, and (iv) written credit default swaps and interest rate swaps that are used to synthetically create investments and that do not qualify for hedge accounting because they do not involve a hedging relationship. For these nonqualified derivatives, changes in market factors can lead to the recognition of fair value changes on the statement of operations without an offsetting gain or loss recognized in earnings for the item being hedged. The Effects of Derivatives on the Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) The following table presents the interim condensed consolidated financial statement location and amount of gain (loss) recognized on fair value, cash flow, net investment in a foreign operation (“NIFO”), nonqualifying hedging relationships and embedded derivatives: Three Months Ended September 30, 2024 Net Investment Income Net Investment Gains (Losses) Net Derivative Gains (Losses) Policyholder Benefits and Claims Interest Credited to PABs Other Expenses OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ (1) $ — N/A $ 185 $ 92 $ — N/A Hedged items 1 — N/A (191) (93) — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) (23) 41 N/A — 32 — N/A Hedged items 22 (30) N/A — (34) — N/A Amount excluded from the assessment of hedge effectiveness — (15) N/A — — — N/A Subtotal (1) (4) N/A (6) (3) — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A $ 286 Amount of gains (losses) reclassified from AOCI into income 5 (1) — — — — (4) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (161) Amount of gains (losses) reclassified from AOCI into income 1 602 — — — — (603) Foreign currency transaction gains (losses) on hedged items — (585) — — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A — Amount of gains (losses) reclassified from AOCI into income — — — — — — — Subtotal 6 16 — — — — (482) Gain (Loss) on NIFO Hedges: Foreign currency exchange rate derivatives (1) N/A — N/A N/A N/A N/A (141) Non-derivative hedging instruments N/A N/A N/A N/A N/A N/A (33) Subtotal N/A — N/A N/A N/A N/A (174) Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A 360 N/A N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A 573 N/A N/A N/A N/A Credit derivatives — purchased (1) — N/A (8) N/A N/A N/A N/A Credit derivatives — written (1) — N/A 25 N/A N/A N/A N/A Equity derivatives (1) (10) N/A (95) N/A N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A (182) N/A N/A N/A N/A Subtotal (10) N/A 673 N/A N/A N/A N/A Earned income on derivatives 33 — 136 (5) (36) — — Synthetic GICs N/A N/A 19 N/A N/A N/A N/A Embedded derivatives N/A N/A (61) N/A N/A N/A N/A Total $ 28 $ 12 $ 767 $ (11) $ (39) $ — $ (656) Three Months Ended September 30, 2023 Net Investment Income Net Investment Gains (Losses) Net Derivative Gains (Losses) Policyholder Benefits and Claims Interest Credited to PABs Other Expenses OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ (2) $ — N/A $ (230) $ (60) $ — N/A Hedged items 3 — N/A 223 59 — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 12 (19) N/A — (27) — N/A Hedged items (12) 14 N/A — 26 — N/A Amount excluded from the assessment of hedge effectiveness — (2) N/A — — — N/A Subtotal 1 (7) N/A (7) (2) — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A $ (711) Amount of gains (losses) reclassified from AOCI into income 11 17 — — — — (28) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (293) Amount of gains (losses) reclassified from AOCI into income 1 (301) — — — 1 299 Foreign currency transaction gains (losses) on hedged items — 288 — — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A — Amount of gains (losses) reclassified from AOCI into income — — — — — — — Subtotal 12 4 — — — 1 (733) Gain (Loss) on NIFO Hedges: Foreign currency exchange rate derivatives (1) N/A 5 N/A N/A N/A N/A 74 Non-derivative hedging instruments N/A N/A N/A N/A N/A N/A 10 Subtotal N/A 5 N/A N/A N/A N/A 84 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A (1,105) N/A N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A (556) N/A N/A N/A N/A Credit derivatives — purchased (1) — N/A 30 N/A N/A N/A N/A Credit derivatives — written (1) — N/A (40) N/A N/A N/A N/A Equity derivatives (1) 8 N/A 120 N/A N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A 13 N/A N/A N/A N/A Subtotal 8 N/A (1,538) N/A N/A N/A N/A Earned income on derivatives 82 — 230 (3) (43) — — Synthetic GICs N/A N/A 20 N/A N/A N/A N/A Embedded derivatives N/A N/A 86 N/A N/A N/A N/A Total $ 103 $ 2 $ (1,202) $ (10) $ (45) $ 1 $ (649) Nine Months Ended September 30, 2024 Net Net Net Policyholder Interest Credited to PABs Other OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ (1) $ — N/A $ 35 $ 34 $ — N/A Hedged items 1 — N/A (54) (38) — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) (21) (16) N/A — 1 — N/A Hedged items 22 12 N/A — 1 — N/A Amount excluded from the assessment of hedge effectiveness — (11) N/A — — — N/A Subtotal 1 (15) N/A (19) (2) — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A $ (196) Amount of gains (losses) reclassified from AOCI into income 18 (2) — — — — (16) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (180) Amount of gains (losses) reclassified from AOCI into income 4 226 — — — — (230) Foreign currency transaction gains (losses) on hedged items — (236) — — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A — Amount of gains (losses) reclassified from AOCI into income — 1 — — — — (1) Subtotal 22 (11) — — — — (623) Gain (Loss) on NIFO Hedges: Foreign currency exchange rate derivatives (1) N/A — N/A N/A N/A N/A 203 Non-derivative hedging instruments N/A N/A N/A N/A N/A N/A 4 Subtotal N/A — N/A N/A N/A N/A 207 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A (211) N/A N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A (697) N/A N/A N/A N/A Credit derivatives — purchased (1) — N/A (6) N/A N/A N/A N/A Credit derivatives — written (1) — N/A 47 N/A N/A N/A N/A Equity derivatives (1) (46) N/A (545) N/A N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A 159 N/A N/A N/A N/A Subtotal (46) N/A (1,253) N/A N/A N/A N/A Earned income on derivatives 116 — 497 (11) (129) — — Synthetic GICs N/A N/A 57 N/A N/A N/A N/A Embedded derivatives N/A N/A (21) N/A N/A N/A N/A Total $ 93 $ (26) $ (720) $ (30) $ (131) $ — $ (416) Nine Months Ended September 30, 2023 Net Investment Income Net Investment Gains (Losses) Net Derivative Gains (Losses) Policyholder Benefits and Claims Interest Credited to PABs Other Expenses OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ (3) $ — N/A $ (239) $ (59) $ — N/A Hedged items 3 — N/A 218 57 — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) (10) (73) N/A — (14) — N/A Hedged items 9 56 N/A — 15 — N/A Amount excluded from the assessment of hedge effectiveness — (2) N/A — — — N/A Subtotal (1) (19) N/A (21) (1) — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A $ (369) Amount of gains (losses) reclassified from AOCI into income 38 77 — — — — (115) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (715) Amount of gains (losses) reclassified from AOCI into income 3 10 — — — 2 (15) Foreign currency transaction gains (losses) on hedged items — (2) — — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (1) Amount of gains (losses) reclassified from AOCI into income — — — — — — — Subtotal 41 85 — — — 2 (1,215) Gain (Loss) on NIFO Hedges: Foreign currency exchange rate derivatives (1) N/A 5 N/A N/A N/A N/A 280 Non-derivative hedging instruments N/A N/A N/A N/A N/A N/A 37 Subtotal N/A 5 N/A N/A N/A N/A 317 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A (1,381) N/A N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A (1,518) N/A N/A N/A N/A Credit derivatives — purchased (1) — N/A (1) N/A N/A N/A N/A Credit derivatives — written (1) — N/A 48 N/A N/A N/A N/A Equity derivatives (1) (34) N/A (801) N/A N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A 455 N/A N/A N/A N/A Subtotal (34) N/A (3,198) N/A N/A N/A N/A Earned income on derivatives 157 — 802 5 (111) — — Synthetic GICs N/A N/A 56 N/A N/A N/A N/A Embedded derivatives N/A N/A 51 N/A N/A N/A N/A Total $ 163 $ 71 $ (2,289) $ (16) $ (112) $ 2 $ (898) __________________ (1) Excludes earned income on derivatives. Fair Value Hedges The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities, and (iii) foreign currency forwards to hedge the foreign currency fair value exposure of foreign currency denominated investments. The following table presents the balance sheet classification, carrying amount and cumulative fair value hedging adjustments for items designated and qualifying as hedged items in fair value hedges: Balance Sheet Line Item Carrying Amount Cumulative Amount September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 (In millions) Fixed maturity securities AFS $ 388 $ 454 $ — $ 3 Mortgage loans $ 305 $ 359 $ (2) $ (11) FPBs $ (2,750) $ (2,863) $ 151 $ 191 PABs $ (2,438) $ (1,911) $ 43 $ 25 __________________ (1) Includes ($96) million and ($111) million of hedging adjustments on discontinued hedging relationships at September 30, 2024 and December 31, 2023, respectively. For the Company’s foreign currency forwards, the change in the estimated fair value of the derivative related to the changes in the difference between the spot price and the forward price is excluded from the assessment of hedge effectiveness. The Company has elected to record changes in estimated fair value of excluded components in earnings. For all other derivatives, all components of each derivative’s gain or loss were included in the assessment of hedge effectiveness. Cash Flow Hedges The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities, (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments, and (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed-rate investments. In certain instances, the Company discontinued cash flow hedge accounting because the forecasted transactions were no longer probable of occurring. Because certain of the forecasted transactions also were not probable of occurring within two months of the anticipated date, the Company reclassified amounts from AOCI into income. These amounts were $10 million and $4 million for the three months and nine months ended September 30, 2024, respectively, and $1 million and $28 million for the three months and nine months ended September 30, 2023, respectively. A t both September 30, 2024 and December 31, 2023, the maximum length of time over which the Company was hedging its exposure to variability in future cash flows for forecasted transactions did not exceed five years. At September 30, 2024 and December 31, 2023, the balance in AOCI associated with cash flow hedges was ($457) million and $166 million, respectively. All components of each derivative’s gain or loss were included in the assessment of hedge effectiveness. At September 30, 2024, the Company expected to reclassify ($46) million of deferred net gains (losses) on derivatives in AOCI to earnings within the next 12 months. NIFO Hedges The Company uses foreign currency exchange rate derivatives, which may include foreign currency forwards and currency options, to hedge portions of its net investments in foreign operations against adverse movements in exchange rates. The Company also designates a portion of its foreign-denominated debt as a non-derivative hedging instrument of its net investments in foreign operations. The Company assesses hedge effectiveness of its derivatives based upon the change in forward rates and assesses its non-derivative hedging instruments based upon the change in spot rates. All components of ea ch derivative’s gain or loss were included in the assessment of hedge effectiveness. When net investments in foreign operations are sold or substantially liquidated, the amounts in AOCI are reclassified to the statement of operations. At September 30, 2024 and December 31, 2023, the cumulative foreign currency translation gain (loss) recorded in AOCI related to NIFO hedges was $888 million and $681 million, respectively. At September 30, 2024 and December 31, 2023 Credit Derivatives In connection with synthetically created credit investment transactions, the Company writes credit default swaps for which it receives a premium to insure credit risk. Such credit derivatives are included within the effects of derivatives on the interim condensed consolidated statements of operations and comprehensive income (loss) table. If a credit event occurs, as defined by the contract, the contract may be cash settled or it may be settled gross by the Company paying the counterparty the specified swap notional amount in exchange for the delivery of par quantities of the referenced credit obligation. The Company can terminate these contracts at any time through cash settlement with the counterparty at an amount equal to the then current estimated fair value of the credit default swaps. The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at: September 30, 2024 December 31, 2023 Rating Agency Designation of Referenced Estimated Maximum Weighted Estimated Maximum Weighted (Dollars in millions) Aaa/Aa/A Single name credit default swaps (3) $ 1 $ 103 1.3 $ 2 $ 150 1.6 Credit default swaps referencing indices 83 4,261 2.4 80 3,830 2.7 Subtotal 84 4,364 2.4 82 3,980 2.6 Baa Single name credit default swaps (3) 1 92 1.6 1 99 2.1 Credit default swaps referencing indices 169 8,195 5.0 145 8,188 5.4 Subtotal 170 8,287 5.0 146 8,287 5.3 Ba Single name credit default swaps (3) — 17 1.4 — 17 2.1 Credit default swaps referencing indices 2 24 2.2 2 25 3.0 Subtotal 2 41 1.9 2 42 2.6 B Credit default swaps referencing indices 10 144 3.9 2 129 5.0 Subtotal 10 144 3.9 2 129 5.0 Caa Credit default swaps referencing indices (1) 15 2.2 (4) 30 2.5 Subtotal (1) 15 2.2 (4) 30 2.5 Total $ 265 $ 12,851 4.1 $ 228 $ 12,468 4.5 _________________ (1) The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service (“Moody’s”), S&P Global Ratings (“S&P”) and Fitch Ratings. If no rating is available from a rating agency, then an internally developed rating is used. (2) The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts. (3) Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or municipals. Credit Risk on Freestanding Derivatives The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements. The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties in jurisdictions in which it understands that close-out netting should be enforceable and establishing and monitoring exposure limits. The Company’s bilateral contracts between two counterparties (“OTC-bilateral”) derivative transactions are governed by International Swaps and Derivatives Association, Inc. (“ISDA”) Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, close-out netting permits the Company (subject to financial regulations such as the Orderly Liquidation Authority under Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act) to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions and to apply collateral to the obligations, without application of the automatic stay, upon the counterparty’s bankruptcy. All of the Company’s ISDA Master Agreements also include Credit Support Annex provisions which require both the pledging and accepting of collateral in connection with its OTC-bilateral derivatives as required by applicable law. Additionally, the Company is required to pledge initial margin for certain new OTC-bilateral derivative transactions to third-party custodians. The Company’s over-the-counter cleared (“OTC-cleared”) derivatives are effected through central clearing counterparties and its exchange-traded derivatives are effected through regulated exchanges. Such positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by brokers and central clearinghouses to such derivatives. See Note 12 for a description of the impact of credit risk on the valuation of derivatives. The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at: September 30, 2024 December 31, 2023 Derivatives Subject to a Master Netting Arrangement or a Similar Arrangement Assets Liabilities Assets Liabilities (In millions) Gross estimated fair value of derivatives: OTC-bilateral (1) $ 8,111 $ 6,036 $ 8,749 $ 6,014 OTC-cleared (1) 191 260 158 277 Exchange-traded 17 8 11 16 Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1) 8,319 6,304 8,918 6,307 Gross amounts not offset on the interim condensed consolidated balance sheets: Gross estimated fair value of derivatives: (2) OTC-bilateral (3,035) (3,035) (3,568) (3,568) OTC-cleared (5) (5) (5) (5) Exchange-traded (3) (3) (1) (1) Cash collateral: (3), (4) OTC-bilateral (2,676) — (3,448) — OTC-cleared (181) (237) (150) (239) Exchange-traded — (4) — (5) Securities collateral: (5) OTC-bilateral (2,313) (2,993) (1,563) (2,427) OTC-cleared — (18) — (33) Exchange-traded — (1) — (10) Net amount after application of master netting agreements and collateral $ 106 $ 8 $ 183 $ 19 __________________ (1) At September 30, 2024 and December 31, 2023, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $147 million and $181 million, respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of ($53) million and $9 million, respectively. (2) Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals. (3) Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the central clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet. For certain collateral agreements, cash collateral is pledged to the Company as initial margin on its OTC-bilateral derivatives. (4) The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange-traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements. At September 30, 2024 and December 31, 2023, th e Company received excess cash collateral of $43 million and $163 million, respectively, and provided excess cash collateral of $93 million and $98 million, respectively, which is not included in the table above due to the foregoing limitation. (5) Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at September 30, 2024, none of the c ollateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At September 30, 2024 and December 31, 2023, the Company received excess securities collateral with an estimated fair value of $441 million and $298 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At September 30, 2024 and December 31, 2023, the Company provided excess securities collateral with an estimated fair value of $1.5 billion, at both periods, for its OTC-bilateral derivatives, $891 million and $945 million, respectively, for its OTC-cleared derivatives, and $181 million and $137 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to the foregoing limitation. The Company’s collateral arrangements for its OTC-bilateral derivatives generally require the counterparty in a net liability position, after considering the effect of netting agreements, to pledge collateral when the collateral amount owed by that counterparty reaches a minimum transfer amount. Substantially all of the Company’s netting agreements for derivatives contain provisions that require both the Company and the counterparty to maintain a specific investment grade credit rating from each of Moody’s and S&P. If a party’s credit or financial strength rating, as applicable, were to fall below that specific investment grade credit rating, that party would be in violation of these provisions, and the other party to the derivatives could terminate the transactions and demand immediate settlement payment based on such party’s reasonable valuation of the derivatives. A small number of these arrangements also include credit-contingent provisions that include a threshold above which collateral must be posted. Such agreements provide for a reduction of these thresholds (on a sliding scale that converges toward zero) in the event of downgrades in the credit ratings of MetLife, Inc. and/or the counterparty. At September 30, 2024, the amount of collateral not provided by the Company due to the existence of these thresholds was $15 million. The followi ng table presents the estimated fair value of the Company’s OTC-bilateral derivatives that were in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged. September 30, 2024 December 31, 2023 Derivatives Derivatives Total Derivatives Derivatives Total (In millions) Estimated fair value of derivatives in a net liability position (1) $ 2,954 $ 47 $ 3,001 $ 2,443 $ 4 $ 2,447 Estimated fair value of collateral provided: Fixed maturity securities AFS $ 3,612 $ 53 $ 3,665 $ 3,011 $ 6 $ 3,017 __________________ (1) After taking into consideration the existence of netting agreements. Embedded Derivatives The Company issues certain products or purchases certain investments that contain embedded derivatives that are required to be separated from their host contracts and accounted for as freestanding derivatives. The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at: Balance Sheet Location September 30, 2024 December 31, 2023 (In millions) Embedded derivatives within liability host contracts: Funds withheld and guarantees on reinsurance Other liabilities $ (53) $ (70) Fixed annuities with equity indexed returns PABs 172 163 Total $ 119 $ 93

Fair Value

Fair Value	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value	12. Fair Value Considerable judgment is often required in interpreting the market data used to develop estimates of fair value, and the use of different assumptions or valuation methodologies may have a material effect on the estimated fair value amounts. Recurring Fair Value Measurements The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy, including those items for which the Company has elected the FVO, are presented below at: September 30, 2024 Fair Value Hierarchy Level 1 Level 2 Level 3 Total Estimated Fair Value (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 70,349 $ 14,502 $ 84,851 Foreign corporate — 41,047 15,705 56,752 Foreign government — 44,091 41 44,132 U.S. government and agency 16,650 18,026 — 34,676 RMBS — 33,367 1,897 35,264 ABS & CLO — 15,138 2,382 17,520 Municipals — 10,798 — 10,798 CMBS — 8,557 1,229 9,786 Total fixed maturity securities AFS 16,650 241,373 35,756 293,779 Equity securities 430 74 242 746 Unit-linked and FVO securities (1) 7,846 267 1,176 9,289 Short-term investments (2) 3,155 1,176 6 4,337 Other investments 44 2,016 1,095 3,155 Derivative assets: (3) Interest rate 2 3,424 — 3,426 Foreign currency exchange rate 2 4,159 25 4,186 Credit — 271 — 271 Equity market 13 272 4 289 Total derivative assets 17 8,126 29 8,172 MRBs — — 310 310 Reinsured MRBs (4) — — 16 16 Separate account assets (5) 69,799 77,991 1,019 148,809 Total assets (6) $ 97,941 $ 331,023 $ 39,649 $ 468,613 Liabilities Derivative liabilities: (3) Interest rate $ 2 $ 2,994 $ — $ 2,996 Foreign currency exchange rate — 2,918 5 2,923 Credit — 76 — 76 Equity market 6 356 — 362 Total derivative liabilities 8 6,344 5 6,357 Embedded derivatives within liability host contracts (7) — — 119 119 MRBs — — 3,117 3,117 Separate account liabilities (5) — 5 — 5 Total liabilities $ 8 $ 6,349 $ 3,241 $ 9,598 December 31, 2023 Fair Value Hierarchy Level 1 Level 2 Level 3 Total Estimated Fair Value (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 67,003 $ 13,714 $ 80,717 Foreign corporate — 40,813 14,631 55,444 Foreign government — 45,438 51 45,489 U.S. government and agency 15,327 16,925 — 32,252 RMBS 3 27,495 1,598 29,096 ABS & CLO — 15,191 2,103 17,294 Municipals — 11,171 — 11,171 CMBS — 9,099 850 9,949 Total fixed maturity securities AFS 15,330 233,135 32,947 281,412 Equity securities 429 79 249 757 Unit-linked and FVO securities (1) 7,520 1,708 1,103 10,331 Short-term investments (2) 5,103 667 27 5,797 Other investments 48 363 975 1,386 Derivative assets: (3) Interest rate 1 3,674 — 3,675 Foreign currency exchange rate 2 4,393 23 4,418 Credit — 228 8 236 Equity market 8 393 7 408 Total derivative assets 11 8,688 38 8,737 MRBs — — 286 286 Reinsured MRBs (4) — — 18 18 Separate account assets (5) 66,229 77,258 1,147 144,634 Total assets (6) $ 94,670 $ 321,898 $ 36,790 $ 453,358 Liabilities Derivative liabilities: (3) Interest rate $ 5 $ 2,805 $ 174 $ 2,984 Foreign currency exchange rate — 2,737 7 2,744 Credit — 84 — 84 Equity market 11 475 — 486 Total derivative liabilities 16 6,101 181 6,298 Embedded derivatives within liability host contracts (7) — — 93 93 MRBs — — 3,179 3,179 Separate account liabilities (5) 4 4 — 8 Total liabilities $ 20 $ 6,105 $ 3,453 $ 9,578 __________________ (1) Unit-linked and FVO securities were primarily comprised of Unit-linked investments at both September 30, 2024 and December 31, 2023. (2) Short-term investments as presented in the tables above differ from the amounts presented on the interim condensed consolidated balance sheets because certain short-term investments are not measured at estimated fair value on a recurring basis. (3) Derivative assets are presented within other invested assets on the interim condensed consolidated balance sheets and derivative liabilities are presented within other liabilities on the interim condensed consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the interim condensed consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables. (4) Reinsured MRBs are presented within premiums, reinsurance and other receivables on the consolidated balance sheets. (5) Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities. Separate account liabilities are set equal to the estimated fair value of separate account assets. Separate account liabilities presented in the tables above represent derivative liabilities. (6) Total assets included in the fair value hierarchy exclude OLPI that are measured at estimated fair value using the net asset value (“NAV”) per share (or its equivalent) practical expedient. The estimated fair value of such investments was $51 million and $52 million at September 30, 2024 and December 31, 2023, respectively. (7) Embedded derivatives within liability host contracts are presented within PABs and other liabilities on the interim condensed consolidated balance sheets. The following describes the valuation methodologies used to measure assets and liabilities at fair value. Investments Securities, Short-term Investments and Other Investments When available, the estimated fair value of these financial instruments is based on quoted prices in active markets that are readily and regularly obtainable. Generally, these are the most liquid of the Company’s securities holdings, and valuation of these securities does not involve management’s judgment. When quoted prices in active markets are not available, the determination of estimated fair value of securities is based on market standard valuation methodologies, giving priority to observable inputs. The significant inputs to the market standard valuation methodologies for certain types of securities with reasonable levels of price transparency are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. When observable inputs are not available, the market standard valuation methodologies rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs can be based, in large part, on management’s judgment or estimation and cannot be supported by reference to market activity. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such investments. The estimated fair value of short-term investments and other investments is determined on a basis consistent with the methodologies described herein. The valuation approaches and key inputs for each category of assets or liabilities that are classified within Level 2 and Level 3 of the fair value hierarchy are presented below. The primary valuation approaches are the market approach, which considers recent prices from market transactions involving identical or similar assets or liabilities, and the income approach, which converts expected future amounts (e.g., cash flows) to a single current, discounted amount. The valuation of most instruments listed below is determined using independent pricing sources, matrix pricing, discounted cash flow methodologies or other similar techniques that use either observable market inputs or unobservable inputs. Instrument Level 2 Observable Inputs Level 3 Unobservable Inputs Fixed maturity securities AFS U.S. corporate and Foreign corporate securities Valuation Approaches: Principally the market and income approaches. Valuation Approaches: Principally the market approach. Key Inputs: Key Inputs: • quoted prices in markets that are not active • illiquidity premium • benchmark yields; spreads off benchmark yields; new issuances; issuer ratings • delta spread adjustments to reflect specific credit-related issues • trades of identical or comparable securities; duration • credit spreads • privately-placed securities are valued using the additional key inputs: • quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2 • market yield curve; call provisions • independent non-binding broker quotations • observable prices and spreads for similar public or private securities that incorporate the credit quality and industry sector of the issuer • delta spread adjustments to reflect specific credit-related issues Foreign government securities, U.S. government and agency securities and Municipals Valuation Approaches: Principally the market approach. Valuation Approaches: Principally the market approach. Key Inputs: Key Inputs: • quoted prices in markets that are not active • independent non-binding broker quotations • benchmark U.S. Treasury yield or other yields • quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2 • the spread off the U.S. Treasury yield curve for the identical security • credit spreads • issuer ratings and issuer spreads; broker-dealer quotations • comparable securities that are actively traded Structured Products Valuation Approaches: Principally the market and income approaches. Valuation Approaches: Principally the market and income approaches. Key Inputs: Key Inputs: • quoted prices in markets that are not active • credit spreads • spreads for actively traded securities; spreads off benchmark yields • quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2 • expected prepayment speeds and volumes • independent non-binding broker quotations • current and forecasted loss severity; ratings; geographic region • credit ratings • weighted average coupon and weighted average maturity • average delinquency rates; DSCR • credit ratings • issuance-specific information, including, but not limited to: • collateral type; structure of the security; vintage of the loans • payment terms of the underlying assets • payment priority within the tranche; deal performance Instrument Level 2 Observable Inputs Level 3 Unobservable Inputs Equity securities Valuation Approaches: Principally the market approach. Valuation Approaches: Principally the market and income approaches. Key Input: Key Inputs: • quoted prices in markets that are not considered active • credit ratings; issuance structures • quoted prices in markets that are not active for identical or similar securities that are less liquid and based on lower levels of trading activity than securities classified in Level 2 • independent non-binding broker quotations Unit-linked and FVO securities, Short-term investments and Other investments Valuation Approaches: Principally the market and income approaches. Valuation Approaches: Principally the market and income approaches. Key Inputs: Key Inputs: • Unit-linked and FVO securities include mutual fund interests without readily determinable fair values given prices are not published publicly. Valuation of these mutual funds is based upon quoted prices or reported NAV provided by the fund managers, which were based on observable inputs. • Unit-linked and FVO securities, short-term investments and other investments are of a similar nature and class to the fixed maturity securities AFS and equity securities described above; accordingly, the valuation approaches and unobservable inputs used in their valuation are also similar to those described above. Other investments also include certain REJV and use the valuation approach and key inputs as described for OLPI below. • Short-term investments and other investments are of a similar nature and class to the fixed maturity securities AFS and equity securities described above; accordingly, the valuation approaches and observable inputs used in their valuation are also similar to those described above. Separate account assets and Separate account liabilities (1) Mutual funds and hedge funds without readily determinable fair values as prices are not published publicly Key Input: • N/A • quoted prices or reported NAV provided by the fund managers OLPI • N/A Valued giving consideration to the underlying holdings of the partnerships and adjusting, if appropriate. Key Inputs: • liquidity; bid/ask spreads; performance record of the fund manager • other relevant variables that may impact the exit value of the particular partnership interest __________________ (1) Estimated fair value equals carrying value, based on the value of the underlying assets, including mutual fund interests, fixed maturity securities, equity securities, derivatives, hedge funds, OLPI, short-term investments and cash and cash equivalents. The estimated fair value of fixed maturity securities, equity securities, derivatives, short-term investments and cash and cash equivalents is determined on a basis consistent with the assets described under “— Securities, Short-term Investments and Other Investments” and “— Derivatives — Freestanding Derivatives.” Derivatives The estimated fair value of derivatives is determined through the use of quoted market prices for exchange-traded derivatives, or through the use of pricing models for OTC-bilateral and OTC-cleared derivatives. The determination of estimated fair value, when quoted market values are not available, is based on market standard valuation methodologies and inputs that management believes are consistent with what other market participants would use when pricing such instruments. Derivative valuations can be affected by changes in interest rates, foreign currency exchange rates, financial indices, credit spreads, default risk, nonperformance risk, volatility, liquidity and changes in estimates and assumptions used in the pricing models. The significant inputs to the pricing models for most OTC-bilateral and OTC-cleared derivatives are inputs that are observable in the market or can be derived principally from, or corroborated by, observable market data. With respect to certain OTC-bilateral and OTC-cleared derivatives, management may rely on inputs that are significant to the estimated fair value that are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. These unobservable inputs may involve significant management judgment or estimation. Unobservable inputs are based on management’s assumptions about the inputs market participants would use in pricing such derivatives. Most inputs for OTC-bilateral and OTC-cleared derivatives are mid-market inputs but, in certain cases, liquidity adjustments are made when they are deemed more representative of exit value. Market liquidity, as well as the use of different methodologies, assumptions and inputs, may have a material effect on the estimated fair values of the Company’s derivatives and could materially affect net income. The credit risk of both the counterparty and the Company is considered in determining the estimated fair value for all OTC-bilateral and OTC-cleared derivatives, and any potential credit adjustment is based on the net exposure by counterparty after taking into account the effects of netting agreements and collateral arrangements. The Company values its OTC-bilateral and OTC-cleared derivatives using standard swap curves which may include a spread to the risk-free rate, depending upon specific collateral arrangements. This credit spread is appropriate for those parties that execute trades at pricing levels consistent with similar collateral arrangements. As the Company and its significant derivative counterparties generally execute trades at such pricing levels and hold sufficient collateral, additional credit risk adjustments are not currently required in the valuation process. The Company’s ability to consistently execute at such pricing levels is, in part, due to the netting agreements and collateral arrangements that are in place with all of its significant derivative counterparties. An evaluation of the requirement to make additional credit risk adjustments is performed by the Company each reporting period. Freestanding Derivatives Level 2 Valuation Approaches and Key Inputs: This level includes all types of derivatives utilized by the Company with the exception of exchange-traded derivatives included within Level 1 and those derivatives with unobservable inputs as described in Level 3. Level 3 Valuation Approaches and Key Inputs: These valuation methodologies generally use the same inputs as described in the corresponding sections for Level 2 measurements of derivatives. However, these derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. Freestanding derivatives are principally valued using the income approach. Valuations of non-option-based derivatives utilize present value techniques, whereas valuations of option-based derivatives utilize option pricing models. Key inputs are as follows: Instrument Interest Rate Foreign Currency Credit Equity Market Inputs common to Level 2 and Level 3 by instrument type • swap yield curves • swap yield curves • swap yield curves • swap yield curves • basis curves • basis curves • credit curves • spot equity index levels • interest rate volatility (1) • currency spot rates • recovery rates • dividend yield curves • cross currency basis curves • equity volatility (1) • currency volatility (1) Level 3 • swap yield curves (2) • swap yield curves (2) • swap yield curves (2) • dividend yield curves (2) • basis curves (2) • basis curves (2) • credit curves (2) • equity volatility (1), (2) • repurchase rates • cross currency basis curves (2) • credit spreads • correlation between model inputs (1) • interest rate volatility (1), (2) • currency correlation • repurchase rates • currency volatility (1) • independent non-binding broker quotations __________________ (1) Option-based only. (2) Extrapolation beyond the observable limits of the curve(s). Embedded Derivatives Embedded derivatives principally include equity-indexed annuity contracts and investment risk within funds withheld related to certain reinsurance agreements. Embedded derivatives are recorded at estimated fair value with changes in estimated fair value reported in net income. The estimated fair value of the embedded derivatives within funds withheld related to certain ceded reinsurance is determined based on the change in estimated fair value of the underlying assets held by the Company in a reference portfolio backing the funds withheld liability. The estimated fair value of the underlying assets is determined as described in “— Investments — Securities, Short-term Investments and Other Investments.” The estimated fair value of these embedded derivatives is included, along with their funds withheld hosts, in other liabilities on the interim condensed consolidated balance sheets with changes in estimated fair value recorded in net derivative gains (losses). Changes in the credit spreads on the underlying assets, interest rates and market volatility may result in significant fluctuations in the estimated fair value of these embedded derivatives that could materially affect net income. The estimated fair value of the embedded equity indexed derivatives, based on the present value of future equity returns to the policyholder using actuarial and present value assumptions including expectations concerning policyholder behavior, is calculated by the Company’s actuarial department. The calculation is based on in-force business and uses standard capital market techniques, such as Black-Scholes, to calculate the value of the portion of the embedded derivative for which the terms are set. The portion of the embedded derivative covering the period beyond where terms are set is calculated as the present value of amounts expected to be spent to provide equity indexed returns in those periods. The valuation of these embedded derivatives also includes the establishment of a risk margin, as well as changes in nonperformance risk. MRBs See Note 6 for information on the Company’s valuation approaches and key inputs for MRBs. Transfers between Levels Overall, transfers between levels occur when there are changes in the observability of inputs and market activity. Transfers into or out of Level 3: Assets and liabilities are transferred into Level 3 when a significant input cannot be corroborated with market observable data. This occurs when market activity decreases significantly and underlying inputs cannot be observed, current prices are not available, and/or when there are significant variances in quoted prices, thereby affecting transparency. Assets and liabilities are transferred out of Level 3 when circumstances change such that a significant input can be corroborated with market observable data. This may be due to a significant increase in market activity, a specific event, or one or more significant input(s) becoming observable. Assets and Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) The following table presents certain quantitative information about the significant unobservable inputs used in the fair value measurement, and the sensitivity of the estimated fair value to changes in those inputs, for the more significant asset and liability classes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at: September 30, 2024 December 31, 2023 Impact of Valuation Significant Range Weighted Range Weighted Fixed maturity securities AFS (3) U.S. corporate and foreign corporate • Matrix pricing • Offered quotes (4) 34 - 133 94 4 - 131 93 Increase • Market pricing • Quoted prices (4) 13 - 116 97 — - 110 92 Increase • Consensus pricing • Offered quotes (4) 92 - 100 96 86 - 102 96 Increase RMBS • Market pricing • Quoted prices (4) — - 121 95 — - 112 93 Increase (5) ABS & CLO • Market pricing • Quoted prices (4) 3 - 106 97 3 - 101 93 Increase (5) Derivatives Interest rate • Present value techniques • Swap yield (6) — - — — 367 - 399 385 Increase (7) Foreign currency exchange rate • Present value techniques • Swap yield (6) 111 - 168 166 185 - 399 193 Increase (7) Credit • Consensus pricing • Offered quotes (8) MRBs and Reinsured MRBs Direct, assumed and ceded guaranteed minimum benefits • Option pricing techniques • Mortality rates: Ages 0 - 40 0% - 0.15% 0.05% 0% - 0.15% 0.05% (9) Ages 41 - 60 0.04% - 0.79% 0.22% 0.04% - 0.75% 0.22% (9) Ages 61 - 115 0% - 100% 1.14% 0% - 100% 1.23% (9) • Lapse rates: Durations 1 - 10 0.14% - 20.10% 12.86% 0.39% - 20.10% 8.72% Decrease (10) Durations 11 - 20 0.39% - 15% 6.05% 0.39% - 15% 4.34% Decrease (10) Durations 21 - 116 0.39% - 15% 8.20% 0.10% - 15% 4.59% Decrease (10) • Utilization rates 0.20% - 22% 0.79% 0.20% - 22% 0.44% Increase (11) • Withdrawal rates 0% - 20% 4.77% 0% - 20% 4.47% (12) • Long-term equity volatilities 14.23% - 22.27% 18.77% 8.05% - 21.85% 18.55% Increase (13) • Nonperformance risk spread 0.11% - 1.49% 0.64% 0.38% - 1.59% 0.73% Decrease (14) __________________ (1) The weighted average for fixed maturity securities AFS and derivatives is determined based on the estimated fair value of the securities and derivatives. The weighted average for MRBs is determined based on a combination of account values and experience data. (2) The impact of a decrease in input would have resulted in the opposite impact on estimated fair value. For MRBs, changes to direct and assumed guaranteed minimum benefits are based on liability positions; changes to ceded guaranteed minimum benefits are based on asset positions. (3) Significant increases (decreases) in expected default rates in isolation would have resulted in substantially lower (higher) valuations. (4) Range and weighted average are presented in accordance with the market convention for fixed maturity securities AFS of dollars per hundred dollars of par. (5) Changes in the assumptions used for the probability of default would have been accompanied by a directionally similar change in the assumption used for the loss severity and a directionally opposite change in the assumptions used for prepayment rates. (6) Ranges represent the rates across different yield curves and are presented in basis points. The swap yield curves are utilized among different types of derivatives to project cash flows, as well as to discount future cash flows to present value. Since this valuation methodology uses a range of inputs across a yield curve to value the derivative, presenting a range is more representative of the unobservable input used in the valuation. (7) Changes in estimated fair value are based on long U.S. dollar net asset positions and will be inversely impacted for short U.S. dollar net asset positions. (8) At September 30, 2024 and December 31, 2023, independent non-binding broker quotations were used in the determination of 0% and less than 1%, respectively, of the total net derivative estimated fair value. (9) Mortality rates vary by age and by demographic characteristics such as gender. Mortality rate assumptions are based on company experience. A mortality improvement assumption is also applied. For any given contract, mortality rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For contracts that contain only a GMDB, any increase (decrease) in mortality rates result in an increase (decrease) in the estimated fair value of MRBs. Generally, for contracts that contain both a GMDB and a living benefit (e.g., GMIB, GMWB, GMAB), any increase (decrease) in mortality rates result in a decrease (increase) in the estimated fair value of MRBs. (10) Base lapse rates are adjusted at the contract level based on a comparison of the actuarially calculated guaranteed values and the current policyholder account value, as well as other factors, such as the applicability of any surrender charges. A dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in the money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies. For any given contract, lapse rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. (11) The utilization rate assumption estimates the percentage of contractholders with GMIBs or a lifetime withdrawal benefit who will elect to utilize the benefit upon becoming eligible. The rates may vary by the type of guarantee, the amount by which the guaranteed amount is greater than the account value, the contract’s withdrawal history and by the age of the policyholder. For any given contract, utilization rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. (12) The withdrawal rate represents the percentage of account balance that any given policyholder will elect to withdraw from the contract each year. The withdrawal rate assumption varies by age and duration of the contract, and also by other factors such as benefit type. For any given contract, withdrawal rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For GMWBs, any increase (decrease) in withdrawal rates results in an increase (decrease) in the estimated fair value of the guarantees. For GMABs and GMIBs, any increase (decrease) in withdrawal rates results in a decrease (increase) in the estimated fair value. (13) Long-term equity volatilities represent equity volatility beyond the period for which observable equity volatilities are available. For any given contract, long-term equity volatility rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. (14) Nonperformance risk spread varies by duration and by currency. For any given contract, multiple nonperformance risk spreads will apply, depending on the duration of the cash flow being discounted for purposes of valuing the MRBs. All other classes of securities classified within Level 3, including those within Unit-linked and FVO securities, Other investments, Separate account assets, and Embedded derivatives within funds withheld related to certain ceded reinsurance, use the same valuation techniques and significant unobservable inputs as previously described for Level 3 securities. Generally, all other classes of assets and liabilities classified within Level 3 that are not included above use the same valuation techniques and significant unobservable inputs as previously described for Level 3. The sensitivity of the estimated fair value to changes in the significant unobservable inputs for these other assets and liabilities is similar in nature to that described in the preceding table. The valuation techniques and significant unobservable inputs used in the fair value measurement for the more significant assets measured at estimated fair value on a nonrecurring basis and determined using significant unobservable inputs (Level 3) are summarized in “— Nonrecurring Fair Value Measurements.” The following tables summarize the change of assets (liabilities) measured at estimated fair value on a recurring basis using significant unobservable inputs (Level 3), excluding MRBs (see Note 6): Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fixed Maturity Securities AFS Corporate (6) Foreign Structured Municipals Equity Securities Unit-linked (In millions) Three Months Ended September 30, 2024 Balance, beginning of period $ 29,240 $ 40 $ 5,867 $ 1 $ 262 $ 1,096 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (10) (8) 6 — (15) 56 Total realized/unrealized gains (losses) included in AOCI 1,169 7 132 — — — Purchases (3) 2,080 2 1,080 — 9 135 Sales (3) (1,255) (1) (539) (1) (14) (111) Issuances (3) — — — — — — Settlements (3) — — — — — — Transfers into Level 3 (4) 94 1 31 — — — Transfers out of Level 3 (4) (1,111) — (1,069) — — — Balance, end of period $ 30,207 $ 41 $ 5,508 $ — $ 242 $ 1,176 Three Months Ended September 30, 2023 Balance, beginning of period $ 25,968 $ 60 $ 4,554 $ 7 $ 250 $ 1,057 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) 3 4 (8) — (5) (31) Total realized/unrealized gains (losses) included in AOCI (996) (9) (10) — — — Purchases (3) 991 4 969 — — 204 Sales (3) (573) (9) (376) — (1) (177) Issuances (3) — — — — — — Settlements (3) — — — — — — Transfers into Level 3 (4) 132 — 70 — — 16 Transfers out of Level 3 (4) (258) (7) (294) (7) — — Balance, end of period $ 25,267 $ 43 $ 4,905 $ — $ 244 $ 1,069 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2024 (5) $ (6) $ (8) $ 12 $ — $ (15) $ 57 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2023 (5) $ 2 $ 4 $ (5) $ — $ (4) $ (32) Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2024 (5) $ 1,159 $ 7 $ 113 $ — $ — $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2023 (5) $ (989) $ (9) $ (14) $ — $ — $ — Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Short-term Other Net Net Embedded Separate (In millions) Three Months Ended September 30, 2024 Balance, beginning of period $ 10 $ 1,073 $ (75) $ (55) $ 1,122 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) — 9 21 (61) (9) Total realized/unrealized gains (losses) included in AOCI — — 7 — — Purchases (3) 1 6 — — 18 Sales (3) (8) (45) — — (93) Issuances (3) — — — — — Settlements (3) — — 72 (3) — Transfers into Level 3 (4) 3 52 — — 1 Transfers out of Level 3 (4) — — (1) — (20) Balance, end of period $ 6 $ 1,095 $ 24 $ (119) $ 1,019 Three Months Ended September 30, 2023 Balance, beginning of period $ 18 $ 964 $ (214) $ (64) $ 1,248 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) — (6) (56) 86 (22) Total realized/unrealized gains (losses) included in AOCI 1 — (110) — — Purchases (3) 14 12 — — 15 Sales (3) (8) — — — (30) Issuances (3) — — — —

Debt

Debt	9 Months Ended
	Sep. 30, 2024
Debt Disclosure [Abstract]
Long-Term Debt	13. Long-term Debt Senior Notes In June and September 2024, MetLife, Inc. issued $500 million and $250 million, respectively, of senior notes due December 2034, which form a single series and bear interest at a fixed rate of 5.300%, payable semi-annually. In connection with the June and September issuances, MetLife, Inc. incurred $4 million and $2 million, respectively, of related costs, which, in each case, will be amortized over the term of the applicable senior notes. In April 2024, MetLife, Inc. redeemed for $438 million in cash all of its £350 million aggregate principal amount outstanding 5.375% senior notes due December 2024. In March 2024, MetLife, Inc. issued the following fixed rate senior notes totaling $752 million, interest on which is payable semi-annually: • ¥7.1 billion due March 2029 which bear interest annually at 1.009%; • ¥23.1 billion due March 2031 which bear interest annually at 1.415%; • ¥16.7 billion due March 2034 which bear interest annually at 1.670%; • ¥11.2 billion due March 2039 which bear interest annually at 1.953%; • ¥15.5 billion due March 2044 which bear interest annually at 2.195%; • ¥23.5 billion due March 2054 which bear interest annually at 2.390%; and • ¥15.2 billion due March 2059 which bear interest annually at 2.448%. In connection with the March 2024 issuances, MetLife, Inc. incurred $6 million of related costs which are amortized over the applicable term of each series of the senior notes.

Equity

Equity	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Equity	14. Equity Preferred Stock Preferred stock authorized, issued and outstanding was as follows at both September 30, 2024 and December 31, 2023: Series Shares Shares Issued and Floating Rate Non-Cumulative Preferred Stock, Series A 27,600,000 24,000,000 5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D 500,000 500,000 5.625% Non-Cumulative Preferred Stock, Series E 32,200 32,200 4.75% Non-Cumulative Preferred Stock, Series F 40,000 40,000 3.85% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G 1,000,000 1,000,000 Series A Junior Participating Preferred Stock 10,000,000 — Not designated 160,827,800 — Total 200,000,000 25,572,200 The per share and aggregate dividends declared for MetLife, Inc.’s preferred stock were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Series Per Share Aggregate Per Share Aggregate Per Share Aggregate Per Share Aggregate (In millions, except per share data) A $ 0.417 $ 10 $ 0.419 $ 9 $ 1.267 $ 30 $ 1.155 $ 27 D $ 29.375 14 $ 29.375 14 $ 58.750 29 $ 58.750 29 E $ 351.563 11 $ 351.563 12 $ 1,054.689 34 $ 1,054.689 34 F $ 296.875 12 $ 296.875 12 $ 890.625 36 $ 890.625 36 G $ 19.250 20 $ 19.250 20 $ 38.500 39 $ 38.500 39 Total $ 67 $ 67 $ 168 $ 165 Common Stock MetLife, Inc. announced that its Board of Directors authorized common stock repurchases as follows: Announcement Date Authorization Amount Authorization Remaining at September 30, 2024 (1) (In millions) May 1, 2024 $ 3,000 $ 2,301 May 25, 2023 $ 1,000 $ — May 3, 2023 $ 3,000 $ — May 4, 2022 $ 3,000 $ — __________________ (1) The Inflation Reduction Act, signed into law on August 16, 2022, imposes a one percent excise tax, net of any allowable offsets, on certain corporate stock buybacks made after December 31, 2022. The authorization remaining at September 30, 2024 does not reflect the applicable excise tax payable. Under these authorizations, MetLife, Inc. may purchase its common stock from the MetLife Policyholder Trust, in the open market (including pursuant to the terms of a pre-set trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934), and in privately negotiated transactions. Common stock repurchases are subject to the discretion of MetLife, Inc.’s Board of Directors and will depend upon the Company’s capital position, liquidity, financial strength and credit ratings, general market conditions, the market price of MetLife, Inc.’s common stock compared to management’s assessment of the stock’s underlying value, applicable regulatory approvals, and other legal and accounting factors. For the nine months ended September 30, 2024 and 2023, MetLife, Inc. repurchased 39,373,496 shares and 36,602,858 shares of its common stock, respectively, through open market purchases for $2.8 billion and $2.2 billion, respectively, excluding applicable excise tax. The excise tax is reflected in treasury stock as part of the cost basis of the common stock repurchased. Stock-Based Compensation Plans Performance Shares and Performance Units Final Performance Shares are paid in shares of MetLife, Inc.’s common stock. Final Performance Units are payable in cash equal to the closing price of MetLife, Inc.’s common stock on a date following the last day of the three-year performance period. The performance factor for the January 1, 2021 – December 31, 2023 performance period was 147.5%, which was determined within a possible range from 0% to 175%. This factor has been applied to the 1,048,303 Performance Shares and 118,848 Performance Units associated with that performance period that vested on December 31, 2023. As a result, in the first quarter of 2024, MetLife, Inc. issued 1,546,247 shares of its common stock (less withholding for taxes and other items, as applicable), excluding shares that payees choose to defer, and MetLife, Inc. or its affiliates paid the cash value of 175,301 Performance Units (less withholding for taxes and other items, as applicable). Dividend Restrictions Insurance Operations For the nine months ended September 30, 2024, American Life Insurance Company paid a dividend of $1.1 billion to MetLife, Inc., for which regulatory approval was obtained as required. See Note 19 of the Notes to Consolidated Financial Statements included in the 2023 Annual Report for additional information on dividend restrictions. AOCI Information regarding changes in the balances of each component of AOCI attributable to MetLife, Inc. was as follows: Three Months Unrealized Investment Gains (Losses), Net of Related Offsets (1) Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument- Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (19,187) $ 99 $ 6,606 $ (73) $ (6,785) $ (1,396) $ (20,736) OCI before reclassifications 9,942 125 (5,891) 99 349 3 4,627 Deferred income tax benefit (expense) (2,082) (101) 1,289 (22) 90 (1) (827) AOCI before reclassifications, net of income tax (11,327) 123 2,004 4 (6,346) (1,394) (16,936) Amounts reclassified from AOCI 121 (607) — — — 32 (454) Deferred income tax benefit (expense) (33) 192 — — — (9) 150 Amounts reclassified from AOCI, net of income tax 88 (415) — — — 23 (304) Balance, end of period $ (11,239) $ (292) $ 2,004 $ 4 $ (6,346) $ (1,371) $ (17,240) Three Months Unrealized Investment Gains (Losses), Net of Related Offsets (1) Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument- Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (17,979) $ 1,179 $ 3,919 $ 108 $ (6,282) $ (1,331) $ (20,386) OCI before reclassifications (12,599) (1,004) 8,223 (142) (348) (1) (5,871) Deferred income tax benefit (expense) 2,871 232 (1,897) 30 (9) — 1,227 AOCI before reclassifications, net of income tax (27,707) 407 10,245 (4) (6,639) (1,332) (25,030) Amounts reclassified from AOCI 710 271 — — — 30 1,011 Deferred income tax benefit (expense) (172) (57) — — — (6) (235) Amounts reclassified from AOCI, net of income tax 538 214 — — — 24 776 Balance, end of period $ (27,169) $ 621 $ 10,245 $ (4) $ (6,639) $ (1,308) $ (24,254) Nine Months Unrealized Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument- Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (14,506) $ 183 $ 2,658 $ 27 $ (6,158) $ (1,446) $ (19,242) OCI before reclassifications 3,450 (376) (807) (28) (136) (1) 2,102 Deferred income tax benefit (expense) (573) 103 153 5 (52) — (364) AOCI before reclassifications, net of income tax (11,629) (90) 2,004 4 (6,346) (1,447) (17,504) Amounts reclassified from AOCI 514 (247) — — — 96 363 Deferred income tax benefit (expense) (124) 45 — — — (20) (99) Amounts reclassified from AOCI, net of income tax 390 (202) — — — 76 264 Balance, end of period $ (11,239) $ (292) $ 2,004 $ 4 $ (6,346) $ (1,371) $ (17,240) Nine Months Unrealized Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument- Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (22,646) $ 1,557 $ 6,115 $ 107 $ (6,377) $ (1,377) $ (22,621) OCI before reclassifications (8,189) (1,085) 5,325 (141) (168) (6) (4,264) Deferred income tax benefit (expense) 1,882 249 (1,195) 30 (94) 1 873 AOCI before reclassifications, net of income tax (28,953) 721 10,245 (4) (6,639) (1,382) (26,012) Amounts reclassified from AOCI 2,316 (130) — — — 90 2,276 Deferred income tax benefit (expense) (532) 30 — — — (16) (518) Amounts reclassified from AOCI, net of income tax 1,784 (100) — — — 74 1,758 Balance, end of period $ (27,169) $ 621 $ 10,245 $ (4) $ (6,639) $ (1,308) $ (24,254) __________________ (1) Primarily unrealized gains (losses) on fixed maturity securities. Information regarding amounts reclassified out of each component of AOCI was as follows: Three Months Nine Months 2024 2023 2024 2023 AOCI Components Amounts Reclassified from AOCI Consolidated Statements of (In millions) Net unrealized investment gains (losses): Net unrealized investment gains (losses) $ (122) $ (730) $ (531) $ (2,420) Net investment gains (losses) Net unrealized investment gains (losses) — 1 — 6 Net investment income Net unrealized investment gains (losses) 1 19 17 98 Net derivative gains (losses) Net unrealized investment gains (losses), before income tax (121) (710) (514) (2,316) Income tax (expense) benefit 33 172 124 532 Net unrealized investment gains (losses), net of income tax (88) (538) (390) (1,784) Deferred gains (losses) on derivatives - cash flow hedges: Interest rate derivatives 5 11 18 38 Net investment income Interest rate derivatives (1) 17 (2) 77 Net investment gains (losses) Foreign currency exchange rate derivatives 1 1 4 3 Net investment income Foreign currency exchange rate derivatives 602 (301) 226 10 Net investment gains (losses) Foreign currency exchange rate derivatives — 1 — 2 Other expenses Credit derivatives — — 1 — Net investment gains (losses) Gains (losses) on cash flow hedges, before income tax 607 (271) 247 130 Income tax (expense) benefit (192) 57 (45) (30) Gains (losses) on cash flow hedges, net of income tax 415 (214) 202 100 Defined benefit plans adjustment: (1) Amortization of net actuarial gains (losses) (35) (33) (104) (98) Amortization of prior service (costs) credit 3 3 8 8 Amortization of defined benefit plan items, before income tax (32) (30) (96) (90) Income tax (expense) benefit 9 6 20 16 Amortization of defined benefit plan items, net of income tax (23) (24) (76) (74) Total reclassifications, net of income tax $ 304 $ (776) $ (264) $ (1,758) __________________ (1) These AOCI components are included in the computation of net periodic benefit costs. See Note 16.

Other Revenues and Other Expens

Other Revenues and Other Expenses	9 Months Ended
	Sep. 30, 2024
Other Income and Expenses [Abstract]
Other Revenues and Other Expenses Disclosure	15. Other Revenues and Other Expenses Other Revenues Information on other revenues, which primarily includes fees related to service contracts from customers, was as follows: Three Months Nine Months 2024 2023 2024 2023 (In millions) Vision fee for service arrangements $ 126 $ 144 $ 402 $ 446 Prepaid legal plans 144 128 437 389 Fee-based investment management 99 103 295 306 Administrative services-only contracts 69 65 205 193 Recordkeeping and administrative services (1) 38 39 113 114 Other revenue from service contracts from customers 78 75 237 214 Total revenues from service contracts from customers 554 554 1,689 1,662 Other 94 52 271 204 Total other revenues $ 648 $ 606 $ 1,960 $ 1,866 __________________ (1) Related to products and businesses no longer actively marketed by the Company. Receivables related to revenues from service contracts from customers were $245 million and $243 million at September 30, 2024 and December 31, 2023, respectively. Other Expenses Information on other expenses was as follows: Three Months Nine Months 2024 2023 2024 2023 (In millions) Employee-related costs (1) $ 892 $ 914 $ 2,742 $ 2,743 Third-party staffing costs 371 362 1,082 1,066 General and administrative expenses 162 209 463 539 Pension, postretirement and postemployment benefit costs 65 59 195 177 Premium taxes, other taxes, and licenses & fees 183 162 530 507 Commissions and other variable expenses 1,515 1,483 4,480 4,347 Capitalization of DAC (691) (742) (2,114) (2,189) Amortization of DAC and VOBA 516 499 1,523 1,448 Amortization of negative VOBA (7) (7) (19) (20) Interest expense on debt 257 265 778 776 Total other expenses $ 3,263 $ 3,204 $ 9,660 $ 9,394 __________________ (1) Includes ($58) million and ($135) million for the three months and nine months ended September 30, 2024, respectively, and $12 million and ($60) million for the three months and nine months ended September 30, 2023, respectively, for the net change in cash surrender value of investments in certain life insurance policies, net of premiums paid.

Employee Benefit Plans

Employee Benefit Plans	9 Months Ended
	Sep. 30, 2024
Retirement Benefits [Abstract]
Employee Benefit Plans	16. Employee Benefit Plans Pension and Other Postretirement Benefit Plans Certain subsidiaries of MetLife, Inc. sponsor a U.S. qualified and various U.S. and non-U.S. nonqualified defined benefit pension plans covering employees who meet specified eligibility requirements. These subsidiaries also provide certain postemployment benefits and certain postretirement medical and life insurance benefits for U.S. and non-U.S. retired employees. The components of net periodic benefit costs, reported in other expenses, were as follows: Three Months 2024 2023 Pension Other Pension Other (In millions) Service costs $ 41 $ — $ 38 $ 1 Interest costs 114 10 118 11 Expected return on plan assets (115) (14) (119) (13) Amortization of net actuarial (gains) losses 42 (7) 40 (7) Amortization of prior service costs (credit) (3) — (3) — Net periodic benefit costs (credit) $ 79 $ (11) $ 74 $ (8) Nine Months 2024 2023 Pension Other Pension Other (In millions) Service costs $ 122 $ 2 $ 113 $ 2 Interest costs 342 30 353 32 Expected return on plan assets (345) (42) (360) (41) Amortization of net actuarial (gains) losses 125 (21) 118 (22) Amortization of prior service costs (credit) (9) — (9) — Net periodic benefit costs (credit) $ 235 $ (31) $ 215 $ (29)

Income Tax

Income Tax	9 Months Ended
	Sep. 30, 2024
Income Tax Disclosure [Abstract]
Income Tax	17. Income Tax For the three months and nine months ended September 30, 2024, the effective tax rate on income (loss) before provision for income tax was 33% and 25%, respectively. The Company’s effective tax rate for the three months ended September 30, 2024 differed from the U.S. statutory rate of 21% primarily due to tax charges from foreign earnings taxed at higher statutory rates than the U.S. statutory rate and foreign losses taxed at lower statutory rates, partially offset by tax benefits from (i) non-taxable investment income and (ii) low income housing and other tax credits, partially offset by the impact of tax equity investments now accounted for under the proportional amortization method. The Company’s effective tax rate for the nine months ended September 30, 2024 differed from the U.S. statutory rate of 21% primarily due to tax charges from foreign earnings taxed at higher statutory rates than the U.S. statutory rate and foreign losses taxed at lower statutory rates, partially offset by tax benefits from (i) non-taxable investment income, (ii) low income housing and other tax credits, partially offset by the impact of tax equity investments now accounted for under the proportional amortization method, and (iii) the corporate tax deduction for stock compensation. For the three months and nine months ended September 30, 2023, the effective tax rate on income (loss) before provision for income tax was 7% and 19%, respectively. The Company’s effective tax rate for the three months ended September 30, 2023 differed from the U.S. statutory rate of 21% primarily due to tax benefits from (i) the reversal of previously non-deductible losses, (ii) low income housing and other tax credits and (iii) foreign earnings taxed at lower statutory rates than the U.S. statutory rate and foreign losses taxed at higher statutory rates, partially offset by the non-taxable investment loss related to the pending disposition of MetLife Malaysia. The Company’s effective tax rate for the nine months ended September 30, 2023 differed from the U.S. statutory rate of 21% primarily due to tax benefits from (i) low income housing and other tax credits, and (ii) non-taxable investment income, largely offset by tax charges from (i) foreign earnings taxed at higher statutory rates than the U.S. statutory rate and foreign losses taxed at lower statutory rates and (ii) the non-taxable investment loss related to the pending disposition of MetLife Malaysia.

Earnings Per Common Share

Earnings Per Common Share	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Earnings Per Common Share	18. Earnings Per Common Share The following table presents the weighted average shares, basic earnings per common share and diluted earnings per common share: Three Months Nine Months 2024 2023 2024 2023 (In millions, except per share data) Weighted Average Shares: Weighted average common stock outstanding - basic 699.3 751.4 710.9 764.1 Incremental common shares from assumed exercise or issuance of stock-based awards 4.4 4.1 4.6 4.6 Weighted average common stock outstanding - diluted 703.7 755.5 715.5 768.7 Net Income (Loss): Net income (loss) $ 1,341 $ 495 $ 3,169 $ 988 Less: Net income (loss) attributable to noncontrolling interests (1) 6 14 17 Less: Preferred stock dividends 67 67 168 165 Net income (loss) available to MetLife, Inc.’s common shareholders $ 1,275 $ 422 $ 2,987 $ 806 Basic $ 1.82 $ 0.56 $ 4.20 $ 1.05 Diluted $ 1.81 $ 0.56 $ 4.17 $ 1.05

Contingencies, Commitments and

Contingencies, Commitments and Guarantees	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Contingencies, Commitments and Guarantees	19. Contingencies, Commitments and Guarantees Contingencies Litigation The Company is a defendant in a large number of litigation matters. Putative or certified class action litigation and other litigation and claims and assessments against the Company, in addition to those discussed below and those otherwise provided for in the Company’s interim condensed consolidated financial statements, have arisen in the course of the Company’s business, including, but not limited to, in connection with its activities as an insurer, mortgage lending bank, employer, investor, investment advisor, broker-dealer, and taxpayer. The Company also receives and responds to subpoenas or other inquiries seeking a broad range of information from state regulators, including state insurance commissioners; state attorneys general or other state governmental authorities; federal regulators, including the U.S. Securities and Exchange Commission; federal governmental authorities, including congressional committees; and the Financial Industry Regulatory Authority, as well as from local and national regulators and government authorities in jurisdictions outside the United States where the Company conducts business. The issues involved in information requests and regulatory matters vary widely, but can include inquiries or investigations concerning the Company’s compliance with applicable insurance and other laws and regulations. The Company cooperates in these inquiries. It is not possible to predict the ultimate outcome of all pending investigations and legal proceedings. The Company establishes liabilities for litigation and regulatory loss contingencies when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. In certain circumstances where liabilities have been established, there may be coverage under one or more corporate insurance policies, pursuant to which there may be an insurance recovery. Insurance recoveries are recognized as gains when any contingencies relating to the insurance claim have been resolved, which is the earlier of when the gains are realized or realizable. It is possible that some of the matters could require the Company to pay damages or make other expenditures or establish accruals in amounts that could not be reasonably estimated at September 30, 2024. While the potential future charges could be material in the particular quarterly or annual periods in which they are recorded, based on information currently known to management, management does not believe any such charges are likely to have a material effect on the Company’s financial position. Given the large and/or indeterminate amounts sought in certain of these matters and the inherent unpredictability of litigation, it is possible that an adverse outcome in certain matters could, from time to time, have a material effect on the Company’s consolidated net income or cash flows in particular quarterly or annual periods. Matters as to Which an Estimate Can Be Made For some matters, the Company is able to estimate a reasonably possible range of loss. For matters where a loss is believed to be reasonably possible, but not probable, the Company has not made an accrual. As of September 30, 2024, the Company estimates the aggregate range of reasonably possible losses in excess of amounts accrued for these matters to be $0 to $125 million. Matters as to Which an Estimate Cannot Be Made For other matters, the Company is not currently able to estimate the reasonably possible loss or range of loss. The Company is often unable to estimate the possible loss or range of loss until developments in such matters have provided sufficient information to support an assessment of the range of possible loss, such as quantification of a damage demand from plaintiffs, discovery from other parties and investigation of factual allegations, rulings by the court on motions or appeals, analysis by experts, and the progress of settlement negotiations. On a quarterly and annual basis, the Company reviews relevant information with respect to litigation contingencies and updates its accruals, disclosures and estimates of reasonably possible losses or ranges of loss based on such reviews. Asbestos-Related Claims MLIC is and has been a defendant in a large number of asbestos-related suits filed primarily in state courts. These suits principally allege that the plaintiff or plaintiffs suffered personal injury resulting from exposure to asbestos and seek both actual and punitive damages. MLIC has never engaged in the business of manufacturing or selling asbestos-containing products, nor has MLIC issued liability or workers’ compensation insurance to companies in the business of manufacturing or selling asbestos-containing products. The lawsuits principally have focused on allegations with respect to certain research, publication and other activities of one or more of MLIC’s employees during the period from the 1920s through approximately the 1950s and allege that MLIC learned or should have learned of certain health risks posed by asbestos and, among other things, improperly publicized or failed to disclose those health risks. MLIC believes that it should not have legal liability in these cases. The outcome of most asbestos litigation matters, however, is uncertain and can be impacted by numerous variables, including differences in legal rulings in various jurisdictions, the nature of the alleged injury and factors unrelated to the ultimate legal merit of the claims asserted against MLIC. MLIC’s defenses include that: (i) MLIC owed no duty to the plaintiffs; (ii) plaintiffs did not rely on any actions of MLIC; (iii) MLIC’s conduct was not the cause of the plaintiffs’ injuries; and (iv) plaintiffs’ exposure occurred after the dangers of asbestos were known. During the course of the litigation, certain trial courts have granted motions dismissing claims against MLIC, while other trial courts have denied MLIC’s motions. There can be no assurance that MLIC will receive favorable decisions on motions in the future. While most cases brought to date have settled, MLIC intends to continue to defend aggressively against claims based on asbestos exposure, including defending claims at trials. As reported in the 2023 Annual Report, MLIC received approximately 2,565 asbestos-related claims in 2023. For the nine months ended September 30, 2024 and 2023, MLIC received approximately 2,251 and 1,924 new asbestos-related claims, respectively. See Note 24 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for historical information concerning asbestos claims and MLIC’s update in its recorded liability at December 31, 2023. The number of asbestos cases that may be brought, the aggregate amount of any liability that MLIC may incur, and the total amount paid in settlements in any given year are uncertain and may vary significantly from year to year. The ability of MLIC to estimate its ultimate asbestos exposure is subject to considerable uncertainty, and the conditions impacting its liability can be dynamic and subject to change. The availability of reliable data is limited and it is difficult to predict the numerous variables that can affect liability estimates, including the number of future claims, the cost to resolve claims, the disease mix and severity of disease in pending and future claims, the willingness of courts to allow plaintiffs to pursue claims against MLIC when exposure to asbestos took place after the dangers of asbestos exposure were well known, and the impact of any possible future adverse verdicts and their amounts. The ability to make estimates regarding ultimate asbestos exposure declines significantly as the estimates relate to years further in the future. In the Company’s judgment, there is a future point after which losses cease to be probable and reasonably estimable. It is reasonably possible that the Company’s total exposure to asbestos claims may be materially greater than the asbestos liability currently accrued and that future charges to income may be necessary, but management does not believe any such charges are likely to have a material effect on the Company’s financial position. The Company believes adequate provision has been made in its interim condensed consolidated financial statements for all probable and reasonably estimable losses for asbestos-related claims. MLIC’s recorded asbestos liability covers pending claims, claims not yet asserted, and legal defense costs and is based on estimates and includes significant assumptions underlying its analysis. MLIC reevaluates on a quarterly and annual basis its exposure from asbestos litigation, including studying its claims experience, reviewing external literature regarding asbestos claims experience in the United States, assessing relevant trends impacting asbestos liability and considering numerous variables that can affect its asbestos liability exposure on an overall or per claim basis. Based upon its regular reevaluation of its exposure from asbestos litigation, MLIC has updated its liability analysis for asbestos-related claims through September 30, 2024. Total Asset Recovery Services, LLC. v. MetLife, Inc., et al. (Supreme Court of the State of New York, County of New York, filed December 27, 2017) Total Asset Recovery Services (the “Relator”) brought an action under the qui tam provision of the New York False Claims Act (the “Act”) on behalf of itself and the Sta te of New York. The Relator originally filed this action under seal in 2010, and the complaint was unsealed on December 19, 2017. The Relator alleges that MetLife, Inc., MLIC, and several other insurance companies violated the Act by filing false unclaimed property reports with the State of New York from 1986 to 2017, to avoid having to escheat the proceeds of more than 25,000 life insurance policies, including policies for which the defendants escheated funds as part of their demutualizations in the late 1990s. The Relator seeks treble damages and other relief. In December of 2020, the Appellate Division of the New York State Supreme Court, First Department, reversed the court’s order granting MetLife, Inc. and MLIC’s motion to dismiss and remanded the case. The Relator filed a Fourth Amended Complaint in January of 2023. On October 13, 2024, the trial court denied the defendants’ motion to dismiss the complaint. The Company intends to defend the action vigorously. Matters Related to Group Annuity Benefits In 2018, the Company announced that it identified a material weakness in its internal control over financial reporting related to the practices and procedures for estimating reserves for certain group annuity benefits. Several regulators have made inquiries into the issue, and it is possible that other jurisdictions may pursue similar investigations or inquiries. The Company could be exposed to lawsuits and additional legal actions relating to the issue. These may result in payments, including damages, fines, penalties, interest and other amounts assessed or awarded by courts or regulatory authorities under applicable escheat, tax, securities, Employee Retirement Income Security Act of 1974, or other laws or regulations. The Company could incur significant costs in connection with these actions. Commitments Mortgage Loan Commitments The Company commits to lend funds under mortgage loan commitments. The amounts of these mortgage loan commitments were $2.4 billion and $4.0 billion at September 30, 2024 and December 31, 2023, respectively. Commitments to Fund Partnership Investments, Bank Credit Facilities and Private Corporate Bond Investments The Company commits to fund partnership investments and to lend funds under bank credit facilities and private corporate bond investments. The amounts of these unfunded commitments were $8.3 billion and $9.2 billion at September 30, 2024 and December 31, 2023, respectively. Guarantees In the normal course of its business, the Company has provided certain indemnities and guarantees to third parties such that it may be required to make payments now or in the future. In the context of acquisition, disposition, investment and other transactions, the Company has provided indemnities and guarantees, including those related to tax, environmental and other specific liabilities and other indemnities and guarantees that are triggered by, among other things, breaches of representations, warranties or covenants provided by the Company. In addition, in the normal course of business, the Company provides indemnifications to counterparties in contracts with triggers similar to the foregoing, as well as for certain other liabilities, such as third-party lawsuits. These obligations are often subject to time limitations that vary in duration, including contractual limitations and those that arise by operation of law, such as applicable statutes of limitation. In some cases, the maximum potential obligation under the indemnities and guarantees is subject to a contractual limitation ranging from less than $1 million to $329 million, with a cumulative maximum of $638 million, while in other cases such limitations are not specified or applicable. Since certain of these obligations are not subject to limitations, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future. Management believes that it is unlikely the Company will have to make any material payments under these indemnities or guarantees. In addition, the Company indemnifies its directors and officers as provided in its charters and by-laws. Also, the Company indemnifies its agents for liabilities incurred as a result of their representation of the Company’s interests. Since these indemnities are generally not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these indemnities in the future. The Company also has minimum fund yield requirements on certain pension funds. Since these guarantees are not subject to limitation with respect to duration or amount, the Company does not believe that it is possible to determine the maximum potential amount that could become due under these guarantees in the future. The Company’s recorded liabilities were $19 million at both September 30, 2024 and December 31, 2023, for indemnities and guarantees.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ 1,342	$ 489	$ 3,155	$ 971

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Business, Basis of Presentati_2

Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to adopt accounting policies and make estimates and assumptions that affect amounts reported on the interim condensed consolidated financial statements. In applying these policies and estimates, management makes subjective and complex judgments that frequently require assumptions about matters that are inherently uncertain. Many of these policies, estimates and related judgments are common in the insurance and financial services industries; others are specific to the Company’s business and operations. Actual results could differ from these estimates.
Consolidation of Subsidiaries	The accompanying interim condensed consolidated financial statements are unaudited and reflect all adjustments (including normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in conformity with GAAP. Interim results are not necessarily indicative of full year performance. The December 31, 2023 consolidated balance sheet data was derived from audited consolidated financial statements included in MetLife, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”), which include all disclosures required by GAAP. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company included in the 2023 Annual Report. Consolidation The accompanying interim condensed consolidated financial statements include the accounts of MetLife, Inc. and its subsidiaries, as well as partnerships and joint ventures in which the Company has a controlling financial interest, and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. Intercompany accounts and transactions have been eliminated. The Company uses the equity method of accounting, unless the fair value option (“FVO”) is applied, for real estate joint ventures and other limited partnership interests (“investee”) when it has more than a minor ownership interest or more than a minor influence over the investee’s operations. The Company generally recognizes its share of the investee’s earnings in net investment income on a three-month lag in instances where the investee’s financial information is not sufficiently timely or when the investee’s reporting period differs from the Company’s reporting period. Closed block assets, liabilities, revenues and expenses are combined on a line-by-line basis with the assets, liabilities, revenues and expenses outside the closed block based on the nature of the particular item.
New Accounting Pronouncements	Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (each, an “ASU”) to the FASB Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The following tables provide a description of ASUs recently issued by the FASB and the impact of their adoption on the Company’s consolidated financial statements. Adopted Accounting Pronouncements The table below describes the impacts of ASUs adopted by the Company. Standard Description Effective Date and Impact on Financial Statements ASU 2023-02, Investments—Equity Method and Joint Ventures (Topic 323): Accounting for Investments in Tax Credit Structures Using the Proportional Amortization Method The amendments in this update permit reporting entities to elect to account for their tax equity investments, regardless of the tax credit program from which the income tax credits are received, using the proportional amortization method if certain conditions are met. In addition, disclosures describing the nature of the investments and related income tax credits and benefits will be required. January 1, 2024. The Company adopted this update, applying a modified retrospective basis. The Company has elected to use the proportional amortization method to account for its tax equity investments that meet the required criteria. The adoption of this update resulted in a decrease to retained earnings of $219 million, net of income tax, primarily related to the Company’s tax equity investments reported within other invested assets, as of January 1, 2024. Future Adoption of Accounting Pronouncements ASUs not listed below were assessed and either determined to be not applicable or are not expected to have a material impact on the Company’s consolidated financial statements or disclosures. ASUs issued but not yet adopted as of September 30, 2024 that are currently being assessed and may or may not have a material impact on the Company’s consolidated financial statements or disclosures are summarized in the table below. Standard Description Effective Date and Impact on Financial Statements ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures Among other things, the amendments in this update require that public business entities, on an annual basis: (i) disclose specific categories in the rate reconciliation; and (ii) provide additional information for reconciling items that meet a quantitative threshold. In addition, the amendments in this update require that all entities disclose on an annual basis the following information about income taxes paid: (i) the amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign taxes; and (ii) the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than five percent of total income taxes paid (net of refunds received). Effective for annual periods beginning January 1, 2025, to be applied prospectively with an option for retrospective application (with early adoption permitted). The Company is currently evaluating the impact of the guidance on its annual disclosures to be included in its 2025 consolidated financial statements. ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures The amendments in this update are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The key amendments include: (i) disclosures on significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”) and included within each reported measure of segment profit or loss on an annual and interim basis; (ii) disclosures on an amount for other segment items by reportable segment and a description of its composition on an annual and interim basis. The other segment items category is the difference between segment revenue less the significant expenses disclosed and each reported measure of segment profit or loss; (iii) providing all annual disclosures on a reportable segment’s profit or loss and assets currently required by FASB ASC Topic 280, Segment Reporting in interim periods; and (iv) specifying the title and position of the CODM. Effective for annual periods beginning January 1, 2024 and interim periods beginning January 1, 2025, to be applied on a retrospective basis unless it is impracticable (with early adoption permitted). The Company will include the applicable enhanced disclosures in its 2024 annual consolidated financial statements.
Closed Block	On April 7, 2000 (the “Demutualization Date”), Metropolitan Life Insurance Company (“MLIC”) converted from a mutual life insurance company to a stock life insurance company and became a wholly-owned subsidiary of MetLife, Inc. The conversion was pursuant to an order by the New York Superintendent of Insurance approving MLIC’s plan of reorganization, as amended (the “Plan of Reorganization”). On the Demutualization Date, MLIC established a closed block for the benefit of holders of certain individual life insurance policies of MLIC. See Note 10 to the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for further information on the closed block. Experience within the closed block, in particular mortality and investment yields, as well as realized and unrealized gains and losses, directly impact the policyholder dividend obligation. Amortization of the closed block DAC, which resides outside of the closed block, is based upon policy count within the closed block.
Investments	Maturities of Fixed Maturity Securities AFS Actual maturities may differ from contractual maturities due to the exercise of call or prepayment options. Fixed maturity securities AFS not due at a single maturity date have been presented in the year of final contractual maturity. Structured Products are shown separately, as they are not due at a single maturity. Evaluation of Fixed Maturity Securities AFS for Credit Loss Evaluation and Measurement Methodologies See Note 11 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report for a description of the Company’s Evaluation and Measurement Methodologies of Fixed Maturity Securities AFS for Credit Loss. ACL Methodology The Company records an allowance for expected lifetime credit loss in earnings within net investment gains (losses) in an amount that represents the portion of the amortized cost basis of mortgage loans that the Company does not expect to collect, resulting in mortgage loans being presented at the net amount expected to be collected. In determining the Company’s ACL, management applies significant judgment to estimate expected lifetime credit loss, including: (i) pooling mortgage loans that share similar risk characteristics, (ii) considering expected lifetime credit loss over the contractual term of its mortgage loans adjusted for expected prepayments and any extensions, and (iii) considering past events and current and forecasted economic conditions. Each of the Company’s commercial, agricultural and residential mortgage loan portfolio segments are evaluated separately. The ACL is calculated for each mortgage loan portfolio segment based on inputs unique to each loan portfolio segment. On a quarterly basis, mortgage loans within a portfolio segment that share similar risk characteristics, such as internal risk ratings or consumer credit scores, are pooled for calculation of ACL. On an ongoing basis, mortgage loans with dissimilar risk characteristics (i.e., loans with significant declines in credit quality), such as collateral dependent mortgage loans (i.e., when the borrower is experiencing financial difficulty, including when foreclosure is reasonably possible or probable), are evaluated individually for credit loss. The ACL for loans evaluated individually are established using the same methodologies for all three portfolio segments. For example, the ACL for a collateral dependent loan is established as the excess of amortized cost over the estimated fair value of the loan’s underlying collateral, less selling cost when foreclosure is probable. Accordingly, the change in the estimated fair value of collateral dependent loans, which are evaluated individually for credit loss, is recorded as a change in the ACL which is recorded on a quarterly basis as a charge or credit to earnings in net investment gains (losses). Commercial and Agricultural Mortgage Loan Portfolio Segments Within each loan portfolio segment, commercial and agricultural loans are pooled by internal risk rating. Estimated lifetime loss rates, which vary by internal risk rating, are applied to the amortized cost of each loan, excluding accrued investment income, on a quarterly basis to develop the ACL. Internal risk ratings are based on an assessment of the loan’s credit quality, which can change over time. The estimated lifetime loss rates are based on several loan portfolio segment-specific factors, including (i) the Company’s experience with defaults and loss severity, (ii) expected default and loss severity over the forecast period, (iii) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, (iv) loan specific characteristics including loan-to-value (“LTV”) ratios, and (v) internal risk ratings. These evaluations are revised as conditions change and new information becomes available. The Company uses its several decades of historical default and loss severity experience which capture multiple economic cycles. The Company uses a forecast of economic assumptions for a two-year period for most of its commercial and agricultural mortgage loans, while a one-year period is used for loans originated in certain markets. After the applicable forecast period, the Company reverts to its historical loss experience using a straight-line basis over two years. For evaluations of commercial mortgage loans, in addition to historical experience, management considers factors that include the impact of a rapid change to the economy, which may not be reflected in the loan portfolio, recent loss and recovery trend experience as compared to historical loss and recovery experience, and loan specific characteristics including debt service coverage ratios (“DSCR”). In estimating expected lifetime credit loss over the term of its commercial mortgage loans, the Company adjusts for expected prepayment and extension experience during the forecast period using historical prepayment and extension experience considering the expected position in the economic cycle and the loan profile (i.e., floating rate, shorter-term fixed rate and longer-term fixed rate) and after the forecast period using long-term historical prepayment experience. For evaluations of agricultural mortgage loans, in addition to historical experience, management considers factors that include increased stress in certain sectors, which may be evidenced by higher delinquency rates, or a change in the number of higher risk loans. In estimating expected lifetime credit loss over the term of its agricultural mortgage loans, the Company’s experience is much less sensitive to the position in the economic cycle and by loan profile; accordingly, historical prepayment experience is used, while extension terms are not prevalent with the Company’s agricultural mortgage loans. Commercial mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, an analysis of the property financial statements and rent roll, lease rollover analysis, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios, DSCR and tenant creditworthiness. The monitoring process focuses on higher risk loans, which include those that are classified as restructured, delinquent or in foreclosure, as well as loans with higher LTV ratios and lower DSCR. Agricultural mortgage loans are reviewed on an ongoing basis, which review includes, but is not limited to, property inspections, market analysis, estimated valuations of the underlying collateral, LTV ratios and borrower creditworthiness, as well as reviews on a geographic and property-type basis. The monitoring process for agricultural mortgage loans also focuses on higher risk loans. For commercial mortgage loans, the primary credit quality indicator is the DSCR, which compares a property’s net operating income to amounts needed to service the principal and interest due under the loan. Generally, the lower the DSCR, the higher the risk of experiencing a credit loss. The Company also reviews the LTV ratio of its commercial mortgage loan portfolio. LTV ratios compare the unpaid principal balance of the loan to the estimated fair value of the underlying collateral. Generally, the higher the LTV ratio, the higher the risk of experiencing a credit loss. The DSCR and the values utilized in calculating the ratio are updated routinely. In addition, the LTV ratio is routinely updated for all but the lowest risk loans as part of the Company’s ongoing review of its commercial mortgage loan portfolio. For agricultural mortgage loans, the Company’s primary credit quality indicator is the LTV ratio. The values utilized in calculating this ratio are developed in connection with the ongoing review of the agricultural mortgage loan portfolio and are routinely updated. After commercial and agricultural mortgage loans are approved, the Company makes commitments to lend and, typically, borrowers draw down on some or all of the commitments. The timing of mortgage loan funding is based on the commitment expiration dates. A liability for credit loss for unfunded commercial and agricultural mortgage loan commitments that is not unconditionally cancellable is recognized in earnings and is reported within net investment gains (losses). The liability is based on estimated lifetime loss rates as described above and the amount of the outstanding commitments, which for lines of credit, considers estimated utilization rates. When the commitment is funded or expires, the liability is adjusted accordingly. Residential Mortgage Loan Portfolio Segment The Company’s residential mortgage loan portfolio is comprised primarily of purchased closed end, amortizing residential mortgage loans, including both performing loans purchased within 12 months of origination and reperforming loans purchased after they have been performing for at least 12 months post-modification. Residential mortgage loans are pooled by loan type (i.e., new origination and reperforming) and pooled by similar risk profiles (including consumer credit score and LTV ratios). Estimated lifetime loss rates, which vary by loan type and risk profile, are applied to the amortized cost of each loan excluding accrued investment income on a quarterly basis to develop the ACL. The estimated lifetime loss rates are based on several factors, including (i) industry historical experience and expected results over the forecast period for defaults, (ii) loss severity, (iii) prepayment rates, (iv) current and forecasted economic conditions including growth, inflation, interest rates and unemployment levels, and (v) loan pool specific characteristics including consumer credit scores, LTV ratios, payment history and home prices. These evaluations are revised as conditions change and new information becomes available. The Company uses industry historical experience which captures multiple economic cycles as the Company has purchased most of its residential mortgage loans in the last five years. The Company uses a forecast of economic assumptions for a two-year period for most of its residential mortgage loans. After the applicable forecast period, the Company reverts to industry historical loss experience using a straight-line basis over one year. For residential mortgage loans, the Company’s primary credit quality indicator is whether the loan is performing or nonperforming. The Company generally defines nonperforming residential mortgage loans as those that are 60 or more days past due and/or in nonaccrual status which is assessed monthly. Generally, nonperforming residential mortgage loans have a higher risk of experiencing a credit loss. Past Due and Nonaccrual Mortgage Loans Leased Real Estate Investments - Operating Leases Variable Interest Entities The Company has invested in legal entities that are VIEs. In certain instances, the Company holds both the power to direct the most significant activities of the entity, as well as an economic interest in the entity and, as such, is deemed to be the primary beneficiary or consolidator of the entity. The determination of the VIE’s primary beneficiary requires an evaluation of the contractual and implied rights and obligations associated with each party’s relationship with or involvement in the entity.
Derivatives	The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities, and (iii) foreign currency forwards to hedge the foreign currency fair value exposure of foreign currency denominated investments. The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities, (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments, and (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed-rate investments. The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements. The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties in jurisdictions in which it understands that close-out netting should be enforceable and establishing and monitoring exposure limits. The Company’s bilateral contracts between two counterparties (“OTC-bilateral”) derivative transactions are governed by International Swaps and Derivatives Association, Inc. (“ISDA”) Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, close-out netting permits the Company (subject to financial regulations such as the Orderly Liquidation Authority under Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act) to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions and to apply collateral to the obligations, without application of the automatic stay, upon the counterparty’s bankruptcy. All of the Company’s ISDA Master Agreements also include Credit Support Annex provisions which require both the pledging and accepting of collateral in connection with its OTC-bilateral derivatives as required by applicable law. Additionally, the Company is required to pledge initial margin for certain new OTC-bilateral derivative transactions to third-party custodians. The Company’s over-the-counter cleared (“OTC-cleared”) derivatives are effected through central clearing counterparties and its exchange-traded derivatives are effected through regulated exchanges. Such positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by brokers and central clearinghouses to such derivatives. See Note 12 for a description of the impact of credit risk on the valuation of derivatives.
Employee Benefit Plans	Certain subsidiaries of MetLife, Inc. sponsor a U.S. qualified and various U.S. and non-U.S. nonqualified defined benefit pension plans covering employees who meet specified eligibility requirements. These subsidiaries also provide certain postemployment benefits and certain postretirement medical and life insurance benefits for U.S. and non-U.S. retired employees.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities (Policies)	9 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	The Company designates and accounts for the following as fair value hedges when they have met the requirements of fair value hedging: (i) interest rate swaps to convert fixed rate assets and liabilities to floating rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency fair value exposure of foreign currency denominated assets and liabilities, and (iii) foreign currency forwards to hedge the foreign currency fair value exposure of foreign currency denominated investments. The Company designates and accounts for the following as cash flow hedges when they have met the requirements of cash flow hedging: (i) interest rate swaps to convert floating rate assets and liabilities to fixed rate assets and liabilities, (ii) foreign currency swaps to hedge the foreign currency cash flow exposure of foreign currency denominated assets and liabilities, (iii) interest rate forwards and credit forwards to lock in the price to be paid for forward purchases of investments, and (iv) interest rate swaps and interest rate forwards to hedge the forecasted purchases of fixed-rate investments. The Company may be exposed to credit-related losses in the event of nonperformance by its counterparties to derivatives. Generally, the current credit exposure of the Company’s derivatives is limited to the net positive estimated fair value of derivatives at the reporting date after taking into consideration the existence of master netting or similar agreements and any collateral received pursuant to such agreements. The Company manages its credit risk related to derivatives by entering into transactions with creditworthy counterparties in jurisdictions in which it understands that close-out netting should be enforceable and establishing and monitoring exposure limits. The Company’s bilateral contracts between two counterparties (“OTC-bilateral”) derivative transactions are governed by International Swaps and Derivatives Association, Inc. (“ISDA”) Master Agreements which provide for legally enforceable set-off and close-out netting of exposures to specific counterparties in the event of early termination of a transaction, which includes, but is not limited to, events of default and bankruptcy. In the event of an early termination, close-out netting permits the Company (subject to financial regulations such as the Orderly Liquidation Authority under Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act) to set off receivables from the counterparty against payables to the same counterparty arising out of all included transactions and to apply collateral to the obligations, without application of the automatic stay, upon the counterparty’s bankruptcy. All of the Company’s ISDA Master Agreements also include Credit Support Annex provisions which require both the pledging and accepting of collateral in connection with its OTC-bilateral derivatives as required by applicable law. Additionally, the Company is required to pledge initial margin for certain new OTC-bilateral derivative transactions to third-party custodians. The Company’s over-the-counter cleared (“OTC-cleared”) derivatives are effected through central clearing counterparties and its exchange-traded derivatives are effected through regulated exchanges. Such positions are marked to market and margined on a daily basis (both initial margin and variation margin), and the Company has minimal exposure to credit-related losses in the event of nonperformance by brokers and central clearinghouses to such derivatives. See Note 12 for a description of the impact of credit risk on the valuation of derivatives.

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2024
Segment Reporting [Abstract]
Segment Reporting Information, by Segment	Three Months Ended September 30, 2024 Group Benefits RIS Asia Latin EMEA MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 5,538 $ 1,451 $ 1,272 $ 1,141 $ 562 $ 673 $ (6) $ 10,631 $ 16 $ 10,647 Universal life and investment-type product policy fees 231 67 420 346 84 80 — 1,228 — 1,228 Net investment income 311 2,133 1,132 435 55 981 96 5,143 84 5,227 Other revenues 377 61 18 9 9 40 98 612 36 648 Net investment gains (losses) — — — — — — — — (77) (77) Net derivative gains (losses) — — — — — — — — 767 767 Total revenues 6,457 3,712 2,842 1,931 710 1,774 188 17,614 826 18,440 Expenses Policyholder benefits and claims and policyholder dividends 4,927 2,247 1,035 1,091 276 1,221 — 10,797 (50) 10,747 Policyholder liability remeasurement (gains) losses — (148) 60 (18) 9 (35) — (132) — (132) MRB remeasurement (gains) losses — — — — — — — — 531 531 Interest credited to PABs 49 874 683 108 17 84 — 1,815 222 2,037 Capitalization of deferred policy acquisition costs (“DAC”) (4) (53) (336) (174) (119) (4) (1) (691) — (691) Amortization of DAC and value of business acquired (“VOBA”) 6 14 217 126 92 58 3 516 — 516 Amortization of negative VOBA — — (6) — (1) — — (7) — (7) Interest expense on debt — 4 — 4 — 4 245 257 — 257 Other expenses 1,007 183 758 485 342 220 164 3,159 29 3,188 Total expenses 5,985 3,121 2,411 1,622 616 1,548 411 15,714 732 16,446 Provision for income tax expense (benefit) 99 119 125 88 24 44 (41) 458 195 653 Adjusted earnings $ 373 $ 472 $ 306 $ 221 $ 70 $ 182 $ (182) 1,442 Adjustments to: Total revenues 826 Total expenses (732) Provision for income tax (expense) benefit (195) Net income (loss) $ 1,341 $ 1,341 Three Months Ended September 30, 2023 Group Benefits RIS Asia Latin EMEA MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 5,276 $ 2,330 $ 1,312 $ 1,116 $ 502 $ 685 $ 9 $ 11,230 $ — $ 11,230 Universal life and investment-type product policy fees 219 82 411 359 79 184 — 1,334 — 1,334 Net investment income 330 2,009 1,023 365 51 1,153 125 5,056 (231) 4,825 Other revenues 371 66 20 9 7 41 103 617 (11) 606 Net investment gains (losses) — — — — — — — — (927) (927) Net derivative gains (losses) — — — — — — — — (1,202) (1,202) Total revenues 6,196 4,487 2,766 1,849 639 2,063 237 18,237 (2,371) 15,866 Expenses Policyholder benefits and claims and policyholder dividends 4,592 3,100 1,095 1,020 230 1,311 4 11,352 (69) 11,283 Policyholder liability remeasurement (gains) losses (29) (76) 108 (4) (9) (7) — (17) — (17) MRB remeasurement (gains) losses — — — — — — — — (796) (796) Interest credited to PABs 50 756 576 106 19 198 — 1,705 (47) 1,658 Capitalization of DAC (5) (41) (404) (171) (114) (5) (2) (742) — (742) Amortization of DAC and VOBA 6 13 204 121 87 65 3 499 — 499 Amortization of negative VOBA — — (6) — (1) — — (7) — (7) Interest expense on debt — 3 — 2 — 4 256 265 — 265 Other expenses 937 138 788 493 315 238 250 3,159 30 3,189 Total expenses 5,551 3,893 2,361 1,567 527 1,804 511 16,214 (882) 15,332 Provision for income tax expense (benefit) 135 124 130 83 24 51 (79) 468 (429) 39 Adjusted earnings $ 510 $ 470 $ 275 $ 199 $ 88 $ 208 $ (195) 1,555 Adjustments to: Total revenues (2,371) Total expenses 882 Provision for income tax (expense) benefit 429 Net income (loss) $ 495 $ 495 Nine Months Ended September 30, 2024 Group Benefits RIS Asia Latin EMEA MetLife Corporate Total Adjustments Total (In millions) Revenues Premiums $ 16,848 $ 4,574 $ 3,785 $ 3,378 $ 1,634 $ 2,078 $ 15 $ 32,312 $ 16 $ 32,328 Universal life and investment-type product policy fees 682 215 1,280 1,089 238 252 1 3,757 — 3,757 Net investment income 939 6,339 3,407 1,219 163 3,007 297 15,371 497 15,868 Other revenues 1,156 185 57 31 24 127 293 1,873 87 1,960 Net investment gains (losses) — — — — — — — — (873) (873) Net derivative gains (losses) — — — — — — — — (720) (720) Total revenues 19,625 11,313 8,529 5,717 2,059 5,464 606 53,313 (993) 52,320 Expenses Policyholder benefits and claims and policyholder dividends 14,943 6,966 3,090 3,092 799 3,724 17 32,631 (30) 32,601 Policyholder liability remeasurement (gains) losses (1) (170) 24 (29) 10 2 — (164) — (164) MRB remeasurement (gains) losses — — — — — — — — (345) (345) Interest credited to PABs 145 2,508 1,987 337 53 293 — 5,323 1,004 6,327 Capitalization of DAC (13) (160) (1,032) (527) (362) (13) (7) (2,114) — (2,114) Amortization of DAC and VOBA 19 45 634 380 265 174 6 1,523 — 1,523 Amortization of negative VOBA — — (16) — (3) — — (19) — (19) Interest expense on debt 1 11 — 11 — 11 744 778 — 778 Other expenses 3,026 500 2,204 1,502 1,002 663 546 9,443 49 9,492 Total expenses 18,120 9,700 6,891 4,766 1,764 4,854 1,306 47,401 678 48,079 Provision for income tax expense (benefit) 315 332 460 271 71 116 (158) 1,407 (335) 1,072 Adjusted earnings $ 1,190 $ 1,281 $ 1,178 $ 680 $ 224 $ 494 $ (542) 4,505 Adjustments to: Total revenues (993) Total expenses (678) Provision for income tax (expense) benefit 335 Net income (loss) $ 3,169 $ 3,169 Nine Months Ended September 30, 2023 Group Benefits RIS Asia Latin EMEA MetLife Corporate Total Adjustments Total Consolidated (In millions) Revenues Premiums $ 16,154 $ 5,512 $ 3,999 $ 3,164 $ 1,497 $ 2,127 $ 44 $ 32,497 $ — $ 32,497 Universal life and investment-type product policy fees 660 232 1,204 1,046 231 537 1 3,911 — 3,911 Net investment income 967 5,771 2,954 1,162 143 3,450 255 14,702 (160) 14,542 Other revenues 1,114 205 61 31 23 143 310 1,887 (21) 1,866 Net investment gains (losses) — — — — — — — — (2,650) (2,650) Net derivative gains (losses) — — — — — — — — (2,289) (2,289) Total revenues 18,895 11,720 8,218 5,403 1,894 6,257 610 52,997 (5,120) 47,877 Expenses Policyholder benefits and claims and policyholder dividends 14,452 7,766 3,282 2,962 728 4,021 32 33,243 31 33,274 Policyholder liability remeasurement (gains) losses (31) (116) 92 (5) (10) 28 — (42) — (42) MRB remeasurement (gains) losses — — — — — — — — (1,425) (1,425) Interest credited to PABs 144 2,104 1,682 310 54 595 — 4,889 566 5,455 Capitalization of DAC (16) (136) (1,202) (470) (341) (17) (7) (2,189) — (2,189) Amortization of DAC and VOBA 19 36 587 344 257 197 8 1,448 — 1,448 Amortization of negative VOBA — — (17) — (3) — — (20) — (20) Interest expense on debt 1 10 — 8 — 10 747 776 — 776 Other expenses 2,819 430 2,373 1,388 929 707 656 9,302 77 9,379 Total expenses 17,388 10,094 6,797 4,537 1,614 5,541 1,436 47,407 (751) 46,656 Provision for income tax expense (benefit) 318 339 435 233 62 139 (265) 1,261 (1,028) 233 Adjusted earnings $ 1,189 $ 1,287 $ 986 $ 633 $ 218 $ 577 $ (561) 4,329 Adjustments to: Total revenues (5,120) Total expenses 751 Provision for income tax (expense) benefit 1,028 Net income (loss) $ 988 $ 988 The following table presents total assets with respect to the Company’s segments, as well as Corporate & Other, at: September 30, 2024 December 31, 2023 (In millions) Group Benefits $ 36,894 $ 36,715 RIS 229,709 218,587 Asia 162,531 157,206 Latin America 73,419 69,177 EMEA 19,653 18,596 MetLife Holdings 146,403 148,524 Corporate & Other 36,367 38,779 Total $ 704,976 $ 687,584

Future Policy Benefits (Tables)

Future Policy Benefits (Tables)	9 Months Ended
	Sep. 30, 2024
Insurance [Abstract]
Schedule of Liability for Future Policy Benefits, by Product Segment	The Company’s FPBs on the interim condensed consolidated balance sheets was as follows at: September 30, 2024 December 31, 2023 (In millions) Traditional and Limited-Payment Contracts: RIS - Annuities $ 67,645 $ 64,324 Asia: Whole and term life & endowments 12,661 12,874 Accident & health 10,598 10,712 Latin America - Fixed annuities 10,906 9,637 MetLife Holdings - Long-term care 15,657 15,240 Deferred Profit Liabilities: RIS - Annuities 3,754 3,697 Asia: Whole and term life & endowments 785 654 Accident & health 913 830 Latin America - Fixed annuities 549 562 Additional Insurance Liabilities: Asia: Variable life 1,227 1,258 Universal and variable universal life 399 424 MetLife Holdings - Universal and variable universal life 2,471 2,362 MetLife Holdings - Participating life 48,629 49,543 Other long-duration (1) 11,340 11,099 Short-duration and other 13,806 13,190 Total $ 201,340 $ 196,406 __________________ (1) This balance represents liabilities for various smaller product lines across multiple segments, as well as Corporate & Other.
Liability for Future Policy Benefit, Activity	Information regarding these products was as follows: Nine Months 2024 2023 (Dollars in millions) Present Value of Expected Net Premiums Balance, beginning of period, at current discount rate at balance sheet date $ — $ — Balance, beginning of period, at original discount rate $ — $ — Effect of changes in cash flow assumptions (1) — — Effect of actual variances from expected experience (2) (32) (89) Adjusted balance (32) (89) Issuances 5,042 4,422 Net premiums collected (5,010) (4,333) Ending balance at original discount rate — — Balance, end of period, at current discount rate at balance sheet date $ — $ — Present Value of Expected FPBs Balance, beginning of period, at current discount rate at balance sheet date $ 64,515 $ 58,695 Balance, beginning of period, at original discount rate $ 64,737 $ 61,426 Effect of changes in cash flow assumptions (1) (195) (284) Effect of actual variances from expected experience (2) (99) (222) Adjusted balance 64,443 60,920 Issuances 5,168 4,420 Interest accrual 2,326 2,145 Benefit payments (4,479) (4,121) Ending balance at original discount rate 67,458 63,364 Effect of changes in discount rate assumptions 338 (5,438) Balance, end of period, at current discount rate at balance sheet date 67,796 57,926 Cumulative amount of fair value hedging adjustments (151) (430) Net liability for FPBs 67,645 57,496 Less: Reinsurance recoverables 2,041 — Net liability for FPBs, net of reinsurance $ 65,604 $ 57,496 Undiscounted - Expected future benefit payments $ 123,186 $ 119,270 Discounted - Expected future benefit payments (at current discount rate at balance sheet date) $ 67,796 $ 57,926 Weighted-average duration of the liability 9 years 9 years Weighted-average interest accretion (original locked-in) rate 4.8 % 4.7 % Weighted-average current discount rate at balance sheet date 5.0 % 6.1 % _________________ (1) For the nine months ended September 30, 2024, the net effect of changes in cash flow assumptions was partially offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $62 million. For the nine months ended September 30, 2023, the net effect of changes in cash flow assumptions was largely offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $211 million. For the nine months ended September 30, 2024 and 2023, the net effect of changes in cash flow assumptions was primarily driven by updates in assumptions related to mortality. (2) For the nine months ended September 30, 2024, the net effect of actual variances from expected experience was partially offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $29 million. For the nine months ended September 30, 2023, the net effect of actual variances from expected experience was largely offset by the corresponding impact in DPL associated with the RIS segment’s annuity products of $95 million. For the nine months ended September 30, 2023, the net effect of actual variances from expected experience was primarily driven by favorable mortality. The Asia segment’s whole and term life & endowment products in Japan and Korea offer various life insurance coverages to customers. Information regarding these products was as follows: Nine Months 2024 2023 (Dollars in millions) Present Value of Expected Net Premiums Balance, beginning of period, at current discount rate at balance sheet date $ 4,561 $ 4,682 Balance, beginning of period, at original discount rate $ 4,793 $ 4,943 Effect of changes in cash flow assumptions (1) 58 11 Effect of actual variances from expected experience (43) (41) Adjusted balance 4,808 4,913 Issuances 386 614 Interest accrual 52 43 Net premiums collected (456) (457) Effect of foreign currency translation (77) (518) Ending balance at original discount rate 4,713 4,595 Effect of changes in discount rate assumptions (236) (319) Effect of foreign currency translation on the effect of changes in discount rate assumptions 3 23 Balance, end of period, at current discount rate at balance sheet date $ 4,480 $ 4,299 Present Value of Expected FPBs Balance, beginning of period, at current discount rate at balance sheet date $ 17,435 $ 17,463 Balance, beginning of period, at original discount rate $ 17,198 $ 18,209 Effect of changes in cash flow assumptions (1) 36 58 Effect of actual variances from expected experience (39) (14) Adjusted balance 17,195 18,253 Issuances 386 614 Interest accrual 276 278 Benefit payments (726) (895) Effect of foreign currency translation (263) (1,847) Ending balance at original discount rate 16,868 16,403 Effect of changes in discount rate assumptions 272 (742) Effect of foreign currency translation on the effect of changes in discount rate assumptions 1 40 Balance, end of period, at current discount rate at balance sheet date 17,141 15,701 Cumulative impact of flooring the future policyholder benefits reserve — 2 Net liability for FPBs 12,661 11,404 Less: Amount due to reinsurer (2) (1) Net liability for FPBs, net of reinsurance $ 12,663 $ 11,405 Undiscounted: Expected future gross premiums $ 9,393 $ 8,911 Expected future benefit payments $ 28,008 $ 26,785 Discounted (at current discount rate at balance sheet date): Expected future gross premiums $ 8,042 $ 7,582 Expected future benefit payments $ 17,141 $ 15,701 Weighted-average duration of the liability 17 years 17 years Weighted -average interest accretion (original locked-in) rate 2.5 % 2.5 % Weighted-average current discount rate at balance sheet date 2.6 % 2.9 % _________________ (1) For the nine months ended September 30, 2024, the net effect of changes in cash flow assumptions was more than offset by the corresponding impact in DPL associated with the Asia segment’s whole and term life products of $28 million. Nine Months 2024 2023 (Dollars in millions) Present Value of Expected Net Premiums Balance, beginning of period, at current discount rate at balance sheet date $ 19,835 $ 21,181 Balance, beginning of period, at original discount rate $ 21,232 $ 22,594 Effect of changes in cash flow assumptions (1) 439 867 Effect of actual variances from expected experience — (75) Adjusted balance 21,671 23,386 Issuances 842 813 Interest accrual 168 179 Net premiums collected (1,394) (1,546) Effect of foreign currency translation and other - net (149) (2,474) Ending balance at original discount rate 21,138 20,358 Effect of changes in discount rate assumptions (1,481) (1,803) Effect of foreign currency translation on the effect of changes in discount rate assumptions 12 136 Balance, end of period, at current discount rate at balance sheet date $ 19,669 $ 18,691 Present Value of Expected FPBs Balance, beginning of period, at current discount rate at balance sheet date $ 30,480 $ 30,879 Balance, beginning of period, at original discount rate $ 36,010 $ 37,189 Effect of changes in cash flow assumptions (1) 439 898 Effect of actual variances from expected experience 4 (99) Adjusted balance 36,453 37,988 Issuances 841 812 Interest accrual 353 367 Benefit payments (939) (958) Effect of foreign currency translation and other - net (323) (4,061) Ending balance at original discount rate 36,385 34,148 Effect of changes in discount rate assumptions (6,207) (6,866) Effect of foreign currency translation on the effect of changes in discount rate assumptions 43 595 Balance, end of period, at current discount rate at balance sheet date 30,221 27,877 Cumulative impact of flooring the future policyholder benefits reserve 46 143 Net liability for FPBs 10,598 9,329 Less: Reinsurance recoverables 164 136 Net liability for FPBs, net of reinsurance $ 10,434 $ 9,193 Undiscounted: Expected future gross premiums $ 41,446 $ 39,891 Expected future benefit payments $ 47,705 $ 44,612 Discounted (at current discount rate at balance sheet date): Expected future gross premiums $ 33,666 $ 32,286 Expected future benefit payments $ 30,221 $ 27,877 Weighted-average duration of the liability 24 years 25 years Weighted-average interest accretion (original locked-in) rate 1.7 % 1.8 % Weighted-average current discount rate at balance sheet date 2.7 % 2.8 % _________________ (1) For the nine months ended September 30, 2024, the net effect of changes in cash flow assumptions was primarily driven by updates in assumptions related to morbidity, substantially offset by policyholder behavior assumptions related to lapses. For the nine months ended September 30, 2023, the net effect of changes in cash flow assumptions was primarily driven by updates in policyholder behavior assumptions related to lapses, partially offset by updates in assumptions associated with mortality and morbidity. Nine Months 2024 2023 (Dollars in millions) Present Value of Expected Net Premiums Balance, beginning of period, at current discount rate at balance sheet date $ — $ — Balance, at beginning of period, at original discount rate $ — $ — Effect of changes in cash flow assumptions (1) — — Effect of actual variances from expected experience (2) — (2) Adjusted balance — (2) Issuances 760 785 Interest accrual 13 16 Net premiums collected (773) (799) Ending balance at original discount rate — — Balance, end of period, at current discount rate at balance sheet date $ — $ — Present Value of Expected FPBs Balance, beginning of period, at current discount rate at balance sheet date $ 9,637 $ 9,265 Balance, beginning of period, at original discount rate $ 9,249 $ 8,240 Effect of changes in cash flow assumptions (1) (4) (5) Effect of actual variances from expected experience (2) (21) (13) Adjusted balance 9,224 8,222 Issuances 789 869 Interest accrual 253 258 Benefit payments (519) (504) Inflation adjustment 270 273 Effect of foreign currency translation (258) (403) Ending balance at original discount rate 9,759 8,715 Effect of changes in discount rate assumptions 1,126 (59) Effect of foreign currency translation on the effect of changes in discount rate assumptions 21 6 Balance, end of period, at current discount rate at balance sheet date 10,906 8,662 Net liability for FPBs $ 10,906 $ 8,662 Undiscounted - Expected future benefit payments $ 14,663 $ 13,204 Discounted - Expected future benefit payments (at current discount rate at balance sheet date) $ 10,906 $ 8,662 Weighted-average duration of the liability 11 years 10 years Weighted-average interest accretion (original locked-in) rate 3.4 % 3.9 % Weighted-average current discount rate at balance sheet date 2.5 % 3.7 % __________________ (1) For the nine months ended September 30, 2024 and 2023, the net effect of changes in cash flow assumptions was largely offset by the corresponding impact in DPL associated with the Latin America segment’s fixed annuity products of $3 million and $4 million, respectively. (2) For the nine months ended September 30, 2024, the net effect of actual variances from expected experience was not offset by the corresponding impact in DPL associated with the Latin America segment’s fixed annuity products primarily due to the variance related to cohorts with no DPL. For the nine months ended September 30, 2023, the net effect of actual variances from expected experience was partially offset by the corresponding impact in DPL associated with the Latin America segment’s fixed annuity products of $2 million. Nine Months 2024 2023 (Dollars in millions) Present Value of Expected Net Premiums Balance, beginning of period, at current discount rate at balance sheet date $ 5,687 $ 5,775 Balance, beginning of period, at original discount rate $ 5,566 $ 5,807 Effect of changes in cash flow assumptions (1) 212 (152) Effect of actual variances from expected experience 34 173 Adjusted balance 5,812 5,828 Interest accrual 213 222 Net premiums collected (424) (438) Ending balance at original discount rate 5,601 5,612 Effect of changes in discount rate assumptions 159 (258) Balance, end of period, at current discount rate at balance sheet date $ 5,760 $ 5,354 Present Value of Expected FPBs Balance, beginning of period, at current discount rate at balance sheet date $ 20,927 $ 19,619 Balance, beginning of period, at original discount rate $ 20,494 $ 20,165 Effect of changes in cash flow assumptions (1) 205 (190) Effect of actual variances from expected experience 45 194 Adjusted balance 20,744 20,169 Interest accrual 812 801 Benefit payments (638) (579) Ending balance at original discount rate 20,918 20,391 Effect of changes in discount rate assumptions 499 (2,012) Balance, end of period, at current discount rate at balance sheet date 21,417 18,379 Net liability for FPBs $ 15,657 $ 13,025 Undiscounted: Expected future gross premiums $ 10,735 $ 10,713 Expected future benefit payments $ 45,098 $ 45,152 Discounted (at current discount rate at balance sheet date): Expected future gross premiums $ 7,319 $ 6,714 Expected future benefit payments $ 21,417 $ 18,379 Weighted-average duration of the liability 14 years 14 years Weighted-average interest accretion (original locked-in) rate 5.4 % 5.5 % Weighted-average current discount rate at balance sheet date 5.2 % 6.3 % __________________ (1)
Additional Liability, Long-Duration Insurance	Information regarding these additional insurance liabilities was as follows: Nine Months 2024 2023 2024 2023 Variable Life Universal and Variable Universal Life (Dollars in millions) Balance, beginning of period $ 1,258 $ 1,381 $ 424 $ 455 Less: Accumulated other comprehensive income (loss) (“AOCI”) adjustment — — (14) (33) Balance, beginning of period, before AOCI adjustment 1,258 1,381 438 488 Effect of changes in cash flow assumptions 17 (4) (23) (2) Effect of actual variances from expected experience (8) (9) (14) (32) Adjusted balance 1,267 1,368 401 454 Assessments accrual (3) (3) — — Interest accrual 13 15 4 5 Excess benefits paid (30) (29) — — Effect of foreign currency translation and other, net (20) (158) (6) (55) Balance, end of period, before AOCI adjustment 1,227 1,193 399 404 Add: AOCI adjustment — — — (18) Balance, end of period $ 1,227 $ 1,193 $ 399 $ 386 Weighted-average duration of the liability 16 years 16 years 42 years 43 years Weighted-average interest accretion rate 1.4 % 1.5 % 1.4 % 1.5 % Nine Months 2024 2023 Universal and Variable Universal Life (Dollars in millions) Balance, beginning of period $ 2,362 $ 2,156 Less: AOCI adjustment (14) (63) Balance, beginning of period, before AOCI adjustment 2,376 2,219 Effect of changes in cash flow assumptions (2) 38 Effect of actual variances from expected experience 36 (10) Adjusted balance 2,410 2,247 Assessments accrual 78 80 Interest accrual 98 92 Excess benefits paid (104) (81) Balance, end of period, before AOCI adjustment 2,482 2,338 Add: AOCI adjustment (11) (65) Balance, end of period 2,471 2,273 Less: Reinsurance recoverables 2,147 766 Balance, end of period, net of reinsurance $ 324 $ 1,507 Weighted-average duration of the liability 15 years 16 years Weighted-average interest accretion rate 5.5 % 5.5 % The Company’s gross premiums or assessments and interest expense recognized in the interim condensed consolidated statements of operations and comprehensive income (loss) for long-duration contracts, excluding MetLife Holdings’ participating life contracts, were as follows: Nine Months 2024 2023 Gross Premiums or Interest Expense (2) Gross Premiums or Interest Expense (2) (In millions) Traditional and Limited-Payment Contracts: RIS - Annuities $ 5,098 $ 2,326 $ 4,433 $ 2,145 Asia: Whole and term life & endowments 850 224 841 235 Accident & health 2,324 185 2,580 188 Latin America - Fixed annuities 773 240 799 242 MetLife Holdings - Long-term care 543 599 547 579 Deferred Profit Liabilities: RIS - Annuities N/A 133 N/A 124 Asia: Whole and term life & endowments N/A 27 N/A 22 Accident & health N/A 15 N/A 13 Latin America - Fixed annuities N/A 15 N/A 17 Additional Insurance Liabilities: Asia: Variable life 85 13 60 15 Universal and variable universal life (32) 4 (20) 5 MetLife Holdings - Universal and variable universal life 492 98 559 92 Other long-duration 3,469 362 3,194 341 Total $ 13,602 $ 4,241 $ 12,993 $ 4,018 __________________ (1) Gross premiums are related to traditional and limited-payment contracts and are included in premiums. Assessments are related to additional insurance liabilities and are included in universal life and investment-type product policy fees and net investment income. (2) Interest expense is included in policyholder benefits and claims.
Liabilities for Unpaid Claims and Claim Expenses	Information regarding the liabilities for unpaid claims and claim adjustment expenses was as follows: Nine Months 2024 2023 (In millions) Balance, beginning of period $ 16,468 $ 16,098 Less: Reinsurance recoverables 2,592 2,452 Net balance, beginning of period 13,876 13,646 Incurred related to: Current period 20,532 19,983 Prior periods (1) 80 327 Total incurred 20,612 20,310 Paid related to: Current period (14,470) (13,991) Prior periods (5,773) (5,883) Total paid (20,243) (19,874) Net balance, end of period 14,245 14,082 Add: Reinsurance recoverables 2,757 2,523 Balance, end of period (included in FPBs and other policy-related balances) $ 17,002 $ 16,605 __________________ (1) For the nine months ended September 30, 2024 and 2023, incurred claims and claim adjustment expenses associated with prior periods increased due to events incurred in prior periods but reported in the respective current period.

Policyholder Account Balances (

Policyholder Account Balances (Tables)	9 Months Ended
	Sep. 30, 2024
Insurance [Abstract]
Policyholder Account Balances	The Company’s PABs on the interim condensed consolidated balance sheets were as follows at: September 30, 2024 December 31, 2023 (In millions) Group Benefits - Group life $ 7,676 $ 7,692 RIS: Capital markets investment products and stable value GICs 65,330 64,140 Annuities and risk solutions 19,572 17,711 Asia: Universal and variable universal life 51,756 49,739 Fixed annuities 38,742 36,863 EMEA - Variable annuities 2,617 2,720 MetLife Holdings: Annuities 10,437 11,537 Life and other 11,284 11,641 Other 17,195 17,226 Total $ 224,609 $ 219,269
Policyholder Account Balance Rollforward	Information regarding this liability was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 7,692 $ 8,028 Deposits 2,857 2,529 Policy charges (493) (475) Surrenders and withdrawals (2,512) (2,432) Benefit payments (9) (9) Net transfers from (to) separate accounts (3) 1 Interest credited 144 143 Balance, end of period $ 7,676 $ 7,785 Weighted-average annual crediting rate 2.5 % 2.4 % At period end: Cash surrender value $ 7,614 $ 7,721 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 265,266 $ 250,611 The RIS segment’s capital markets investment products and stable value GICs in PABs are investment-type products, mainly funding agreements. Information regarding this liability was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 64,140 $ 63,723 Deposits 56,170 54,674 Surrenders and withdrawals (57,068) (56,873) Interest credited 1,811 1,524 Effect of foreign currency translation and other, net 277 369 Balance, end of period $ 65,330 $ 63,417 Weighted-average annual crediting rate 3.8 % 3.2 % Cash surrender value at period end $ 1,953 $ 2,110 Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 17,711 $ 15,549 Deposits 2,367 2,007 Policy charges (122) (133) Surrenders and withdrawals (239) (134) Benefit payments (731) (615) Net transfers from (to) separate accounts 20 54 Interest credited 556 469 Other 10 (133) Balance, end of period $ 19,572 $ 17,064 Weighted-average annual crediting rate 4.0 % 3.9 % At period end: Cash surrender value $ 8,476 $ 7,693 Net amount at risk, excluding offsets from ceded reinsurance: In the event of death $ 44,437 $ 42,043 Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 49,739 $ 46,417 Deposits 4,694 5,439 Policy charges (812) (888) Surrenders and withdrawals (2,483) (2,018) Benefit payments (345) (393) Interest credited 1,153 979 Effect of foreign currency translation and other, net (190) (1,906) Balance, end of period $ 51,756 $ 47,630 Weighted-average annual crediting rate 3.1 % 2.8 % At period end: Cash surrender value $ 46,366 $ 40,663 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 89,793 $ 91,861 Information regarding the Asia segment’s fixed annuity PAB liability in Japan was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 36,863 $ 32,454 Deposits 5,002 6,230 Policy charges (2) (2) Surrenders and withdrawals (2,248) (1,665) Benefit payments (1,718) (1,614) Interest credited 784 629 Effect of foreign currency translation and other, net 61 (552) Balance, end of period $ 38,742 $ 35,480 Weighted-average annual crediting rate 2.8 % 2.5 % At period end: Cash surrender value $ 35,005 $ 30,289 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 8 $ — Information regarding the EMEA segment’s variable annuity PABs in the United Kingdom was as follows: Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 2,720 $ 2,802 Deposits 2 3 Policy charges (44) (48) Surrenders and withdrawals (214) (206) Benefit payments (95) (95) Interest credited (1) 117 69 Effect of foreign currency translation and other, net 131 46 Balance, end of period $ 2,617 $ 2,571 Weighted-average annual crediting rate 6.0 % 3.5 % At period end: Cash surrender value $ 2,617 $ 2,571 Net amount at risk, excluding offsets from reinsurance: In the event of death $ 426 $ 577 At annuitization or exercise of other living benefits $ 550 $ 725 __________________ (1) Interest credited on EMEA’s variable annuity products represents gains or losses which are passed through to the policyholder based on the underlying unit-linked investment fund returns, which may be positive or negative depending on market conditions. There are no GMCR on these products. Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 11,537 $ 13,286 Deposits 121 115 Policy charges (10) (12) Surrenders and withdrawals (1,292) (1,425) Benefit payments (298) (320) Net transfers from (to) separate accounts 105 48 Interest credited 265 299 Other 9 15 Balance, end of period $ 10,437 $ 12,006 Weighted-average annual crediting rate 3.3 % 3.2 % At period end: Cash surrender value $ 9,866 $ 11,263 Net amount at risk, excluding offsets from ceded reinsurance (1): In the event of death $ 2,238 $ 3,970 At annuitization or exercise of other living benefits $ 657 $ 923 __________________ (1) Includes amounts for certain variable annuities recorded as PABs with the related guarantees recorded as MRBs which are disclosed in “MetLife Holdings – Annuities” in Note 6. Nine Months 2024 2023 (Dollars in millions) Balance, beginning of period $ 11,641 $ 12,402 Deposits 549 617 Policy charges (519) (529) Surrenders and withdrawals (744) (892) Benefit payments (114) (120) Net transfers from (to) separate accounts 26 29 Interest credited 318 336 Other 127 1 Balance, end of period $ 11,284 $ 11,844 Weighted-average annual crediting rate 3.8 % 3.8 % At period end: Cash surrender value $ 10,722 $ 11,360 Net amount at risk, excluding offsets from ceded reinsurance: In the event of death (1) $ 64,816 $ 68,972 __________________ (1) Including offsets from ceded reinsurance, the net amount at risk at both September 30, 2024 and December 31, 2023, would be reduced by 99%.
Policyholder Account Balance, Guaranteed Minimum Crediting Rate	The Group Benefits segment’s group life product account values by range of guaranteed minimum crediting rates (“GMCR”) and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ 456 $ 72 $ 877 $ 4,141 $ 5,546 Equal to or greater than 2% but less than 4% 1,266 8 59 1 1,334 Equal to or greater than 4% 684 — 39 36 759 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 37 Total $ 2,406 $ 80 $ 975 $ 4,178 $ 7,676 September 30, 2023 Equal to or greater than 0% but less than 2% $ — $ 82 $ 887 $ 4,595 $ 5,564 Equal to or greater than 2% but less than 4% 1,223 10 62 2 1,297 Equal to or greater than 4% 733 1 42 34 810 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 114 Total $ 1,956 $ 93 $ 991 $ 4,631 $ 7,785 The RIS segment’s capital markets investment products and stable value GICs account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ — $ 2,754 $ 2,754 Equal to or greater than 2% but less than 4% — — — 148 148 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 62,428 Total $ — $ — $ — $ 2,902 $ 65,330 September 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 1 $ 2,620 $ 2,621 Equal to or greater than 2% but less than 4% — — — — — Products with either a fixed rate or no GMCR N/A N/A N/A N/A 60,796 Total $ — $ — $ 1 $ 2,620 $ 63,417 The RIS segment’s annuity and risk solutions account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ 19 $ 2,403 $ 2,422 Equal to or greater than 2% but less than 4% 198 35 109 417 759 Equal to or greater than 4% 4,131 — 472 6 4,609 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 11,782 Total $ 4,329 $ 35 $ 600 $ 2,826 $ 19,572 September 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 22 $ 1,525 $ 1,547 Equal to or greater than 2% but less than 4% 260 33 94 437 824 Equal to or greater than 4% 4,363 — 277 6 4,646 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 10,047 Total $ 4,623 $ 33 $ 393 $ 1,968 $ 17,064 The Asia segment’s universal and variable universal life account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ 10,681 $ 18 $ 235 $ 1,449 $ 12,383 Equal to or greater than 2% but less than 4% 7,829 15,730 5,397 9,650 38,606 Equal to or greater than 4% 241 — — — 241 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 526 Total $ 18,751 $ 15,748 $ 5,632 $ 11,099 $ 51,756 September 30, 2023 Equal to or greater than 0% but less than 2% $ 9,986 $ 25 $ 233 $ 729 $ 10,973 Equal to or greater than 2% but less than 4% 5,742 17,923 5,628 6,633 35,926 Equal to or greater than 4% 256 — — — 256 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 475 Total $ 15,984 $ 17,948 $ 5,861 $ 7,362 $ 47,630 The Asia segment’s fixed annuity account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than Equal to or Equal to or Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ 385 $ 460 $ 5,250 $ 31,353 $ 37,448 Equal to or greater than 2% but less than 4% — 5 — — 5 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 1,289 Total $ 385 $ 465 $ 5,250 $ 31,353 $ 38,742 September 30, 2023 Equal to or greater than 0% but less than 2% $ 315 $ 574 $ 6,494 $ 26,811 $ 34,194 Equal to or greater than 2% but less than 4% — 6 — — 6 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 1,280 Total $ 315 $ 580 $ 6,494 $ 26,811 $ 35,480 The MetLife Holdings segment’s annuity account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than 0% but less than 0.50% above GMCR Equal to or greater than 0.50% but less than 1.50% above GMCR Equal to or greater than 1.50% above GMCR Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ 3 $ 166 $ 444 $ 52 $ 665 Equal to or greater than 2% but less than 4% 1,378 6,188 501 153 8,220 Equal to or greater than 4% 745 404 17 — 1,166 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 386 Total $ 2,126 $ 6,758 $ 962 $ 205 $ 10,437 September 30, 2023 Equal to or greater than 0% but less than 2% $ 235 $ 245 $ 292 $ 227 $ 999 Equal to or greater than 2% but less than 4% 2,887 5,828 457 130 9,302 Equal to or greater than 4% 965 274 26 — 1,265 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 440 Total $ 4,087 $ 6,347 $ 775 $ 357 $ 12,006 The MetLife Holdings segment’s life and other products account values by range of GMCR and the related range of differences between rates being credited to policyholders and the respective guaranteed minimums were as follows at: Range of GMCR At GMCR Greater than 0% but less than 0.50% above GMCR Equal to or greater than 0.50% but less than 1.50% above GMCR Equal to or greater than 1.50% above GMCR Total (In millions) September 30, 2024 Equal to or greater than 0% but less than 2% $ — $ — $ 17 $ 58 $ 75 Equal to or greater than 2% but less than 4% 4,159 171 265 536 5,131 Equal to or greater than 4% 4,911 122 405 9 5,447 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 631 Total $ 9,070 $ 293 $ 687 $ 603 $ 11,284 September 30, 2023 Equal to or greater than 0% but less than 2% $ — $ — $ 19 $ 54 $ 73 Equal to or greater than 2% but less than 4% 4,595 172 285 554 5,606 Equal to or greater than 4% 5,109 126 414 15 5,664 Products with either a fixed rate or no GMCR N/A N/A N/A N/A 501 Total $ 9,704 $ 298 $ 718 $ 623 $ 11,844

Market Risk Benefits (Tables)

Market Risk Benefits (Tables)	9 Months Ended
	Sep. 30, 2024
Insurance [Abstract]
Market Risk Benefit	The Company’s MRB assets and MRB liabilities on the interim condensed consolidated balance sheets were as follows at: September 30, 2024 December 31, 2023 Asset Liability Net Asset Liability Net (In millions) Asia - Retirement Assurance $ — $ 197 $ 197 $ — $ 203 $ 203 MetLife Holdings - Annuities 179 2,787 2,608 156 2,878 2,722 Other 131 133 2 130 98 (32) Total $ 310 $ 3,117 $ 2,807 $ 286 $ 3,179 $ 2,893
Market Risk Benefit, Activity	Information regarding this liability was as follows: Nine Months 2024 2023 (In millions) Balance, beginning of period $ 203 $ 226 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ 205 $ 233 Attributed fees collected 3 2 Benefit payments (9) (9) Effect of changes in interest rates 4 2 Actual policyholder behavior different from expected behavior (2) (1) Effect of changes in future expected policyholder behavior and other assumptions — (1) Effect of foreign currency translation and other, net (3) (30) Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk 198 196 Cumulative effect of changes in the instrument-specific credit risk (1) (3) Balance, end of period $ 197 $ 193 At period end: Net amount at risk, excluding offsets from hedging: At annuitization or exercise of other living benefits $ 122 $ 116 Weighted-average attained age of contractholders: At annuitization or exercise of other living benefits 58 years 58 years Nine Months 2024 2023 (In millions) Balance, beginning of period $ 2,722 $ 3,225 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ 2,772 $ 3,360 Attributed fees collected 266 286 Benefit payments (67) (36) Effect of changes in interest rates (70) (881) Effect of changes in capital markets (527) (542) Effect of changes in equity index volatility 37 (84) Actual policyholder behavior different from expected behavior 176 95 Effect of changes in future expected policyholder behavior and other assumptions 12 9 Effect of foreign currency translation and other, net (1) 34 118 Effect of changes in risk margin (7) (46) Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk 2,626 2,279 Cumulative effect of changes in the instrument-specific credit risk (19) (16) Effect of foreign currency translation on the cumulative instrument-specific credit risk 1 5 Balance, end of period $ 2,608 $ 2,268 At period end: Net amount at risk, excluding offsets from hedging (2): In the event of death $ 2,243 $ 3,979 At annuitization or exercise of other living benefits $ 643 $ 921 Weighted-average attained age of contractholders: In the event of death 71 years 70 years At annuitization or exercise of other living benefits 68 years 70 years __________________ (1) Included is the covariance impact from aggregating the market observable inputs, mostly driven by interest rate and capital market volatility. (2) Includes amounts for certain variable annuity guarantees recorded as MRBs on contracts also recorded as PABs which are disclosed in “MetLife Holdings – Annuities” in Note 5. Nine Months 2024 2023 (In millions) Balance, beginning of period $ (32) $ 32 Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk $ (50) $ 24 Attributed fees collected 38 23 Benefit payments (5) (23) Effect of changes in interest rates (12) (98) Effect of changes in capital markets (8) (15) Effect of changes in equity index volatility — (4) Actual policyholder behavior different from expected behavior 6 (21) Effect of changes in future expected policyholder behavior and other assumptions (2) 2 Effect of foreign currency translation and other, net 22 37 Effect of changes in risk margin (1) (2) Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk (12) (77) Cumulative effect of changes in the instrument-specific credit risk 13 20 Effect of foreign currency translation on the cumulative instrument-specific credit risk 1 — Balance, end of period 2 (57) Less: Reinsurance recoverable 16 18 Balance, end of period, net of reinsurance $ (14) $ (75)

Separate Account (Tables)

Separate Account (Tables)	9 Months Ended
	Sep. 30, 2024
Separate Accounts Disclosure [Abstract]
Separate Account Liabilities	The Company’s separate account liabilities on the interim condensed consolidated balance sheets were as follows at: September 30, 2024 December 31, 2023 (In millions) RIS: Stable Value and Risk Solutions $ 40,448 $ 41,343 Annuities 11,989 11,659 Latin America - Pensions 44,158 41,320 MetLife Holdings - Annuities 29,349 29,224 Other 22,865 21,088 Total $ 148,809 $ 144,634
Separate Account, Liability Rollforward	The balances of and changes in separate account liabilities were as follows: RIS Stable Value and Risk Solutions RIS Annuities Latin America MetLife Holdings (In millions) Nine Months Ended September 30, 2024 Balance, beginning of period $ 41,343 $ 11,659 $ 41,320 $ 29,224 Premiums and deposits 1,669 34 5,082 175 Policy charges (214) (16) (198) (454) Surrenders and withdrawals (3,799) (609) (3,913) (2,798) Benefit payments (81) — (1,231) (377) Investment performance 2,152 561 4,075 3,691 Net transfers from (to) general account (21) — — (105) Effect of foreign currency translation and other, net (1) (601) 360 (977) (7) Balance, end of period $ 40,448 $ 11,989 $ 44,158 $ 29,349 Nine Months Ended September 30, 2023 Balance, beginning of period $ 48,265 $ 11,694 $ 39,428 $ 28,499 Premiums and deposits 1,857 154 6,181 190 Policy charges (223) (17) (219) (460) Surrenders and withdrawals (8,696) (636) (4,485) (2,114) Benefit payments (74) — (1,301) (350) Investment performance 711 (157) (216) 1,740 Net transfers from (to) general account (57) 3 — (49) Effect of foreign currency translation and other, net (1) (1,280) 111 (1,915) (1) Balance, end of period $ 40,503 $ 11,152 $ 37,473 $ 27,455 Cash surrender value at September 30, 2024 (2) $ 35,632 N/A $ 44,158 $ 29,210 Cash surrender value at September 30, 2023 (2) $ 36,246 N/A $ 37,473 $ 27,320 __________________ (1) The effect of foreign currency translation and other, net for RIS stable value and risk solutions primarily includes changes related to unsettled trades of mortgage-backed securities. (2) Cash surrender value represents the amount of the contractholders’ account balances distributable at the balance sheet date less policy loans and certain surrender charges.
Fair Value, Separate Account Investment	The Company’s aggregate fair value of assets, by major investment asset category, supporting separate account liabilities was as follows at: September 30, 2024 Group Benefits RIS Asia Latin America EMEA MetLife Holdings Total (In millions) Fixed maturity securities: Bonds: Foreign government $ — $ 508 $ 1,271 $ 524 $ 3,139 $ — $ 5,442 U.S. government and agency — 9,875 — 12,228 — 19 22,122 Public utilities — 1,157 239 — — 7 1,403 Municipals — 295 20 — — 13 328 Corporate bonds: Materials — 131 — — — 1 132 Communications — 807 16 — — 4 827 Consumer — 1,910 38 — — 11 1,959 Energy — 822 113 — — 3 938 Financial — 2,697 558 5,371 307 19 8,952 Industrial and other — 748 68 3,759 — 2 4,577 Technology — 531 — — — 2 533 Foreign — 1,935 — 3,227 54 12 5,228 Total corporate bonds — 9,581 793 12,357 361 54 23,146 Total bonds — 21,416 2,323 25,109 3,500 93 52,441 Mortgage-backed securities — 9,372 — — — 40 9,412 Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”) — 2,357 18 — — 13 2,388 Redeemable preferred stock — 9 — — — — 9 Total fixed maturity securities — 33,154 2,341 25,109 3,500 146 64,250 Equity securities: Common stock: Industrial, miscellaneous and all other — 2,426 2,417 2,413 807 — 8,063 Banks, trust and insurance companies — 730 333 442 378 — 1,883 Public utilities — 73 24 — 123 — 220 Non-redeemable preferred stock — — 130 — — — 130 Mutual funds 1,320 9,435 3,153 11,835 200 36,250 62,193 Total equity securities 1,320 12,664 6,057 14,690 1,508 36,250 72,489 Other invested assets — 1,372 369 4,287 98 — 6,126 Total investments 1,320 47,190 8,767 44,086 5,106 36,396 142,865 Other assets — 5,348 454 72 68 2 5,944 Total $ 1,320 $ 52,538 $ 9,221 $ 44,158 $ 5,174 $ 36,398 $ 148,809 December 31, 2023 Group RIS Asia Latin America EMEA MetLife Holdings Total (In millions) Fixed maturity securities: Bonds: Foreign government $ — $ 509 $ 1,190 $ 1,051 $ 2,638 $ — $ 5,388 U.S. government and agency — 9,673 — 9,920 — 18 19,611 Public utilities — 1,077 308 — — 4 1,389 Municipals — 380 31 — — 13 424 Corporate bonds: Materials — 144 — — — — 144 Communications — 893 8 — — 3 904 Consumer — 1,882 39 — — 8 1,929 Energy — 911 105 — — 2 1,018 Financial — 2,717 551 6,006 398 15 9,687 Industrial and other — 764 38 3,598 — 3 4,403 Technology — 547 — — — 3 550 Foreign — 1,920 — 3,095 27 13 5,055 Total corporate bonds — 9,778 741 12,699 425 47 23,690 Total bonds — 21,417 2,270 23,670 3,063 82 50,502 Mortgage-backed securities — 9,671 — — — 35 9,706 ABS & CLO — 2,557 18 — — 11 2,586 Redeemable preferred stock — 9 — — — — 9 Total fixed maturity securities — 33,654 2,288 23,670 3,063 128 62,803 Equity securities: Common stock: Industrial, miscellaneous and all other — 2,411 2,661 2,453 677 — 8,202 Banks, trust and insurance companies — 731 269 392 341 — 1,733 Public utilities — 67 19 — 72 — 158 Non-redeemable preferred stock — — 115 — — — 115 Mutual funds 1,159 8,517 2,929 10,099 109 35,418 58,231 Total equity securities 1,159 11,726 5,993 12,944 1,199 35,418 68,439 Other invested assets — 1,620 403 4,212 30 — 6,265 Total investments 1,159 47,000 8,684 40,826 4,292 35,546 137,507 Other assets — 6,093 503 494 35 2 7,127 Total $ 1,159 $ 53,093 $ 9,187 $ 41,320 $ 4,327 $ 35,548 $ 144,634

Deferred Policy Acquisition C_2

Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue (Tables)	9 Months Ended
	Sep. 30, 2024
Deferred Policy Acquisition Costs and Present Value of Future Insurance Profits, Net [Abstract]
Deferred Policy Acquisition Costs	Information regarding total DAC and VOBA by segment, as well as Corporate & Other, was as follows at: Group Benefits RIS Asia (1) Latin America (2) EMEA (2) MetLife Holdings (3) Corporate & Other Total (In millions) DAC: Balance at January 1, 2024 $ 258 $ 397 $ 10,864 $ 1,950 $ 1,618 $ 3,271 $ 30 $ 18,388 Capitalizations 13 160 1,032 527 362 13 7 2,114 Amortization (19) (43) (579) (348) (254) (171) (6) (1,420) Effect of foreign currency translation and other, net — — (71) (224) (5) — — (300) Balance at September 30, 2024 $ 252 $ 514 $ 11,246 $ 1,905 $ 1,721 $ 3,113 $ 31 $ 18,782 Balance at January 1, 2023 $ 265 $ 267 $ 10,270 $ 1,542 $ 1,480 $ 3,791 $ 29 $ 17,644 Capitalizations 16 136 1,202 470 341 17 7 2,189 Amortization (19) (34) (518) (306) (245) (194) (8) (1,324) Effect of foreign currency translation and other, net — — (600) 125 (27) — — (502) Balance at September 30, 2023 $ 262 $ 369 $ 10,354 $ 1,831 $ 1,549 $ 3,614 $ 28 $ 18,007 VOBA: Balance at January 1, 2024 $ — $ 16 $ 1,119 $ 497 $ 113 $ 18 $ — $ 1,763 Amortization — (2) (55) (32) (11) (3) — (103) Effect of foreign currency translation and other, net — — (19) (22) — — — (41) Balance at September 30, 2024 $ — $ 14 $ 1,045 $ 443 $ 102 $ 15 $ — $ 1,619 Balance at January 1, 2023 $ — $ 19 $ 1,290 $ 545 $ 127 $ 28 $ — $ 2,009 Amortization — (2) (69) (38) (12) (3) — (124) Effect of foreign currency translation and other, net — — (144) (10) (1) — — (155) Balance at September 30, 2023 $ — $ 17 $ 1,077 $ 497 $ 114 $ 25 $ — $ 1,730 Total DAC and VOBA: Balance at September 30, 2024 $ 20,401 Balance at September 30, 2023 $ 19,737 Balance at December 31, 2023 $ 20,151 __________________ (1) Includes DAC balances primarily related to accident & health, universal and variable universal life, variable life and fixed annuity products and VOBA balances primarily related to accident & health products. (2) Includes DAC balances primarily related to universal life and variable universal life products. (3) Includes DAC balances primarily related to universal life, variable universal life, whole life, term life and variable annuity products.
Unearned Revenue	Information regarding the Company’s unearned revenue primarily related to universal life and variable universal life products by segment included in other policy-related balances was as follows: Nine Months RIS Asia Latin EMEA MetLife Total (In millions) Balance, beginning of period $ 31 $ 2,850 $ 989 $ 608 $ 59 $ 4,537 Deferrals 1 424 111 72 12 620 Amortization (4) (167) (88) (51) (4) (314) Effect of foreign currency translation and other, net — (9) (124) 3 — (130) Balance, end of period $ 28 $ 3,098 $ 888 $ 632 $ 67 $ 4,713 Nine Months RIS Asia Latin EMEA MetLife Total (In millions) Balance, beginning of period $ 36 $ 2,382 $ 848 $ 559 $ 281 $ 4,106 Deferrals 2 477 108 71 41 699 Amortization (5) (129) (87) (47) (16) (284) Effect of foreign currency translation and other, net — (49) 85 4 — 40 Balance, end of period $ 33 $ 2,681 $ 954 $ 587 $ 306 $ 4,561

Closed Block (Tables)

Closed Block (Tables)	9 Months Ended
	Sep. 30, 2024
Closed Block Disclosure [Abstract]
Closed block liabilities and assets	Information regarding the liabilities and assets designated to the closed block was as follows at: September 30, 2024 December 31, 2023 (In millions) Closed Block Liabilities FPBs $ 35,229 $ 36,142 Other policy-related balances 284 319 Policyholder dividends payable 178 174 Policyholder dividend obligation — — Current income tax payable 13 — Other liabilities 896 668 Total closed block liabilities 36,600 37,303 Assets Designated to the Closed Block Investments: Fixed maturity securities available-for-sale (“AFS”), at estimated fair value 19,915 19,939 Equity securities, at estimated fair value 10 10 Mortgage loans 5,856 6,151 Policy loans 3,850 3,960 Real estate and real estate joint ventures (“REJV”) 676 668 Other invested assets 418 496 Total investments 30,725 31,224 Cash and cash equivalents 957 717 Accrued investment income 382 383 Premiums, reinsurance and other receivables 36 54 Current income tax recoverable — 3 Deferred income tax asset 239 312 Total assets designated to the closed block 32,339 32,693 Excess of closed block liabilities over assets designated to the closed block 4,261 4,610 AOCI: Unrealized investment gains (losses), net of income tax (551) (820) Unrealized gains (losses) on derivatives, net of income tax 116 130 Total amounts included in AOCI (435) (690) Maximum future earnings to be recognized from closed block assets and liabilities $ 3,826 $ 3,920
Closed block revenues and expenses	Information regarding the closed block revenues and expenses was as follows: Three Months Nine Months 2024 2023 2024 2023 (In millions) Revenues Premiums $ 214 $ 219 $ 648 $ 680 Net investment income 336 345 1,021 1,024 Net investment gains (losses) 1 4 (19) 13 Net derivative gains (losses) (1) (2) 6 1 Total revenues 550 566 1,656 1,718 Expenses Policyholder benefits and claims 390 403 1,209 1,261 Policyholder dividends 90 89 266 275 Other expenses 21 21 61 65 Total expenses 501 513 1,536 1,601 Revenues, net of expenses before provision for income tax expense (benefit) 49 53 120 117 Provision for income tax expense (benefit) 11 11 26 24 Revenues, net of expenses and provision for income tax expense (benefit) $ 38 $ 42 $ 94 $ 93

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Fixed Maturity Securities Available-for-Sale by Sector	The following table presents fixed maturity securities AFS by sector. U.S. corporate and foreign corporate sectors include redeemable preferred stock. Residential mortgage-backed securities (“RMBS”) includes agency, prime, prime investor, non-qualified residential mortgage, alternative, reperforming and sub-prime mortgage-backed securities. ABS & CLO includes securities collateralized by consumer loans, corporate loans and broadly syndicated bank loans. Municipals includes taxable and tax-exempt revenue bonds and, to a much lesser extent, general obligations of states, municipalities and political subdivisions. Commercial mortgage-backed securities (“CMBS”) primarily includes securities collateralized by multiple commercial mortgage loans. RMBS, ABS & CLO and CMBS are, collectively, “Structured Products.” September 30, 2024 December 31, 2023 Amortized Gross Unrealized Estimated Amortized Gross Unrealized Estimated Sector Allowance for Credit Loss (“ACL”) Gains Losses ACL Gains Losses (In millions) U.S. corporate $ 88,612 $ (60) $ 2,275 $ 5,976 $ 84,851 $ 85,563 $ (68) $ 1,894 $ 6,672 $ 80,717 Foreign corporate 59,282 (15) 2,164 4,679 56,752 59,123 (2) 1,750 5,427 55,444 Foreign government 47,586 (62) 1,776 5,168 44,132 48,260 (88) 1,754 4,437 45,489 U.S. government and agency 37,727 — 589 3,640 34,676 35,374 — 590 3,712 32,252 RMBS 36,761 (1) 630 2,126 35,264 31,479 (1) 353 2,735 29,096 ABS & CLO 17,750 (10) 138 358 17,520 17,910 (7) 54 663 17,294 Municipals 11,521 — 354 1,077 10,798 11,991 — 408 1,228 11,171 CMBS 10,167 (14) 167 534 9,786 10,855 (18) 73 961 9,949 Total fixed maturity securities AFS $ 309,406 $ (162) $ 8,093 $ 23,558 $ 293,779 $ 300,555 $ (184) $ 6,876 $ 25,835 $ 281,412
Available-for-sale fixed maturity securities by contractual maturity date	The amortized cost, net of ACL, and estimated fair value of fixed maturity securities AFS, by contractual maturity date, were as follows at September 30, 2024: Due in One Due After Due After Due After Structured Total Fixed Maturity Securities AFS (In millions) Amortized cost, net of ACL $ 11,313 $ 48,735 $ 54,449 $ 130,094 $ 64,653 $ 309,244 Estimated fair value $ 11,361 $ 48,895 $ 54,079 $ 116,874 $ 62,570 $ 293,779
Schedule of Unrealized Loss on Investments [Table Text Block]	The following table presents the estimated fair value and gross unrealized losses of fixed maturity securities AFS in an unrealized loss position without an ACL by sector and aggregated by length of time that the securities have been in a continuous unrealized loss position. September 30, 2024 December 31, 2023 Less than 12 Months Equal to or Greater Less than 12 Months Equal to or Greater Sector & Credit Quality Estimated Gross Estimated Gross Estimated Gross Estimated Gross (Dollars in millions) U.S. corporate $ 4,384 $ 685 $ 41,061 $ 5,258 $ 4,722 $ 420 $ 45,373 $ 6,208 Foreign corporate 2,505 181 28,069 4,477 3,210 187 32,355 5,240 Foreign government 2,828 432 19,170 4,735 3,913 246 19,715 4,187 U.S. government and agency 3,426 159 15,987 3,481 7,856 368 13,960 3,344 RMBS 1,926 73 15,673 2,053 3,465 60 17,128 2,675 ABS & CLO 2,441 17 5,833 341 1,662 31 11,438 629 Municipals 209 87 5,241 990 483 34 5,449 1,194 CMBS 433 15 5,433 517 1,034 36 6,671 917 Total fixed maturity securities AFS $ 18,152 $ 1,649 $ 136,467 $ 21,852 $ 26,345 $ 1,382 $ 152,089 $ 24,394 Investment grade $ 15,804 $ 1,577 $ 131,959 $ 21,256 $ 24,834 $ 1,287 $ 146,138 $ 23,675 Below investment grade 2,348 72 4,508 596 1,511 95 5,951 719 Total fixed maturity securities AFS $ 18,152 $ 1,649 $ 136,467 $ 21,852 $ 26,345 $ 1,382 $ 152,089 $ 24,394 Total number of securities in an unrealized loss position 2,855 11,063 2,922 13,049
Debt Securities, Available-for-sale, Allowance for Credit Loss	The rollforward of ACL for fixed maturity securities AFS by sector is as follows: U.S. Foreign Foreign RMBS ABS & CLO CMBS Total (In millions) Three Months Ended September 30, 2024 Balance, at beginning of period $ 37 $ 2 $ 58 $ 1 $ 9 $ 14 $ 121 ACL not previously recorded 27 13 — — — — 40 Changes for securities with previously recorded ACL (1) — 4 — 1 — 4 Securities sold or exchanged (3) — — — — — (3) Balance, at end of period $ 60 $ 15 $ 62 $ 1 $ 10 $ 14 $ 162 Three Months Ended September 30, 2023 Balance, at beginning of period $ 69 $ 2 $ 115 $ — $ — $ 11 $ 197 ACL not previously recorded — — — 1 7 2 10 Changes for securities with previously recorded ACL — — (7) — — 3 (4) Securities sold or exchanged (2) — (19) — — — (21) Balance, at end of period $ 67 $ 2 $ 89 $ 1 $ 7 $ 16 $ 182 U.S. Foreign Foreign RMBS ABS & CLO CMBS Total (In millions) Nine Months Ended September 30, 2024 Balance, at beginning of period $ 68 $ 2 $ 88 $ 1 $ 7 $ 18 $ 184 ACL not previously recorded 41 13 — — — — 54 Changes for securities with previously recorded ACL 10 — (1) — 3 2 14 Securities sold or exchanged (59) — (25) — — (6) (90) Balance, at end of period $ 60 $ 15 $ 62 $ 1 $ 10 $ 14 $ 162 Nine Months Ended September 30, 2023 Balance, at beginning of period $ 29 $ 5 $ 130 $ — $ — $ 19 $ 183 ACL not previously recorded 36 — — 1 7 2 46 Changes for securities with previously recorded ACL 6 — (22) — — 6 (10) Securities sold or exchanged (4) (3) (19) — — (11) (37) Balance, at end of period $ 67 $ 2 $ 89 $ 1 $ 7 $ 16 $ 182
Debt Securities, Trading, and Equity Securities, FV-NI	The following table presents equity securities by security type: September 30, 2024 December 31, 2023 Cost Net Unrealized Estimated Fair Value Cost Net Unrealized Estimated Security Type (In millions) Common stock (2) $ 453 $ 193 $ 646 $ 424 $ 239 $ 663 Non-redeemable preferred stock 100 — 100 90 4 94 Total $ 553 $ 193 $ 746 $ 514 $ 243 $ 757 ________________ (1) Represents cumulative changes in estimated fair value, recognized in earnings, and not in OCI. (2) Includes common stock, exchange traded funds, certain mutual funds and certain real estate investment trusts. The following table presents these investments by asset type. Unit-linked investments are primarily equity securities (including mutual funds). FVO securities include fixed maturity and equity securities to support asset and liability management strategies for certain insurance products and investments in certain separate accounts. September 30, 2024 December 31, 2023 Cost or Net Unrealized Estimated Fair Value Cost or Net Unrealized Estimated Asset Type (In millions) Unit-linked investments $ 6,263 $ 1,345 $ 7,608 $ 7,770 $ 1,112 $ 8,882 FVO securities 1,025 656 1,681 972 477 1,449 Total $ 7,288 $ 2,001 $ 9,289 $ 8,742 $ 1,589 $ 10,331 ________________ (1) Represents cumulative changes in estimated fair value, recognized in earnings, and not in OCI.
Disclosure of Mortgage Loans Net of Valuation Allowance	Mortgage loans are summarized as follows at: September 30, 2024 December 31, 2023 Portfolio Segment Carrying % of Carrying % of (Dollars in millions) Commercial $ 57,949 64.1 % $ 60,326 65.2 % Agricultural 19,469 21.5 19,805 21.4 Residential 13,844 15.3 13,096 14.2 Total amortized cost 91,262 100.9 93,227 100.8 ACL (847) (0.9) (721) (0.8) Total mortgage loans $ 90,415 100.0 % $ 92,506 100.0 % __________________ (1) Includes certain mortgage loans originated for third parties of $7.7 billion at amortized cost ($7.5 billion commercial and $259 million agricultural) and the related ACL of $88 million, with the corresponding mortgage loan secured financing liability of $7.7 billion included in other liabilities on the consolidated balance sheet at September 30, 2024. The consolidated balance sheet at December 31, 2023 includes certain mortgage loans originated for third parties of $8.5 billion at amortized cost ($8.2 billion commercial and $246 million agricultural) and the related ACL of $73 million, with the corresponding mortgage loan secured financing liability of $8.5 billion included in other liabilities. The investment income on the mortgage loans originated for third parties and the interest expense on the related mortgage loan secured financing liability was $87 million and $272 million for the three months and nine months ended September 30, 2024, respectively, and were recorded in investment income and investment expenses, both within net investment income.
Allowance for Loan and Lease Losses, Provision for Loss, Net	The rollforward of ACL for mortgage loans, by portfolio segment, is as follows: Nine Months 2024 2023 Commercial Agricultural Residential Total Commercial Agricultural Residential Total (In millions) Balance, beginning of period $ 367 $ 172 $ 182 $ 721 $ 218 $ 119 $ 190 $ 527 Provision (release) 212 40 (21) 231 147 52 2 201 Charge-offs, net of recoveries (28) (77) — (105) (10) (13) — (23) Balance, end of period $ 551 $ 135 $ 161 $ 847 $ 355 $ 158 $ 192 $ 705
Financing Receivable, Modified	These mortgage loan modifications are summarized as follows: Three Months Ended September 30, 2024 2023 Maturity Extension Weighted Average Maturity Extension Weighted Average Amortized Cost Affected Loans % of Book Value Amortized Cost Affected Loans % of Book Value (Dollars in millions) Commercial $ 39 Less than one year <1% $ 145 Less than one year <1% Nine Months Ended September 30, 2024 2023 Maturity Extension Weighted Average Maturity Extension Weighted Average Amortized Cost Affected Loans % of Book Value Amortized Cost Affected Loans % of Book Value (Dollars in millions) Commercial $ 236 Less than one year <1 % $ 367 Less than one year <1 %
Disclosure of the mortgage loans portfolio segment by the recorded investment, prior to valuation allowances, by credit quality indicator categories	The amortized cost of commercial mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2024: Credit Quality Indicator 2024 2023 2022 2021 2020 Prior Revolving Total % of (Dollars in millions) LTV ratios: Less than 65% $ 2,007 $ 2,545 $ 2,668 $ 3,168 $ 1,495 $ 13,882 $ 2,398 $ 28,163 48.6 % 65% to 75% 462 374 4,012 2,267 297 4,230 — 11,642 20.1 76% to 80% 2 16 611 287 428 2,789 — 4,133 7.1 Greater than 80% 37 57 1,119 1,412 1,679 9,707 — 14,011 24.2 Total $ 2,508 $ 2,992 $ 8,410 $ 7,134 $ 3,899 $ 30,608 $ 2,398 $ 57,949 100.0 % DSCR: > 1.20x $ 2,284 $ 1,983 $ 7,448 $ 6,496 $ 3,715 $ 25,911 $ 2,398 $ 50,235 86.7 % 1.00x - 1.20x 148 603 711 490 105 2,485 — 4,542 7.8 <1.00x 76 406 251 148 79 2,212 — 3,172 5.5 Total $ 2,508 $ 2,992 $ 8,410 $ 7,134 $ 3,899 $ 30,608 $ 2,398 $ 57,949 100.0 % The amortized cost of agricultural mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2024: Credit Quality Indicator 2024 2023 2022 2021 2020 Prior Revolving Total % of (Dollars in millions) LTV ratios: Less than 65% $ 459 $ 1,177 $ 2,792 $ 2,602 $ 2,639 $ 7,090 $ 1,427 $ 18,186 93.4 % 65% to 75% 9 56 44 306 119 512 104 1,150 5.9 76% to 80% — — 24 — 3 — 3 30 0.2 Greater than 80% — — — 14 29 46 14 103 0.5 Total $ 468 $ 1,233 $ 2,860 $ 2,922 $ 2,790 $ 7,648 $ 1,548 $ 19,469 100.0 % The amortized cost of residential mortgage loans by credit quality indicator and vintage year was as follows at September 30, 2024: Credit Quality Indicator 2024 2023 2022 2021 2020 Prior Revolving Total % of (Dollars in millions) Performance indicators: Performing $ 805 $ 927 $ 2,493 $ 1,747 $ 326 $ 7,112 $ — $ 13,410 96.9 % Nonperforming (1) 2 34 75 24 15 284 — 434 3.1 Total $ 807 $ 961 $ 2,568 $ 1,771 $ 341 $ 7,396 $ — $ 13,844 100.0 % __________________ (1) Includes residential mortgage loans in process of foreclosure of $136 million and $140 million at September 30, 2024 and December 31, 2023, respectively.
Schedule of Past Due and Non Accrual Mortgage Loans	The past due and nonaccrual mortgage loans at amortized cost, prior to ACL by portfolio segment, were as follows: Past Due Past Due Nonaccrual Portfolio Segment September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 (In millions) Commercial $ 724 $ 75 $ 16 $ 3 $ 1,072 $ 427 Agricultural 346 40 238 — 118 206 Residential 434 418 24 16 412 402 Total $ 1,504 $ 533 $ 278 $ 19 $ 1,602 $ 1,035
Disclosure Real Estate and Real Estate Joint Ventures	Real estate investments, by income type, as well as income earned, were as follows at and for the periods indicated: September 30, 2024 December 31, 2023 Three Months Nine Months 2024 2023 2024 2023 Income Type Carrying Value Income (In millions) Wholly-owned real estate: Leased real estate $ 4,536 $ 4,446 $ 88 $ 89 $ 255 $ 271 Other real estate 687 507 79 71 204 206 REJV 8,508 8,379 11 (64) (191) (218) Total real estate and REJV $ 13,731 $ 13,332 $ 178 $ 96 $ 268 $ 259
Fair Value, Concentration of Risk	Investments in any counterparty that were greater than 10% of the Company’s equity, other than the U.S. government and its agencies, at estimated fair value, were in fixed income securities of the following foreign governments and their agencies: September 30, 2024 December 31, 2023 (In millions) Japan $ 21,688 $ 22,606 South Korea $ 6,654 $ 6,411 Mexico $ 3,651 $ 3,778
Securities Lending and Repurchase Agreements	A summary of these transactions and agreements accounted for as secured borrowings were as follows: September 30, 2024 December 31, 2023 Securities (1) Securities (1) Agreement Type Estimated Cash Collateral Received from Counterparties (2) Reinvestment Estimated Fair Value Cash Collateral Received from Counterparties (2) Reinvestment (In millions) Securities lending $ 11,079 $ 11,257 $ 11,178 $ 10,510 $ 10,788 $ 10,553 Repurchase agreements $ 3,010 $ 2,975 $ 2,895 $ 3,029 $ 2,975 $ 2,913 __________________ (1) These securities were included within fixed maturity securities AFS and cash equivalents at September 30, 2024 and within fixed maturity securities AFS, short-term investments and cash equivalents at December 31, 2023. (2) The liability for cash collateral is included within payables for collateral under securities loaned and other transactions. Contractual maturities of these transactions and agreements accounted for as secured borrowings were as follows: September 30, 2024 December 31, 2023 Remaining Maturities Remaining Maturities Security Type Open (1) 1 Month Over 1 Month to 6 Months Over 6 Total Open (1) 1 Month Over 1 Month to 6 Months Over 6 Total (In millions) Cash collateral liability by security type: Securities lending: U.S. government and agency $ 2,295 $ 6,077 $ 1,459 $ — $ 9,831 $ 1,393 $ 4,106 $ 3,919 $ — $ 9,418 Foreign government — 232 1,018 — 1,250 — 483 624 — 1,107 Agency RMBS — 176 — — 176 — 88 175 — 263 Total $ 2,295 $ 6,485 $ 2,477 $ — $ 11,257 $ 1,393 $ 4,677 $ 4,718 $ — $ 10,788 Repurchase agreements: U.S. government and agency $ — $ 2,975 $ — $ — $ 2,975 $ — $ 2,975 $ — $ — $ 2,975 __________________ (1) The related security could be returned to the Company on the next business day, which would require the Company to immediately return the cash collateral.
Invested Assets on Deposit, Held in Trust and Pledged as Collateral	Invested assets on deposit, held in trust and pledged as collateral are presented below at estimated fair value for all asset classes, except mortgage loans, which are presented at carrying value, and were as follows at: September 30, 2024 December 31, 2023 (In millions) Invested assets on deposit (regulatory deposits) $ 1,584 $ 1,596 Invested assets held in trust (external reinsurance agreements) (1) 989 941 Invested assets pledged as collateral (2) 29,423 26,017 Total invested assets on deposit, held in trust and pledged as collateral $ 31,996 $ 28,554 __________________ (1) Represents assets held in trust related to third-party reinsurance agreements. Excludes assets held in trust related to reinsurance agreements between wholly-owned subsidiaries of $2.0 billion at both September 30, 2024 and December 31, 2023. (2) The Company has pledged invested assets in connection with various agreements and transactions, including funding agreements, repurchase agreements and a collateral financing arrangement (see Notes 5, 16 and 17 of the Notes to the Consolidated Financial Statements included in the 2023 Annual Report). For information regarding invested assets pledged in connection with derivative transactions, see Note 11.
Schedule of Variable Interest Entities	The following table presents the total assets and total liabilities relating to investment - related VIEs for which the Company has concluded that it is the primary beneficiary and which are consolidated at: September 30, 2024 December 31, 2023 Asset Type Total Total Total Total (In millions) Investment funds (primarily other invested assets and REJV) $ 691 $ 181 $ 282 $ 1 Renewable energy partnership (primarily other invested assets) 64 — 64 — Total $ 755 $ 181 $ 346 $ 1 Unconsolidated VIEs The carrying amount and maximum exposure to loss relating to VIEs in which the Company holds a significant variable interest but is not the primary beneficiary and which have not been consolidated were as follows at: September 30, 2024 December 31, 2023 Asset Type Carrying Maximum Carrying Maximum (In millions) Fixed maturity securities AFS (2) $ 60,218 $ 60,218 $ 54,182 $ 54,182 Other limited partnership interests (“OLPI”) 13,300 17,937 14,034 19,591 Other investments (REJV, FVO securities and mortgage loans) 1,307 1,324 1,039 1,055 Other invested assets 1,061 1,197 1,206 1,275 Total $ 75,886 $ 80,676 $ 70,461 $ 76,103 __________________ (1) The maximum exposure to loss relating to fixed maturity securities AFS and FVO securities is equal to their carrying amounts or the carrying amounts of retained interests. The maximum exposure to loss relating to OLPI, REJV and mortgage loans is equal to the carrying amounts plus any unrecognized unfunded commitments. For certain of its investments in other invested assets, the Company’s return is in the form of income tax credits which are guaranteed by creditworthy third parties. For such investments, the maximum exposure to loss is equal to the carrying amounts plus any unfunded commitments, reduced by income tax credits guaranteed by third parties. Such a maximum loss would be expected to occur only upon bankruptcy of the issuer or investee. (2) For variable interests in Structured Products included within fixed maturity securities AFS, the Company’s involvement is limited to that of a passive investor in mortgage-backed or asset-backed securities issued by trusts that do not have substantial equity.
Components of Net Investment Income	The composition of net investment income by asset type was as follows: Three Months Nine Months Asset Type 2024 2023 2024 2023 (In millions) Fixed maturity securities AFS $ 3,457 $ 3,314 $ 10,100 $ 9,681 Equity securities 4 5 18 27 FVO securities 76 (17) 183 81 Mortgage loans 1,184 1,189 3,565 3,536 Policy loans 116 120 339 358 Real estate and REJV 178 96 268 259 OLPI 87 206 713 456 Cash, cash equivalents and short-term investments 299 268 840 733 Operating joint ventures 92 4 136 36 Other 159 180 502 458 Subtotal investment income 5,652 5,365 16,664 15,625 Less: Investment expenses 571 544 1,703 1,686 Subtotal, net 5,081 4,821 14,961 13,939 Unit-linked investments 146 4 907 603 Net investment income $ 5,227 $ 4,825 $ 15,868 $ 14,542 Net Investment Income Information Net realized and unrealized gains (losses) recognized in net investment income: Net realized gains (losses) from sales and disposals (primarily FVO securities and Unit-linked investments) $ 65 $ 47 $ 199 $ 126 Net unrealized gains (losses) from changes in estimated fair value (primarily FVO securities and Unit-linked investments) 121 (80) 840 572 Net realized and unrealized gains (losses) recognized in net investment income $ 186 $ (33) $ 1,039 $ 698 Changes in estimated fair value subsequent to purchase of FVO securities and Unit-linked investments still held at the end of the respective periods and recognized in net investment income $ 209 $ (63) $ 813 $ 506 Equity method investments net investment income (primarily REJV, OLPI, tax credit and renewable energy partnerships and operating joint ventures) $ 201 $ 95 $ 687 $ 174
Components of Net Investment Gains (Losses)	The composition of net investment gains (losses) by asset type and transaction type was as follows: Three Months Nine Months Asset Type 2024 2023 2024 2023 (In millions) Fixed maturity securities AFS $ (157) $ (698) $ (488) $ (2,274) Equity securities (31) (14) (22) 66 Mortgage loans (151) 11 (246) (194) Real estate and REJV (excluding changes in estimated fair value) 128 1 175 32 OLPI (excluding changes in estimated fair value) (1) 4 — (55) 12 Other gains (losses) (57) (161) (28) (141) Subtotal (264) (861) (664) (2,499) Change in estimated fair value of OLPI and REJV (1) (3) 5 (6) Non-investment portfolio gains (losses) 188 (63) (214) (145) Subtotal 187 (66) (209) (151) Net investment gains (losses) $ (77) $ (927) $ (873) $ (2,650) Transaction Type Realized gains (losses) on investments sold or disposed (1) $ (39) $ (281) $ (369) $ (847) Impairment (losses) (17) (591) (17) (1,496) Recognized gains (losses): Change in ACL recognized in earnings (150) 25 (231) (199) Unrealized net gains (losses) recognized in earnings (59) (17) (42) 37 Total recognized gains (losses) (209) 8 (273) (162) Non-investment portfolio gains (losses) 188 (63) (214) (145) Net investment gains (losses) $ (77) $ (927) $ (873) $ (2,650) Net Investment Gains (Losses) Information Changes in estimated fair value subsequent to purchase of equity securities still held at the end of the respective periods and recognized in net investment gains (losses) $ (36) $ (10) $ (23) $ 9 Other gains (losses) include: Gains (losses) on disposed investments which were previously in a qualified cash flow hedging relationship $ — $ 2 $ — $ (20) Foreign currency gains (losses) $ 170 $ (21) $ 5 $ (7) Net Realized Investment Gains (Losses) From Sales and Disposals of Investments Recognized in net investment gains (losses) $ (39) $ (281) $ (369) $ (847) Recognized in net investment income 65 47 199 126 Net realized investment gains (losses) from sales and disposals of investments $ 26 $ (234) $ (170) $ (721) __________________ (1) Includes a net loss of $46 million for the nine months ended September 30, 2024 for private equity investments sold. For the nine months ended September 30, 2024, the Company sold $798 million in portfolios of investments to a fund for proceeds of $752 million in cash and receivables secured by the value of the fund. The Company’s investment management business has entered into an agreement to serve as the investment manager of the fund for which it will receive a management fee.
Schedule of Realized Gain (Loss)	The composition of net investment gains (losses) for these securities is as follows: Three Months Nine Months Fixed Maturity Securities AFS 2024 2023 2024 2023 (In millions) Proceeds $ 6,815 $ 9,263 $ 21,273 $ 32,719 Gross investment gains $ 111 $ 63 $ 388 $ 429 Gross investment (losses) (228) (334) (898) (1,403) Realized gains (losses) on sales and disposals (117) (271) (510) (974) Net credit loss (provision) release (change in ACL recognized in earnings) (40) 17 22 — Impairment (losses) — (444) — (1,300) Net credit loss (provision) release and impairment (losses) (40) (427) 22 (1,300) Net investment gains (losses) $ (157) $ (698) $ (488) $ (2,274) Equity Securities Realized gains (losses) on sales and disposals $ 27 $ — $ 25 $ 22 Unrealized net gains (losses) recognized in earnings (58) (14) (47) 44 Net investment gains (losses) $ (31) $ (14) $ (22) $ 66

Derivatives (Tables)

Derivatives (Tables)	9 Months Ended
	Sep. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Primary Risks Managed by Derivatives	The following table presents the primary underlying risk exposure, gross notional amount and estimated fair value of the Company’s derivatives, excluding embedded derivatives, held at: September 30, 2024 December 31, 2023 Primary Underlying Risk Exposure Gross Estimated Fair Value Gross Estimated Fair Value Assets Liabilities Assets Liabilities (In millions) Derivatives Designated as Hedging Instruments: Fair value hedges: Interest rate swaps Interest rate $ 5,188 $ 1,134 $ 554 $ 4,550 $ 1,257 $ 535 Foreign currency swaps Foreign currency exchange rate 1,664 43 7 1,475 55 — Foreign currency forwards Foreign currency exchange rate 350 — 69 450 — 65 Subtotal 7,202 1,177 630 6,475 1,312 600 Cash flow hedges: Interest rate swaps Interest rate 4,155 — 259 4,156 1 265 Interest rate forwards Interest rate 5,090 59 923 6,115 51 938 Foreign currency swaps Foreign currency exchange rate 45,985 2,458 1,655 43,906 2,457 1,509 Subtotal 55,230 2,517 2,837 54,177 2,509 2,712 Net investment in a foreign operation hedges: Foreign currency forwards Foreign currency exchange rate 205 7 — 503 — 8 Currency options Foreign currency exchange rate 3,000 412 — 3,000 394 — Subtotal 3,205 419 — 3,503 394 8 Total qualifying hedges 65,637 4,113 3,467 64,155 4,215 3,320 Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate swaps Interest rate 29,675 1,654 1,062 29,801 1,497 1,102 Interest rate floors Interest rate 9,228 48 — 15,321 41 — Interest rate caps Interest rate 29,052 130 1 30,016 373 — Interest rate futures Interest rate 1,732 2 2 1,243 1 5 Interest rate options Interest rate 43,481 269 119 43,926 385 103 Interest rate forwards Interest rate 2,934 130 76 2,383 69 36 Synthetic GICs Interest rate 49,081 — — 49,066 — — Foreign currency swaps Foreign currency exchange rate 10,755 981 231 11,891 1,200 356 Foreign currency forwards Foreign currency exchange rate 13,511 283 961 14,128 310 806 Currency futures Foreign currency exchange rate 321 2 — 314 2 — Currency options Foreign currency exchange rate — — — 50 — — Credit default swaps — purchased Credit 2,801 4 74 2,877 3 79 Credit default swaps — written Credit 12,851 267 2 12,468 233 5 Equity futures Equity market 1,866 13 6 2,163 8 11 Equity index options Equity market 14,106 276 263 19,421 399 255 Equity variance swaps Equity market 114 — 3 99 — 2 Equity total return swaps Equity market 2,301 — 90 1,912 1 218 Longevity swaps (1) Longevity 1,000 — — — — — Total non-designated or nonqualifying derivatives 224,809 4,059 2,890 237,079 4,522 2,978 Total $ 290,446 $ 8,172 $ 6,357 $ 301,234 $ 8,737 $ 6,298 __________________ (1) Longevity swaps are used by the Company to mitigate risk associated with life expectancy and unanticipated changes in mortality rates. Included in the table above, the Company uses various over-the-counter (“OTC”) and exchange traded derivatives to hedge variable annuity guarantees. The table below presents the gross notional amount, estimated fair value and primary underlying risk exposure of the derivatives hedging variable annuity guarantees accounted for as MRBs: September 30, 2024 December 31, 2023 Primary Underlying Risk Exposure Gross Estimated Fair Value Gross Estimated Fair Value Assets Liabilities Assets Liabilities (In millions) Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate $ 9,092 $ 13 $ 603 $ 9,096 $ 13 $ 663 Foreign currency exchange rate 577 20 1 716 22 2 Equity market 4,659 94 193 5,189 77 373 $ 14,328 $ 127 $ 797 $ 15,001 $ 112 $ 1,038
The Effects of Derivatives on the Interim Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)	The following table presents the interim condensed consolidated financial statement location and amount of gain (loss) recognized on fair value, cash flow, net investment in a foreign operation (“NIFO”), nonqualifying hedging relationships and embedded derivatives: Three Months Ended September 30, 2024 Net Investment Income Net Investment Gains (Losses) Net Derivative Gains (Losses) Policyholder Benefits and Claims Interest Credited to PABs Other Expenses OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ (1) $ — N/A $ 185 $ 92 $ — N/A Hedged items 1 — N/A (191) (93) — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) (23) 41 N/A — 32 — N/A Hedged items 22 (30) N/A — (34) — N/A Amount excluded from the assessment of hedge effectiveness — (15) N/A — — — N/A Subtotal (1) (4) N/A (6) (3) — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A $ 286 Amount of gains (losses) reclassified from AOCI into income 5 (1) — — — — (4) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (161) Amount of gains (losses) reclassified from AOCI into income 1 602 — — — — (603) Foreign currency transaction gains (losses) on hedged items — (585) — — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A — Amount of gains (losses) reclassified from AOCI into income — — — — — — — Subtotal 6 16 — — — — (482) Gain (Loss) on NIFO Hedges: Foreign currency exchange rate derivatives (1) N/A — N/A N/A N/A N/A (141) Non-derivative hedging instruments N/A N/A N/A N/A N/A N/A (33) Subtotal N/A — N/A N/A N/A N/A (174) Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A 360 N/A N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A 573 N/A N/A N/A N/A Credit derivatives — purchased (1) — N/A (8) N/A N/A N/A N/A Credit derivatives — written (1) — N/A 25 N/A N/A N/A N/A Equity derivatives (1) (10) N/A (95) N/A N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A (182) N/A N/A N/A N/A Subtotal (10) N/A 673 N/A N/A N/A N/A Earned income on derivatives 33 — 136 (5) (36) — — Synthetic GICs N/A N/A 19 N/A N/A N/A N/A Embedded derivatives N/A N/A (61) N/A N/A N/A N/A Total $ 28 $ 12 $ 767 $ (11) $ (39) $ — $ (656) Three Months Ended September 30, 2023 Net Investment Income Net Investment Gains (Losses) Net Derivative Gains (Losses) Policyholder Benefits and Claims Interest Credited to PABs Other Expenses OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ (2) $ — N/A $ (230) $ (60) $ — N/A Hedged items 3 — N/A 223 59 — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) 12 (19) N/A — (27) — N/A Hedged items (12) 14 N/A — 26 — N/A Amount excluded from the assessment of hedge effectiveness — (2) N/A — — — N/A Subtotal 1 (7) N/A (7) (2) — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A $ (711) Amount of gains (losses) reclassified from AOCI into income 11 17 — — — — (28) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (293) Amount of gains (losses) reclassified from AOCI into income 1 (301) — — — 1 299 Foreign currency transaction gains (losses) on hedged items — 288 — — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A — Amount of gains (losses) reclassified from AOCI into income — — — — — — — Subtotal 12 4 — — — 1 (733) Gain (Loss) on NIFO Hedges: Foreign currency exchange rate derivatives (1) N/A 5 N/A N/A N/A N/A 74 Non-derivative hedging instruments N/A N/A N/A N/A N/A N/A 10 Subtotal N/A 5 N/A N/A N/A N/A 84 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A (1,105) N/A N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A (556) N/A N/A N/A N/A Credit derivatives — purchased (1) — N/A 30 N/A N/A N/A N/A Credit derivatives — written (1) — N/A (40) N/A N/A N/A N/A Equity derivatives (1) 8 N/A 120 N/A N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A 13 N/A N/A N/A N/A Subtotal 8 N/A (1,538) N/A N/A N/A N/A Earned income on derivatives 82 — 230 (3) (43) — — Synthetic GICs N/A N/A 20 N/A N/A N/A N/A Embedded derivatives N/A N/A 86 N/A N/A N/A N/A Total $ 103 $ 2 $ (1,202) $ (10) $ (45) $ 1 $ (649) Nine Months Ended September 30, 2024 Net Net Net Policyholder Interest Credited to PABs Other OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ (1) $ — N/A $ 35 $ 34 $ — N/A Hedged items 1 — N/A (54) (38) — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) (21) (16) N/A — 1 — N/A Hedged items 22 12 N/A — 1 — N/A Amount excluded from the assessment of hedge effectiveness — (11) N/A — — — N/A Subtotal 1 (15) N/A (19) (2) — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A $ (196) Amount of gains (losses) reclassified from AOCI into income 18 (2) — — — — (16) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (180) Amount of gains (losses) reclassified from AOCI into income 4 226 — — — — (230) Foreign currency transaction gains (losses) on hedged items — (236) — — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A — Amount of gains (losses) reclassified from AOCI into income — 1 — — — — (1) Subtotal 22 (11) — — — — (623) Gain (Loss) on NIFO Hedges: Foreign currency exchange rate derivatives (1) N/A — N/A N/A N/A N/A 203 Non-derivative hedging instruments N/A N/A N/A N/A N/A N/A 4 Subtotal N/A — N/A N/A N/A N/A 207 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A (211) N/A N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A (697) N/A N/A N/A N/A Credit derivatives — purchased (1) — N/A (6) N/A N/A N/A N/A Credit derivatives — written (1) — N/A 47 N/A N/A N/A N/A Equity derivatives (1) (46) N/A (545) N/A N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A 159 N/A N/A N/A N/A Subtotal (46) N/A (1,253) N/A N/A N/A N/A Earned income on derivatives 116 — 497 (11) (129) — — Synthetic GICs N/A N/A 57 N/A N/A N/A N/A Embedded derivatives N/A N/A (21) N/A N/A N/A N/A Total $ 93 $ (26) $ (720) $ (30) $ (131) $ — $ (416) Nine Months Ended September 30, 2023 Net Investment Income Net Investment Gains (Losses) Net Derivative Gains (Losses) Policyholder Benefits and Claims Interest Credited to PABs Other Expenses OCI (In millions) Gain (Loss) on Fair Value Hedges: Interest rate derivatives: Derivatives designated as hedging instruments (1) $ (3) $ — N/A $ (239) $ (59) $ — N/A Hedged items 3 — N/A 218 57 — N/A Foreign currency exchange rate derivatives: Derivatives designated as hedging instruments (1) (10) (73) N/A — (14) — N/A Hedged items 9 56 N/A — 15 — N/A Amount excluded from the assessment of hedge effectiveness — (2) N/A — — — N/A Subtotal (1) (19) N/A (21) (1) — N/A Gain (Loss) on Cash Flow Hedges: Interest rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A $ (369) Amount of gains (losses) reclassified from AOCI into income 38 77 — — — — (115) Foreign currency exchange rate derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (715) Amount of gains (losses) reclassified from AOCI into income 3 10 — — — 2 (15) Foreign currency transaction gains (losses) on hedged items — (2) — — — — — Credit derivatives: (1) Amount of gains (losses) deferred in AOCI N/A N/A N/A N/A N/A N/A (1) Amount of gains (losses) reclassified from AOCI into income — — — — — — — Subtotal 41 85 — — — 2 (1,215) Gain (Loss) on NIFO Hedges: Foreign currency exchange rate derivatives (1) N/A 5 N/A N/A N/A N/A 280 Non-derivative hedging instruments N/A N/A N/A N/A N/A N/A 37 Subtotal N/A 5 N/A N/A N/A N/A 317 Gain (Loss) on Derivatives Not Designated or Not Qualifying as Hedging Instruments: Interest rate derivatives (1) — N/A (1,381) N/A N/A N/A N/A Foreign currency exchange rate derivatives (1) — N/A (1,518) N/A N/A N/A N/A Credit derivatives — purchased (1) — N/A (1) N/A N/A N/A N/A Credit derivatives — written (1) — N/A 48 N/A N/A N/A N/A Equity derivatives (1) (34) N/A (801) N/A N/A N/A N/A Foreign currency transaction gains (losses) on hedged items — N/A 455 N/A N/A N/A N/A Subtotal (34) N/A (3,198) N/A N/A N/A N/A Earned income on derivatives 157 — 802 5 (111) — — Synthetic GICs N/A N/A 56 N/A N/A N/A N/A Embedded derivatives N/A N/A 51 N/A N/A N/A N/A Total $ 163 $ 71 $ (2,289) $ (16) $ (112) $ 2 $ (898) __________________ (1) Excludes earned income on derivatives.
Fair Value Hedges	The following table presents the balance sheet classification, carrying amount and cumulative fair value hedging adjustments for items designated and qualifying as hedged items in fair value hedges: Balance Sheet Line Item Carrying Amount Cumulative Amount September 30, 2024 December 31, 2023 September 30, 2024 December 31, 2023 (In millions) Fixed maturity securities AFS $ 388 $ 454 $ — $ 3 Mortgage loans $ 305 $ 359 $ (2) $ (11) FPBs $ (2,750) $ (2,863) $ 151 $ 191 PABs $ (2,438) $ (1,911) $ 43 $ 25 __________________ (1) Includes ($96) million and ($111) million of hedging adjustments on discontinued hedging relationships at September 30, 2024 and December 31, 2023, respectively.
Schedule of estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps	The following table presents the estimated fair value, maximum amount of future payments and weighted average years to maturity of written credit default swaps at: September 30, 2024 December 31, 2023 Rating Agency Designation of Referenced Estimated Maximum Weighted Estimated Maximum Weighted (Dollars in millions) Aaa/Aa/A Single name credit default swaps (3) $ 1 $ 103 1.3 $ 2 $ 150 1.6 Credit default swaps referencing indices 83 4,261 2.4 80 3,830 2.7 Subtotal 84 4,364 2.4 82 3,980 2.6 Baa Single name credit default swaps (3) 1 92 1.6 1 99 2.1 Credit default swaps referencing indices 169 8,195 5.0 145 8,188 5.4 Subtotal 170 8,287 5.0 146 8,287 5.3 Ba Single name credit default swaps (3) — 17 1.4 — 17 2.1 Credit default swaps referencing indices 2 24 2.2 2 25 3.0 Subtotal 2 41 1.9 2 42 2.6 B Credit default swaps referencing indices 10 144 3.9 2 129 5.0 Subtotal 10 144 3.9 2 129 5.0 Caa Credit default swaps referencing indices (1) 15 2.2 (4) 30 2.5 Subtotal (1) 15 2.2 (4) 30 2.5 Total $ 265 $ 12,851 4.1 $ 228 $ 12,468 4.5 _________________ (1) The rating agency designations are based on availability and the midpoint of the applicable ratings among Moody’s Investors Service (“Moody’s”), S&P Global Ratings (“S&P”) and Fitch Ratings. If no rating is available from a rating agency, then an internally developed rating is used. (2) The weighted average years to maturity of the credit default swaps is calculated based on weighted average gross notional amounts. (3) Single name credit default swaps may be referenced to the credit of corporations, foreign governments, or municipals.
Estimated Fair Value of Derivative Assets and Liabilities after Master Netting Agreements and Cash Collateral	The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at: September 30, 2024 December 31, 2023 Derivatives Subject to a Master Netting Arrangement or a Similar Arrangement Assets Liabilities Assets Liabilities (In millions) Gross estimated fair value of derivatives: OTC-bilateral (1) $ 8,111 $ 6,036 $ 8,749 $ 6,014 OTC-cleared (1) 191 260 158 277 Exchange-traded 17 8 11 16 Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1) 8,319 6,304 8,918 6,307 Gross amounts not offset on the interim condensed consolidated balance sheets: Gross estimated fair value of derivatives: (2) OTC-bilateral (3,035) (3,035) (3,568) (3,568) OTC-cleared (5) (5) (5) (5) Exchange-traded (3) (3) (1) (1) Cash collateral: (3), (4) OTC-bilateral (2,676) — (3,448) — OTC-cleared (181) (237) (150) (239) Exchange-traded — (4) — (5) Securities collateral: (5) OTC-bilateral (2,313) (2,993) (1,563) (2,427) OTC-cleared — (18) — (33) Exchange-traded — (1) — (10) Net amount after application of master netting agreements and collateral $ 106 $ 8 $ 183 $ 19 __________________ (1) At September 30, 2024 and December 31, 2023, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $147 million and $181 million, respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of ($53) million and $9 million, respectively. (2) Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals. (3) Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the central clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet. For certain collateral agreements, cash collateral is pledged to the Company as initial margin on its OTC-bilateral derivatives. (4) The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange-traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements. At September 30, 2024 and December 31, 2023, th e Company received excess cash collateral of $43 million and $163 million, respectively, and provided excess cash collateral of $93 million and $98 million, respectively, which is not included in the table above due to the foregoing limitation. (5) Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at September 30, 2024, none of the c ollateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At September 30, 2024 and December 31, 2023, the Company received excess securities collateral with an estimated fair value of $441 million and $298 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At September 30, 2024 and December 31, 2023, the Company provided excess securities collateral with an estimated fair value of $1.5 billion, at both periods, for its OTC-bilateral derivatives, $891 million and $945 million, respectively, for its OTC-cleared derivatives, and $181 million and $137 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to the foregoing limitation.
Estimated Fair Value of Derivative Assets and Liabilities after Master Netting Agreements and Cash Collateral	The estimated fair values of the Company’s net derivative assets and net derivative liabilities after the application of master netting agreements and collateral were as follows at: September 30, 2024 December 31, 2023 Derivatives Subject to a Master Netting Arrangement or a Similar Arrangement Assets Liabilities Assets Liabilities (In millions) Gross estimated fair value of derivatives: OTC-bilateral (1) $ 8,111 $ 6,036 $ 8,749 $ 6,014 OTC-cleared (1) 191 260 158 277 Exchange-traded 17 8 11 16 Total gross estimated fair value of derivatives presented on the interim condensed consolidated balance sheets (1) 8,319 6,304 8,918 6,307 Gross amounts not offset on the interim condensed consolidated balance sheets: Gross estimated fair value of derivatives: (2) OTC-bilateral (3,035) (3,035) (3,568) (3,568) OTC-cleared (5) (5) (5) (5) Exchange-traded (3) (3) (1) (1) Cash collateral: (3), (4) OTC-bilateral (2,676) — (3,448) — OTC-cleared (181) (237) (150) (239) Exchange-traded — (4) — (5) Securities collateral: (5) OTC-bilateral (2,313) (2,993) (1,563) (2,427) OTC-cleared — (18) — (33) Exchange-traded — (1) — (10) Net amount after application of master netting agreements and collateral $ 106 $ 8 $ 183 $ 19 __________________ (1) At September 30, 2024 and December 31, 2023, derivative assets included income (expense) accruals reported in accrued investment income or in other liabilities of $147 million and $181 million, respectively, and derivative liabilities included (income) expense accruals reported in accrued investment income or in other liabilities of ($53) million and $9 million, respectively. (2) Estimated fair value of derivatives is limited to the amount that is subject to set-off and includes income or expense accruals. (3) Cash collateral received by the Company for OTC-bilateral and OTC-cleared derivatives, where the central clearinghouse treats variation margin as collateral, is included in cash and cash equivalents, short-term investments or in fixed maturity securities AFS, and the obligation to return it is included in payables for collateral under securities loaned and other transactions on the balance sheet. For certain collateral agreements, cash collateral is pledged to the Company as initial margin on its OTC-bilateral derivatives. (4) The receivable for the return of cash collateral provided by the Company is inclusive of initial margin on exchange-traded and OTC-cleared derivatives and is included in premiums, reinsurance and other receivables on the balance sheet. The amount of cash collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements. At September 30, 2024 and December 31, 2023, th e Company received excess cash collateral of $43 million and $163 million, respectively, and provided excess cash collateral of $93 million and $98 million, respectively, which is not included in the table above due to the foregoing limitation. (5) Securities collateral received by the Company is held in separate custodial accounts and is not recorded on the balance sheet. Subject to certain constraints, the Company is permitted by contract to sell or re-pledge this collateral, but at September 30, 2024, none of the c ollateral had been sold or re-pledged. Securities collateral pledged by the Company is reported in fixed maturity securities AFS on the balance sheet. Subject to certain constraints, the counterparties are permitted by contract to sell or re-pledge this collateral. The amount of securities collateral offset in the table above is limited to the net estimated fair value of derivatives after application of netting agreements and cash collateral. At September 30, 2024 and December 31, 2023, the Company received excess securities collateral with an estimated fair value of $441 million and $298 million, respectively, for its OTC-bilateral derivatives, which are not included in the table above due to the foregoing limitation. At September 30, 2024 and December 31, 2023, the Company provided excess securities collateral with an estimated fair value of $1.5 billion, at both periods, for its OTC-bilateral derivatives, $891 million and $945 million, respectively, for its OTC-cleared derivatives, and $181 million and $137 million, respectively, for its exchange-traded derivatives, which are not included in the table above due to the foregoing limitation.
Estimated Fair Value of OTC-bilateral derivatives after considering effect of netting agreements	The followi ng table presents the estimated fair value of the Company’s OTC-bilateral derivatives that were in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged. September 30, 2024 December 31, 2023 Derivatives Derivatives Total Derivatives Derivatives Total (In millions) Estimated fair value of derivatives in a net liability position (1) $ 2,954 $ 47 $ 3,001 $ 2,443 $ 4 $ 2,447 Estimated fair value of collateral provided: Fixed maturity securities AFS $ 3,612 $ 53 $ 3,665 $ 3,011 $ 6 $ 3,017 __________________ (1) After taking into consideration the existence of netting agreements. The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at: Balance Sheet Location September 30, 2024 December 31, 2023 (In millions) Embedded derivatives within liability host contracts: Funds withheld and guarantees on reinsurance Other liabilities $ (53) $ (70) Fixed annuities with equity indexed returns PABs 172 163 Total $ 119 $ 93
Embedded Derivatives	The followi ng table presents the estimated fair value of the Company’s OTC-bilateral derivatives that were in a net liability position after considering the effect of netting agreements, together with the estimated fair value and balance sheet location of the collateral pledged. September 30, 2024 December 31, 2023 Derivatives Derivatives Total Derivatives Derivatives Total (In millions) Estimated fair value of derivatives in a net liability position (1) $ 2,954 $ 47 $ 3,001 $ 2,443 $ 4 $ 2,447 Estimated fair value of collateral provided: Fixed maturity securities AFS $ 3,612 $ 53 $ 3,665 $ 3,011 $ 6 $ 3,017 __________________ (1) After taking into consideration the existence of netting agreements. The following table presents the estimated fair value and balance sheet location of the Company’s embedded derivatives that have been separated from their host contracts at: Balance Sheet Location September 30, 2024 December 31, 2023 (In millions) Embedded derivatives within liability host contracts: Funds withheld and guarantees on reinsurance Other liabilities $ (53) $ (70) Fixed annuities with equity indexed returns PABs 172 163 Total $ 119 $ 93

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Recurring Fair Value Measurements	The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy, including those items for which the Company has elected the FVO, are presented below at: September 30, 2024 Fair Value Hierarchy Level 1 Level 2 Level 3 Total Estimated Fair Value (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 70,349 $ 14,502 $ 84,851 Foreign corporate — 41,047 15,705 56,752 Foreign government — 44,091 41 44,132 U.S. government and agency 16,650 18,026 — 34,676 RMBS — 33,367 1,897 35,264 ABS & CLO — 15,138 2,382 17,520 Municipals — 10,798 — 10,798 CMBS — 8,557 1,229 9,786 Total fixed maturity securities AFS 16,650 241,373 35,756 293,779 Equity securities 430 74 242 746 Unit-linked and FVO securities (1) 7,846 267 1,176 9,289 Short-term investments (2) 3,155 1,176 6 4,337 Other investments 44 2,016 1,095 3,155 Derivative assets: (3) Interest rate 2 3,424 — 3,426 Foreign currency exchange rate 2 4,159 25 4,186 Credit — 271 — 271 Equity market 13 272 4 289 Total derivative assets 17 8,126 29 8,172 MRBs — — 310 310 Reinsured MRBs (4) — — 16 16 Separate account assets (5) 69,799 77,991 1,019 148,809 Total assets (6) $ 97,941 $ 331,023 $ 39,649 $ 468,613 Liabilities Derivative liabilities: (3) Interest rate $ 2 $ 2,994 $ — $ 2,996 Foreign currency exchange rate — 2,918 5 2,923 Credit — 76 — 76 Equity market 6 356 — 362 Total derivative liabilities 8 6,344 5 6,357 Embedded derivatives within liability host contracts (7) — — 119 119 MRBs — — 3,117 3,117 Separate account liabilities (5) — 5 — 5 Total liabilities $ 8 $ 6,349 $ 3,241 $ 9,598 December 31, 2023 Fair Value Hierarchy Level 1 Level 2 Level 3 Total Estimated Fair Value (In millions) Assets Fixed maturity securities AFS: U.S. corporate $ — $ 67,003 $ 13,714 $ 80,717 Foreign corporate — 40,813 14,631 55,444 Foreign government — 45,438 51 45,489 U.S. government and agency 15,327 16,925 — 32,252 RMBS 3 27,495 1,598 29,096 ABS & CLO — 15,191 2,103 17,294 Municipals — 11,171 — 11,171 CMBS — 9,099 850 9,949 Total fixed maturity securities AFS 15,330 233,135 32,947 281,412 Equity securities 429 79 249 757 Unit-linked and FVO securities (1) 7,520 1,708 1,103 10,331 Short-term investments (2) 5,103 667 27 5,797 Other investments 48 363 975 1,386 Derivative assets: (3) Interest rate 1 3,674 — 3,675 Foreign currency exchange rate 2 4,393 23 4,418 Credit — 228 8 236 Equity market 8 393 7 408 Total derivative assets 11 8,688 38 8,737 MRBs — — 286 286 Reinsured MRBs (4) — — 18 18 Separate account assets (5) 66,229 77,258 1,147 144,634 Total assets (6) $ 94,670 $ 321,898 $ 36,790 $ 453,358 Liabilities Derivative liabilities: (3) Interest rate $ 5 $ 2,805 $ 174 $ 2,984 Foreign currency exchange rate — 2,737 7 2,744 Credit — 84 — 84 Equity market 11 475 — 486 Total derivative liabilities 16 6,101 181 6,298 Embedded derivatives within liability host contracts (7) — — 93 93 MRBs — — 3,179 3,179 Separate account liabilities (5) 4 4 — 8 Total liabilities $ 20 $ 6,105 $ 3,453 $ 9,578 __________________ (1) Unit-linked and FVO securities were primarily comprised of Unit-linked investments at both September 30, 2024 and December 31, 2023. (2) Short-term investments as presented in the tables above differ from the amounts presented on the interim condensed consolidated balance sheets because certain short-term investments are not measured at estimated fair value on a recurring basis. (3) Derivative assets are presented within other invested assets on the interim condensed consolidated balance sheets and derivative liabilities are presented within other liabilities on the interim condensed consolidated balance sheets. The amounts are presented gross in the tables above to reflect the presentation on the interim condensed consolidated balance sheets, but are presented net for purposes of the rollforward in the Fair Value Measurements Using Significant Unobservable Inputs (Level 3) tables. (4) Reinsured MRBs are presented within premiums, reinsurance and other receivables on the consolidated balance sheets. (5) Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders whose liability is reflected within separate account liabilities. Separate account liabilities are set equal to the estimated fair value of separate account assets. Separate account liabilities presented in the tables above represent derivative liabilities. (6) Total assets included in the fair value hierarchy exclude OLPI that are measured at estimated fair value using the net asset value (“NAV”) per share (or its equivalent) practical expedient. The estimated fair value of such investments was $51 million and $52 million at September 30, 2024 and December 31, 2023, respectively. (7) Embedded derivatives within liability host contracts are presented within PABs and other liabilities on the interim condensed consolidated balance sheets.
Fair Value Inputs, Quantitative Information	The following table presents certain quantitative information about the significant unobservable inputs used in the fair value measurement, and the sensitivity of the estimated fair value to changes in those inputs, for the more significant asset and liability classes measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at: September 30, 2024 December 31, 2023 Impact of Valuation Significant Range Weighted Range Weighted Fixed maturity securities AFS (3) U.S. corporate and foreign corporate • Matrix pricing • Offered quotes (4) 34 - 133 94 4 - 131 93 Increase • Market pricing • Quoted prices (4) 13 - 116 97 — - 110 92 Increase • Consensus pricing • Offered quotes (4) 92 - 100 96 86 - 102 96 Increase RMBS • Market pricing • Quoted prices (4) — - 121 95 — - 112 93 Increase (5) ABS & CLO • Market pricing • Quoted prices (4) 3 - 106 97 3 - 101 93 Increase (5) Derivatives Interest rate • Present value techniques • Swap yield (6) — - — — 367 - 399 385 Increase (7) Foreign currency exchange rate • Present value techniques • Swap yield (6) 111 - 168 166 185 - 399 193 Increase (7) Credit • Consensus pricing • Offered quotes (8) MRBs and Reinsured MRBs Direct, assumed and ceded guaranteed minimum benefits • Option pricing techniques • Mortality rates: Ages 0 - 40 0% - 0.15% 0.05% 0% - 0.15% 0.05% (9) Ages 41 - 60 0.04% - 0.79% 0.22% 0.04% - 0.75% 0.22% (9) Ages 61 - 115 0% - 100% 1.14% 0% - 100% 1.23% (9) • Lapse rates: Durations 1 - 10 0.14% - 20.10% 12.86% 0.39% - 20.10% 8.72% Decrease (10) Durations 11 - 20 0.39% - 15% 6.05% 0.39% - 15% 4.34% Decrease (10) Durations 21 - 116 0.39% - 15% 8.20% 0.10% - 15% 4.59% Decrease (10) • Utilization rates 0.20% - 22% 0.79% 0.20% - 22% 0.44% Increase (11) • Withdrawal rates 0% - 20% 4.77% 0% - 20% 4.47% (12) • Long-term equity volatilities 14.23% - 22.27% 18.77% 8.05% - 21.85% 18.55% Increase (13) • Nonperformance risk spread 0.11% - 1.49% 0.64% 0.38% - 1.59% 0.73% Decrease (14) __________________ (1) The weighted average for fixed maturity securities AFS and derivatives is determined based on the estimated fair value of the securities and derivatives. The weighted average for MRBs is determined based on a combination of account values and experience data. (2) The impact of a decrease in input would have resulted in the opposite impact on estimated fair value. For MRBs, changes to direct and assumed guaranteed minimum benefits are based on liability positions; changes to ceded guaranteed minimum benefits are based on asset positions. (3) Significant increases (decreases) in expected default rates in isolation would have resulted in substantially lower (higher) valuations. (4) Range and weighted average are presented in accordance with the market convention for fixed maturity securities AFS of dollars per hundred dollars of par. (5) Changes in the assumptions used for the probability of default would have been accompanied by a directionally similar change in the assumption used for the loss severity and a directionally opposite change in the assumptions used for prepayment rates. (6) Ranges represent the rates across different yield curves and are presented in basis points. The swap yield curves are utilized among different types of derivatives to project cash flows, as well as to discount future cash flows to present value. Since this valuation methodology uses a range of inputs across a yield curve to value the derivative, presenting a range is more representative of the unobservable input used in the valuation. (7) Changes in estimated fair value are based on long U.S. dollar net asset positions and will be inversely impacted for short U.S. dollar net asset positions. (8) At September 30, 2024 and December 31, 2023, independent non-binding broker quotations were used in the determination of 0% and less than 1%, respectively, of the total net derivative estimated fair value. (9) Mortality rates vary by age and by demographic characteristics such as gender. Mortality rate assumptions are based on company experience. A mortality improvement assumption is also applied. For any given contract, mortality rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For contracts that contain only a GMDB, any increase (decrease) in mortality rates result in an increase (decrease) in the estimated fair value of MRBs. Generally, for contracts that contain both a GMDB and a living benefit (e.g., GMIB, GMWB, GMAB), any increase (decrease) in mortality rates result in a decrease (increase) in the estimated fair value of MRBs. (10) Base lapse rates are adjusted at the contract level based on a comparison of the actuarially calculated guaranteed values and the current policyholder account value, as well as other factors, such as the applicability of any surrender charges. A dynamic lapse function reduces the base lapse rate when the guaranteed amount is greater than the account value as in the money contracts are less likely to lapse. Lapse rates are also generally assumed to be lower in periods when a surrender charge applies. For any given contract, lapse rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. (11) The utilization rate assumption estimates the percentage of contractholders with GMIBs or a lifetime withdrawal benefit who will elect to utilize the benefit upon becoming eligible. The rates may vary by the type of guarantee, the amount by which the guaranteed amount is greater than the account value, the contract’s withdrawal history and by the age of the policyholder. For any given contract, utilization rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. (12) The withdrawal rate represents the percentage of account balance that any given policyholder will elect to withdraw from the contract each year. The withdrawal rate assumption varies by age and duration of the contract, and also by other factors such as benefit type. For any given contract, withdrawal rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. For GMWBs, any increase (decrease) in withdrawal rates results in an increase (decrease) in the estimated fair value of the guarantees. For GMABs and GMIBs, any increase (decrease) in withdrawal rates results in a decrease (increase) in the estimated fair value. (13) Long-term equity volatilities represent equity volatility beyond the period for which observable equity volatilities are available. For any given contract, long-term equity volatility rates vary throughout the period over which cash flows are projected for purposes of valuing the MRBs. (14) Nonperformance risk spread varies by duration and by currency. For any given contract, multiple nonperformance risk spreads will apply, depending on the duration of the cash flow being discounted for purposes of valuing the MRBs.
Fair Value, Measured on Recurring Basis, Unobservable Input Reconciliation	The following tables summarize the change of assets (liabilities) measured at estimated fair value on a recurring basis using significant unobservable inputs (Level 3), excluding MRBs (see Note 6): Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fixed Maturity Securities AFS Corporate (6) Foreign Structured Municipals Equity Securities Unit-linked (In millions) Three Months Ended September 30, 2024 Balance, beginning of period $ 29,240 $ 40 $ 5,867 $ 1 $ 262 $ 1,096 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (10) (8) 6 — (15) 56 Total realized/unrealized gains (losses) included in AOCI 1,169 7 132 — — — Purchases (3) 2,080 2 1,080 — 9 135 Sales (3) (1,255) (1) (539) (1) (14) (111) Issuances (3) — — — — — — Settlements (3) — — — — — — Transfers into Level 3 (4) 94 1 31 — — — Transfers out of Level 3 (4) (1,111) — (1,069) — — — Balance, end of period $ 30,207 $ 41 $ 5,508 $ — $ 242 $ 1,176 Three Months Ended September 30, 2023 Balance, beginning of period $ 25,968 $ 60 $ 4,554 $ 7 $ 250 $ 1,057 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) 3 4 (8) — (5) (31) Total realized/unrealized gains (losses) included in AOCI (996) (9) (10) — — — Purchases (3) 991 4 969 — — 204 Sales (3) (573) (9) (376) — (1) (177) Issuances (3) — — — — — — Settlements (3) — — — — — — Transfers into Level 3 (4) 132 — 70 — — 16 Transfers out of Level 3 (4) (258) (7) (294) (7) — — Balance, end of period $ 25,267 $ 43 $ 4,905 $ — $ 244 $ 1,069 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2024 (5) $ (6) $ (8) $ 12 $ — $ (15) $ 57 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2023 (5) $ 2 $ 4 $ (5) $ — $ (4) $ (32) Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2024 (5) $ 1,159 $ 7 $ 113 $ — $ — $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2023 (5) $ (989) $ (9) $ (14) $ — $ — $ — Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Short-term Other Net Net Embedded Separate (In millions) Three Months Ended September 30, 2024 Balance, beginning of period $ 10 $ 1,073 $ (75) $ (55) $ 1,122 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) — 9 21 (61) (9) Total realized/unrealized gains (losses) included in AOCI — — 7 — — Purchases (3) 1 6 — — 18 Sales (3) (8) (45) — — (93) Issuances (3) — — — — — Settlements (3) — — 72 (3) — Transfers into Level 3 (4) 3 52 — — 1 Transfers out of Level 3 (4) — — (1) — (20) Balance, end of period $ 6 $ 1,095 $ 24 $ (119) $ 1,019 Three Months Ended September 30, 2023 Balance, beginning of period $ 18 $ 964 $ (214) $ (64) $ 1,248 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) — (6) (56) 86 (22) Total realized/unrealized gains (losses) included in AOCI 1 — (110) — — Purchases (3) 14 12 — — 15 Sales (3) (8) — — — (30) Issuances (3) — — — — — Settlements (3) — — 91 (27) — Transfers into Level 3 (4) — — — — 6 Transfers out of Level 3 (4) — — — — (10) Balance, end of period $ 25 $ 970 $ (289) $ (5) $ 1,207 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2024 (5) $ — $ 11 $ 15 $ (61) $ — Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2023 (5) $ — $ (6) $ (57) $ 86 $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2024 (5) $ — $ — $ — $ — $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2023 (5) $ — $ — $ (92) $ — $ — Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Fixed Maturity Securities AFS Corporate (6) Foreign Structured Municipals Equity Unit-linked (In millions) Nine Months Ended September 30, 2024 Balance, beginning of period $ 28,345 $ 51 $ 4,551 $ — $ 249 $ 1,103 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) (70) (6) 19 — (26) 121 Total realized/unrealized gains (losses) included in AOCI 502 3 172 — — — Purchases (3) 4,618 1 1,614 — 31 139 Sales (3) (2,212) (1) (792) — (12) (167) Issuances (3) — — — — — — Settlements (3) — — — — — — Transfers into Level 3 (4) 55 1 179 — — — Transfers out of Level 3 (4) (1,031) (8) (235) — — (20) Balance, end of period $ 30,207 $ 41 $ 5,508 $ — $ 242 $ 1,176 Nine Months Ended September 30, 2023 Balance, beginning of period $ 24,401 $ 103 $ 4,269 $ — $ 259 $ 787 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) — 3 (10) — 1 63 Total realized/unrealized gains (losses) included in AOCI (659) (7) (42) — — — Purchases (3) 3,282 7 1,099 — 2 227 Sales (3) (1,562) (11) (537) — (18) (21) Issuances (3) — — — — — — Settlements (3) — — — — — — Transfers into Level 3 (4) 305 4 240 — — 17 Transfers out of Level 3 (4) (500) (56) (114) — — (4) Balance, end of period $ 25,267 $ 43 $ 4,905 $ — $ 244 $ 1,069 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2024 (5) $ (17) $ (6) $ 23 $ — $ (20) $ 124 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2023 (5) $ (2) $ 3 $ 1 $ — $ (6) $ 62 Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2024 (5) $ 489 $ 3 $ 144 $ — $ — $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2023 (5) $ (685) $ (7) $ (48) $ — $ — $ — Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Short-term Other Net Net Embedded Separate (In millions) Nine Months Ended September 30, 2024 Balance, beginning of period $ 27 $ 975 $ (143) $ (93) $ 1,147 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) 1 21 5 (21) (46) Total realized/unrealized gains (losses) included in AOCI (1) — (28) — — Purchases (3) 5 54 — — 15 Sales (3) (26) (186) — — (92) Issuances (3) — — — — — Settlements (3) — — 201 (5) — Transfers into Level 3 (4) — 231 — — 2 Transfers out of Level 3 (4) — — (11) — (7) Balance, end of period $ 6 $ 1,095 $ 24 $ (119) $ 1,019 Nine Months Ended September 30, 2023 Balance, beginning of period $ 57 $ 926 $ (170) $ (17) $ 1,210 Total realized/unrealized gains (losses) included in net income (loss) (1), (2) — 19 (21) 51 (62) Total realized/unrealized gains (losses) included in AOCI 1 — (59) — — Purchases (3) 25 25 — — 181 Sales (3) (48) — — — (128) Issuances (3) — — — — — Settlements (3) — — 121 (39) 1 Transfers into Level 3 (4) — — — — 14 Transfers out of Level 3 (4) (10) — (160) — (9) Balance, end of period $ 25 $ 970 $ (289) $ (5) $ 1,207 Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2024 (5) $ 1 $ 19 $ 2 $ (21) $ — Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at September 30, 2023 (5) $ — $ 20 $ (28) $ 51 $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2024 (5) $ — $ — $ — $ — $ — Changes in unrealized gains (losses) included in AOCI for the instruments still held at September 30, 2023 (5) $ — $ — $ (85) $ — $ — __________________ (1) Amortization of premium/accretion of discount is included within net investment income. Impairments and changes in ACL charged to net income (loss) on certain securities are included in net investment gains (losses), while changes in estimated fair value of Unit-linked and FVO securities are included in net investment income. Lapses associated with net embedded derivatives are included in net derivative gains (losses). Substantially all realized/unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses). (2) Interest and dividend accruals, as well as cash interest coupons and dividends received, are excluded from the rollforward. (3) Items purchased/issued and then sold/settled in the same period are excluded from the rollforward. Fees attributed to embedded derivatives are included in settlements. (4) Items transferred into and then out of Level 3 in the same period are excluded from the rollforward. (5) Changes in unrealized gains (losses) included in net income (loss) and included in AOCI relate to assets and liabilities still held at the end of the respective periods. Substantially all changes in unrealized gains (losses) included in net income (loss) for net derivatives and net embedded derivatives are reported in net derivative gains (losses). (6) Comprised of U.S. and foreign corporate securities. (7) Freestanding derivative assets and liabilities are presented net for purposes of the rollforward. (8) Embedded derivative assets and liabilities are presented net for purposes of the rollforward. (9) Investment performance related to separate account assets is fully offset by corresponding amounts credited to contractholders within separate account liabilities. Therefore, such changes in estimated fair value are not recorded in net income (loss). For the purpose of this disclosure, these changes are presented within net income (loss). Separate account assets and liabilities are presented net for the purposes of the rollforward.
Nonrecurring Fair Value Measurements	The following table presents information for assets measured at estimated fair value on a nonrecurring basis during the periods and still held at the reporting dates (for example, when there is evidence of impairment), using significant unobservable inputs (Level 3). September 30, 2024 December 31, 2023 (In millions) Carrying value after measurement: Mortgage loans (1) $ 1,087 $ 474 Other invested assets (2) $ 63 $ 63 Three Months Nine Months 2024 2023 2024 2023 (In millions) Realized gains (losses) net: Mortgage loans (1) $ (100) $ (49) $ (253) $ (190) __________________ (1) Estimated fair values of impaired mortgage loans are based on the underlying collateral or discounted cash flows. See Note 10. (2) The Company recognized an impairment loss in connection with the pending disposition of MetLife Malaysia. See Note 3.
Fair Value of Financial Instruments Carried at Other Than Fair Value	The carrying values and estimated fair values for such financial instruments, and their corresponding placement in the fair value hierarchy, are summarized as follows at: September 30, 2024 Fair Value Hierarchy Carrying Value Level 1 Level 2 Level 3 Total Estimated Fair Value (In millions) Assets Mortgage loans $ 90,415 $ — $ — $ 86,994 $ 86,994 Policy loans $ 8,822 $ — $ — $ 9,550 $ 9,550 Other invested assets $ 1,247 $ — $ 715 $ 532 $ 1,247 Premiums, reinsurance and other receivables $ 4,752 $ — $ 725 $ 4,029 $ 4,754 Other assets $ 242 $ — $ 73 $ 174 $ 247 Liabilities PABs $ 141,467 $ — $ — $ 139,362 $ 139,362 Long-term debt $ 15,271 $ — $ 15,499 $ — $ 15,499 Collateral financing arrangement $ 529 $ — $ — $ 460 $ 460 Junior subordinated debt securities $ 3,163 $ — $ 3,714 $ — $ 3,714 Other liabilities $ 10,594 $ — $ 1,486 $ 8,936 $ 10,422 Separate account liabilities $ 78,004 $ — $ 78,004 $ — $ 78,004 December 31, 2023 Fair Value Hierarchy Carrying Level 1 Level 2 Level 3 Total (In millions) Assets Mortgage loans $ 92,506 $ — $ — $ 87,753 $ 87,753 Policy loans $ 8,788 $ — $ — $ 9,516 $ 9,516 Other invested assets $ 919 $ — $ 714 $ 205 $ 919 Premiums, reinsurance and other receivables $ 5,182 $ — $ 791 $ 4,400 $ 5,191 Other assets $ 268 $ — $ 82 $ 184 $ 266 Liabilities PABs $ 138,233 $ — $ — $ 134,025 $ 134,025 Long-term debt $ 15,516 $ — $ 15,621 $ — $ 15,621 Collateral financing arrangement $ 637 $ — $ — $ 551 $ 551 Junior subordinated debt securities $ 3,161 $ — $ 3,552 $ — $ 3,552 Other liabilities $ 10,556 $ — $ 609 $ 9,651 $ 10,260 Separate account liabilities $ 75,705 $ — $ 75,705 $ — $ 75,705

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Schedule of Stock by Class	Preferred stock authorized, issued and outstanding was as follows at both September 30, 2024 and December 31, 2023: Series Shares Shares Issued and Floating Rate Non-Cumulative Preferred Stock, Series A 27,600,000 24,000,000 5.875% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series D 500,000 500,000 5.625% Non-Cumulative Preferred Stock, Series E 32,200 32,200 4.75% Non-Cumulative Preferred Stock, Series F 40,000 40,000 3.85% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G 1,000,000 1,000,000 Series A Junior Participating Preferred Stock 10,000,000 — Not designated 160,827,800 — Total 200,000,000 25,572,200
Dividends Declared	The per share and aggregate dividends declared for MetLife, Inc.’s preferred stock were as follows: Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Series Per Share Aggregate Per Share Aggregate Per Share Aggregate Per Share Aggregate (In millions, except per share data) A $ 0.417 $ 10 $ 0.419 $ 9 $ 1.267 $ 30 $ 1.155 $ 27 D $ 29.375 14 $ 29.375 14 $ 58.750 29 $ 58.750 29 E $ 351.563 11 $ 351.563 12 $ 1,054.689 34 $ 1,054.689 34 F $ 296.875 12 $ 296.875 12 $ 890.625 36 $ 890.625 36 G $ 19.250 20 $ 19.250 20 $ 38.500 39 $ 38.500 39 Total $ 67 $ 67 $ 168 $ 165
Class of Treasury Stock	MetLife, Inc. announced that its Board of Directors authorized common stock repurchases as follows: Announcement Date Authorization Amount Authorization Remaining at September 30, 2024 (1) (In millions) May 1, 2024 $ 3,000 $ 2,301 May 25, 2023 $ 1,000 $ — May 3, 2023 $ 3,000 $ — May 4, 2022 $ 3,000 $ — __________________ (1) The Inflation Reduction Act, signed into law on August 16, 2022, imposes a one percent excise tax, net of any allowable offsets, on certain corporate stock buybacks made after December 31, 2022. The authorization remaining at September 30, 2024 does not reflect the applicable excise tax payable.
Components of Accumulated Other Comprehensive Income (Loss)	Information regarding changes in the balances of each component of AOCI attributable to MetLife, Inc. was as follows: Three Months Unrealized Investment Gains (Losses), Net of Related Offsets (1) Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument- Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (19,187) $ 99 $ 6,606 $ (73) $ (6,785) $ (1,396) $ (20,736) OCI before reclassifications 9,942 125 (5,891) 99 349 3 4,627 Deferred income tax benefit (expense) (2,082) (101) 1,289 (22) 90 (1) (827) AOCI before reclassifications, net of income tax (11,327) 123 2,004 4 (6,346) (1,394) (16,936) Amounts reclassified from AOCI 121 (607) — — — 32 (454) Deferred income tax benefit (expense) (33) 192 — — — (9) 150 Amounts reclassified from AOCI, net of income tax 88 (415) — — — 23 (304) Balance, end of period $ (11,239) $ (292) $ 2,004 $ 4 $ (6,346) $ (1,371) $ (17,240) Three Months Unrealized Investment Gains (Losses), Net of Related Offsets (1) Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument- Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (17,979) $ 1,179 $ 3,919 $ 108 $ (6,282) $ (1,331) $ (20,386) OCI before reclassifications (12,599) (1,004) 8,223 (142) (348) (1) (5,871) Deferred income tax benefit (expense) 2,871 232 (1,897) 30 (9) — 1,227 AOCI before reclassifications, net of income tax (27,707) 407 10,245 (4) (6,639) (1,332) (25,030) Amounts reclassified from AOCI 710 271 — — — 30 1,011 Deferred income tax benefit (expense) (172) (57) — — — (6) (235) Amounts reclassified from AOCI, net of income tax 538 214 — — — 24 776 Balance, end of period $ (27,169) $ 621 $ 10,245 $ (4) $ (6,639) $ (1,308) $ (24,254) Nine Months Unrealized Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument- Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (14,506) $ 183 $ 2,658 $ 27 $ (6,158) $ (1,446) $ (19,242) OCI before reclassifications 3,450 (376) (807) (28) (136) (1) 2,102 Deferred income tax benefit (expense) (573) 103 153 5 (52) — (364) AOCI before reclassifications, net of income tax (11,629) (90) 2,004 4 (6,346) (1,447) (17,504) Amounts reclassified from AOCI 514 (247) — — — 96 363 Deferred income tax benefit (expense) (124) 45 — — — (20) (99) Amounts reclassified from AOCI, net of income tax 390 (202) — — — 76 264 Balance, end of period $ (11,239) $ (292) $ 2,004 $ 4 $ (6,346) $ (1,371) $ (17,240) Nine Months Unrealized Deferred FPBs Discount Rate Remeasurement Gains (Losses) MRBs Instrument- Specific Credit Risk Remeasurement Gains (Losses) Foreign Defined Total (In millions) Balance, beginning of period $ (22,646) $ 1,557 $ 6,115 $ 107 $ (6,377) $ (1,377) $ (22,621) OCI before reclassifications (8,189) (1,085) 5,325 (141) (168) (6) (4,264) Deferred income tax benefit (expense) 1,882 249 (1,195) 30 (94) 1 873 AOCI before reclassifications, net of income tax (28,953) 721 10,245 (4) (6,639) (1,382) (26,012) Amounts reclassified from AOCI 2,316 (130) — — — 90 2,276 Deferred income tax benefit (expense) (532) 30 — — — (16) (518) Amounts reclassified from AOCI, net of income tax 1,784 (100) — — — 74 1,758 Balance, end of period $ (27,169) $ 621 $ 10,245 $ (4) $ (6,639) $ (1,308) $ (24,254) __________________ (1) Primarily unrealized gains (losses) on fixed maturity securities.
Reclassification out of Accumulated Other Comprehensive Income (Loss)	Information regarding amounts reclassified out of each component of AOCI was as follows: Three Months Nine Months 2024 2023 2024 2023 AOCI Components Amounts Reclassified from AOCI Consolidated Statements of (In millions) Net unrealized investment gains (losses): Net unrealized investment gains (losses) $ (122) $ (730) $ (531) $ (2,420) Net investment gains (losses) Net unrealized investment gains (losses) — 1 — 6 Net investment income Net unrealized investment gains (losses) 1 19 17 98 Net derivative gains (losses) Net unrealized investment gains (losses), before income tax (121) (710) (514) (2,316) Income tax (expense) benefit 33 172 124 532 Net unrealized investment gains (losses), net of income tax (88) (538) (390) (1,784) Deferred gains (losses) on derivatives - cash flow hedges: Interest rate derivatives 5 11 18 38 Net investment income Interest rate derivatives (1) 17 (2) 77 Net investment gains (losses) Foreign currency exchange rate derivatives 1 1 4 3 Net investment income Foreign currency exchange rate derivatives 602 (301) 226 10 Net investment gains (losses) Foreign currency exchange rate derivatives — 1 — 2 Other expenses Credit derivatives — — 1 — Net investment gains (losses) Gains (losses) on cash flow hedges, before income tax 607 (271) 247 130 Income tax (expense) benefit (192) 57 (45) (30) Gains (losses) on cash flow hedges, net of income tax 415 (214) 202 100 Defined benefit plans adjustment: (1) Amortization of net actuarial gains (losses) (35) (33) (104) (98) Amortization of prior service (costs) credit 3 3 8 8 Amortization of defined benefit plan items, before income tax (32) (30) (96) (90) Income tax (expense) benefit 9 6 20 16 Amortization of defined benefit plan items, net of income tax (23) (24) (76) (74) Total reclassifications, net of income tax $ 304 $ (776) $ (264) $ (1,758) __________________ (1) These AOCI components are included in the computation of net periodic benefit costs. See Note 16.

Other Revenues and Other Expe_2

Other Revenues and Other Expenses (Tables)	9 Months Ended
	Sep. 30, 2024
Other Income and Expenses [Abstract]
Disaggregation of Revenue	Information on other revenues, which primarily includes fees related to service contracts from customers, was as follows: Three Months Nine Months 2024 2023 2024 2023 (In millions) Vision fee for service arrangements $ 126 $ 144 $ 402 $ 446 Prepaid legal plans 144 128 437 389 Fee-based investment management 99 103 295 306 Administrative services-only contracts 69 65 205 193 Recordkeeping and administrative services (1) 38 39 113 114 Other revenue from service contracts from customers 78 75 237 214 Total revenues from service contracts from customers 554 554 1,689 1,662 Other 94 52 271 204 Total other revenues $ 648 $ 606 $ 1,960 $ 1,866 __________________ (1) Related to products and businesses no longer actively marketed by the Company.
Other Expenses	Information on other expenses was as follows: Three Months Nine Months 2024 2023 2024 2023 (In millions) Employee-related costs (1) $ 892 $ 914 $ 2,742 $ 2,743 Third-party staffing costs 371 362 1,082 1,066 General and administrative expenses 162 209 463 539 Pension, postretirement and postemployment benefit costs 65 59 195 177 Premium taxes, other taxes, and licenses & fees 183 162 530 507 Commissions and other variable expenses 1,515 1,483 4,480 4,347 Capitalization of DAC (691) (742) (2,114) (2,189) Amortization of DAC and VOBA 516 499 1,523 1,448 Amortization of negative VOBA (7) (7) (19) (20) Interest expense on debt 257 265 778 776 Total other expenses $ 3,263 $ 3,204 $ 9,660 $ 9,394 __________________ (1) Includes ($58) million and ($135) million for the three months and nine months ended September 30, 2024, respectively, and $12 million and ($60) million for the three months and nine months ended September 30, 2023, respectively, for the net change in cash surrender value of investments in certain life insurance policies, net of premiums paid.

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	9 Months Ended
	Sep. 30, 2024
Retirement Benefits [Abstract]
Net periodic benefit costs	The components of net periodic benefit costs, reported in other expenses, were as follows: Three Months 2024 2023 Pension Other Pension Other (In millions) Service costs $ 41 $ — $ 38 $ 1 Interest costs 114 10 118 11 Expected return on plan assets (115) (14) (119) (13) Amortization of net actuarial (gains) losses 42 (7) 40 (7) Amortization of prior service costs (credit) (3) — (3) — Net periodic benefit costs (credit) $ 79 $ (11) $ 74 $ (8) Nine Months 2024 2023 Pension Other Pension Other (In millions) Service costs $ 122 $ 2 $ 113 $ 2 Interest costs 342 30 353 32 Expected return on plan assets (345) (42) (360) (41) Amortization of net actuarial (gains) losses 125 (21) 118 (22) Amortization of prior service costs (credit) (9) — (9) — Net periodic benefit costs (credit) $ 235 $ (31) $ 215 $ (29)

Earnings Per Common Share (Tabl

Earnings Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2024
Earnings Per Share [Abstract]
Earnings Per Common Share	The following table presents the weighted average shares, basic earnings per common share and diluted earnings per common share: Three Months Nine Months 2024 2023 2024 2023 (In millions, except per share data) Weighted Average Shares: Weighted average common stock outstanding - basic 699.3 751.4 710.9 764.1 Incremental common shares from assumed exercise or issuance of stock-based awards 4.4 4.1 4.6 4.6 Weighted average common stock outstanding - diluted 703.7 755.5 715.5 768.7 Net Income (Loss): Net income (loss) $ 1,341 $ 495 $ 3,169 $ 988 Less: Net income (loss) attributable to noncontrolling interests (1) 6 14 17 Less: Preferred stock dividends 67 67 168 165 Net income (loss) available to MetLife, Inc.’s common shareholders $ 1,275 $ 422 $ 2,987 $ 806 Basic $ 1.82 $ 0.56 $ 4.20 $ 1.05 Diluted $ 1.81 $ 0.56 $ 4.17 $ 1.05

Business, Basis of Presentati_3

Business, Basis of Presentation and Summary of Significant Accounting Policies (Narrative) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2024 USD ($) Segment	Jan. 01, 2024 USD ($)	Dec. 31, 2023 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of segments | Segment	6
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained earnings, decrease	$ (41,765)		$ (40,146)
Cumulative Effect, Period of Adoption, Adjustment | Pro Forma | Accounting Standards Update 2023-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained earnings, decrease		$ 219

Segment Information (Earnings)

Segment Information (Earnings) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues
Premiums	$ 10,647	$ 11,230	$ 32,328	$ 32,497
Universal life and investment-type product policy fees	1,228	1,334	3,757	3,911
Net investment income	5,227	4,825	15,868	14,542
Other revenues	648	606	1,960	1,866
Net investment gains (losses)	(77)	(927)	(873)	(2,650)
Net derivative gains (losses)	767	(1,202)	(720)	(2,289)
Total revenues	18,440	15,866	52,320	47,877
Expenses
Policyholder benefits and claims and policyholder dividends	10,747	11,283	32,601	33,274
Policyholder liability remeasurement (gains) losses	(132)	(17)	(164)	(42)
Market risk benefit remeasurement (gains) losses	531	(796)	(345)	(1,425)
Interest credited to policyholder account balances	2,037	1,658	6,327	5,455
Capitalization of DAC	(691)	(742)	(2,114)	(2,189)
Amortization of DAC and VOBA	516	499	1,523	1,448
Amortization of negative VOBA	(7)	(7)	(19)	(20)
Interest expense on debt	257	265	778	776
Other expenses	3,188	3,189	9,492	9,379
Total expenses	16,446	15,332	48,079	46,656
Provision for income tax expense (benefit)	653	39	1,072	233
Net income (loss)	1,341	495	3,169	988
Operating Segments
Revenues
Premiums	10,631	11,230	32,312	32,497
Universal life and investment-type product policy fees	1,228	1,334	3,757	3,911
Net investment income	5,143	5,056	15,371	14,702
Other revenues	612	617	1,873	1,887
Net investment gains (losses)	0	0	0	0
Net derivative gains (losses)	0	0	0	0
Total revenues	17,614	18,237	53,313	52,997
Expenses
Policyholder benefits and claims and policyholder dividends	10,797	11,352	32,631	33,243
Policyholder liability remeasurement (gains) losses	(132)	(17)	(164)	(42)
Market risk benefit remeasurement (gains) losses	0	0	0	0
Interest credited to policyholder account balances	1,815	1,705	5,323	4,889
Capitalization of DAC	(691)	(742)	(2,114)	(2,189)
Amortization of DAC and VOBA	516	499	1,523	1,448
Amortization of negative VOBA	(7)	(7)	(19)	(20)
Interest expense on debt	257	265	778	776
Other expenses	3,159	3,159	9,443	9,302
Total expenses	15,714	16,214	47,401	47,407
Provision for income tax expense (benefit)	458	468	1,407	1,261
Adjusted earnings	1,442	1,555	4,505	4,329
Segment Reconciling Items
Revenues
Premiums	16	0	16	0
Universal life and investment-type product policy fees	0	0	0	0
Net investment income	84	(231)	497	(160)
Other revenues	36	(11)	87	(21)
Net investment gains (losses)	(77)	(927)	(873)	(2,650)
Net derivative gains (losses)	767	(1,202)	(720)	(2,289)
Total revenues	826	(2,371)	(993)	(5,120)
Expenses
Policyholder benefits and claims and policyholder dividends	(50)	(69)	(30)	31
Policyholder liability remeasurement (gains) losses	0	0	0	0
Market risk benefit remeasurement (gains) losses	531	(796)	(345)	(1,425)
Interest credited to policyholder account balances	222	(47)	1,004	566
Capitalization of DAC	0	0	0	0
Amortization of DAC and VOBA	0	0	0	0
Amortization of negative VOBA	0	0	0	0
Interest expense on debt	0	0	0	0
Other expenses	29	30	49	77
Total expenses	732	(882)	678	(751)
Provision for income tax expense (benefit)	195	(429)	(335)	(1,028)
Group Benefits
Expenses
Capitalization of DAC			(13)	(16)
Group Benefits | Operating Segments
Revenues
Premiums	5,538	5,276	16,848	16,154
Universal life and investment-type product policy fees	231	219	682	660
Net investment income	311	330	939	967
Other revenues	377	371	1,156	1,114
Net investment gains (losses)	0	0	0	0
Net derivative gains (losses)	0	0	0	0
Total revenues	6,457	6,196	19,625	18,895
Expenses
Policyholder benefits and claims and policyholder dividends	4,927	4,592	14,943	14,452
Policyholder liability remeasurement (gains) losses	0	(29)	(1)	(31)
Market risk benefit remeasurement (gains) losses	0	0	0	0
Interest credited to policyholder account balances	49	50	145	144
Capitalization of DAC	(4)	(5)	(13)	(16)
Amortization of DAC and VOBA	6	6	19	19
Amortization of negative VOBA	0	0	0	0
Interest expense on debt	0	0	1	1
Other expenses	1,007	937	3,026	2,819
Total expenses	5,985	5,551	18,120	17,388
Provision for income tax expense (benefit)	99	135	315	318
Adjusted earnings	373	510	1,190	1,189
RIS
Expenses
Capitalization of DAC			(160)	(136)
RIS | Operating Segments
Revenues
Premiums	1,451	2,330	4,574	5,512
Universal life and investment-type product policy fees	67	82	215	232
Net investment income	2,133	2,009	6,339	5,771
Other revenues	61	66	185	205
Net investment gains (losses)	0	0	0	0
Net derivative gains (losses)	0	0	0	0
Total revenues	3,712	4,487	11,313	11,720
Expenses
Policyholder benefits and claims and policyholder dividends	2,247	3,100	6,966	7,766
Policyholder liability remeasurement (gains) losses	(148)	(76)	(170)	(116)
Market risk benefit remeasurement (gains) losses	0	0	0	0
Interest credited to policyholder account balances	874	756	2,508	2,104
Capitalization of DAC	(53)	(41)	(160)	(136)
Amortization of DAC and VOBA	14	13	45	36
Amortization of negative VOBA	0	0	0	0
Interest expense on debt	4	3	11	10
Other expenses	183	138	500	430
Total expenses	3,121	3,893	9,700	10,094
Provision for income tax expense (benefit)	119	124	332	339
Adjusted earnings	472	470	1,281	1,287
Asia
Expenses
Capitalization of DAC			(1,032)	(1,202)
Asia | Operating Segments
Revenues
Premiums	1,272	1,312	3,785	3,999
Universal life and investment-type product policy fees	420	411	1,280	1,204
Net investment income	1,132	1,023	3,407	2,954
Other revenues	18	20	57	61
Net investment gains (losses)	0	0	0	0
Net derivative gains (losses)	0	0	0	0
Total revenues	2,842	2,766	8,529	8,218
Expenses
Policyholder benefits and claims and policyholder dividends	1,035	1,095	3,090	3,282
Policyholder liability remeasurement (gains) losses	60	108	24	92
Market risk benefit remeasurement (gains) losses	0	0	0	0
Interest credited to policyholder account balances	683	576	1,987	1,682
Capitalization of DAC	(336)	(404)	(1,032)	(1,202)
Amortization of DAC and VOBA	217	204	634	587
Amortization of negative VOBA	(6)	(6)	(16)	(17)
Interest expense on debt	0	0	0	0
Other expenses	758	788	2,204	2,373
Total expenses	2,411	2,361	6,891	6,797
Provision for income tax expense (benefit)	125	130	460	435
Adjusted earnings	306	275	1,178	986
Latin America
Expenses
Capitalization of DAC			(527)	(470)
Latin America | Operating Segments
Revenues
Premiums	1,141	1,116	3,378	3,164
Universal life and investment-type product policy fees	346	359	1,089	1,046
Net investment income	435	365	1,219	1,162
Other revenues	9	9	31	31
Net investment gains (losses)	0	0	0	0
Net derivative gains (losses)	0	0	0	0
Total revenues	1,931	1,849	5,717	5,403
Expenses
Policyholder benefits and claims and policyholder dividends	1,091	1,020	3,092	2,962
Policyholder liability remeasurement (gains) losses	(18)	(4)	(29)	(5)
Market risk benefit remeasurement (gains) losses	0	0	0	0
Interest credited to policyholder account balances	108	106	337	310
Capitalization of DAC	(174)	(171)	(527)	(470)
Amortization of DAC and VOBA	126	121	380	344
Amortization of negative VOBA	0	0	0	0
Interest expense on debt	4	2	11	8
Other expenses	485	493	1,502	1,388
Total expenses	1,622	1,567	4,766	4,537
Provision for income tax expense (benefit)	88	83	271	233
Adjusted earnings	221	199	680	633
EMEA
Expenses
Capitalization of DAC			(362)	(341)
EMEA | Operating Segments
Revenues
Premiums	562	502	1,634	1,497
Universal life and investment-type product policy fees	84	79	238	231
Net investment income	55	51	163	143
Other revenues	9	7	24	23
Net investment gains (losses)	0	0	0	0
Net derivative gains (losses)	0	0	0	0
Total revenues	710	639	2,059	1,894
Expenses
Policyholder benefits and claims and policyholder dividends	276	230	799	728
Policyholder liability remeasurement (gains) losses	9	(9)	10	(10)
Market risk benefit remeasurement (gains) losses	0	0	0	0
Interest credited to policyholder account balances	17	19	53	54
Capitalization of DAC	(119)	(114)	(362)	(341)
Amortization of DAC and VOBA	92	87	265	257
Amortization of negative VOBA	(1)	(1)	(3)	(3)
Interest expense on debt	0	0	0	0
Other expenses	342	315	1,002	929
Total expenses	616	527	1,764	1,614
Provision for income tax expense (benefit)	24	24	71	62
Adjusted earnings	70	88	224	218
MetLife Holdings
Expenses
Capitalization of DAC			(13)	(17)
MetLife Holdings | Operating Segments
Revenues
Premiums	673	685	2,078	2,127
Universal life and investment-type product policy fees	80	184	252	537
Net investment income	981	1,153	3,007	3,450
Other revenues	40	41	127	143
Net investment gains (losses)	0	0	0	0
Net derivative gains (losses)	0	0	0	0
Total revenues	1,774	2,063	5,464	6,257
Expenses
Policyholder benefits and claims and policyholder dividends	1,221	1,311	3,724	4,021
Policyholder liability remeasurement (gains) losses	(35)	(7)	2	28
Market risk benefit remeasurement (gains) losses	0	0	0	0
Interest credited to policyholder account balances	84	198	293	595
Capitalization of DAC	(4)	(5)	(13)	(17)
Amortization of DAC and VOBA	58	65	174	197
Amortization of negative VOBA	0	0	0	0
Interest expense on debt	4	4	11	10
Other expenses	220	238	663	707
Total expenses	1,548	1,804	4,854	5,541
Provision for income tax expense (benefit)	44	51	116	139
Adjusted earnings	182	208	494	577
Corporate & Other
Expenses
Capitalization of DAC			(7)	(7)
Corporate & Other | Operating Segments
Revenues
Premiums	(6)	9	15	44
Universal life and investment-type product policy fees	0	0	1	1
Net investment income	96	125	297	255
Other revenues	98	103	293	310
Net investment gains (losses)	0	0	0	0
Net derivative gains (losses)	0	0	0	0
Total revenues	188	237	606	610
Expenses
Policyholder benefits and claims and policyholder dividends	0	4	17	32
Policyholder liability remeasurement (gains) losses	0	0	0	0
Market risk benefit remeasurement (gains) losses	0	0	0	0
Interest credited to policyholder account balances	0	0	0	0
Capitalization of DAC	(1)	(2)	(7)	(7)
Amortization of DAC and VOBA	3	3	6	8
Amortization of negative VOBA	0	0	0	0
Interest expense on debt	245	256	744	747
Other expenses	164	250	546	656
Total expenses	411	511	1,306	1,436
Provision for income tax expense (benefit)	(41)	(79)	(158)	(265)
Adjusted earnings	$ (182)	$ (195)	$ (542)	$ (561)

Segment Information (Total Asse

Segment Information (Total Assets) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Total assets	$ 704,976	$ 687,584
Group Benefits
Segment Reporting Information [Line Items]
Total assets	36,894	36,715
RIS
Segment Reporting Information [Line Items]
Total assets	229,709	218,587
Asia
Segment Reporting Information [Line Items]
Total assets	162,531	157,206
Latin America
Segment Reporting Information [Line Items]
Total assets	73,419	69,177
EMEA
Segment Reporting Information [Line Items]
Total assets	19,653	18,596
MetLife Holdings
Segment Reporting Information [Line Items]
Total assets	146,403	148,524
Corporate & Other
Segment Reporting Information [Line Items]
Total assets	$ 36,367	$ 38,779

Segment Information (Narrative)

Segment Information (Narrative) (Details)	9 Months Ended
	Sep. 30, 2024 Segment
Segment Reporting [Abstract]
Number of segments	6

Future Policy Benefits - FPB on

Future Policy Benefits - FPB on Balance Sheet (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023
Net liability for FPBs	$ 201,340	$ 196,406
Fixed & Immediate Annuities | RIS
Net liability for FPBs	67,645	64,324	$ 57,496
Whole and Term Life & Endowments | Asia
Net liability for FPBs	12,661	12,874	11,404
Accident & health insurance | Asia
Net liability for FPBs	10,598	10,712	9,329
Fixed Annuity | Latin America
Net liability for FPBs	10,906	9,637	8,662
Long-term Care | MetLife Holdings
Net liability for FPBs	15,657	15,240	$ 13,025
Fixed & Immediate Annuities for Deferred Profit Liabilities | RIS
Net liability for FPBs	3,754	3,697
Whole and Term Life & Endowments for Deferred Profit Liabilities | Asia
Net liability for FPBs	785	654
Accident and Health Insurance Product Line for Deferred Profit Liabilities | Asia
Net liability for FPBs	913	830
Fixed Annuity for Deferred Profit Liabilities | Latin America
Net liability for FPBs	549	562
Variable Life | Asia
Net liability for FPBs	1,227	1,258
Universal and Variable Universal Life | Asia
Net liability for FPBs	399	424
Universal and Variable Universal Life | MetLife Holdings
Net liability for FPBs	2,471	2,362
Participating Life Insurance Contract | MetLife Holdings
Net liability for FPBs	48,629	49,543
Long-Duration Insurance, Other
Net liability for FPBs	11,340	11,099
Short-Duration Insurance, Other
Net liability for FPBs	$ 13,806	$ 13,190

Future Policy Benefits - Disagg

Future Policy Benefits - Disaggregate Rollforwards (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]
Net liability for FPBs	$ 201,340		$ 196,406
Fixed & Immediate Annuities | RIS
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]
Balance, beginning of period, at current discount rate at balance sheet date	0	$ 0
Balance, beginning of period, at original discount rate	0	0
Effect of changes in cash flow assumptions (1)	0	0
Effect of actual variances from expected experience (2)	(32)	(89)
Adjusted balance	(32)	(89)
Issuances	5,042	4,422
Net premiums collected	(5,010)	(4,333)
Ending balance at original discount rate	0	0
Balance, end of period, at current discount rate at balance sheet date	0	0
Balance, beginning of period, at current discount rate at balance sheet date	64,515	58,695
Balance, beginning of period, at original discount rate	64,737	61,426
Effect of changes in cash flow assumptions (1)	(195)	(284)
Effect of actual variances from expected experience (2)	(99)	(222)
Adjusted balance	64,443	60,920
Issuances	5,168	4,420
Interest accrual	2,326	2,145
Benefit payments	(4,479)	(4,121)
Ending balance at original discount rate	67,458	63,364
Effect of changes in discount rate assumptions	338	(5,438)
Balance, end of period, at current discount rate at balance sheet date	67,796	57,926
Cumulative amount of fair value hedging adjustments	(151)	(430)
Net liability for FPBs	67,645	57,496	64,324
Less: Reinsurance recoverables	2,041	0
Net liability for FPBs, net of reinsurance	65,604	57,496
Undiscounted - Expected future benefit payments	123,186	119,270
Discounted - Expected future benefit payments	$ 67,796	$ 57,926	64,515
Weighted-average duration of the liability	9 years	9 years
Weighted-average interest accretion (original locked-in) rate	4.80%	4.70%
Weighted-average current discount rate at balance sheet date	5%	6.10%
Deferred Profit Liability Offset to Changes in Cash Flow Assumptions	$ 62	$ 211
Deferred Profit Liability Offset to Actual Versus Expected	29	95
Whole and Term Life & Endowments | Asia
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]
Balance, beginning of period, at current discount rate at balance sheet date	4,561	4,682
Balance, beginning of period, at original discount rate	4,793	4,943
Effect of changes in cash flow assumptions (1)	58	11
Effect of actual variances from expected experience (2)	(43)	(41)
Adjusted balance	4,808	4,913
Issuances	386	614
Interest accrual	52	43
Net premiums collected	(456)	(457)
Effect of foreign currency translation	(77)	(518)
Ending balance at original discount rate	4,713	4,595
Effect of changes in discount rate assumptions	(236)	(319)
Effect of foreign currency translation on the effect of changes in discount rate assumptions	3	23
Balance, end of period, at current discount rate at balance sheet date	4,480	4,299
Balance, beginning of period, at current discount rate at balance sheet date	17,435	17,463
Balance, beginning of period, at original discount rate	17,198	18,209
Effect of changes in cash flow assumptions (1)	36	58
Effect of actual variances from expected experience (2)	(39)	(14)
Adjusted balance	17,195	18,253
Issuances	386	614
Interest accrual	276	278
Benefit payments	(726)	(895)
Effect of foreign currency translation	(263)	(1,847)
Ending balance at original discount rate	16,868	16,403
Effect of changes in discount rate assumptions	272	(742)
Effect of foreign currency translation on the effect of changes in discount rate assumptions	1	40
Balance, end of period, at current discount rate at balance sheet date	17,141	15,701
Cumulative impact of flooring the future policyholder benefits reserve	0	2
Net liability for FPBs	12,661	11,404	12,874
Less: Reinsurance recoverables	(2)	(1)
Net liability for FPBs, net of reinsurance	12,663	11,405
Undiscounted - Expected future gross premiums	9,393	8,911
Undiscounted - Expected future benefit payments	28,008	26,785
Discounted - Expected future gross premiums	8,042	7,582
Discounted - Expected future benefit payments	$ 17,141	$ 15,701	17,435
Weighted-average duration of the liability	17 years	17 years
Weighted-average interest accretion (original locked-in) rate	2.50%	2.50%
Weighted-average current discount rate at balance sheet date	2.60%	2.90%
Deferred Profit Liability Offset to Changes in Cash Flow Assumptions	$ 28
Accident & health insurance | Asia
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]
Balance, beginning of period, at current discount rate at balance sheet date	19,835	$ 21,181
Balance, beginning of period, at original discount rate	21,232	22,594
Effect of changes in cash flow assumptions (1)	439	867
Effect of actual variances from expected experience (2)	0	(75)
Adjusted balance	21,671	23,386
Issuances	842	813
Interest accrual	168	179
Net premiums collected	(1,394)	(1,546)
Effect of foreign currency translation	(149)	(2,474)
Ending balance at original discount rate	21,138	20,358
Effect of changes in discount rate assumptions	(1,481)	(1,803)
Effect of foreign currency translation on the effect of changes in discount rate assumptions	12	136
Balance, end of period, at current discount rate at balance sheet date	19,669	18,691
Balance, beginning of period, at current discount rate at balance sheet date	30,480	30,879
Balance, beginning of period, at original discount rate	36,010	37,189
Effect of changes in cash flow assumptions (1)	439	898
Effect of actual variances from expected experience (2)	4	(99)
Adjusted balance	36,453	37,988
Issuances	841	812
Interest accrual	353	367
Benefit payments	(939)	(958)
Effect of foreign currency translation	(323)	(4,061)
Ending balance at original discount rate	36,385	34,148
Effect of changes in discount rate assumptions	(6,207)	(6,866)
Effect of foreign currency translation on the effect of changes in discount rate assumptions	43	595
Balance, end of period, at current discount rate at balance sheet date	30,221	27,877
Cumulative impact of flooring the future policyholder benefits reserve	46	143
Net liability for FPBs	10,598	9,329	10,712
Less: Reinsurance recoverables	164	136
Net liability for FPBs, net of reinsurance	10,434	9,193
Undiscounted - Expected future gross premiums	41,446	39,891
Undiscounted - Expected future benefit payments	47,705	44,612
Discounted - Expected future gross premiums	33,666	32,286
Discounted - Expected future benefit payments	$ 30,221	$ 27,877	30,480
Weighted-average duration of the liability	24 years	25 years
Weighted-average interest accretion (original locked-in) rate	1.70%	1.80%
Weighted-average current discount rate at balance sheet date	2.70%	2.80%
Fixed Annuity | Latin America
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]
Balance, beginning of period, at current discount rate at balance sheet date	$ 0	$ 0
Balance, beginning of period, at original discount rate	0	0
Effect of changes in cash flow assumptions (1)	0	0
Effect of actual variances from expected experience (2)	0	(2)
Adjusted balance	0	(2)
Issuances	760	785
Interest accrual	13	16
Net premiums collected	(773)	(799)
Ending balance at original discount rate	0	0
Balance, end of period, at current discount rate at balance sheet date	0	0
Balance, beginning of period, at current discount rate at balance sheet date	9,637	9,265
Balance, beginning of period, at original discount rate	9,249	8,240
Effect of changes in cash flow assumptions (1)	(4)	(5)
Effect of actual variances from expected experience (2)	(21)	(13)
Adjusted balance	9,224	8,222
Issuances	789	869
Interest accrual	253	258
Benefit payments	(519)	(504)
Inflation adjustment	270	273
Effect of foreign currency translation	(258)	(403)
Ending balance at original discount rate	9,759	8,715
Effect of changes in discount rate assumptions	1,126	(59)
Effect of foreign currency translation on the effect of changes in discount rate assumptions	21	6
Balance, end of period, at current discount rate at balance sheet date	10,906	8,662
Net liability for FPBs	10,906	8,662	9,637
Undiscounted - Expected future benefit payments	14,663	13,204
Discounted - Expected future benefit payments	$ 10,906	$ 8,662	9,637
Weighted-average duration of the liability	11 years	10 years
Weighted-average interest accretion (original locked-in) rate	3.40%	3.90%
Weighted-average current discount rate at balance sheet date	2.50%	3.70%
Deferred Profit Liability Offset to Changes in Cash Flow Assumptions	$ 3	$ 4
Deferred Profit Liability Offset to Actual Versus Expected		2
Long-term Care | MetLife Holdings
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]
Balance, beginning of period, at current discount rate at balance sheet date	5,687	5,775
Balance, beginning of period, at original discount rate	5,566	5,807
Effect of changes in cash flow assumptions (1)	212	(152)
Effect of actual variances from expected experience (2)	34	173
Adjusted balance	5,812	5,828
Interest accrual	213	222
Net premiums collected	(424)	(438)
Ending balance at original discount rate	5,601	5,612
Effect of changes in discount rate assumptions	159	(258)
Balance, end of period, at current discount rate at balance sheet date	5,760	5,354
Balance, beginning of period, at current discount rate at balance sheet date	20,927	19,619
Balance, beginning of period, at original discount rate	20,494	20,165
Effect of changes in cash flow assumptions (1)	205	(190)
Effect of actual variances from expected experience (2)	45	194
Adjusted balance	20,744	20,169
Interest accrual	812	801
Benefit payments	(638)	(579)
Ending balance at original discount rate	20,918	20,391
Effect of changes in discount rate assumptions	499	(2,012)
Balance, end of period, at current discount rate at balance sheet date	21,417	18,379
Net liability for FPBs	15,657	13,025	15,240
Undiscounted - Expected future gross premiums	10,735	10,713
Undiscounted - Expected future benefit payments	45,098	45,152
Discounted - Expected future gross premiums	7,319	6,714
Discounted - Expected future benefit payments	$ 21,417	$ 18,379	$ 20,927
Weighted-average duration of the liability	14 years	14 years
Weighted-average interest accretion (original locked-in) rate	5.40%	5.50%
Weighted-average current discount rate at balance sheet date	5.20%	6.30%

Future Policy Benefits - FPB -

Future Policy Benefits - FPB - Additional Insurance Liabilities (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Variable Life | Asia
Additional Liability, Long-Duration Insurance [Roll Forward]
Balance, beginning of period	$ 1,258	$ 1,381
Less: AOCI adjustment	0	0
Balance, beginning of period, before AOCI adjustment	1,258	1,381
Effect of changes in cash flow assumptions	17	(4)
Effect of actual variances from expected experience	(8)	(9)
Adjusted balance	1,267	1,368
Assessments accrual	(3)	(3)
Interest accrual	13	15
Excess benefits paid	(30)	(29)
Effect of foreign currency translation and other, net	(20)	(158)
Balance, end of period, before AOCI adjustment	1,227	1,193
Add: AOCI adjustment	0	0
Balance, end of period	$ 1,227	$ 1,193
Weighted-average duration of the liability	16 years	16 years
Weighted-average interest accretion rate	1.40%	1.50%
Universal and Variable Universal Life | Asia
Additional Liability, Long-Duration Insurance [Roll Forward]
Balance, beginning of period	$ 424	$ 455
Less: AOCI adjustment	(14)	(33)
Balance, beginning of period, before AOCI adjustment	438	488
Effect of changes in cash flow assumptions	(23)	(2)
Effect of actual variances from expected experience	(14)	(32)
Adjusted balance	401	454
Assessments accrual	0	0
Interest accrual	4	5
Excess benefits paid	0	0
Effect of foreign currency translation and other, net	(6)	(55)
Balance, end of period, before AOCI adjustment	399	404
Add: AOCI adjustment	0	(18)
Balance, end of period	$ 399	$ 386
Weighted-average duration of the liability	42 years	43 years
Weighted-average interest accretion rate	1.40%	1.50%
Universal and Variable Universal Life | MetLife Holdings
Additional Liability, Long-Duration Insurance [Roll Forward]
Balance, beginning of period	$ 2,362	$ 2,156
Less: AOCI adjustment	(14)	(63)
Balance, beginning of period, before AOCI adjustment	2,376	2,219
Effect of changes in cash flow assumptions	(2)	38
Effect of actual variances from expected experience	36	(10)
Adjusted balance	2,410	2,247
Assessments accrual	78	80
Interest accrual	98	92
Excess benefits paid	(104)	(81)
Balance, end of period, before AOCI adjustment	2,482	2,338
Add: AOCI adjustment	(11)	(65)
Balance, end of period	2,471	2,273
Less: Reinsurance recoverables	2,147	766
Balance, end of period, net of reinsurance	$ 324	$ 1,507
Weighted-average duration of the liability	15 years	16 years
Weighted-average interest accretion rate	5.50%	5.50%

Future Policy Benefits - FPB In

Future Policy Benefits - FPB Income Statement (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Principal Transaction Revenue [Line Items]
Gross Premiums or Assessments (1)	$ 13,602	$ 12,993
Interest Expense (2)	4,241	4,018
Fixed & Immediate Annuities | RIS
Principal Transaction Revenue [Line Items]
Gross Premiums or Assessments (1)	5,098	4,433
Interest Expense (2)	2,326	2,145
Whole and Term Life & Endowments | Asia
Principal Transaction Revenue [Line Items]
Gross Premiums or Assessments (1)	850	841
Interest Expense (2)	224	235
Accident & health insurance | Asia
Principal Transaction Revenue [Line Items]
Gross Premiums or Assessments (1)	2,324	2,580
Interest Expense (2)	185	188
Fixed Annuity | Latin America
Principal Transaction Revenue [Line Items]
Gross Premiums or Assessments (1)	773	799
Interest Expense (2)	240	242
Long-term Care | MetLife Holdings
Principal Transaction Revenue [Line Items]
Gross Premiums or Assessments (1)	543	547
Interest Expense (2)	599	579
Fixed & Immediate Annuities for Deferred Profit Liabilities | RIS
Principal Transaction Revenue [Line Items]
Interest Expense (2)	133	124
Whole and Term Life & Endowments for Deferred Profit Liabilities | Asia
Principal Transaction Revenue [Line Items]
Interest Expense (2)	27	22
Accident and Health Insurance Product Line for Deferred Profit Liabilities | Asia
Principal Transaction Revenue [Line Items]
Interest Expense (2)	15	13
Fixed Annuity for Deferred Profit Liabilities | Latin America
Principal Transaction Revenue [Line Items]
Interest Expense (2)	15	17
Variable Life | Asia
Principal Transaction Revenue [Line Items]
Gross Premiums or Assessments (1)	85	60
Interest Expense (2)	13	15
Universal and Variable Universal Life | Asia
Principal Transaction Revenue [Line Items]
Gross Premiums or Assessments (1)	(32)	(20)
Interest Expense (2)	4	5
Universal and Variable Universal Life | MetLife Holdings
Principal Transaction Revenue [Line Items]
Gross Premiums or Assessments (1)	492	559
Interest Expense (2)	98	92
Long-Duration Insurance, Other
Principal Transaction Revenue [Line Items]
Gross Premiums or Assessments (1)	3,469	3,194
Interest Expense (2)	$ 362	$ 341

Future Policy Benefits (Rollfor

Future Policy Benefits (Rollforward of Unpaid Claims) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Balance, beginning of period	$ 16,468	$ 16,098
Less: Reinsurance recoverables	2,592	2,452
Net balance, beginning of period	13,876	13,646
Incurred related to:
Current period	20,532	19,983
Prior periods (1)	80	327
Total incurred	20,612	20,310
Paid related to:
Current period	(14,470)	(13,991)
Prior periods	(5,773)	(5,883)
Total paid	(20,243)	(19,874)
Net balance, end of period	14,245	14,082
Add: Reinsurance recoverables	2,757	2,523
Balance, end of period (included in FPBs and other policy-related balances)	$ 17,002	$ 16,605

Future Policy Benefits - Narrat

Future Policy Benefits - Narrative (Details) $ in Millions	9 Months Ended
	Sep. 30, 2024 USD ($)
Insurance [Abstract]
Liability for Future Policy Benefit, Adverse Development, Expense, Loss At Issue	$ 129

Policyholder Account Balances -

Policyholder Account Balances - Amounts on Balance Sheet (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Policyholder Account Balance [Line Items]
Policyholder account balance	$ 224,609	$ 219,269
Other Products
Policyholder Account Balance [Line Items]
Policyholder account balance	17,195	17,226
Group Life - Term | Group Benefits
Policyholder Account Balance [Line Items]
Policyholder account balance	7,676	7,692	$ 7,785	$ 8,028
Capital Markets Investment Products and Stable Value GICs | RIS
Policyholder Account Balance [Line Items]
Policyholder account balance	65,330	64,140	63,417	63,723
Annuities and Risk Solutions | RIS
Policyholder Account Balance [Line Items]
Policyholder account balance	19,572	17,711	17,064	15,549
Universal and Variable Universal Life | Asia
Policyholder Account Balance [Line Items]
Policyholder account balance	51,756	49,739	47,630	46,417
Fixed Annuity | Asia
Policyholder Account Balance [Line Items]
Policyholder account balance	38,742	36,863	35,480	32,454
Fixed Annuity | MetLife Holdings
Policyholder Account Balance [Line Items]
Policyholder account balance	10,437	11,537	12,006	13,286
Variable Annuity | EMEA
Policyholder Account Balance [Line Items]
Policyholder account balance	2,617	2,720	2,571	2,802
Life and Other | MetLife Holdings
Policyholder Account Balance [Line Items]
Policyholder account balance	$ 11,284	$ 11,641	$ 11,844	$ 12,402

Policyholder Account Balances_2

Policyholder Account Balances - LDTI Rollforward (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Policyholder Account Balance [Roll Forward]
Balance, beginning of period	$ 219,269
Balance, end of period	224,609
Group Life - Term | Group Benefits
Policyholder Account Balance [Roll Forward]
Balance, beginning of period	7,692	$ 8,028
Deposits	2,857	2,529
Policy charges	(493)	(475)
Surrenders and withdrawals	(2,512)	(2,432)
Benefit payments	(9)	(9)
Net transfers from (to) separate accounts	(3)	1
Interest credited	144	143
Balance, end of period	$ 7,676	$ 7,785
Weighted-average annual crediting rate	2.50%	2.40%
Cash surrender value	$ 7,614	$ 7,721
Group Life - Term | In the event of death | Group Benefits
Policyholder Account Balance [Roll Forward]
Net amount at risk	265,266	250,611
Capital Markets Investment Products and Stable Value GICs | RIS
Policyholder Account Balance [Roll Forward]
Balance, beginning of period	64,140	63,723
Deposits	56,170	54,674
Surrenders and withdrawals	(57,068)	(56,873)
Interest credited	1,811	1,524
Effect of foreign currency translation and other, net	277	369
Balance, end of period	$ 65,330	$ 63,417
Weighted-average annual crediting rate	3.80%	3.20%
Cash surrender value	$ 1,953	$ 2,110
Annuities and Risk Solutions | RIS
Policyholder Account Balance [Roll Forward]
Balance, beginning of period	17,711	15,549
Deposits	2,367	2,007
Policy charges	(122)	(133)
Surrenders and withdrawals	(239)	(134)
Benefit payments	(731)	(615)
Net transfers from (to) separate accounts	20	54
Interest credited	556	469
Other	10	(133)
Balance, end of period	$ 19,572	$ 17,064
Weighted-average annual crediting rate	4%	3.90%
Cash surrender value	$ 8,476	$ 7,693
Annuities and Risk Solutions | In the event of death | RIS
Policyholder Account Balance [Roll Forward]
Net amount at risk	44,437	42,043
Universal and Variable Universal Life | Asia
Policyholder Account Balance [Roll Forward]
Balance, beginning of period	49,739	46,417
Deposits	4,694	5,439
Policy charges	(812)	(888)
Surrenders and withdrawals	(2,483)	(2,018)
Benefit payments	(345)	(393)
Interest credited	1,153	979
Effect of foreign currency translation and other, net	(190)	(1,906)
Balance, end of period	$ 51,756	$ 47,630
Weighted-average annual crediting rate	3.10%	2.80%
Cash surrender value	$ 46,366	$ 40,663
Universal and Variable Universal Life | In the event of death | Asia
Policyholder Account Balance [Roll Forward]
Net amount at risk	89,793	91,861
Fixed Annuity | Asia
Policyholder Account Balance [Roll Forward]
Balance, beginning of period	36,863	32,454
Deposits	5,002	6,230
Policy charges	(2)	(2)
Surrenders and withdrawals	(2,248)	(1,665)
Benefit payments	(1,718)	(1,614)
Interest credited	784	629
Effect of foreign currency translation and other, net	61	(552)
Balance, end of period	$ 38,742	$ 35,480
Weighted-average annual crediting rate	2.80%	2.50%
Cash surrender value	$ 35,005	$ 30,289
Fixed Annuity | MetLife Holdings
Policyholder Account Balance [Roll Forward]
Balance, beginning of period	11,537	13,286
Deposits	121	115
Policy charges	(10)	(12)
Surrenders and withdrawals	(1,292)	(1,425)
Benefit payments	(298)	(320)
Net transfers from (to) separate accounts	105	48
Interest credited	265	299
Other	9	15
Balance, end of period	$ 10,437	$ 12,006
Weighted-average annual crediting rate	3.30%	3.20%
Cash surrender value	$ 9,866	$ 11,263
Fixed Annuity | In the event of death | Asia
Policyholder Account Balance [Roll Forward]
Net amount at risk	8	0
Fixed Annuity | In the event of death | MetLife Holdings
Policyholder Account Balance [Roll Forward]
Net amount at risk	2,238	3,970
Fixed Annuity | At annuitization or exercise of other living benefits | MetLife Holdings
Policyholder Account Balance [Roll Forward]
Net amount at risk	657	923
Variable Annuity | EMEA
Policyholder Account Balance [Roll Forward]
Balance, beginning of period	2,720	2,802
Deposits	2	3
Policy charges	(44)	(48)
Surrenders and withdrawals	(214)	(206)
Benefit payments	(95)	(95)
Interest credited	117	69
Effect of foreign currency translation and other, net	131	46
Balance, end of period	$ 2,617	$ 2,571
Weighted-average annual crediting rate	6%	3.50%
Cash surrender value	$ 2,617	$ 2,571
Variable Annuity | In the event of death | EMEA
Policyholder Account Balance [Roll Forward]
Net amount at risk	426	577
Variable Annuity | At annuitization or exercise of other living benefits | EMEA
Policyholder Account Balance [Roll Forward]
Net amount at risk	550	725
Life and Other | MetLife Holdings
Policyholder Account Balance [Roll Forward]
Balance, beginning of period	11,641	12,402
Deposits	549	617
Policy charges	(519)	(529)
Surrenders and withdrawals	(744)	(892)
Benefit payments	(114)	(120)
Net transfers from (to) separate accounts	26	29
Interest credited	318	336
Other	127	1
Balance, end of period	$ 11,284	$ 11,844
Weighted-average annual crediting rate	3.80%	3.80%
Cash surrender value	$ 10,722	$ 11,360
Net amount at risk percentage after taking reinsurance into consideration	99%		99%
Life and Other | In the event of death | MetLife Holdings
Policyholder Account Balance [Roll Forward]
Net amount at risk	$ 64,816	$ 68,972

Policyholder Account Balances_3

Policyholder Account Balances - Range of Guaranteed Minimum Crediting Rate (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 224,609	$ 219,269
Group Life - Term | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	7,676	7,692	$ 7,785	$ 8,028
Group Life - Term | Equal to or greater than 0% but less than 2% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 5,546		$ 5,564
Group Life - Term | Equal to or greater than 0% but less than 2% | Group Benefits | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	0%		0%
Group Life - Term | Equal to or greater than 0% but less than 2% | Group Benefits | Maximum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	2%		2%
Group Life - Term | Equal to or greater than 2% but less than 4% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 1,334		$ 1,297
Group Life - Term | Equal to or greater than 2% but less than 4% | Group Benefits | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	2%		2%
Group Life - Term | Equal to or greater than 2% but less than 4% | Group Benefits | Maximum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	4%		4%
Group Life - Term | Equal to or greater than 4% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 759		$ 810
Group Life - Term | Equal to or greater than 4% | Group Benefits | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	4%		4%
Group Life - Term | Products with either a fixed rate or no GMCR | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 37		$ 114
Group Life - Term | At GMCR | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	2,406		1,956
Group Life - Term | At GMCR | Equal to or greater than 0% but less than 2% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	456		0
Group Life - Term | At GMCR | Equal to or greater than 2% but less than 4% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	1,266		1,223
Group Life - Term | At GMCR | Equal to or greater than 4% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	684		733
Group Life - Term | Greater than 0% but less than 0.50% above GMCR | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	80		93
Group Life - Term | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 0% but less than 2% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	72		82
Group Life - Term | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 2% but less than 4% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	8		10
Group Life - Term | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 4% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		1
Group Life - Term | Equal to or greater than 0.50% but less than 1.50% above GMCR | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	975		991
Group Life - Term | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	877		887
Group Life - Term | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	59		62
Group Life - Term | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 4% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	39		42
Group Life - Term | Equal to or greater than 1.50% above GMCR | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	4,178		4,631
Group Life - Term | Equal to or greater than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	4,141		4,595
Group Life - Term | Equal to or greater than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	1		2
Group Life - Term | Equal to or greater than 1.50% above GMCR | Equal to or greater than 4% | Group Benefits
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	36		34
Capital Markets Investment Products and Stable Value GICs | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	65,330	64,140	63,417	63,723
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 0% but less than 2% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 2,754		$ 2,621
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 0% but less than 2% | RIS | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	0%		0%
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 0% but less than 2% | RIS | Maximum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	2%		2%
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 2% but less than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 148		$ 0
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 2% but less than 4% | RIS | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	2%		2%
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 2% but less than 4% | RIS | Maximum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	4%		4%
Capital Markets Investment Products and Stable Value GICs | Products with either a fixed rate or no GMCR | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 62,428		$ 60,796
Capital Markets Investment Products and Stable Value GICs | At GMCR | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Capital Markets Investment Products and Stable Value GICs | At GMCR | Equal to or greater than 0% but less than 2% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Capital Markets Investment Products and Stable Value GICs | At GMCR | Equal to or greater than 2% but less than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Capital Markets Investment Products and Stable Value GICs | Greater than 0% but less than 0.50% above GMCR | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Capital Markets Investment Products and Stable Value GICs | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 0% but less than 2% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Capital Markets Investment Products and Stable Value GICs | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 2% but less than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 0.50% but less than 1.50% above GMCR | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		1
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		1
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 1.50% above GMCR | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	2,902		2,620
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	2,754		2,620
Capital Markets Investment Products and Stable Value GICs | Equal to or greater than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	148		0
Annuities and Risk Solutions | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	19,572	17,711	17,064	15,549
Annuities and Risk Solutions | Equal to or greater than 0% but less than 2% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 2,422		$ 1,547
Annuities and Risk Solutions | Equal to or greater than 0% but less than 2% | RIS | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	0%		0%
Annuities and Risk Solutions | Equal to or greater than 0% but less than 2% | RIS | Maximum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	2%		2%
Annuities and Risk Solutions | Equal to or greater than 2% but less than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 759		$ 824
Annuities and Risk Solutions | Equal to or greater than 2% but less than 4% | RIS | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	2%		2%
Annuities and Risk Solutions | Equal to or greater than 2% but less than 4% | RIS | Maximum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	4%		4%
Annuities and Risk Solutions | Equal to or greater than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 4,609		$ 4,646
Annuities and Risk Solutions | Equal to or greater than 4% | RIS | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	4%		4%
Annuities and Risk Solutions | Products with either a fixed rate or no GMCR | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 11,782		$ 10,047
Annuities and Risk Solutions | At GMCR | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	4,329		4,623
Annuities and Risk Solutions | At GMCR | Equal to or greater than 0% but less than 2% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Annuities and Risk Solutions | At GMCR | Equal to or greater than 2% but less than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	198		260
Annuities and Risk Solutions | At GMCR | Equal to or greater than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	4,131		4,363
Annuities and Risk Solutions | Greater than 0% but less than 0.50% above GMCR | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	35		33
Annuities and Risk Solutions | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 0% but less than 2% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Annuities and Risk Solutions | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 2% but less than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	35		33
Annuities and Risk Solutions | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Annuities and Risk Solutions | Equal to or greater than 0.50% but less than 1.50% above GMCR | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	600		393
Annuities and Risk Solutions | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	19		22
Annuities and Risk Solutions | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	109		94
Annuities and Risk Solutions | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	472		277
Annuities and Risk Solutions | Equal to or greater than 1.50% above GMCR | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	2,826		1,968
Annuities and Risk Solutions | Equal to or greater than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	2,403		1,525
Annuities and Risk Solutions | Equal to or greater than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	417		437
Annuities and Risk Solutions | Equal to or greater than 1.50% above GMCR | Equal to or greater than 4% | RIS
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	6		6
Universal and Variable Universal Life | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	51,756	49,739	47,630	46,417
Universal and Variable Universal Life | Equal to or greater than 0% but less than 2% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 12,383		$ 10,973
Universal and Variable Universal Life | Equal to or greater than 0% but less than 2% | Asia | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	0%		0%
Universal and Variable Universal Life | Equal to or greater than 0% but less than 2% | Asia | Maximum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	2%		2%
Universal and Variable Universal Life | Equal to or greater than 2% but less than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 38,606		$ 35,926
Universal and Variable Universal Life | Equal to or greater than 2% but less than 4% | Asia | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	2%		2%
Universal and Variable Universal Life | Equal to or greater than 2% but less than 4% | Asia | Maximum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	4%		4%
Universal and Variable Universal Life | Equal to or greater than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 241		$ 256
Universal and Variable Universal Life | Equal to or greater than 4% | Asia | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	4%		4%
Universal and Variable Universal Life | Products with either a fixed rate or no GMCR | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 526		$ 475
Universal and Variable Universal Life | At GMCR | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	18,751		15,984
Universal and Variable Universal Life | At GMCR | Equal to or greater than 0% but less than 2% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	10,681		9,986
Universal and Variable Universal Life | At GMCR | Equal to or greater than 2% but less than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	7,829		5,742
Universal and Variable Universal Life | At GMCR | Equal to or greater than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	241		256
Universal and Variable Universal Life | Greater than 0% but less than 0.50% above GMCR | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	15,748		17,948
Universal and Variable Universal Life | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 0% but less than 2% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	18		25
Universal and Variable Universal Life | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 2% but less than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	15,730		17,923
Universal and Variable Universal Life | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Universal and Variable Universal Life | Equal to or greater than 0.50% but less than 1.50% above GMCR | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	5,632		5,861
Universal and Variable Universal Life | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	235		233
Universal and Variable Universal Life | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	5,397		5,628
Universal and Variable Universal Life | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Universal and Variable Universal Life | Equal to or greater than 1.50% above GMCR | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	11,099		7,362
Universal and Variable Universal Life | Equal to or greater than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	1,449		729
Universal and Variable Universal Life | Equal to or greater than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	9,650		6,633
Universal and Variable Universal Life | Equal to or greater than 1.50% above GMCR | Equal to or greater than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Fixed Annuity | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	38,742	36,863	35,480	32,454
Fixed Annuity | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	10,437	11,537	12,006	13,286
Fixed Annuity | Equal to or greater than 0% but less than 2% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 37,448		$ 34,194
Fixed Annuity | Equal to or greater than 0% but less than 2% | Asia | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	0%		0%
Fixed Annuity | Equal to or greater than 0% but less than 2% | Asia | Maximum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	2%		2%
Fixed Annuity | Equal to or greater than 0% but less than 2% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 665		$ 999
Fixed Annuity | Equal to or greater than 0% but less than 2% | MetLife Holdings | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	0%		0%
Fixed Annuity | Equal to or greater than 0% but less than 2% | MetLife Holdings | Maximum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	2%		2%
Fixed Annuity | Equal to or greater than 2% but less than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 5		$ 6
Fixed Annuity | Equal to or greater than 2% but less than 4% | Asia | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	2%		2%
Fixed Annuity | Equal to or greater than 2% but less than 4% | Asia | Maximum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	4%		4%
Fixed Annuity | Equal to or greater than 2% but less than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 8,220		$ 9,302
Fixed Annuity | Equal to or greater than 2% but less than 4% | MetLife Holdings | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	2%		2%
Fixed Annuity | Equal to or greater than 2% but less than 4% | MetLife Holdings | Maximum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	4%		4%
Fixed Annuity | Equal to or greater than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 1,166		$ 1,265
Fixed Annuity | Equal to or greater than 4% | MetLife Holdings | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	4%		4%
Fixed Annuity | Products with either a fixed rate or no GMCR | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 1,289		$ 1,280
Fixed Annuity | Products with either a fixed rate or no GMCR | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	386		440
Fixed Annuity | At GMCR | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	385		315
Fixed Annuity | At GMCR | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	2,126		4,087
Fixed Annuity | At GMCR | Equal to or greater than 0% but less than 2% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	385		315
Fixed Annuity | At GMCR | Equal to or greater than 0% but less than 2% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	3		235
Fixed Annuity | At GMCR | Equal to or greater than 2% but less than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Fixed Annuity | At GMCR | Equal to or greater than 2% but less than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	1,378		2,887
Fixed Annuity | At GMCR | Equal to or greater than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	745		965
Fixed Annuity | Greater than 0% but less than 0.50% above GMCR | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	465		580
Fixed Annuity | Greater than 0% but less than 0.50% above GMCR | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	6,758		6,347
Fixed Annuity | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 0% but less than 2% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	460		574
Fixed Annuity | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 0% but less than 2% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	166		245
Fixed Annuity | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 2% but less than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	5		6
Fixed Annuity | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 2% but less than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	6,188		5,828
Fixed Annuity | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	404		274
Fixed Annuity | Equal to or greater than 0.50% but less than 1.50% above GMCR | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	5,250		6,494
Fixed Annuity | Equal to or greater than 0.50% but less than 1.50% above GMCR | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	962		775
Fixed Annuity | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	5,250		6,494
Fixed Annuity | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	444		292
Fixed Annuity | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Fixed Annuity | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	501		457
Fixed Annuity | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	17		26
Fixed Annuity | Equal to or greater than 1.50% above GMCR | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	31,353		26,811
Fixed Annuity | Equal to or greater than 1.50% above GMCR | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	205		357
Fixed Annuity | Equal to or greater than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	31,353		26,811
Fixed Annuity | Equal to or greater than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	52		227
Fixed Annuity | Equal to or greater than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | Asia
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Fixed Annuity | Equal to or greater than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	153		130
Fixed Annuity | Equal to or greater than 1.50% above GMCR | Equal to or greater than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Variable Annuity | EMEA
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	2,617	2,720	2,571	2,802
Life and Other | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	11,284	$ 11,641	11,844	$ 12,402
Life and Other | Equal to or greater than 0% but less than 2% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 75		$ 73
Life and Other | Equal to or greater than 0% but less than 2% | MetLife Holdings | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	0%		0%
Life and Other | Equal to or greater than 0% but less than 2% | MetLife Holdings | Maximum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	2%		2%
Life and Other | Equal to or greater than 2% but less than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 5,131		$ 5,606
Life and Other | Equal to or greater than 2% but less than 4% | MetLife Holdings | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	2%		2%
Life and Other | Equal to or greater than 2% but less than 4% | MetLife Holdings | Maximum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	4%		4%
Life and Other | Equal to or greater than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 5,447		$ 5,664
Life and Other | Equal to or greater than 4% | MetLife Holdings | Minimum
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance range of guaranteed minimum credit rating	4%		4%
Life and Other | Products with either a fixed rate or no GMCR | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 631		$ 501
Life and Other | At GMCR | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	9,070		9,704
Life and Other | At GMCR | Equal to or greater than 0% but less than 2% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Life and Other | At GMCR | Equal to or greater than 2% but less than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	4,159		4,595
Life and Other | At GMCR | Equal to or greater than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	4,911		5,109
Life and Other | Greater than 0% but less than 0.50% above GMCR | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	293		298
Life and Other | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 0% but less than 2% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	0		0
Life and Other | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 2% but less than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	171		172
Life and Other | Greater than 0% but less than 0.50% above GMCR | Equal to or greater than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	122		126
Life and Other | Equal to or greater than 0.50% but less than 1.50% above GMCR | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	687		718
Life and Other | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	17		19
Life and Other | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	265		285
Life and Other | Equal to or greater than 0.50% but less than 1.50% above GMCR | Equal to or greater than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	405		414
Life and Other | Equal to or greater than 1.50% above GMCR | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	603		623
Life and Other | Equal to or greater than 1.50% above GMCR | Equal to or greater than 0% but less than 2% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	58		54
Life and Other | Equal to or greater than 1.50% above GMCR | Equal to or greater than 2% but less than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	536		554
Life and Other | Equal to or greater than 1.50% above GMCR | Equal to or greater than 4% | MetLife Holdings
Policyholder Account Balance, Guaranteed Minimum Crediting Rate [Line Items]
Policyholder account balance	$ 9		$ 15

Market Risk Benefits Balance Sh

Market Risk Benefits Balance Sheet (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Market Risk Benefit [Line Items]
Asset	$ 310	$ 286
Liability	3,117	3,179
Net	2,807	2,893
Retirement Assurance | Asia
Market Risk Benefit [Line Items]
Asset	0	0
Liability	197	203
Net	197	203	$ 193	$ 226
Investment Product | MetLife Holdings
Market Risk Benefit [Line Items]
Asset	179	156
Liability	2,787	2,878
Net	2,608	2,722
Insurance, Other
Market Risk Benefit [Line Items]
Asset	131	130
Liability	133	98
Net	$ 2	$ (32)	$ (57)	$ 32

Market Risk Benefits Rollforwar

Market Risk Benefits Rollforward (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Market Risk Benefit [Line Items]
Beginning balance	$ 2,893
Ending balance	2,807
Retirement Assurance | Asia
Market Risk Benefit [Line Items]
Beginning balance	203	$ 226
Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk	205	233
Attributed fees collected	3	2
Benefit payments	(9)	(9)
Effect of changes in interest rates	4	2
Actual policyholder behavior different from expected behavior	(2)	(1)
Effect of changes in future expected policyholder behavior and other assumptions	0	(1)
Effect of foreign currency translation and other, net	(3)	(30)
Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk	198	196
Cumulative effect of changes in the instrument-specific credit risk	(1)	(3)
Ending balance	197	193
Retirement Assurance | Asia | At annuitization or exercise of other living benefits
Market Risk Benefit [Line Items]
Net amount at risk	$ 122	$ 116
Average attained age of policyholders	58 years	58 years
Variable Annuity | MetLife Holdings
Market Risk Benefit [Line Items]
Beginning balance	$ 2,722	$ 3,225
Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk	2,772	3,360
Attributed fees collected	266	286
Benefit payments	(67)	(36)
Effect of changes in interest rates	(70)	(881)
Effect of changes in capital markets	(527)	(542)
Effect of changes in equity index volatility	37	(84)
Actual policyholder behavior different from expected behavior	176	95
Effect of changes in future expected policyholder behavior and other assumptions	12	9
Effect of foreign currency translation and other, net	34	118
Effect of changes in risk margin	(7)	(46)
Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk	2,626	2,279
Cumulative effect of changes in the instrument-specific credit risk	(19)	(16)
Effect of foreign currency translation on the cumulative instrument-specific credit risk	1	5
Ending balance	2,608	2,268
Variable Annuity | MetLife Holdings | In the event of death
Market Risk Benefit [Line Items]
Net amount at risk	$ 2,243	$ 3,979
Average attained age of policyholders	71 years	70 years
Variable Annuity | MetLife Holdings | At annuitization or exercise of other living benefits
Market Risk Benefit [Line Items]
Net amount at risk	$ 643	$ 921
Average attained age of policyholders	68 years	70 years
Insurance, Other
Market Risk Benefit [Line Items]
Beginning balance	$ (32)	$ 32
Balance, beginning of period, before effect of cumulative changes in the instrument-specific credit risk	(50)	24
Attributed fees collected	38	23
Benefit payments	(5)	(23)
Effect of changes in interest rates	(12)	(98)
Effect of changes in capital markets	(8)	(15)
Effect of changes in equity index volatility	0	(4)
Actual policyholder behavior different from expected behavior	6	(21)
Effect of changes in future expected policyholder behavior and other assumptions	(2)	2
Effect of foreign currency translation and other, net	22	37
Effect of changes in risk margin	(1)	(2)
Balance, end of period, before the cumulative effect of changes in the instrument-specific credit risk	(12)	(77)
Cumulative effect of changes in the instrument-specific credit risk	13	20
Effect of foreign currency translation on the cumulative instrument-specific credit risk	1	0
Ending balance	2	(57)
Less: Reinsurance recoverable	16	18
Balance, end of period, net of reinsurance	$ (14)	$ (75)

Separate Account Liabilities Ba

Separate Account Liabilities Balance Sheet (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Separate Account, Liability [Line Items]
Separate account liabilities	$ 148,809	$ 144,634
Latin America | Pension Plan
Separate Account, Liability [Line Items]
Separate account liabilities	44,158	41,320	$ 37,473	$ 39,428
Stable Value and Risk Solutions | RIS
Separate Account, Liability [Line Items]
Separate account liabilities	40,448	41,343	40,503	48,265
Annuities | RIS
Separate Account, Liability [Line Items]
Separate account liabilities	11,989	11,659	11,152	11,694
Annuities | MetLife Holdings
Separate Account, Liability [Line Items]
Separate account liabilities	29,349	29,224	$ 27,455	$ 28,499
Insurance, Other
Separate Account, Liability [Line Items]
Separate account liabilities	$ 22,865	$ 21,088

Separate Account Liabilities Ro

Separate Account Liabilities Rollforward (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Separate Account, Liability [Roll Forward]
Balance, beginning of period	$ 144,634
Balance, end of period	148,809
RIS | Stable Value and Risk Solutions
Separate Account, Liability [Roll Forward]
Balance, beginning of period	41,343	$ 48,265
Premiums and deposits	1,669	1,857
Policy charges	(214)	(223)
Surrenders and withdrawals	(3,799)	(8,696)
Benefit payments	(81)	(74)
Investment performance	2,152	711
Net transfers from (to) general account	(21)	(57)
Effect of foreign currency translation and other, net (1)	(601)	(1,280)
Balance, end of period	40,448	40,503
Cash Surrender Value	35,632	36,246
RIS | Annuities
Separate Account, Liability [Roll Forward]
Balance, beginning of period	11,659	11,694
Premiums and deposits	34	154
Policy charges	(16)	(17)
Surrenders and withdrawals	(609)	(636)
Benefit payments	0	0
Investment performance	561	(157)
Net transfers from (to) general account	0	3
Effect of foreign currency translation and other, net (1)	360	111
Balance, end of period	11,989	11,152
Latin America | Pension Plan
Separate Account, Liability [Roll Forward]
Balance, beginning of period	41,320	39,428
Premiums and deposits	5,082	6,181
Policy charges	(198)	(219)
Surrenders and withdrawals	(3,913)	(4,485)
Benefit payments	(1,231)	(1,301)
Investment performance	4,075	(216)
Net transfers from (to) general account	0	0
Effect of foreign currency translation and other, net (1)	(977)	(1,915)
Balance, end of period	44,158	37,473
Cash Surrender Value	44,158	37,473
MetLife Holdings | Annuities
Separate Account, Liability [Roll Forward]
Balance, beginning of period	29,224	28,499
Premiums and deposits	175	190
Policy charges	(454)	(460)
Surrenders and withdrawals	(2,798)	(2,114)
Benefit payments	(377)	(350)
Investment performance	3,691	1,740
Net transfers from (to) general account	(105)	(49)
Effect of foreign currency translation and other, net (1)	(7)	(1)
Balance, end of period	29,349	27,455
Cash Surrender Value	$ 29,210	$ 27,320

Separate Account Assets Fair Va

Separate Account Assets Fair Value (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Fair Value, Separate Account Investment [Line Items]
Separate account assets	$ 148,809	$ 144,634
Other invested assets
Fair Value, Separate Account Investment [Line Items]
Separate account assets	6,126	6,265
Separate Account, Debt Security | Materials
Fair Value, Separate Account Investment [Line Items]
Separate account assets	132	144
Separate Account, Debt Security | Communications
Fair Value, Separate Account Investment [Line Items]
Separate account assets	827	904
Separate Account, Debt Security | Consumer
Fair Value, Separate Account Investment [Line Items]
Separate account assets	1,959	1,929
Separate Account, Debt Security | Energy
Fair Value, Separate Account Investment [Line Items]
Separate account assets	938	1,018
Separate Account, Debt Security | Financial Services Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	8,952	9,687
Separate Account, Debt Security | Commercial and Industrial Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	4,577	4,403
Separate Account, Debt Security | Foreign
Fair Value, Separate Account Investment [Line Items]
Separate account assets	5,228	5,055
Separate Account, Debt Security | Technology
Fair Value, Separate Account Investment [Line Items]
Separate account assets	533	550
Separate Account, Debt Security | Foreign government
Fair Value, Separate Account Investment [Line Items]
Separate account assets	5,442	5,388
Separate Account, Debt Security | U.S. government and agency
Fair Value, Separate Account Investment [Line Items]
Separate account assets	22,122	19,611
Separate Account, Debt Security | Public utilities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	1,403	1,389
Separate Account, Debt Security | Municipals
Fair Value, Separate Account Investment [Line Items]
Separate account assets	328	424
Separate Account, Debt Security | Total corporate bonds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	23,146	23,690
Separate Account, Debt Security | Total bonds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	52,441	50,502
Separate Account, Debt Security | Mortgage-backed securities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	9,412	9,706
Separate Account, Debt Security | Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”)
Fair Value, Separate Account Investment [Line Items]
Separate account assets	2,388	2,586
Separate Account, Debt Security | Redeemable preferred stock
Fair Value, Separate Account Investment [Line Items]
Separate account assets	9	9
Separate Account, Debt Security | Total fixed maturity securities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	64,250	62,803
Separate Account, Equity Security
Fair Value, Separate Account Investment [Line Items]
Separate account assets	72,489	68,439
Separate Account, Equity Security | Non-redeemable preferred Stock
Fair Value, Separate Account Investment [Line Items]
Separate account assets	130	115
Separate Account, Equity Security | Financial Services Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	1,883	1,733
Separate Account, Equity Security | Commercial and Industrial Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	8,063	8,202
Separate Account, Equity Security | Public utilities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	220	158
Separate Account, Equity Security | Mutual funds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	62,193	58,231
Investments
Fair Value, Separate Account Investment [Line Items]
Separate account assets	142,865	137,507
Other Assets
Fair Value, Separate Account Investment [Line Items]
Separate account assets	5,944	7,127
RIS
Fair Value, Separate Account Investment [Line Items]
Separate account assets	52,538	53,093
RIS | Other invested assets
Fair Value, Separate Account Investment [Line Items]
Separate account assets	1,372	1,620
RIS | Separate Account, Debt Security | Materials
Fair Value, Separate Account Investment [Line Items]
Separate account assets	131	144
RIS | Separate Account, Debt Security | Communications
Fair Value, Separate Account Investment [Line Items]
Separate account assets	807	893
RIS | Separate Account, Debt Security | Consumer
Fair Value, Separate Account Investment [Line Items]
Separate account assets	1,910	1,882
RIS | Separate Account, Debt Security | Energy
Fair Value, Separate Account Investment [Line Items]
Separate account assets	822	911
RIS | Separate Account, Debt Security | Financial Services Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	2,697	2,717
RIS | Separate Account, Debt Security | Commercial and Industrial Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	748	764
RIS | Separate Account, Debt Security | Foreign
Fair Value, Separate Account Investment [Line Items]
Separate account assets	1,935	1,920
RIS | Separate Account, Debt Security | Technology
Fair Value, Separate Account Investment [Line Items]
Separate account assets	531	547
RIS | Separate Account, Debt Security | Foreign government
Fair Value, Separate Account Investment [Line Items]
Separate account assets	508	509
RIS | Separate Account, Debt Security | U.S. government and agency
Fair Value, Separate Account Investment [Line Items]
Separate account assets	9,875	9,673
RIS | Separate Account, Debt Security | Public utilities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	1,157	1,077
RIS | Separate Account, Debt Security | Municipals
Fair Value, Separate Account Investment [Line Items]
Separate account assets	295	380
RIS | Separate Account, Debt Security | Total corporate bonds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	9,581	9,778
RIS | Separate Account, Debt Security | Total bonds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	21,416	21,417
RIS | Separate Account, Debt Security | Mortgage-backed securities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	9,372	9,671
RIS | Separate Account, Debt Security | Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”)
Fair Value, Separate Account Investment [Line Items]
Separate account assets	2,357	2,557
RIS | Separate Account, Debt Security | Redeemable preferred stock
Fair Value, Separate Account Investment [Line Items]
Separate account assets	9	9
RIS | Separate Account, Debt Security | Total fixed maturity securities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	33,154	33,654
RIS | Separate Account, Equity Security
Fair Value, Separate Account Investment [Line Items]
Separate account assets	12,664	11,726
RIS | Separate Account, Equity Security | Non-redeemable preferred Stock
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
RIS | Separate Account, Equity Security | Financial Services Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	730	731
RIS | Separate Account, Equity Security | Commercial and Industrial Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	2,426	2,411
RIS | Separate Account, Equity Security | Public utilities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	73	67
RIS | Separate Account, Equity Security | Mutual funds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	9,435	8,517
RIS | Investments
Fair Value, Separate Account Investment [Line Items]
Separate account assets	47,190	47,000
RIS | Other Assets
Fair Value, Separate Account Investment [Line Items]
Separate account assets	5,348	6,093
Asia
Fair Value, Separate Account Investment [Line Items]
Separate account assets	9,221	9,187
Asia | Other invested assets
Fair Value, Separate Account Investment [Line Items]
Separate account assets	369	403
Asia | Separate Account, Debt Security | Materials
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Asia | Separate Account, Debt Security | Communications
Fair Value, Separate Account Investment [Line Items]
Separate account assets	16	8
Asia | Separate Account, Debt Security | Consumer
Fair Value, Separate Account Investment [Line Items]
Separate account assets	38	39
Asia | Separate Account, Debt Security | Energy
Fair Value, Separate Account Investment [Line Items]
Separate account assets	113	105
Asia | Separate Account, Debt Security | Financial Services Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	558	551
Asia | Separate Account, Debt Security | Commercial and Industrial Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	68	38
Asia | Separate Account, Debt Security | Foreign
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Asia | Separate Account, Debt Security | Technology
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Asia | Separate Account, Debt Security | Foreign government
Fair Value, Separate Account Investment [Line Items]
Separate account assets	1,271	1,190
Asia | Separate Account, Debt Security | U.S. government and agency
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Asia | Separate Account, Debt Security | Public utilities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	239	308
Asia | Separate Account, Debt Security | Municipals
Fair Value, Separate Account Investment [Line Items]
Separate account assets	20	31
Asia | Separate Account, Debt Security | Total corporate bonds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	793	741
Asia | Separate Account, Debt Security | Total bonds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	2,323	2,270
Asia | Separate Account, Debt Security | Mortgage-backed securities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Asia | Separate Account, Debt Security | Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”)
Fair Value, Separate Account Investment [Line Items]
Separate account assets	18	18
Asia | Separate Account, Debt Security | Redeemable preferred stock
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Asia | Separate Account, Debt Security | Total fixed maturity securities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	2,341	2,288
Asia | Separate Account, Equity Security
Fair Value, Separate Account Investment [Line Items]
Separate account assets	6,057	5,993
Asia | Separate Account, Equity Security | Non-redeemable preferred Stock
Fair Value, Separate Account Investment [Line Items]
Separate account assets	130	115
Asia | Separate Account, Equity Security | Financial Services Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	333	269
Asia | Separate Account, Equity Security | Commercial and Industrial Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	2,417	2,661
Asia | Separate Account, Equity Security | Public utilities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	24	19
Asia | Separate Account, Equity Security | Mutual funds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	3,153	2,929
Asia | Investments
Fair Value, Separate Account Investment [Line Items]
Separate account assets	8,767	8,684
Asia | Other Assets
Fair Value, Separate Account Investment [Line Items]
Separate account assets	454	503
Latin America
Fair Value, Separate Account Investment [Line Items]
Separate account assets	44,158	41,320
Latin America | Other invested assets
Fair Value, Separate Account Investment [Line Items]
Separate account assets	4,287	4,212
Latin America | Separate Account, Debt Security | Materials
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Latin America | Separate Account, Debt Security | Communications
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Latin America | Separate Account, Debt Security | Consumer
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Latin America | Separate Account, Debt Security | Energy
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Latin America | Separate Account, Debt Security | Financial Services Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	5,371	6,006
Latin America | Separate Account, Debt Security | Commercial and Industrial Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	3,759	3,598
Latin America | Separate Account, Debt Security | Foreign
Fair Value, Separate Account Investment [Line Items]
Separate account assets	3,227	3,095
Latin America | Separate Account, Debt Security | Technology
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Latin America | Separate Account, Debt Security | Foreign government
Fair Value, Separate Account Investment [Line Items]
Separate account assets	524	1,051
Latin America | Separate Account, Debt Security | U.S. government and agency
Fair Value, Separate Account Investment [Line Items]
Separate account assets	12,228	9,920
Latin America | Separate Account, Debt Security | Public utilities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Latin America | Separate Account, Debt Security | Municipals
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Latin America | Separate Account, Debt Security | Total corporate bonds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	12,357	12,699
Latin America | Separate Account, Debt Security | Total bonds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	25,109	23,670
Latin America | Separate Account, Debt Security | Mortgage-backed securities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Latin America | Separate Account, Debt Security | Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”)
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Latin America | Separate Account, Debt Security | Redeemable preferred stock
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Latin America | Separate Account, Debt Security | Total fixed maturity securities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	25,109	23,670
Latin America | Separate Account, Equity Security
Fair Value, Separate Account Investment [Line Items]
Separate account assets	14,690	12,944
Latin America | Separate Account, Equity Security | Non-redeemable preferred Stock
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Latin America | Separate Account, Equity Security | Financial Services Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	442	392
Latin America | Separate Account, Equity Security | Commercial and Industrial Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	2,413	2,453
Latin America | Separate Account, Equity Security | Public utilities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Latin America | Separate Account, Equity Security | Mutual funds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	11,835	10,099
Latin America | Investments
Fair Value, Separate Account Investment [Line Items]
Separate account assets	44,086	40,826
Latin America | Other Assets
Fair Value, Separate Account Investment [Line Items]
Separate account assets	72	494
EMEA
Fair Value, Separate Account Investment [Line Items]
Separate account assets	5,174	4,327
EMEA | Other invested assets
Fair Value, Separate Account Investment [Line Items]
Separate account assets	98	30
EMEA | Separate Account, Debt Security | Materials
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
EMEA | Separate Account, Debt Security | Communications
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
EMEA | Separate Account, Debt Security | Consumer
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
EMEA | Separate Account, Debt Security | Energy
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
EMEA | Separate Account, Debt Security | Financial Services Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	307	398
EMEA | Separate Account, Debt Security | Commercial and Industrial Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
EMEA | Separate Account, Debt Security | Foreign
Fair Value, Separate Account Investment [Line Items]
Separate account assets	54	27
EMEA | Separate Account, Debt Security | Technology
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
EMEA | Separate Account, Debt Security | Foreign government
Fair Value, Separate Account Investment [Line Items]
Separate account assets	3,139	2,638
EMEA | Separate Account, Debt Security | U.S. government and agency
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
EMEA | Separate Account, Debt Security | Public utilities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
EMEA | Separate Account, Debt Security | Municipals
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
EMEA | Separate Account, Debt Security | Total corporate bonds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	361	425
EMEA | Separate Account, Debt Security | Total bonds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	3,500	3,063
EMEA | Separate Account, Debt Security | Mortgage-backed securities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
EMEA | Separate Account, Debt Security | Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”)
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
EMEA | Separate Account, Debt Security | Redeemable preferred stock
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
EMEA | Separate Account, Debt Security | Total fixed maturity securities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	3,500	3,063
EMEA | Separate Account, Equity Security
Fair Value, Separate Account Investment [Line Items]
Separate account assets	1,508	1,199
EMEA | Separate Account, Equity Security | Non-redeemable preferred Stock
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
EMEA | Separate Account, Equity Security | Financial Services Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	378	341
EMEA | Separate Account, Equity Security | Commercial and Industrial Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	807	677
EMEA | Separate Account, Equity Security | Public utilities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	123	72
EMEA | Separate Account, Equity Security | Mutual funds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	200	109
EMEA | Investments
Fair Value, Separate Account Investment [Line Items]
Separate account assets	5,106	4,292
EMEA | Other Assets
Fair Value, Separate Account Investment [Line Items]
Separate account assets	68	35
MetLife Holdings
Fair Value, Separate Account Investment [Line Items]
Separate account assets	36,398	35,548
MetLife Holdings | Other invested assets
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
MetLife Holdings | Separate Account, Debt Security | Materials
Fair Value, Separate Account Investment [Line Items]
Separate account assets	1	0
MetLife Holdings | Separate Account, Debt Security | Communications
Fair Value, Separate Account Investment [Line Items]
Separate account assets	4	3
MetLife Holdings | Separate Account, Debt Security | Consumer
Fair Value, Separate Account Investment [Line Items]
Separate account assets	11	8
MetLife Holdings | Separate Account, Debt Security | Energy
Fair Value, Separate Account Investment [Line Items]
Separate account assets	3	2
MetLife Holdings | Separate Account, Debt Security | Financial Services Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	19	15
MetLife Holdings | Separate Account, Debt Security | Commercial and Industrial Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	2	3
MetLife Holdings | Separate Account, Debt Security | Foreign
Fair Value, Separate Account Investment [Line Items]
Separate account assets	12	13
MetLife Holdings | Separate Account, Debt Security | Technology
Fair Value, Separate Account Investment [Line Items]
Separate account assets	2	3
MetLife Holdings | Separate Account, Debt Security | Foreign government
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
MetLife Holdings | Separate Account, Debt Security | U.S. government and agency
Fair Value, Separate Account Investment [Line Items]
Separate account assets	19	18
MetLife Holdings | Separate Account, Debt Security | Public utilities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	7	4
MetLife Holdings | Separate Account, Debt Security | Municipals
Fair Value, Separate Account Investment [Line Items]
Separate account assets	13	13
MetLife Holdings | Separate Account, Debt Security | Total corporate bonds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	54	47
MetLife Holdings | Separate Account, Debt Security | Total bonds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	93	82
MetLife Holdings | Separate Account, Debt Security | Mortgage-backed securities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	40	35
MetLife Holdings | Separate Account, Debt Security | Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”)
Fair Value, Separate Account Investment [Line Items]
Separate account assets	13	11
MetLife Holdings | Separate Account, Debt Security | Redeemable preferred stock
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
MetLife Holdings | Separate Account, Debt Security | Total fixed maturity securities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	146	128
MetLife Holdings | Separate Account, Equity Security
Fair Value, Separate Account Investment [Line Items]
Separate account assets	36,250	35,418
MetLife Holdings | Separate Account, Equity Security | Non-redeemable preferred Stock
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
MetLife Holdings | Separate Account, Equity Security | Financial Services Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
MetLife Holdings | Separate Account, Equity Security | Commercial and Industrial Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
MetLife Holdings | Separate Account, Equity Security | Public utilities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
MetLife Holdings | Separate Account, Equity Security | Mutual funds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	36,250	35,418
MetLife Holdings | Investments
Fair Value, Separate Account Investment [Line Items]
Separate account assets	36,396	35,546
MetLife Holdings | Other Assets
Fair Value, Separate Account Investment [Line Items]
Separate account assets	2	2
Group Benefits
Fair Value, Separate Account Investment [Line Items]
Separate account assets	1,320	1,159
Group Benefits | Other invested assets
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Materials
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Communications
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Consumer
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Energy
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Financial Services Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Commercial and Industrial Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Foreign
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Technology
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Foreign government
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | U.S. government and agency
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Public utilities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Municipals
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Total corporate bonds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Total bonds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Mortgage-backed securities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Asset-backed securities and collateralized loan obligations (collectively, “ABS & CLO”)
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Redeemable preferred stock
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Debt Security | Total fixed maturity securities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Equity Security
Fair Value, Separate Account Investment [Line Items]
Separate account assets	1,320	1,159
Group Benefits | Separate Account, Equity Security | Non-redeemable preferred Stock
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Equity Security | Financial Services Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Equity Security | Commercial and Industrial Sector
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Equity Security | Public utilities
Fair Value, Separate Account Investment [Line Items]
Separate account assets	0	0
Group Benefits | Separate Account, Equity Security | Mutual funds
Fair Value, Separate Account Investment [Line Items]
Separate account assets	1,320	1,159
Group Benefits | Investments
Fair Value, Separate Account Investment [Line Items]
Separate account assets	1,320	1,159
Group Benefits | Other Assets
Fair Value, Separate Account Investment [Line Items]
Separate account assets	$ 0	$ 0

Deferred Policy Acquisition C_3

Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue - DAC VOBA by Segment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
DAC:
DAC, Beginning Balance			$ 18,388	$ 17,644
Capitalizations	$ 691	$ 742	2,114	2,189
Amortization			(1,420)	(1,324)
Effect of foreign currency translation and other, net			(300)	(502)
DAC, Ending Balance	18,782	18,007	18,782	18,007
VOBA:
VOBA Net, Beginning Balance			1,763	2,009
Amortization			(103)	(124)
Effect of foreign currency translation and other, net			(41)	(155)
VOBA Net, Ending Balance	1,619	1,730	1,619	1,730
Deferred policy acquisition costs and value of business acquired	20,401	19,737	20,401	19,737	$ 20,151
Group Benefits
DAC:
DAC, Beginning Balance			258	265
Capitalizations			13	16
Amortization			(19)	(19)
Effect of foreign currency translation and other, net			0	0
DAC, Ending Balance	252	262	252	262
VOBA:
VOBA Net, Beginning Balance			0	0
Amortization			0	0
Effect of foreign currency translation and other, net			0	0
VOBA Net, Ending Balance	0	0	0	0
RIS
DAC:
DAC, Beginning Balance			397	267
Capitalizations			160	136
Amortization			(43)	(34)
Effect of foreign currency translation and other, net			0	0
DAC, Ending Balance	514	369	514	369
VOBA:
VOBA Net, Beginning Balance			16	19
Amortization			(2)	(2)
Effect of foreign currency translation and other, net			0	0
VOBA Net, Ending Balance	14	17	14	17
Asia
DAC:
DAC, Beginning Balance			10,864	10,270
Capitalizations			1,032	1,202
Amortization			(579)	(518)
Effect of foreign currency translation and other, net			(71)	(600)
DAC, Ending Balance	11,246	10,354	11,246	10,354
VOBA:
VOBA Net, Beginning Balance			1,119	1,290
Amortization			(55)	(69)
Effect of foreign currency translation and other, net			(19)	(144)
VOBA Net, Ending Balance	1,045	1,077	1,045	1,077
Latin America
DAC:
DAC, Beginning Balance			1,950	1,542
Capitalizations			527	470
Amortization			(348)	(306)
Effect of foreign currency translation and other, net			(224)	125
DAC, Ending Balance	1,905	1,831	1,905	1,831
VOBA:
VOBA Net, Beginning Balance			497	545
Amortization			(32)	(38)
Effect of foreign currency translation and other, net			(22)	(10)
VOBA Net, Ending Balance	443	497	443	497
EMEA
DAC:
DAC, Beginning Balance			1,618	1,480
Capitalizations			362	341
Amortization			(254)	(245)
Effect of foreign currency translation and other, net			(5)	(27)
DAC, Ending Balance	1,721	1,549	1,721	1,549
VOBA:
VOBA Net, Beginning Balance			113	127
Amortization			(11)	(12)
Effect of foreign currency translation and other, net			0	(1)
VOBA Net, Ending Balance	102	114	102	114
MetLife Holdings
DAC:
DAC, Beginning Balance			3,271	3,791
Capitalizations			13	17
Amortization			(171)	(194)
Effect of foreign currency translation and other, net			0	0
DAC, Ending Balance	3,113	3,614	3,113	3,614
VOBA:
VOBA Net, Beginning Balance			18	28
Amortization			(3)	(3)
Effect of foreign currency translation and other, net			0	0
VOBA Net, Ending Balance	15	25	15	25
Corporate & Other
DAC:
DAC, Beginning Balance			30	29
Capitalizations			7	7
Amortization			(6)	(8)
Effect of foreign currency translation and other, net			0	0
DAC, Ending Balance	31	28	31	28
VOBA:
VOBA Net, Beginning Balance			0	0
Amortization			0	0
Effect of foreign currency translation and other, net			0	0
VOBA Net, Ending Balance	$ 0	$ 0	$ 0	$ 0

Deferred Policy Acquisition C_4

Deferred Policy Acquisition Costs, Value of Business Acquired and Unearned Revenue - Unearned Revenue (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Unearned Revenue [Roll Forward]
Deferred Revenue, Current, Beginning Balance	$ 4,537	$ 4,106
Deferrals	620	699
Amortization	(314)	(284)
Effect of foreign currency translation and other - net	(130)	40
Deferred Revenue, Current, Ending Balance	4,713	4,561
RIS
Unearned Revenue [Roll Forward]
Deferred Revenue, Current, Beginning Balance	31	36
Deferrals	1	2
Amortization	(4)	(5)
Effect of foreign currency translation and other - net	0	0
Deferred Revenue, Current, Ending Balance	28	33
Asia
Unearned Revenue [Roll Forward]
Deferred Revenue, Current, Beginning Balance	2,850	2,382
Deferrals	424	477
Amortization	(167)	(129)
Effect of foreign currency translation and other - net	(9)	(49)
Deferred Revenue, Current, Ending Balance	3,098	2,681
Latin America
Unearned Revenue [Roll Forward]
Deferred Revenue, Current, Beginning Balance	989	848
Deferrals	111	108
Amortization	(88)	(87)
Effect of foreign currency translation and other - net	(124)	85
Deferred Revenue, Current, Ending Balance	888	954
EMEA
Unearned Revenue [Roll Forward]
Deferred Revenue, Current, Beginning Balance	608	559
Deferrals	72	71
Amortization	(51)	(47)
Effect of foreign currency translation and other - net	3	4
Deferred Revenue, Current, Ending Balance	632	587
MetLife Holdings
Unearned Revenue [Roll Forward]
Deferred Revenue, Current, Beginning Balance	59	281
Deferrals	12	41
Amortization	(4)	(16)
Effect of foreign currency translation and other - net	0	0
Deferred Revenue, Current, Ending Balance	$ 67	$ 306

Closed Block (Liabilities and A

Closed Block (Liabilities and Assets) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Closed Block Liabilities
FPBs	$ 35,229	$ 36,142
Other policy-related balances	284	319
Policyholder dividends payable	178	174
Policyholder dividend obligation	0	0
Current income tax payable	13	0
Other liabilities	896	668
Total closed block liabilities	36,600	37,303
Assets Designated to the Closed Block
Fixed maturity securities available-for-sale (“AFS”), at estimated fair value	19,915	19,939
Equity securities, at estimated fair value	10	10
Mortgage loans	5,856	6,151
Policy loans	3,850	3,960
Real estate and real estate joint ventures (“REJV”)	676	668
Other invested assets	418	496
Total investments	30,725	31,224
Cash and cash equivalents	957	717
Accrued investment income	382	383
Premiums, reinsurance and other receivables	36	54
Current income tax recoverable	0	3
Deferred income tax asset	239	312
Total assets designated to the closed block	32,339	32,693
Excess of closed block liabilities over assets designated to the closed block	4,261	4,610
AOCI:
Unrealized investment gains (losses), net of income tax	(551)	(820)
Unrealized gains (losses) on derivatives, net of income tax	116	130
Total amounts included in AOCI	(435)	(690)
Maximum future earnings to be recognized from closed block assets and liabilities	$ 3,826	$ 3,920

Closed Block (Revenues and Expe

Closed Block (Revenues and Expenses) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues
Premiums	$ 214	$ 219	$ 648	$ 680
Net investment income	336	345	1,021	1,024
Net investment gains (losses)	1	4	(19)	13
Net derivative gains (losses)	(1)	(2)	6	1
Total revenues	550	566	1,656	1,718
Expenses
Policyholder benefits and claims	390	403	1,209	1,261
Policyholder dividends	90	89	266	275
Other expenses	21	21	61	65
Total expenses	501	513	1,536	1,601
Revenues, net of expenses before provision for income tax expense (benefit)	49	53	120	117
Provision for income tax expense (benefit)	11	11	26	24
Revenues, net of expenses and provision for income tax expense (benefit)	$ 38	$ 42	$ 94	$ 93

Investments (Fixed Maturity Sec

Investments (Fixed Maturity Securities Available-For-Sale by Sector) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 309,406		$ 300,555
Allowance for Credit Loss for Debt Securities	(162)	$ (121)	(184)	$ (182)	$ (197)	$ (183)
Gross Unrealized Gains	8,093		6,876
Gross Unrealized Losses	23,558		25,835
Estimated Fair Value of Fixed Maturity Securities AFS	293,779		281,412
U.S. corporate
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	88,612		85,563
Allowance for Credit Loss for Debt Securities	(60)	(37)	(68)	(67)	(69)	(29)
Gross Unrealized Gains	2,275		1,894
Gross Unrealized Losses	5,976		6,672
Estimated Fair Value of Fixed Maturity Securities AFS	84,851		80,717
Foreign corporate
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	59,282		59,123
Allowance for Credit Loss for Debt Securities	(15)	(2)	(2)	(2)	(2)	(5)
Gross Unrealized Gains	2,164		1,750
Gross Unrealized Losses	4,679		5,427
Estimated Fair Value of Fixed Maturity Securities AFS	56,752		55,444
Foreign government
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	47,586		48,260
Allowance for Credit Loss for Debt Securities	(62)	(58)	(88)	(89)	(115)	(130)
Gross Unrealized Gains	1,776		1,754
Gross Unrealized Losses	5,168		4,437
Estimated Fair Value of Fixed Maturity Securities AFS	44,132		45,489
U.S. government and agency
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	37,727		35,374
Allowance for Credit Loss for Debt Securities	0		0
Gross Unrealized Gains	589		590
Gross Unrealized Losses	3,640		3,712
Estimated Fair Value of Fixed Maturity Securities AFS	34,676		32,252
RMBS
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	36,761		31,479
Allowance for Credit Loss for Debt Securities	(1)	(1)	(1)	(1)	0	0
Gross Unrealized Gains	630		353
Gross Unrealized Losses	2,126		2,735
Estimated Fair Value of Fixed Maturity Securities AFS	35,264		29,096
ABS & CLO
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	17,750		17,910
Allowance for Credit Loss for Debt Securities	(10)	(9)	(7)	(7)	0	0
Gross Unrealized Gains	138		54
Gross Unrealized Losses	358		663
Estimated Fair Value of Fixed Maturity Securities AFS	17,520		17,294
Municipals
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	11,521		11,991
Allowance for Credit Loss for Debt Securities	0		0
Gross Unrealized Gains	354		408
Gross Unrealized Losses	1,077		1,228
Estimated Fair Value of Fixed Maturity Securities AFS	10,798		11,171
CMBS
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	10,167		10,855
Allowance for Credit Loss for Debt Securities	(14)	$ (14)	(18)	$ (16)	$ (11)	$ (19)
Gross Unrealized Gains	167		73
Gross Unrealized Losses	534		961
Estimated Fair Value of Fixed Maturity Securities AFS	$ 9,786		$ 9,949

Investments (Maturities of Fixe

Investments (Maturities of Fixed Maturity Securities) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Available-for-sale Securities, Debt Maturities [Abstract]
Amortized Cost, Due in one year or less	$ 11,313
Amortized Cost, Due after one year through five years	48,735
Amortized Cost, Due after five years through ten years	54,449
Amortized Cost, Due after ten years	130,094
Amortized Cost, Structured Securities	64,653
Amortized Cost, net of ACL	309,244
Estimated Fair Value, Due in one year or less	11,361
Estimated Fair Value, Due after one year through five years	48,895
Estimated Fair Value, Due after five years through ten years	54,079
Estimated Fair Value, Due after ten years	116,874
Estimated Fair Value, Structured Securities	62,570
Estimated Fair Value of Fixed Maturity Securities AFS	$ 293,779	$ 281,412

Investments (Continuous Gross U

Investments (Continuous Gross Unrealized Losses for Fixed Maturity Securities Available-For-Sale) (Details) $ in Millions	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Debt Securities, Available-for-sale [Line Items]
Less than 12 months Estimated Fair Value	$ 18,152	$ 26,345
Less than 12 months Gross Unrealized Loss	$ 1,649	$ 1,382
Total number of securities in an unrealized loss position less than 12 months	2,855	2,922
Equal to or Greater than 12 Months Estimated Fair Value	$ 136,467	$ 152,089
Equal to or Greater than 12 Months Gross Unrealized Loss	$ 21,852	$ 24,394
Total number of securities in an unrealized loss position equal or greater than 12 months	11,063	13,049
U.S. corporate
Debt Securities, Available-for-sale [Line Items]
Less than 12 months Estimated Fair Value	$ 4,384	$ 4,722
Less than 12 months Gross Unrealized Loss	685	420
Equal to or Greater than 12 Months Estimated Fair Value	41,061	45,373
Equal to or Greater than 12 Months Gross Unrealized Loss	5,258	6,208
Foreign corporate
Debt Securities, Available-for-sale [Line Items]
Less than 12 months Estimated Fair Value	2,505	3,210
Less than 12 months Gross Unrealized Loss	181	187
Equal to or Greater than 12 Months Estimated Fair Value	28,069	32,355
Equal to or Greater than 12 Months Gross Unrealized Loss	4,477	5,240
Foreign government
Debt Securities, Available-for-sale [Line Items]
Less than 12 months Estimated Fair Value	2,828	3,913
Less than 12 months Gross Unrealized Loss	432	246
Equal to or Greater than 12 Months Estimated Fair Value	19,170	19,715
Equal to or Greater than 12 Months Gross Unrealized Loss	4,735	4,187
U.S. government and agency
Debt Securities, Available-for-sale [Line Items]
Less than 12 months Estimated Fair Value	3,426	7,856
Less than 12 months Gross Unrealized Loss	159	368
Equal to or Greater than 12 Months Estimated Fair Value	15,987	13,960
Equal to or Greater than 12 Months Gross Unrealized Loss	3,481	3,344
RMBS
Debt Securities, Available-for-sale [Line Items]
Less than 12 months Estimated Fair Value	1,926	3,465
Less than 12 months Gross Unrealized Loss	73	60
Equal to or Greater than 12 Months Estimated Fair Value	15,673	17,128
Equal to or Greater than 12 Months Gross Unrealized Loss	2,053	2,675
ABS & CLO
Debt Securities, Available-for-sale [Line Items]
Less than 12 months Estimated Fair Value	2,441	1,662
Less than 12 months Gross Unrealized Loss	17	31
Equal to or Greater than 12 Months Estimated Fair Value	5,833	11,438
Equal to or Greater than 12 Months Gross Unrealized Loss	341	629
Municipals
Debt Securities, Available-for-sale [Line Items]
Less than 12 months Estimated Fair Value	209	483
Less than 12 months Gross Unrealized Loss	87	34
Equal to or Greater than 12 Months Estimated Fair Value	5,241	5,449
Equal to or Greater than 12 Months Gross Unrealized Loss	990	1,194
CMBS
Debt Securities, Available-for-sale [Line Items]
Less than 12 months Estimated Fair Value	433	1,034
Less than 12 months Gross Unrealized Loss	15	36
Equal to or Greater than 12 Months Estimated Fair Value	5,433	6,671
Equal to or Greater than 12 Months Gross Unrealized Loss	517	917
Investment Grade
Debt Securities, Available-for-sale [Line Items]
Less than 12 months Estimated Fair Value	15,804	24,834
Less than 12 months Gross Unrealized Loss	1,577	1,287
Equal to or Greater than 12 Months Estimated Fair Value	131,959	146,138
Equal to or Greater than 12 Months Gross Unrealized Loss	21,256	23,675
Below Investment Grade
Debt Securities, Available-for-sale [Line Items]
Less than 12 months Estimated Fair Value	2,348	1,511
Less than 12 months Gross Unrealized Loss	72	95
Equal to or Greater than 12 Months Estimated Fair Value	4,508	5,951
Equal to or Greater than 12 Months Gross Unrealized Loss	$ 596	$ 719

Investments (ACL for Fixed Matu

Investments (ACL for Fixed Maturity Securities AFS By Sector) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items]
Allowance, beginning of period	$ 121	$ 197	$ 184	$ 183
ACL not previously recorded	40	10	54	46
Changes for securities with previously recorded ACL	4	(4)	14	(10)
Securities sold or exchanged	(3)	(21)	(90)	(37)
Allowance, end of period	162	182	162	182
U.S. corporate
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items]
Allowance, beginning of period	37	69	68	29
ACL not previously recorded	27	0	41	36
Changes for securities with previously recorded ACL	(1)	0	10	6
Securities sold or exchanged	(3)	(2)	(59)	(4)
Allowance, end of period	60	67	60	67
Foreign corporate
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items]
Allowance, beginning of period	2	2	2	5
ACL not previously recorded	13	0	13	0
Changes for securities with previously recorded ACL	0	0	0	0
Securities sold or exchanged	0	0	0	(3)
Allowance, end of period	15	2	15	2
Foreign government
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items]
Allowance, beginning of period	58	115	88	130
ACL not previously recorded	0	0	0	0
Changes for securities with previously recorded ACL	4	(7)	(1)	(22)
Securities sold or exchanged	0	(19)	(25)	(19)
Allowance, end of period	62	89	62	89
RMBS
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items]
Allowance, beginning of period	1	0	1	0
ACL not previously recorded	0	1	0	1
Changes for securities with previously recorded ACL	0	0	0	0
Securities sold or exchanged	0	0	0	0
Allowance, end of period	1	1	1	1
ABS & CLO
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items]
Allowance, beginning of period	9	0	7	0
ACL not previously recorded	0	7	0	7
Changes for securities with previously recorded ACL	1	0	3	0
Securities sold or exchanged	0	0	0	0
Allowance, end of period	10	7	10	7
CMBS
Debt Securities, Available-for-sale, Allowance for Credit Loss [Line Items]
Allowance, beginning of period	14	11	18	19
ACL not previously recorded	0	2	0	2
Changes for securities with previously recorded ACL	0	3	2	6
Securities sold or exchanged	0	0	(6)	(11)
Allowance, end of period	$ 14	$ 16	$ 14	$ 16

Investments (Equity Securities)

Investments (Equity Securities) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Debt and Equity Securities, FV-NI [Line Items]
Equity Securities, FV-NI, Unrealized Gains (Losses)	$ 2,001	$ 1,589
Equity securities	746	757
Common Stock
Debt and Equity Securities, FV-NI [Line Items]
Equity Securities, FV-NI, Cost	453	424
Equity Securities, FV-NI, Unrealized Gains (Losses)	193	239
Equity securities	646	663
Non-redeemable preferred Stock
Debt and Equity Securities, FV-NI [Line Items]
Equity Securities, FV-NI, Cost	100	90
Equity Securities, FV-NI, Unrealized Gains (Losses)	0	4
Equity securities	100	94
Equity Securities
Debt and Equity Securities, FV-NI [Line Items]
Equity Securities, FV-NI, Cost	553	514
Equity Securities, FV-NI, Unrealized Gains (Losses)	193	243
Equity securities	$ 746	$ 757

Investments (Contractholder-Dir

Investments (Contractholder-Directed Equity Securities and FVO Securities) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Debt and Equity Securities, FV-NI [Line Items]
Debt Securities, Trading, and Equity Securities, FV-NI, Cost	$ 7,288	$ 8,742
Contracted-Directed Equity Securities and FVO Securities, FV-NI, Unrealized Gains (Losses)	2,001	1,589
Contractholder-directed equity securities and fair value option securities, at estimated fair value	9,289	10,331
Unit-linked investments
Debt and Equity Securities, FV-NI [Line Items]
Debt Securities, Trading, and Equity Securities, FV-NI, Cost	6,263	7,770
Contracted-Directed Equity Securities and FVO Securities, FV-NI, Unrealized Gains (Losses)	1,345	1,112
Contractholder-directed equity securities and fair value option securities, at estimated fair value	7,608	8,882
FVO securities
Debt and Equity Securities, FV-NI [Line Items]
Debt Securities, Trading, and Equity Securities, FV-NI, Cost	1,025	972
Contracted-Directed Equity Securities and FVO Securities, FV-NI, Unrealized Gains (Losses)	656	477
Contractholder-directed equity securities and fair value option securities, at estimated fair value	$ 1,681	$ 1,449

Investments (Mortgage Loans by

Investments (Mortgage Loans by Portfolio Segment) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage Loans, Gross	$ 91,262		$ 91,262		$ 93,227
Allowance for Credit Loss	(847)	$ (705)	(847)	$ (705)	(721)	$ (527)
Total mortgage loans	$ 90,415		$ 90,415		$ 92,506
Percentage Of mortgage total recorded investment To Mortgage Loans On Real Estate Commercial And Consumer Net	100.90%		100.90%		100.80%
Percentage of Allowance for Credit Losses for Financing Receivables	(0.90%)		(0.90%)		(0.80%)
Percentage Of Mortgage Loans On Real Estate To Mortgage Loans On Real Estate Commercial And Consumer Net	100%		100%		100%
Other Liabilities	$ 38,162		$ 38,162		$ 35,805
Investment Income, Investment Expense	571	544	1,703	1,686
Loans Originated For Third Party
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage Loans, Gross	7,700		7,700		8,500
Allowance for Credit Loss	(88)		(88)		(73)
Other Liabilities	7,700		7,700		8,500
Mortgage Income On Loans Originated For Third Party
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross Investment Income, Operating	87		272
Mortgage Expense On Loans Originated For Third Party
Accounts, Notes, Loans and Financing Receivable [Line Items]
Investment Income, Investment Expense	87		272
Commercial Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage Loans, Gross	57,949		57,949		60,326
Allowance for Credit Loss	$ (551)	(355)	$ (551)	(355)	$ (367)	(218)
Percentage Of Mortgage Loans, Gross	64.10%		64.10%		65.20%
Commercial Mortgage Loans | Loans Originated For Third Party
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage Loans, Gross	$ 7,500		$ 7,500		$ 8,200
Residential Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage Loans, Gross	13,844		13,844		13,096
Allowance for Credit Loss	$ (161)	(192)	$ (161)	(192)	$ (182)	(190)
Percentage Of Mortgage Loans, Gross	15.30%		15.30%		14.20%
Agricultural Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage Loans, Gross	$ 19,469		$ 19,469		$ 19,805
Allowance for Credit Loss	$ (135)	$ (158)	$ (135)	$ (158)	$ (172)	$ (119)
Percentage Of Mortgage Loans, Gross	21.50%		21.50%		21.40%
Agricultural Mortgage Loans | Loans Originated For Third Party
Accounts, Notes, Loans and Financing Receivable [Line Items]
Mortgage Loans, Gross	$ 259		$ 259		$ 246

Investments (Mortgage Loans All

Investments (Mortgage Loans Allowance for Credit Loss Rollforward by Portfolio Segment) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Balance, beginning of period	$ 721	$ 527
Provision (release)	231	201
Charge-offs, net of recoveries	(105)	(23)
Balance, end of period	847	705
Commercial Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Balance, beginning of period	367	218
Provision (release)	212	147
Charge-offs, net of recoveries	(28)	(10)
Balance, end of period	551	355
Residential Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Balance, beginning of period	182	190
Provision (release)	(21)	2
Charge-offs, net of recoveries	0	0
Balance, end of period	161	192
Agricultural Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Balance, beginning of period	172	119
Provision (release)	40	52
Charge-offs, net of recoveries	(77)	(13)
Balance, end of period	$ 135	$ 158

Investments (Modifications to B

Investments (Modifications to Borrowers Experiencing Financial Difficulty) (Details) - Commercial Mortgage Loans - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Maximum
Accounts, Notes, Loans and Financing Receivable [Line Items]
Financing Receivable, Modified, Weighted Average Term Increase	Less than one year	Less than one year	Less than one year	Less than one year
Financing Receivable, Modified in Period, to Total Financing Receivables, Percentage	1%	1%	1%	1%
Extended Maturity
Accounts, Notes, Loans and Financing Receivable [Line Items]
Financing Receivable, Troubled Debt Restructuring, Postmodification	$ 39	$ 145	$ 236	$ 367

Investments (Credit Quality of

Investments (Credit Quality of Commercial Mortgage Loans) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Financing Receivable, Credit Quality Indicator [Line Items]
Mortgage Loans, Gross	$ 91,262	$ 93,227
Commercial Mortgage Loans
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	2,508
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	2,992
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	8,410
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	7,134
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	3,899
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	30,608
Financing Receivable, Revolving	2,398
Mortgage Loans, Gross	$ 57,949	$ 60,326
Loans Receivable Commercial Mortgage Percentage	100%
Commercial Mortgage Loans | Greater than 1.20x
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 2,284
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	1,983
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	7,448
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	6,496
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	3,715
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	25,911
Financing Receivable, Revolving	2,398
Mortgage Loans, Gross	$ 50,235
Loans Receivable Commercial Mortgage Percentage	86.70%
Commercial Mortgage Loans | 1.00x - 1.20x
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 148
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	603
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	711
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	490
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	105
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	2,485
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 4,542
Loans Receivable Commercial Mortgage Percentage	7.80%
Commercial Mortgage Loans | Less than 1.00x
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 76
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	406
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	251
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	148
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	79
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	2,212
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 3,172
Loans Receivable Commercial Mortgage Percentage	5.50%
Commercial Mortgage Loans | Less than 65%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 2,007
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	2,545
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	2,668
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	3,168
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	1,495
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	13,882
Financing Receivable, Revolving	2,398
Mortgage Loans, Gross	$ 28,163
Loans Receivable Commercial Mortgage Percentage	48.60%
Commercial Mortgage Loans | 65% to 75%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 462
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	374
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	4,012
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	2,267
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	297
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	4,230
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 11,642
Loans Receivable Commercial Mortgage Percentage	20.10%
Commercial Mortgage Loans | 76% to 80%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 2
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	16
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	611
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	287
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	428
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	2,789
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 4,133
Loans Receivable Commercial Mortgage Percentage	7.10%
Commercial Mortgage Loans | Greater than 80%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 37
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	57
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	1,119
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	1,412
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	1,679
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	9,707
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 14,011
Loans Receivable Commercial Mortgage Percentage	24.20%

Investments (Credit Quality o_2

Investments (Credit Quality of Agricultural and Residential Mortgage Loans) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Financing Receivable, Credit Quality Indicator [Line Items]
Mortgage Loans, Gross	$ 91,262	$ 93,227
Mortgage Loans in Process of Foreclosure, Amount	136	140
Residential Mortgage Loans
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	807
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	961
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	2,568
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	1,771
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	341
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	7,396
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 13,844	13,096
Loans Receivable Residential Mortgage Percentage	100%
Residential Mortgage Loans | Performing
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 805
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	927
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	2,493
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	1,747
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	326
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	7,112
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 13,410
Loans Receivable Residential Mortgage Percentage	96.90%
Residential Mortgage Loans | Nonperforming
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 2
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	34
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	75
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	24
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	15
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	284
Financing Receivable, Revolving	0
Mortgage Loans, Gross	$ 434
Loans Receivable Residential Mortgage Percentage	3.10%
Agricultural Mortgage Loans
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 468
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	1,233
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	2,860
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	2,922
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	2,790
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	7,648
Financing Receivable, Revolving	1,548
Mortgage Loans, Gross	$ 19,469	$ 19,805
Loans Receivable Agricultural Mortgage Percentage	100%
Agricultural Mortgage Loans | Less than 65%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 459
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	1,177
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	2,792
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	2,602
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	2,639
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	7,090
Financing Receivable, Revolving	1,427
Mortgage Loans, Gross	$ 18,186
Loans Receivable Agricultural Mortgage Percentage	93.40%
Agricultural Mortgage Loans | 65% to 75%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 9
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	56
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	44
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	306
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	119
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	512
Financing Receivable, Revolving	104
Mortgage Loans, Gross	$ 1,150
Loans Receivable Agricultural Mortgage Percentage	5.90%
Agricultural Mortgage Loans | 76% to 80%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 0
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	0
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	24
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	0
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	3
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	0
Financing Receivable, Revolving	3
Mortgage Loans, Gross	$ 30
Loans Receivable Agricultural Mortgage Percentage	0.20%
Agricultural Mortgage Loans | Greater than 80%
Financing Receivable, Credit Quality Indicator [Line Items]
Financing Receivable, Year One, Originated, Current Fiscal Year	$ 0
Financing Receivable, Year Two, Originated, Fiscal Year before Current Fiscal Year	0
Financing Receivable, Year Three, Originated, Two Years before Current Fiscal Year	0
Financing Receivable, Year Four, Originated, Three Years before Current Fiscal Year	14
Financing Receivable, Year Five, Originated, Four Years before Current Fiscal Year	29
Financing Receivable, Originated, More than Five Years before Current Fiscal Year	46
Financing Receivable, Revolving	14
Mortgage Loans, Gross	$ 103
Loans Receivable Agricultural Mortgage Percentage	0.50%

Investments (Past Due and Inter

Investments (Past Due and Interest Accrual Status of Mortgage Loans) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	$ 91,262	$ 93,227
Greater than 90 Days Past Due and Still Accruing Interest	278	19
Financing Receivable, Nonaccrual	1,602	1,035
Financial Asset, Past Due
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	1,504	533
Commercial Mortgage Loans
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	57,949	60,326
Greater than 90 Days Past Due and Still Accruing Interest	16	3
Financing Receivable, Nonaccrual	1,072	427
Commercial Mortgage Loans | Financial Asset, Past Due
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	724	75
Residential Mortgage Loans
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	13,844	13,096
Greater than 90 Days Past Due and Still Accruing Interest	24	16
Financing Receivable, Nonaccrual	412	402
Residential Mortgage Loans | Financial Asset, Past Due
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	434	418
Agricultural Mortgage Loans
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	19,469	19,805
Greater than 90 Days Past Due and Still Accruing Interest	238	0
Financing Receivable, Nonaccrual	118	206
Agricultural Mortgage Loans | Financial Asset, Past Due
Financing Receivable, Nonaccrual [Line Items]
Mortgage Loans, Gross	$ 346	$ 40

Investments (Real Estate and Re

Investments (Real Estate and Real Estate Joint Ventures) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Real Estate [Line Items]
Leased real estate investments, Carrying Value	$ 4,536		$ 4,536		$ 4,446
Other real estate investments, Carrying Value	687		687		507
Real estate joint ventures, Carrying Value	8,508		8,508		8,379
Real Estate Investments, Net	13,731		13,731		$ 13,332
Income (Loss) from Equity Method Investments	201	$ 95	687	$ 174
Real Estate and Real Estate Joint Ventures
Real Estate [Line Items]
Gross Investment Income, Operating	178	96	268	259
Leased real estate
Real Estate [Line Items]
Operating Lease, Lease Income	$ 88	$ 89	$ 255	$ 271
Operating Lease, Lease Income	Revenues	Revenues	Revenues	Revenues
Other real estate
Real Estate [Line Items]
Operating Lease, Lease Income	$ 79	$ 71	$ 204	$ 206
Operating Lease, Lease Income		Revenues	Revenues	Revenues
REJV
Real Estate [Line Items]
Income (Loss) from Equity Method Investments	$ 11	$ (64)	$ (191)	$ (218)

Investments (Concentrations of

Investments (Concentrations of Credit Risk) (Details) - Foreign government - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Japan
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Fair Value, Concentration of Risk, Investments	$ 21,688	$ 22,606
Republic of Korea
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Fair Value, Concentration of Risk, Investments	6,654	6,411
MEXICO
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]
Fair Value, Concentration of Risk, Investments	$ 3,651	$ 3,778

Investments (Securities Lending

Investments (Securities Lending and Repurchase Agreements) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	$ 11,257	$ 10,788
Reinvestment portfolio - estimated fair value	11,178	10,553
Estimated fair value
Securities Financing Transaction [Line Items]
Securities loaned	11,079	10,510
Securities Sold under Agreements to Repurchase	3,010	3,029
Repurchase Agreements
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	2,975	2,975
Reinvestment portfolio - estimated fair value	$ 2,895	$ 2,913

Investments (Securities Lendi_2

Investments (Securities Lending and Repurchase Agreements Remaining Tenor) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	$ 11,257	$ 10,788
U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	9,831	9,418
Foreign government
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	1,250	1,107
Agency RMBS
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	176	263
Open (1)
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	2,295	1,393
Open (1) | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	2,295	1,393
Open (1) | Foreign government
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Open (1) | Agency RMBS
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
1 Month or Less
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	6,485	4,677
1 Month or Less | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	6,077	4,106
1 Month or Less | Foreign government
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	232	483
1 Month or Less | Agency RMBS
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	176	88
Over 1 Month to 6 Months
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	2,477	4,718
Over 1 Month to 6 Months | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	1,459	3,919
Over 1 Month to 6 Months | Foreign government
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	1,018	624
Over 1 Month to 6 Months | Agency RMBS
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	175
Over 6 Months to 1 Year
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Over 6 Months to 1 Year | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Over 6 Months to 1 Year | Foreign government
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Over 6 Months to 1 Year | Agency RMBS
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Repurchase Agreements
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	2,975	2,975
Repurchase Agreements | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	2,975	2,975
Repurchase Agreements | Open (1) | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Repurchase Agreements | 1 Month or Less | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	2,975	2,975
Repurchase Agreements | Over 1 Month to 6 Months | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	0	0
Repurchase Agreements | Over 6 Months to 1 Year | U.S. government and agency
Securities Financing Transaction [Line Items]
Cash collateral on deposit from counterparties	$ 0	$ 0

Investments (Invested Assets on

Investments (Invested Assets on Deposit, Held In Trust and Pledged as Collateral) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Investment Holdings, Other than Securities [Line Items]
Invested assets on deposit (regulatory deposits)	$ 1,584	$ 1,596
Invested assets held in trust (external reinsurance agreements) (1)	989	941
Invested assets pledged as collateral	29,423	26,017
Total invested assets on deposit, held in trust and pledged as collateral	31,996	28,554
Affiliated Entity
Investment Holdings, Other than Securities [Line Items]
Invested assets held in trust (external reinsurance agreements) (1)	$ 2,000	$ 2,000

Investments (Consolidated Varia

Investments (Consolidated Variable Interest Entities) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Variable Interest Entity [Line Items]
Total Assets	$ 704,976	$ 687,584
Total Liabilities	673,812	657,331
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Total Assets	755	346
Total Liabilities	181	1
Investment funds (primarily other invested assets and REJV) | Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Total Assets	691	282
Total Liabilities	181	1
Renewable energy partnership (primarily other invested assets) | Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Total Assets	64	64
Total Liabilities	$ 0	$ 0

Investments (Unconsolidated Var

Investments (Unconsolidated Variable Interest Entities) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Variable Interest Entity [Line Items]
Total Assets	$ 704,976	$ 687,584
Variable Interest Entity, Not Primary Beneficiary
Variable Interest Entity [Line Items]
Total Assets	75,886	70,461
Maximum Exposure to Loss	80,676	76,103
Variable Interest Entity, Not Primary Beneficiary | Fixed Maturity Securities
Variable Interest Entity [Line Items]
Total Assets	60,218	54,182
Maximum Exposure to Loss	60,218	54,182
Variable Interest Entity, Not Primary Beneficiary | Other limited partnership interests
Variable Interest Entity [Line Items]
Total Assets	13,300	14,034
Maximum Exposure to Loss	17,937	19,591
Variable Interest Entity, Not Primary Beneficiary | Other Investments
Variable Interest Entity [Line Items]
Total Assets	1,307	1,039
Maximum Exposure to Loss	1,324	1,055
Variable Interest Entity, Not Primary Beneficiary | Other invested assets
Variable Interest Entity [Line Items]
Total Assets	1,061	1,206
Maximum Exposure to Loss	$ 1,197	$ 1,275

Investments (Net Investment Inc

Investments (Net Investment Income) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net Investment Income [Line Items]
Less: Investment expenses	$ 571	$ 544	$ 1,703	$ 1,686
Net investment income	5,227	4,825	15,868	14,542
Securities Investment
Net Investment Income [Line Items]
Gross Investment Income, Operating	5,652	5,365	16,664	15,625
Net investment income	5,081	4,821	14,961	13,939
Fixed maturity securities AFS
Net Investment Income [Line Items]
Gross Investment Income, Operating	3,457	3,314	10,100	9,681
Equity Securities
Net Investment Income [Line Items]
Gross Investment Income, Operating	4	5	18	27
FVO securities
Net Investment Income [Line Items]
Net investment income	76	(17)	183	81
Mortgage loans
Net Investment Income [Line Items]
Gross Investment Income, Operating	1,184	1,189	3,565	3,536
Policy loans
Net Investment Income [Line Items]
Gross Investment Income, Operating	116	120	339	358
Real Estate and Real Estate Joint Ventures
Net Investment Income [Line Items]
Gross Investment Income, Operating	178	96	268	259
OLPI
Net Investment Income [Line Items]
Gross Investment Income, Operating	87	206	713	456
Cash, cash equivalents and short-term investments
Net Investment Income [Line Items]
Gross Investment Income, Operating	299	268	840	733
Operating joint ventures
Net Investment Income [Line Items]
Gross Investment Income, Operating	92	4	136	36
Other Investments
Net Investment Income [Line Items]
Gross Investment Income, Operating	159	180	502	458
Unit-linked investments
Net Investment Income [Line Items]
Net investment income	$ 146	$ 4	$ 907	$ 603

Investments (Supplemental Net I

Investments (Supplemental Net Investment Income) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net Investment Income [Line Items]
Net realized investment gains (losses) from sales and disposals of investments	$ 26	$ (234)	$ (170)	$ (721)
Changes in estimated fair value subsequent to purchase of equity securities still held at the end of the respective periods and recognized in net investment gains (losses)	(58)	(14)	(47)	44
Income (Loss) from Equity Method Investments	201	95	687	174
Net investment income
Net Investment Income [Line Items]
Net realized investment gains (losses) from sales and disposals of investments	65	47	199	126
Debt and Equity Securities, Unrealized Gain (Loss)	121	(80)	840	572
Debt and Equity Securities, Gain (Loss)	186	(33)	1,039	698
Unit-linked investments
Net Investment Income [Line Items]
Changes in estimated fair value subsequent to purchase of equity securities still held at the end of the respective periods and recognized in net investment gains (losses)	$ 209	$ (63)	$ 813	$ 506

Investments (Components of Net

Investments (Components of Net Investment Gains Losses - Asset Type) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Marketable Securities, Gain (Loss) [Abstract]
Fixed maturity securities AFS	$ (157)	$ (698)	$ (488)	$ (2,274)
Net investment gains (losses)	(31)	(14)	(22)	66
Other net investment gains (losses):
Mortgage loans	(151)	11	(246)	(194)
Real estate and real estate joint ventures (excluding changes in estimated fair value)	128	1	175	32
Other limited partnership interests (excluding changes in estimated fair value)	4	0	(55)	12
Other gains (losses)	(57)	(161)	(28)	(141)
Subtotal - investment portfolio gains (losses)	(264)	(861)	(664)	(2,499)
Change In Estimated Fair Value Of Other Limited Partnership Interests And Real Estate Joint Ventures	(1)	(3)	5	(6)
Non-investment portfolio gains (losses)	188	(63)	(214)	(145)
Subtotal	187	(66)	(209)	(151)
Net investment gains (losses)	$ (77)	$ (927)	$ (873)	$ (2,650)

Investments (Components of Ne_2

Investments (Components of Net Investment Gains Losses - Transaction Type) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Gain (Loss) on Securities [Line Items]
Realized gains (losses) on investments sold or disposed	$ (39)	$ (281)	$ (369)	$ (847)
Impairment (losses)	(17)	(591)	(17)	(1,496)
Change in ACL recognized in earnings	(150)	25	(231)	(199)
Unrealized net gains (losses) recognized in earnings	(59)	(17)	(42)	37
Total recognized gains (losses)	(209)	8	(273)	(162)
Non-investment portfolio gains (losses)	188	(63)	(214)	(145)
Net investment gains (losses)	$ (77)	$ (927)	(873)	$ (2,650)
Private Equity Funds
Gain (Loss) on Securities [Line Items]
Realized gains (losses) on investments sold or disposed			46
Portfolio of investments, amount sold			798
Proceeds from sale of equity method investment			$ 752

Investments (Supplemental Net_2

Investments (Supplemental Net Investment Gains (Losses)) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net Investment Income [Line Items]
Changes in estimated fair value subsequent to purchase of equity securities still held at the end of the respective periods and recognized in net investment gains (losses)	$ (58)	$ (14)	$ (47)	$ 44
Realized gains (losses) on investments sold or disposed	(39)	(281)	(369)	(847)
Foreign currency gains (losses)	170	(21)	5	(7)
Net realized investment gains (losses) from sales and disposals of investments	26	(234)	(170)	(721)
Net investment income
Net Investment Income [Line Items]
Net realized investment gains (losses) from sales and disposals of investments	65	47	199	126
Cash Flow Hedging
Net Investment Income [Line Items]
Realized gains (losses) on investments sold or disposed	0	2	0	(20)
Equity Securities
Net Investment Income [Line Items]
Changes in estimated fair value subsequent to purchase of equity securities still held at the end of the respective periods and recognized in net investment gains (losses)	$ (36)	$ (10)	$ (23)	$ 9

Investments (Fixed Maturity S_2

Investments (Fixed Maturity Securities AFS - Sales and Disposals and Credit Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Debt Securities, Available-for-sale [Line Items]
Proceeds	$ 6,815	$ 9,263	$ 21,273	$ 32,719
Gross investment gains	111	63	388	429
Gross investment (losses)	(228)	(334)	(898)	(1,403)
Realized gains (losses) on sales and disposals	(117)	(271)	(510)	(974)
Net credit loss (provision) release (change in ACL recognized in earnings)	(40)	17	22	0
Impairment (losses)	0	(444)	0	(1,300)
Net credit loss (provision) release and impairment (losses)	(40)	(427)	22	(1,300)
Net investment gains (losses)	(39)	(281)	(369)	(847)
Equity securities	27	0	25	22
Changes in estimated fair value subsequent to purchase of equity securities still held at the end of the respective periods and recognized in net investment gains (losses)	(58)	(14)	(47)	44
Net investment gains (losses)	(31)	(14)	(22)	66
Fixed Maturity Securities
Debt Securities, Available-for-sale [Line Items]
Net investment gains (losses)	$ (157)	$ (698)	$ (488)	$ (2,274)

Investments (Fixed Maturity S_3

Investments (Fixed Maturity Securities AFS - Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]
Estimated Fair Value of Fixed Maturity Securities AFS	$ 293,779	$ 281,412
Gross Unrealized Gains (Losses)	$ (23,558)	$ (25,835)

Investments (Evaluation of Fixe

Investments (Evaluation of Fixed Maturity Securities AFS in an Unrealized Loss Position- Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	$ 23,500
Equal to or Greater than 12 Months Gross Unrealized Loss	21,852	$ 24,394
Below Investment Grade
Debt Securities, Available-for-sale [Line Items]
Equal to or Greater than 12 Months Gross Unrealized Loss	596	$ 719
Fixed maturity securities without an allowance for credit loss
Debt Securities, Available-for-sale [Line Items]
Change in Gross Unrealized Temporary Loss	$ 2,300

Investments (Mortgage Loans - N

Investments (Mortgage Loans - Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums	$ (863)		$ (863)		$ (736)
Financing Receivable, Purchase	753	$ 221	1,500	$ 1,200
Financing Receivable, Sale	$ 168		168
Mortgage Loans Contributed To Joint Ventures			$ 218
Percentage of Mortgage Loans Classified as Performing	98%		98%		99%
Commercial Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest Receivable	$ 269		$ 269		$ 277
Amortized Cost of Mortgage Loans Delinquent during the period			182
Residential Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest Receivable	104		104		95
Agricultural Mortgage Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest Receivable	$ 189		$ 189		$ 204

Investments (Real Estate and _2

Investments (Real Estate and Real Estate Joint ventures - Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Investments, All Other Investments [Abstract]
Real Estate Acquired Through Foreclosure	$ 264		$ 264		$ 190
Depreciation	32	$ 26	91	$ 84
Real Estate Investment Property, Net	$ 1,000		$ 1,000		$ 952

Investments (Tax Equity Investm

Investments (Tax Equity Investments - Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Carrying Value of Tax Equity Investments	$ 737	$ 737	$ 1,000
Income Tax credits and other income tax benefits	37	112
Tax Equity Investments Amortization Expense	$ 33	$ 100

Investments (Cash Equivalents -

Investments (Cash Equivalents - Narrative) (Details) - USD ($) $ in Billions	Sep. 30, 2024	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Cash equivalents	$ 12.1	$ 10.8

Investments (Invested Assets _2

Investments (Invested Assets on Deposit, Held in Trust and Pledged as Collateral - Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Federal Home Loan Bank Stock	$ 715	$ 714

Derivatives (Primary Risks) (De

Derivatives (Primary Risks) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	$ 290,446		$ 290,446		$ 301,234
Estimated Fair Value Assets	8,172		8,172		8,737
Estimated Fair Value Liabilities	6,357		6,357		6,298
Gain (Loss) on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net	10	$ 1	4	$ 28
Accumulated Other Comprehensive Income Loss	(457)		(457)		166
Cash Flow Hedges [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0	0	0	0
Cash Flow Hedges [Member] | Foreign currency swaps
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0	0	0	0
Cash Flow Hedges [Member] | Interest Rate Contract
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0	0	0	0
Not Designated as Hedging Instrument, Economic Hedge | Derivative Contract [Domain]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net			(395)	(740)
Derivatives Designated as Hedging Instruments:
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	65,637		65,637		64,155
Estimated Fair Value Assets	4,113		4,113		4,215
Estimated Fair Value Liabilities	3,467		3,467		3,320
Derivatives Designated as Hedging Instruments: | Fair Value Hedges [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	7,202		7,202		6,475
Estimated Fair Value Assets	1,177		1,177		1,312
Estimated Fair Value Liabilities	630		630		600
Derivatives Designated as Hedging Instruments: | Fair Value Hedges [Member] | Interest rate swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	5,188		5,188		4,550
Estimated Fair Value Assets	1,134		1,134		1,257
Estimated Fair Value Liabilities	554		554		535
Derivatives Designated as Hedging Instruments: | Fair Value Hedges [Member] | Foreign currency swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	1,664		1,664		1,475
Estimated Fair Value Assets	43		43		55
Estimated Fair Value Liabilities	7		7		0
Derivatives Designated as Hedging Instruments: | Fair Value Hedges [Member] | Foreign currency forwards
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	350		350		450
Estimated Fair Value Assets	0		0		0
Estimated Fair Value Liabilities	69		69		65
Derivatives Designated as Hedging Instruments: | Cash Flow Hedges [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	55,230		55,230		54,177
Estimated Fair Value Assets	2,517		2,517		2,509
Estimated Fair Value Liabilities	2,837		2,837		2,712
Derivatives Designated as Hedging Instruments: | Cash Flow Hedges [Member] | Interest rate swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	4,155		4,155		4,156
Estimated Fair Value Assets	0		0		1
Estimated Fair Value Liabilities	259		259		265
Derivatives Designated as Hedging Instruments: | Cash Flow Hedges [Member] | Interest rate forwards
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	5,090		5,090		6,115
Estimated Fair Value Assets	59		59		51
Estimated Fair Value Liabilities	923		923		938
Derivatives Designated as Hedging Instruments: | Cash Flow Hedges [Member] | Foreign currency swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	45,985		45,985		43,906
Estimated Fair Value Assets	2,458		2,458		2,457
Estimated Fair Value Liabilities	1,655		1,655		1,509
Derivatives Designated as Hedging Instruments: | Foreign Operations Hedges [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	3,205		3,205		3,503
Estimated Fair Value Assets	419		419		394
Estimated Fair Value Liabilities	0		0		8
Derivatives Designated as Hedging Instruments: | Foreign Operations Hedges [Member] | Foreign currency forwards
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	205		205		503
Estimated Fair Value Assets	7		7		0
Estimated Fair Value Liabilities	0		0		8
Derivatives Designated as Hedging Instruments: | Foreign Operations Hedges [Member] | Currency options
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	3,000		3,000		3,000
Estimated Fair Value Assets	412		412		394
Estimated Fair Value Liabilities	0		0		0
Derivatives Not Designated or Not Qualifying as Hedging Instruments:
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	224,809		224,809		237,079
Estimated Fair Value Assets	4,059		4,059		4,522
Estimated Fair Value Liabilities	2,890		2,890		2,978
Derivative, Gain (Loss) on Derivative, Net	673	$ (1,538)	(1,253)	$ (3,198)
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	29,675		29,675		29,801
Estimated Fair Value Assets	1,654		1,654		1,497
Estimated Fair Value Liabilities	1,062		1,062		1,102
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate forwards
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	2,934		2,934		2,383
Estimated Fair Value Assets	130		130		69
Estimated Fair Value Liabilities	76		76		36
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate floors
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	9,228		9,228		15,321
Estimated Fair Value Assets	48		48		41
Estimated Fair Value Liabilities	0		0		0
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate caps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	29,052		29,052		30,016
Estimated Fair Value Assets	130		130		373
Estimated Fair Value Liabilities	1		1		0
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate futures
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	1,732		1,732		1,243
Estimated Fair Value Assets	2		2		1
Estimated Fair Value Liabilities	2		2		5
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Interest rate options
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	43,481		43,481		43,926
Estimated Fair Value Assets	269		269		385
Estimated Fair Value Liabilities	119		119		103
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Synthetic GICs
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	49,081		49,081		49,066
Estimated Fair Value Assets	0		0		0
Estimated Fair Value Liabilities	0		0		0
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Foreign currency swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	10,755		10,755		11,891
Estimated Fair Value Assets	981		981		1,200
Estimated Fair Value Liabilities	231		231		356
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Foreign currency forwards
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	13,511		13,511		14,128
Estimated Fair Value Assets	283		283		310
Estimated Fair Value Liabilities	961		961		806
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Currency futures
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	321		321		314
Estimated Fair Value Assets	2		2		2
Estimated Fair Value Liabilities	0		0		0
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Currency options
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	0		0		50
Estimated Fair Value Assets	0		0		0
Estimated Fair Value Liabilities	0		0		0
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Credit default swaps — purchased
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	2,801		2,801		2,877
Estimated Fair Value Assets	4		4		3
Estimated Fair Value Liabilities	74		74		79
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Credit default swaps — written
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	12,851		12,851		12,468
Estimated Fair Value Assets	267		267		233
Estimated Fair Value Liabilities	2		2		5
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Equity futures
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	1,866		1,866		2,163
Estimated Fair Value Assets	13		13		8
Estimated Fair Value Liabilities	6		6		11
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Equity index options
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	14,106		14,106		19,421
Estimated Fair Value Assets	276		276		399
Estimated Fair Value Liabilities	263		263		255
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Equity variance swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	114		114		99
Estimated Fair Value Assets	0		0		0
Estimated Fair Value Liabilities	3		3		2
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Equity total return swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	2,301		2,301		1,912
Estimated Fair Value Assets	0		0		1
Estimated Fair Value Liabilities	90		90		218
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Longevity Swaps
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	1,000		1,000		0
Derivative Liability, Not Subject to Master Netting Arrangement	0		0		0
Derivative Asset, Not Subject to Master Netting Arrangement	0		0		0
Derivatives Not Designated or Not Qualifying as Hedging Instruments: | Derivatives hedging MRBs
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	14,328		14,328		15,001
Estimated Fair Value Assets	127		127		112
Estimated Fair Value Liabilities	797		797		1,038
Not Designated as Hedging Instrument, Economic Hedge | Interest Rate Contract
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	9,092		9,092		9,096
Estimated Fair Value Assets	13		13		13
Estimated Fair Value Liabilities	603		603		663
Not Designated as Hedging Instrument, Economic Hedge | Foreign currency exchange rate
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	577		577		716
Estimated Fair Value Assets	20		20		22
Estimated Fair Value Liabilities	1		1		2
Not Designated as Hedging Instrument, Economic Hedge | Equity
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	4,659		4,659		5,189
Estimated Fair Value Assets	94		94		77
Estimated Fair Value Liabilities	$ 193		$ 193		$ 373

Derivatives (Effects on the Con

Derivatives (Effects on the Consolidated Statement of Operations and Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	$ 5,227	$ 4,825	$ 15,868	$ 14,542
Net investment gains (losses)	(77)	(927)	(873)	(2,650)
Gain (Loss) on Derivative Instruments, Net, Pretax	(767)	1,202	720	2,289
Policyholder Benefits and Claims Incurred, Net	(10,597)	(11,130)	(32,156)	(32,811)
Interest credited to PABs	(2,037)	(1,658)	(6,327)	(5,455)
Operating Expenses	3,263	3,204	9,660	9,394
Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	10	8	46	34
Derivative, Gain (Loss) on Derivative, Net	(673)	1,538	1,253	3,198
Operating Expenses	0	0	0	0
Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	1	1	1	1
Net investment gains (losses)	(4)	(7)	(15)	(19)
Policyholder Benefits and Claims Incurred, Net	(6)	(7)	(19)	(21)
Interest credited to PABs	(3)	(2)	(2)	(1)
Operating Expenses	0	0	0	0
Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	6	12	22	41
Net investment gains (losses)	16	4	(11)	85
Derivative, Gain (Loss) on Derivative, Net	0	0	0	0
Interest credited to PABs	0	0	0	0
Operating Expenses	0	1	0	2
Other Comprehensive Income (Loss), before Tax	(482)	(733)	(623)	(1,215)
Net Investment Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment gains (losses)	0	5	0	5
Other Comprehensive Income (Loss), before Tax	(174)	84	207	317
Foreign Exchange Forward [Member] | Net Investment Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), before Tax				280
Designated as Hedging Instrument [Member] | Net Investment Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment gains (losses)	0	5	0	5
Other Comprehensive Income (Loss), before Tax	(141)	74	203
Interest Rate Contract | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	5	11	18	38
Net investment gains (losses)	(1)	17	(2)	77
Derivative, Gain (Loss) on Derivative, Net	0	0	0	0
Policyholder Benefits and Claims Incurred, Net	0	0	0	0
Interest credited to PABs	0	0	0	0
Operating Expenses	0	0	0	0
Other Comprehensive Income (Loss), before Tax	(4)	(28)	(16)	(115)
Credit forwards [Member] | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	0	0	0	0
Net investment gains (losses)	0	0	1	0
Derivative, Gain (Loss) on Derivative, Net	0	0	0	0
Policyholder Benefits and Claims Incurred, Net	0	0	0	0
Interest credited to PABs	0	0	0	0
Operating Expenses	0	0	0	0
Other Comprehensive Income (Loss), before Tax	0	0	(1)	0
Currency Swap [Member] | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	1	1	4	3
Net investment gains (losses)	602	(301)	226	10
Derivative, Gain (Loss) on Derivative, Net	0	0	0	0
Policyholder Benefits and Claims Incurred, Net	0	0	0	0
Interest credited to PABs	0	0	0	0
Operating Expenses	0	1	0	2
Other Comprehensive Income (Loss), before Tax	(603)	299	(230)	(15)
Derivative [Member] | Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	0	0	0	0
Net investment gains (losses)	(15)	(2)	(11)	(2)
Policyholder Benefits and Claims Incurred, Net	0	0	0	0
Interest credited to PABs	0	0	0	0
Operating Expenses	0	0	0	0
Derivative [Member] | Interest rate swaps | Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	1	2	1	3
Net investment gains (losses)	0	0	0	0
Policyholder Benefits and Claims Incurred, Net	(185)	230	(35)	239
Interest credited to PABs	(92)	(60)	(34)	(59)
Operating Expenses	0	0	0	0
Derivative [Member] | Currency Swap [Member] | Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	23	12	21	10
Net investment gains (losses)	41	(19)	(16)	(73)
Policyholder Benefits and Claims Incurred, Net	0	0	0	0
Interest credited to PABs	(32)	(27)	(1)	(14)
Operating Expenses	0	0	0	0
Debt Securities [Member] | Interest rate swaps | Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	1	3	1	3
Net investment gains (losses)	0	0	0	0
Policyholder Benefits and Claims Incurred, Net	(191)	223	(54)	218
Interest credited to PABs	(93)	(59)	(38)	(57)
Operating Expenses	0	0	0	0
Debt Securities [Member] | Currency Swap [Member] | Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	22	12	22	9
Net investment gains (losses)	(30)	14	12	56
Policyholder Benefits and Claims Incurred, Net	0	0	0	0
Interest credited to PABs	(34)	(26)	(1)	(15)
Operating Expenses	0	0	0	0
Non-derivative [Domain] [Member] | Net Investment Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), before Tax	(33)	10	4	37
Foreign Currency Gain (Loss) [Member] | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	0	0	0	0
Net investment gains (losses)	(585)	288	(236)	(2)
Derivative, Gain (Loss) on Derivative, Net	0	0	0	0
Policyholder Benefits and Claims Incurred, Net	0	0	0	0
Interest credited to PABs	0	0	0	0
Operating Expenses	0	0	0	0
Other Comprehensive Income (Loss), before Tax	0	0	0	0
Accumulated Other Comprehensive Income (Loss) | Credit forwards [Member] | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), before Tax	0	0	0	(1)
Accumulated Other Comprehensive Income (Loss) | Currency Swap [Member] | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), before Tax	(161)	(293)	(180)	(715)
Accumulated Other Comprehensive Income (Loss) | Interest rate swaps | Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), before Tax	286	(711)	(196)	(369)
Foreign Exchange [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	0	0	0	0
Derivative, Gain (Loss) on Derivative, Net	(573)	556	697	1,518
Credit derivatives — purchased | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	0	0	0	0
Derivative, Gain (Loss) on Derivative, Net	8	(30)	6	1
Credit derivatives — written | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	0	0	0	0
Derivative, Gain (Loss) on Derivative, Net	(25)	40	(47)	(48)
Equity Market Risk [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	10	8	46	34
Derivative, Gain (Loss) on Derivative, Net	95	(120)	545	801
Interest Rate Risk [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	0	0	0	0
Derivative, Gain (Loss) on Derivative, Net	(360)	1,105	211	1,381
Foreign Currency Gain (Loss) [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	0	0	0	0
Derivative, Gain (Loss) on Derivative, Net	182	(13)	(159)	(455)
Net Derivative Gain (Loss) [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	33	82	116	157
Net investment gains (losses)	0	$ 0	0	$ 0
Derivative, Gain (Loss) on Derivative, Net	(136)		(497)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]		Gain (Loss) on Derivative Instruments, Net, Pretax		Gain (Loss) on Derivative Instruments, Net, Pretax
Policyholder Benefits and Claims Incurred, Net	5	$ 3	11	$ (5)
Interest credited to PABs	(36)	(43)	(129)	(111)
Other Comprehensive Income (Loss), before Tax	0	0	0	0
Net Embedded Derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Derivative Instruments, Net, Pretax	(61)	86	(21)	51
Synthetic GICs [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Gain (Loss) on Derivative, Net	(19)		(57)
Gain (Loss) on Derivative Instruments, Net, Pretax		(20)		(56)
Effects of Derivatives on Consolidated Statements of Operations and Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Net investment income	28	103	93	163
Net investment gains (losses)	12	2	(26)	71
Derivative, Gain (Loss) on Derivative, Net	(767)	1,202	720	2,289
Policyholder Benefits and Claims Incurred, Net	11	10	30	16
Interest credited to PABs	39	45	131	112
Operating Expenses	0	1	0	2
Other Comprehensive Income (Loss), before Tax	$ (656)	$ (649)	$ (416)	$ (898)

Derivatives (Fair Value Hedges)

Derivatives (Fair Value Hedges) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Collateral, Right to Reclaim Cash	$ 93	$ 98
Fixed maturity securities AFS | Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Hedged Asset, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)	(96)	(111)
Debt Instruments, Carrying Amount	388	454
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease)	0	3
Mortgages | Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt Instruments, Carrying Amount	305	359
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease)	(2)	(11)
Future policy benefits [Member] | Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt Instruments, Carrying Amount	2,750	2,863
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease)	151	191
Policyholder Account Balances [Member] | Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Debt Instruments, Carrying Amount	2,438	1,911
Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease)	$ 43	$ 25

Derivatives (Cash Flow Hedges)

Derivatives (Cash Flow Hedges) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Discontinuation of Cash Flow Hedge Due to Forecasted Transaction Probable of Not Occurring, Net	$ 10	$ 1	$ 4	$ 28
Accumulated Other Comprehensive Income Loss	$ (457)		$ (457)		$ 166

Derivatives (Hedges of Net Inve

Derivatives (Hedges of Net Investments in Foreign Operations) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives used in Net Investment Hedge, Net of Tax	$ 888	$ 681
Debt Designated as Non-derivative Hedging Instrument	$ 294	$ 298

Derivatives (Credit Derivatives

Derivatives (Credit Derivatives) (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 265	$ 228
Maximum Amount of Future Payments under Credit Default Swaps	$ 12,851	$ 12,468
Weighted Average Years to Maturity	4 years 1 month 6 days	4 years 6 months
Aaa/Aa/A
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 84	$ 82
Maximum Amount of Future Payments under Credit Default Swaps	$ 4,364	$ 3,980
Weighted Average Years to Maturity	2 years 4 months 24 days	2 years 7 months 6 days
Aaa/Aa/A | Single name credit default swaps (3)
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 1	$ 2
Maximum Amount of Future Payments under Credit Default Swaps	$ 103	$ 150
Weighted Average Years to Maturity	1 year 3 months 18 days	1 year 7 months 6 days
Aaa/Aa/A | Credit default swaps referencing indices
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 83	$ 80
Maximum Amount of Future Payments under Credit Default Swaps	$ 4,261	$ 3,830
Weighted Average Years to Maturity	2 years 4 months 24 days	2 years 8 months 12 days
Baa
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 170	$ 146
Maximum Amount of Future Payments under Credit Default Swaps	$ 8,287	$ 8,287
Weighted Average Years to Maturity	5 years	5 years 3 months 18 days
Baa | Single name credit default swaps (3)
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 1	$ 1
Maximum Amount of Future Payments under Credit Default Swaps	$ 92	$ 99
Weighted Average Years to Maturity	1 year 7 months 6 days	2 years 1 month 6 days
Baa | Credit default swaps referencing indices
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 169	$ 145
Maximum Amount of Future Payments under Credit Default Swaps	$ 8,195	$ 8,188
Weighted Average Years to Maturity	5 years	5 years 4 months 24 days
B
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 10	$ 2
Maximum Amount of Future Payments under Credit Default Swaps	$ 144	$ 129
Weighted Average Years to Maturity	3 years 10 months 24 days	5 years
B | Credit default swaps referencing indices
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 10	$ 2
Maximum Amount of Future Payments under Credit Default Swaps	$ 144	$ 129
Weighted Average Years to Maturity	3 years 10 months 24 days	5 years
Caa
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ (1)	$ (4)
Maximum Amount of Future Payments under Credit Default Swaps	$ 15	$ 30
Weighted Average Years to Maturity	2 years 2 months 12 days	2 years 6 months
Caa | Credit default swaps referencing indices
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ (1)	$ (4)
Maximum Amount of Future Payments under Credit Default Swaps	$ 15	$ 30
Weighted Average Years to Maturity	2 years 2 months 12 days	2 years 6 months
Ba
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 2	$ 2
Maximum Amount of Future Payments under Credit Default Swaps	$ 41	$ 42
Weighted Average Years to Maturity	1 year 10 months 24 days	2 years 7 months 6 days
Ba | Single name credit default swaps (3)
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 0	$ 0
Maximum Amount of Future Payments under Credit Default Swaps	$ 17	$ 17
Weighted Average Years to Maturity	1 year 4 months 24 days	2 years 1 month 6 days
Ba | Credit default swaps referencing indices
Credit Derivatives [Line Items]
Estimated Fair Value of Credit Default Swaps	$ 2	$ 2
Maximum Amount of Future Payments under Credit Default Swaps	$ 24	$ 25
Weighted Average Years to Maturity	2 years 2 months 12 days	3 years

Derivatives (Estimated Fair Val

Derivatives (Estimated Fair Value of Derivative Assets and Liabilities after Master Netting Agreements and Cash Collateral) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Offsetting Assets [Line Items]
Estimated fair value of derivative assets presented in the consolidated balance sheets	$ 8,319	$ 8,918
Estimated fair value of derivative liabilities presented in the consolidated balance sheets	6,304	6,307
Net amount of derivative assets after application of master netting agreements and cash collateral	106	183
Net amount of derivative liabilities after application of master netting agreements and cash collateral	8	19
Over the Counter [Member]
Offsetting Assets [Line Items]
Gross estimated fair value of derivative assets	8,111	8,749
Gross estimated fair value of derivative liabilities	6,036	6,014
Gross estimated fair value of derivative assets	(3,035)	(3,568)
Gross estimated fair value of derivative liabilities	(3,035)	(3,568)
Cash collateral on derivative assets	(2,676)	(3,448)
Cash collateral on derivative liabilities	0	0
Securities collateral on derivative assets	(2,313)	(1,563)
Securities collateral on derivative liabilities	(2,993)	(2,427)
Cleared [Member]
Offsetting Assets [Line Items]
Gross estimated fair value of derivative assets	191	158
Gross estimated fair value of derivative liabilities	260	277
Gross estimated fair value of derivative assets	(5)	(5)
Gross estimated fair value of derivative liabilities	(5)	(5)
Cash collateral on derivative assets	(181)	(150)
Cash collateral on derivative liabilities	(237)	(239)
Securities collateral on derivative assets	0	0
Securities collateral on derivative liabilities	(18)	(33)
Exchange-traded
Offsetting Assets [Line Items]
Gross estimated fair value of derivative assets	17	11
Gross estimated fair value of derivative liabilities	8	16
Gross estimated fair value of derivative assets	(3)	(1)
Gross estimated fair value of derivative liabilities	(3)	(1)
Cash collateral on derivative assets	0	0
Cash collateral on derivative liabilities	(4)	(5)
Securities collateral on derivative assets	0	0
Securities collateral on derivative liabilities	$ (1)	$ (10)

Derivatives (Credit Risk on Fre

Derivatives (Credit Risk on Freestanding Derivatives) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Credit Derivatives [Line Items]
Estimated fair value of derivatives in a net liability position (1)	$ 3,001	$ 2,447
Derivative, Collateral, Right to Reclaim Cash	93	98
Derivative Asset, Fair Value, Amount Not Offset Against Collateral	8,319	8,918
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	6,304	6,307
Derivative Asset, Fair Value, Amount Offset Against Collateral	106	183
Derivative Liability, Fair Value, Amount Offset Against Collateral	8	19
Derivative assets	8,172	8,737
Derivative liabilities	6,357	6,298
Derivative, Collateral, Obligation to Return Cash	43	163
Collateral Amount Not Provided Due to Downgrade Threshold	15
Customer Securities for which Entity has Right to Sell or Repledge, Fair Value of Securities Sold or Repledged	0
Exchange Traded [Member]
Credit Derivatives [Line Items]
Derivative, Collateral, Right to Reclaim Securities	181	137
Gross estimated fair value of derivative assets	17	11
Gross estimated fair value of derivative liabilities	8	16
Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset	(3)	(1)
Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset	(3)	(1)
Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash, Offset Against Derivative Asset	0	0
Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Offset	(4)	(5)
Derivative Asset, Collateral, Obligation to Return Securities, Offset	0	0
Derivative Liability, Collateral, Right to Reclaim Securities, Offset	(1)	(10)
Over the Counter [Member]
Credit Derivatives [Line Items]
Derivative, Collateral, Right to Reclaim Securities	1,500	1,500
Gross estimated fair value of derivative assets	8,111	8,749
Gross estimated fair value of derivative liabilities	6,036	6,014
Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset	(3,035)	(3,568)
Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset	(3,035)	(3,568)
Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash, Offset Against Derivative Asset	(2,676)	(3,448)
Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Offset	0	0
Derivative Asset, Collateral, Obligation to Return Securities, Offset	(2,313)	(1,563)
Derivative Liability, Collateral, Right to Reclaim Securities, Offset	(2,993)	(2,427)
Derivative, Collateral, Obligation to Return Securities	441	298
Exchange Cleared [Member]
Credit Derivatives [Line Items]
Derivative, Collateral, Right to Reclaim Securities	891	945
Gross estimated fair value of derivative assets	191	158
Gross estimated fair value of derivative liabilities	260	277
Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset	(5)	(5)
Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset	(5)	(5)
Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash, Offset Against Derivative Asset	(181)	(150)
Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Offset	(237)	(239)
Derivative Asset, Collateral, Obligation to Return Securities, Offset	0	0
Derivative Liability, Collateral, Right to Reclaim Securities, Offset	(18)	(33)
Fixed maturity securities AFS
Credit Derivatives [Line Items]
Estimated fair value of collateral provided:	3,665	3,017
Accrued Liabilities [Member]
Credit Derivatives [Line Items]
Derivative assets	147	181
Derivative liabilities	(53)	9
Derivatives Subject to Credit- Contingent Provisions
Credit Derivatives [Line Items]
Estimated fair value of derivatives in a net liability position (1)	2,954	2,443
Derivatives Subject to Credit- Contingent Provisions | Fixed maturity securities AFS
Credit Derivatives [Line Items]
Estimated fair value of collateral provided:	3,612	3,011
Derivatives Not Subject to Credit- Contingent Provisions
Credit Derivatives [Line Items]
Estimated fair value of derivatives in a net liability position (1)	47	4
Derivatives Not Subject to Credit- Contingent Provisions | Fixed maturity securities AFS
Credit Derivatives [Line Items]
Estimated fair value of collateral provided:	$ 53	$ 6

Derivatives (Embedded Derivativ

Derivatives (Embedded Derivatives) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Derivatives, Fair Value [Line Items]
Total	$ (119)	$ (93)
Funds withheld and guarantees on reinsurance | Other liabilities
Derivatives, Fair Value [Line Items]
Total	(53)	(70)
Fixed annuities with equity indexed returns [Member] | Policyholder account balances
Derivatives, Fair Value [Line Items]
Total	$ (172)	$ (163)

Derivatives (Narrative) (Detail

Derivatives (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Derivatives, Fair Value [Line Items]
Collateral Amount Not Provided Due to Downgrade Threshold	$ 15		$ 15
Derivative Instrument Detail [Abstract]
Net amounts reclassified into net derivatives gains (losses) on discontinued cash flow hedges	10	$ 1	$ 4	$ 28
Hedging exposure to variability in future cash flows for specific length of time			5 years		5 years
Accumulated Other Comprehensive Income Loss	(457)		$ (457)		$ 166
Cumulative foreign currency translation gain (loss) recorded in accumulated other comprehensive income (loss) for net investment in foreign operations hedges	888		888		681
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months			(46)
Debt Designated as Non-derivative Hedging Instrument	$ 294		$ 294		$ 298

Fair Value (Recurring Fair Valu

Fair Value (Recurring Fair Value Measurements) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	$ 293,779	$ 281,412
Equity securities	746	757
Unit-linked and FVO securities	9,289	10,331
Short-term investments	4,609	6,045
Derivative assets	8,172	8,737
Market risk benefits, at estimated fair value	310	286
Separate account assets	148,809	144,634
Liabilities [Abstract]
Derivative liabilities	6,357	6,298
Embedded derivatives within liability host contracts	119	93
Market risk benefits, at estimated fair value	3,117	3,179
Separate account liabilities	148,809	144,634
Recurring
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	293,779	281,412
Equity securities	746	757
Unit-linked and FVO securities	9,289	10,331
Short-term investments	4,337	5,797
Other investments	3,155	1,386
Derivative assets	8,172	8,737
Market risk benefits, at estimated fair value	310	286
Reinsured MRB Assets	16	18
Separate account assets	148,809	144,634
Total assets	468,613	453,358
Investments, fair value	51	52
Liabilities [Abstract]
Derivative liabilities	6,357	6,298
Embedded derivatives within liability host contracts	119	93
Market risk benefits, at estimated fair value	3,117	3,179
Total liabilities	9,598	9,578
Recurring | Interest rate
Assets [Abstract]
Derivative assets	3,426	3,675
Liabilities [Abstract]
Derivative liabilities	2,996	2,984
Recurring | Foreign currency exchange rate contracts
Assets [Abstract]
Derivative assets	4,186	4,418
Liabilities [Abstract]
Derivative liabilities	2,923	2,744
Recurring | Credit
Assets [Abstract]
Derivative assets	271	236
Liabilities [Abstract]
Derivative liabilities	76	84
Recurring | Equity market contracts
Assets [Abstract]
Derivative assets	289	408
Liabilities [Abstract]
Derivative liabilities	362	486
Recurring | Separate account liabilities
Liabilities [Abstract]
Separate account liabilities	5	8
Recurring | U.S. corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	84,851	80,717
Recurring | Foreign corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	56,752	55,444
Recurring | Foreign government
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	44,132	45,489
Recurring | U.S. government and agency
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	34,676	32,252
Recurring | RMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	35,264	29,096
Recurring | ABS & CLO
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	17,520	17,294
Recurring | Municipals
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	10,798	11,171
Recurring | CMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	9,786	9,949
Recurring | Level 1
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	16,650	15,330
Equity securities	430	429
Unit-linked and FVO securities	7,846	7,520
Short-term investments	3,155	5,103
Other investments	44	48
Derivative assets	17	11
Market risk benefits, at estimated fair value	0	0
Reinsured MRB Assets	0	0
Separate account assets	69,799	66,229
Total assets	97,941	94,670
Liabilities [Abstract]
Derivative liabilities	8	16
Embedded derivatives within liability host contracts	0	0
Market risk benefits, at estimated fair value	0	0
Total liabilities	8	20
Recurring | Level 1 | Interest rate
Assets [Abstract]
Derivative assets	2	1
Liabilities [Abstract]
Derivative liabilities	2	5
Recurring | Level 1 | Foreign currency exchange rate contracts
Assets [Abstract]
Derivative assets	2	2
Liabilities [Abstract]
Derivative liabilities	0	0
Recurring | Level 1 | Credit
Assets [Abstract]
Derivative assets	0	0
Liabilities [Abstract]
Derivative liabilities	0	0
Recurring | Level 1 | Equity market contracts
Assets [Abstract]
Derivative assets	13	8
Liabilities [Abstract]
Derivative liabilities	6	11
Recurring | Level 1 | Separate account liabilities
Liabilities [Abstract]
Separate account liabilities	0	4
Recurring | Level 1 | U.S. corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 1 | Foreign corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 1 | Foreign government
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 1 | U.S. government and agency
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	16,650	15,327
Recurring | Level 1 | RMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	3
Recurring | Level 1 | ABS & CLO
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 1 | Municipals
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 1 | CMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 2
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	241,373	233,135
Equity securities	74	79
Unit-linked and FVO securities	267	1,708
Short-term investments	1,176	667
Other investments	2,016	363
Derivative assets	8,126	8,688
Market risk benefits, at estimated fair value	0	0
Reinsured MRB Assets	0	0
Separate account assets	77,991	77,258
Total assets	331,023	321,898
Liabilities [Abstract]
Derivative liabilities	6,344	6,101
Embedded derivatives within liability host contracts	0	0
Market risk benefits, at estimated fair value	0	0
Total liabilities	6,349	6,105
Recurring | Level 2 | Interest rate
Assets [Abstract]
Derivative assets	3,424	3,674
Liabilities [Abstract]
Derivative liabilities	2,994	2,805
Recurring | Level 2 | Foreign currency exchange rate contracts
Assets [Abstract]
Derivative assets	4,159	4,393
Liabilities [Abstract]
Derivative liabilities	2,918	2,737
Recurring | Level 2 | Credit
Assets [Abstract]
Derivative assets	271	228
Liabilities [Abstract]
Derivative liabilities	76	84
Recurring | Level 2 | Equity market contracts
Assets [Abstract]
Derivative assets	272	393
Liabilities [Abstract]
Derivative liabilities	356	475
Recurring | Level 2 | Separate account liabilities
Liabilities [Abstract]
Separate account liabilities	5	4
Recurring | Level 2 | U.S. corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	70,349	67,003
Recurring | Level 2 | Foreign corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	41,047	40,813
Recurring | Level 2 | Foreign government
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	44,091	45,438
Recurring | Level 2 | U.S. government and agency
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	18,026	16,925
Recurring | Level 2 | RMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	33,367	27,495
Recurring | Level 2 | ABS & CLO
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	15,138	15,191
Recurring | Level 2 | Municipals
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	10,798	11,171
Recurring | Level 2 | CMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	8,557	9,099
Recurring | Level 3
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	35,756	32,947
Equity securities	242	249
Unit-linked and FVO securities	1,176	1,103
Short-term investments	6	27
Other investments	1,095	975
Derivative assets	29	38
Market risk benefits, at estimated fair value	310	286
Reinsured MRB Assets	16	18
Separate account assets	1,019	1,147
Total assets	39,649	36,790
Liabilities [Abstract]
Derivative liabilities	5	181
Embedded derivatives within liability host contracts	119	93
Market risk benefits, at estimated fair value	3,117	3,179
Total liabilities	3,241	3,453
Recurring | Level 3 | Interest rate
Assets [Abstract]
Derivative assets	0	0
Liabilities [Abstract]
Derivative liabilities	0	174
Recurring | Level 3 | Foreign currency exchange rate contracts
Assets [Abstract]
Derivative assets	25	23
Liabilities [Abstract]
Derivative liabilities	5	7
Recurring | Level 3 | Credit
Assets [Abstract]
Derivative assets	0	8
Liabilities [Abstract]
Derivative liabilities	0	0
Recurring | Level 3 | Equity market contracts
Assets [Abstract]
Derivative assets	4	7
Liabilities [Abstract]
Derivative liabilities	0	0
Recurring | Level 3 | Separate account liabilities
Liabilities [Abstract]
Separate account liabilities	0	0
Recurring | Level 3 | U.S. corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	14,502	13,714
Recurring | Level 3 | Foreign corporate
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	15,705	14,631
Recurring | Level 3 | Foreign government
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	41	51
Recurring | Level 3 | U.S. government and agency
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 3 | RMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	1,897	1,598
Recurring | Level 3 | ABS & CLO
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	2,382	2,103
Recurring | Level 3 | Municipals
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	0	0
Recurring | Level 3 | CMBS
Assets [Abstract]
Estimated Fair Value of Fixed Maturity Securities AFS	$ 1,229	$ 850

Fair Value (Quantitative Inform

Fair Value (Quantitative Information) (Details)	Sep. 30, 2024	Dec. 31, 2023
Minimum | Interest rate | Measurement Input, Swap Yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	0	367
Minimum | Foreign currency exchange rate | Measurement Input, Swap Yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	111	185
Minimum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 0 - 40
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0	0
Minimum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 41 - 60
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0004	0.0004
Minimum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 61 - 115
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0	0
Minimum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 1 - 10
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0014	0.0039
Minimum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 11 - 20
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0039	0.0039
Minimum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 21 - 116
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0039	0.0010
Minimum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Utilization Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0020	0.0020
Minimum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Withdrawal Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0	0
Minimum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Long-Term Equity Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.1423	0.0805
Minimum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Nonperformance risk spread
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0011	0.0038
Minimum | U.S. corporate and foreign corporate | Valuation Technique, Matrix Pricing | Measurement Input, Offered Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	34	4
Minimum | U.S. corporate and foreign corporate | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	13	0
Minimum | U.S. corporate and foreign corporate | Valuation Technique, Consensus Pricing Model | Measurement Input, Offered Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	92	86
Minimum | RMBS | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	0	0
Minimum | ABS & CLO | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	3	3
Maximum | Interest rate | Measurement Input, Swap Yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	0	399
Maximum | Foreign currency exchange rate | Measurement Input, Swap Yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	168	399
Maximum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 0 - 40
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0015	0.0015
Maximum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 41 - 60
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0079	0.0075
Maximum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 61 - 115
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	1	1
Maximum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 1 - 10
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.2010	0.2010
Maximum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 11 - 20
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.15	0.15
Maximum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 21 - 116
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.15	0.15
Maximum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Utilization Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.22	0.22
Maximum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Withdrawal Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.20	0.20
Maximum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Long-Term Equity Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.2227	0.2185
Maximum | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Nonperformance risk spread
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0149	0.0159
Maximum | U.S. corporate and foreign corporate | Valuation Technique, Matrix Pricing | Measurement Input, Offered Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	133	131
Maximum | U.S. corporate and foreign corporate | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	116	110
Maximum | U.S. corporate and foreign corporate | Valuation Technique, Consensus Pricing Model | Measurement Input, Offered Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	100	102
Maximum | RMBS | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	121	112
Maximum | ABS & CLO | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	106	101
Weighted Average | Interest rate | Measurement Input, Swap Yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	0	385
Weighted Average | Foreign currency exchange rate | Measurement Input, Swap Yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Asset (Liability) Net, Measurement Input	166	193
Weighted Average | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 0 - 40
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0005	0.0005
Weighted Average | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 41 - 60
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0022	0.0022
Weighted Average | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Mortality rates: Ages 61 - 115
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0114	0.0123
Weighted Average | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 1 - 10
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.1286	0.0872
Weighted Average | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 11 - 20
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0605	0.0434
Weighted Average | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Lapse rates: Durations 21 - 116
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0820	0.0459
Weighted Average | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Utilization Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0079	0.0044
Weighted Average | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Withdrawal Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0477	0.0447
Weighted Average | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Measurement Input, Long-Term Equity Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.1877	0.1855
Weighted Average | Market Risk Benefits and Reinsured Market Risk Benefits direct, assumed and ceded guaranteed minimum benefits | Nonperformance risk spread
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
MRBs and Reinsured MRBs direct, assumed and ceded guaranteed minimum benefits	0.0064	0.0073
Weighted Average | U.S. corporate and foreign corporate | Valuation Technique, Matrix Pricing | Measurement Input, Offered Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	94	93
Weighted Average | U.S. corporate and foreign corporate | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	97	92
Weighted Average | U.S. corporate and foreign corporate | Valuation Technique, Consensus Pricing Model | Measurement Input, Offered Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	96	96
Weighted Average | RMBS | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	95	93
Weighted Average | ABS & CLO | Valuation Technique, Market Approach | Measurement Input, Quoted Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt Securities, Available-for-sale, Measurement Input	97	93

Fair Value (Unobservable Input

Fair Value (Unobservable Input Reconciliation) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net Derivatives
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	$ 15	$ (57)	$ 2	$ (28)
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	(92)	0	(85)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Balance, beginning of period	(75)	(214)	(143)	(170)
Total realized/unrealized gains (losses) included in net income (loss)	21	(56)	5	(21)
Total realized/unrealized gains (losses) included in AOCI	7	(110)	(28)	(59)
Purchases	0	0	0	0
Sales	0	0	0	0
Issuances	0	0	0	0
Settlements	72	91	201	121
Transfers into Level 3	0	0	0	0
Transfers out of Level 3	(1)	0	(11)	(160)
Balance, end of period	24	(289)	24	(289)
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	15	(57)	2	(28)
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	(92)	0	(85)
Net Embedded Derivatives
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	(61)	86	(21)	51
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Balance, beginning of period	(55)	(64)	(93)	(17)
Total realized/unrealized gains (losses) included in net income (loss)	(61)	86	(21)	51
Total realized/unrealized gains (losses) included in AOCI	0	0	0	0
Purchases	0	0	0	0
Sales	0	0	0	0
Issuances	0	0	0	0
Settlements	(3)	(27)	(5)	(39)
Transfers into Level 3	0	0	0	0
Transfers out of Level 3	0	0	0	0
Balance, end of period	(119)	(5)	(119)	(5)
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	(61)	86	(21)	51
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0	0
Corporate fixed maturity securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	29,240	25,968	28,345	24,401
Total realized/unrealized gains (losses) included in net income (loss)	(10)	3	(70)	0
Total realized/unrealized gains (losses) included in AOCI	1,169	(996)	502	(659)
Purchases	2,080	991	4,618	3,282
Sales	(1,255)	(573)	(2,212)	(1,562)
Issuances	0	0	0	0
Settlements	0	0	0	0
Transfers into Level 3	94	132	55	305
Transfers out of Level 3	(1,111)	(258)	(1,031)	(500)
Balance, end of period	30,207	25,267	30,207	25,267
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	(6)	2	(17)	(2)
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	1,159	(989)	489	(685)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	(6)	2	(17)	(2)
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	1,159	(989)	489	(685)
Foreign government
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	40	60	51	103
Total realized/unrealized gains (losses) included in net income (loss)	(8)	4	(6)	3
Total realized/unrealized gains (losses) included in AOCI	7	(9)	3	(7)
Purchases	2	4	1	7
Sales	(1)	(9)	(1)	(11)
Issuances	0	0	0	0
Settlements	0	0	0	0
Transfers into Level 3	1	0	1	4
Transfers out of Level 3	0	(7)	(8)	(56)
Balance, end of period	41	43	41	43
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	(8)	4	(6)	3
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	7	(9)	3	(7)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	(8)	4	(6)	3
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	7	(9)	3	(7)
Structured Products
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	5,867	4,554	4,551	4,269
Total realized/unrealized gains (losses) included in net income (loss)	6	(8)	19	(10)
Total realized/unrealized gains (losses) included in AOCI	132	(10)	172	(42)
Purchases	1,080	969	1,614	1,099
Sales	(539)	(376)	(792)	(537)
Issuances	0	0	0	0
Settlements	0	0	0	0
Transfers into Level 3	31	70	179	240
Transfers out of Level 3	(1,069)	(294)	(235)	(114)
Balance, end of period	5,508	4,905	5,508	4,905
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	12	(5)	23	1
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	113	(14)	144	(48)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	12	(5)	23	1
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	113	(14)	144	(48)
Municipals
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	1	7	0	0
Total realized/unrealized gains (losses) included in net income (loss)	0	0	0	0
Total realized/unrealized gains (losses) included in AOCI	0	0	0	0
Purchases	0	0	0	0
Sales	(1)	0	0	0
Issuances	0	0	0	0
Settlements	0	0	0	0
Transfers into Level 3	0	0	0	0
Transfers out of Level 3	0	(7)	0	0
Balance, end of period	0	0	0	0
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	0	0	0	0
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	0	0	0	0
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0	0
Equity Securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	262	250	249	259
Total realized/unrealized gains (losses) included in net income (loss)	(15)	(5)	(26)	1
Total realized/unrealized gains (losses) included in AOCI	0	0	0	0
Purchases	9	0	31	2
Sales	(14)	(1)	(12)	(18)
Issuances	0	0	0	0
Settlements	0	0	0	0
Transfers into Level 3	0	0	0	0
Transfers out of Level 3	0	0	0	0
Balance, end of period	242	244	242	244
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	(15)	(4)	(20)	(6)
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	(15)	(4)	(20)	(6)
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0	0
Unit-linked and FVO Securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	1,096	1,057	1,103	787
Total realized/unrealized gains (losses) included in net income (loss)	56	(31)	121	63
Total realized/unrealized gains (losses) included in AOCI	0	0	0	0
Purchases	135	204	139	227
Sales	(111)	(177)	(167)	(21)
Issuances	0	0	0	0
Settlements	0	0	0	0
Transfers into Level 3	0	16	0	17
Transfers out of Level 3	0	0	(20)	(4)
Balance, end of period	1,176	1,069	1,176	1,069
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	57	(32)	124	62
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	57	(32)	124	62
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0	0
Short-term Investments
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	10	18	27	57
Total realized/unrealized gains (losses) included in net income (loss)	0	0	1	0
Total realized/unrealized gains (losses) included in AOCI	0	1	(1)	1
Purchases	1	14	5	25
Sales	(8)	(8)	(26)	(48)
Issuances	0	0	0	0
Settlements	0	0	0	0
Transfers into Level 3	3	0	0	0
Transfers out of Level 3	0	0	0	(10)
Balance, end of period	6	25	6	25
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	0	0	1	0
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	0	0	1	0
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0	0
Other Investments
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	1,073	964	975	926
Total realized/unrealized gains (losses) included in net income (loss)	9	(6)	21	19
Total realized/unrealized gains (losses) included in AOCI	0	0	0	0
Purchases	6	12	54	25
Sales	(45)	0	(186)	0
Issuances	0	0	0	0
Settlements	0	0	0	0
Transfers into Level 3	52	0	231	0
Transfers out of Level 3	0	0	0	0
Balance, end of period	1,095	970	1,095	970
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	11	(6)	19	20
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	11	(6)	19	20
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0	0
Separate Accounts
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	1,122	1,248	1,147	1,210
Total realized/unrealized gains (losses) included in net income (loss)	(9)	(22)	(46)	(62)
Total realized/unrealized gains (losses) included in AOCI	0	0	0	0
Purchases	18	15	15	181
Sales	(93)	(30)	(92)	(128)
Issuances	0	0	0	0
Settlements	0	0	0	1
Transfers into Level 3	1	6	2	14
Transfers out of Level 3	(20)	(10)	(7)	(9)
Balance, end of period	1,019	1,207	1,019	1,207
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	0	0	0	0
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	0	0	0	0
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Changes in unrealized gains (losses) included in net income (loss) for the instruments still held at end of period	0	0	0	0
Changes in unrealized gains (losses) included in AOCI for the instruments still held at end of period	$ 0	$ 0	$ 0	$ 0

Fair Value (Nonrecurring Fair V

Fair Value (Nonrecurring Fair Value Measurements) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total mortgage loans	$ 90,415		$ 90,415		$ 92,506
Other invested assets, at estimated fair value (2)	19,706		19,706		18,202
Fair Value, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Adjustment	(100)	$ (49)	(253)	$ (190)
Level 3 | Fair Value, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total mortgage loans	1,087		1,087		474
Other invested assets, at estimated fair value (2)	$ 63		$ 63		$ 63

Fair Value (Financial Instrumen

Fair Value (Financial Instruments Carried at Other Than Fair Value) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Assets
Policy loans	$ 8,822	$ 8,788
Liabilities
Collateral financing arrangement	529	637
Junior subordinated debt securities	3,163	3,161
Separate account liabilities	148,809	144,634
Carrying Value
Assets
Mortgage loans	90,415	92,506
Policy loans	8,822	8,788
Other invested assets	1,247	919
Premiums, reinsurance and other receivables	4,752	5,182
Other assets	242	268
Liabilities
Policyholder account balances	141,467	138,233
Long-term debt	15,271	15,516
Collateral financing arrangement	529	637
Junior subordinated debt securities	3,163	3,161
Other liabilities	10,594	10,556
Separate account liabilities	78,004	75,705
Estimated Fair Value
Assets
Mortgage loans	86,994	87,753
Policy loans	9,550	9,516
Other invested assets	1,247	919
Premiums, reinsurance and other receivables	4,754	5,191
Other assets	247	266
Liabilities
Policyholder account balances	139,362	134,025
Long-term debt	15,499	15,621
Collateral financing arrangement	460	551
Junior subordinated debt securities	3,714	3,552
Other liabilities	10,422	10,260
Separate account liabilities	78,004	75,705
Estimated Fair Value | Level 1
Assets
Mortgage loans	0	0
Policy loans	0	0
Other invested assets	0	0
Premiums, reinsurance and other receivables	0	0
Other assets	0	0
Liabilities
Policyholder account balances	0	0
Long-term debt	0	0
Collateral financing arrangement	0	0
Junior subordinated debt securities	0	0
Other liabilities	0	0
Separate account liabilities	0	0
Estimated Fair Value | Level 2
Assets
Mortgage loans	0	0
Policy loans	0	0
Other invested assets	715	714
Premiums, reinsurance and other receivables	725	791
Other assets	73	82
Liabilities
Policyholder account balances	0	0
Long-term debt	15,499	15,621
Collateral financing arrangement	0	0
Junior subordinated debt securities	3,714	3,552
Other liabilities	1,486	609
Separate account liabilities	78,004	75,705
Estimated Fair Value | Level 3
Assets
Mortgage loans	86,994	87,753
Policy loans	9,550	9,516
Other invested assets	532	205
Premiums, reinsurance and other receivables	4,029	4,400
Other assets	174	184
Liabilities
Policyholder account balances	139,362	134,025
Long-term debt	0	0
Collateral financing arrangement	460	551
Junior subordinated debt securities	0	0
Other liabilities	8,936	9,651
Separate account liabilities	$ 0	$ 0

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details) £ in Millions, $ in Millions, ¥ in Billions	1 Months Ended		3 Months Ended
	Apr. 30, 2024 USD ($)	Apr. 30, 2024 GBP (£)	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Jun. 05, 2024 USD ($)	Apr. 11, 2024	Mar. 07, 2024 USD ($)	Mar. 07, 2024 JPY (¥)
JPY senior debt $744 million March 2029 to 2059
Debt Instrument, Redemption [Line Items]
Debt Instrument, Face Amount | $								$ 752
Payments of Debt Issuance Costs | $					$ 6
JYP senior debt 7.1 billion March 2029
Debt Instrument, Redemption [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								1.009%	1.009%
JYP senior debt 23.1 billion March 2031
Debt Instrument, Redemption [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								1.415%	1.415%
JYP senior debt 16.7 billion March 2034
Debt Instrument, Redemption [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								1.67%	1.67%
JYP senior debt 11.2 billion March 2039
Debt Instrument, Redemption [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								1.953%	1.953%
JYP senior debt 15.5 billion March 2044
Debt Instrument, Redemption [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								2.195%	2.195%
JYP senior debt 23.5 billion March 2054
Debt Instrument, Redemption [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								2.39%	2.39%
JYP senior debt 15.2 billion March 2059
Debt Instrument, Redemption [Line Items]
Debt Instrument, Interest Rate, Stated Percentage								2.448%	2.448%
JPY senior debt 7.1 billion March 2029
Debt Instrument, Redemption [Line Items]
Debt Instrument, Face Amount									¥ 7.1
JPY senior debt 23.1 billion March 2031
Debt Instrument, Redemption [Line Items]
Debt Instrument, Face Amount									23.1
JPY senior debt 16.7 billion March 2034
Debt Instrument, Redemption [Line Items]
Debt Instrument, Face Amount									16.7
JPY senior debt 11.2 billion March 2039
Debt Instrument, Redemption [Line Items]
Debt Instrument, Face Amount									11.2
JPY senior debt 15.5 billion March 2044
Debt Instrument, Redemption [Line Items]
Debt Instrument, Face Amount									15.5
JPY senior debt 23.5 billion March 2054
Debt Instrument, Redemption [Line Items]
Debt Instrument, Face Amount									23.5
JPY senior debt 15.2 billion March 2059
Debt Instrument, Redemption [Line Items]
Debt Instrument, Face Amount									¥ 15.2
senior debt Sterling 350 million 5.3753% due Dec 2024
Debt Instrument, Redemption [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							5.375%
Early Repayment of Senior Debt	$ 438	£ 350
senior debt $500M 5.30% due December 2034
Debt Instrument, Redemption [Line Items]
Debt Instrument, Face Amount | $						$ 500
Payments of Debt Issuance Costs | $				$ 4
senior debt $750M 5.30% due December 2034
Debt Instrument, Redemption [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			5.30%
senior debt $2500M 5.30% due December 2034
Debt Instrument, Redemption [Line Items]
Debt Instrument, Face Amount | $			$ 250
Payments of Debt Issuance Costs | $			$ 2

Equity Equity (Preferred Stock

Equity Equity (Preferred Stock Classification) (Details) - shares	Sep. 30, 2024	Dec. 31, 2023
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	200,000,000	200,000,000
Preferred Stock, Shares Issued	25,572,200	25,572,200
Preferred Stock, Shares Outstanding	25,572,200	25,572,200
Floating Rate Non-Cumulative Preferred Stock, Series A, par value $0.01
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	27,600,000	27,600,000
Preferred Stock, Shares Issued	24,000,000	24,000,000
Preferred Stock, Shares Outstanding	24,000,000	24,000,000
Series D Preferred Stock
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	500,000	500,000
Preferred Stock, Shares Issued	500,000	500,000
Preferred Stock, Shares Outstanding	500,000	500,000
Series E Preferred Stock
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	32,200	32,200
Preferred Stock, Shares Issued	32,200	32,200
Preferred Stock, Shares Outstanding	32,200	32,200
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	40,000	40,000
Preferred Stock, Shares Issued	40,000	40,000
Preferred Stock, Shares Outstanding	40,000	40,000
Series G Preferred Stock
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred Stock, Shares Issued	1,000,000	1,000,000
Preferred Stock, Shares Outstanding	1,000,000	1,000,000
Series A Junior Preferred Stock
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Not Designated Preferred Stock
Class of Stock [Line Items]
Preferred Stock, Shares Authorized	160,827,800	160,827,800
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

Equity Equity (Preferred Stoc_2

Equity Equity (Preferred Stock Dividends) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Dividends Payable [Line Items]
Dividends, Preferred Stock, Cash	$ 67	$ 67	$ 168	$ 165
Floating Rate Non-Cumulative Preferred Stock, Series A, par value $0.01
Dividends Payable [Line Items]
Preferred Stock, Dividends Per Share, Declared	$ 0.417	$ 0.419	$ 1.267	$ 1.155
Dividends, Preferred Stock, Cash	$ 10	$ 9	$ 30	$ 27
Series D Preferred Stock
Dividends Payable [Line Items]
Preferred Stock, Dividends Per Share, Declared	$ 29.375	$ 29.375	$ 58.750	$ 58.750
Dividends, Preferred Stock, Cash	$ 14	$ 14	$ 29	$ 29
Series E Preferred Stock
Dividends Payable [Line Items]
Preferred Stock, Dividends Per Share, Declared	$ 351.563	$ 351.563	$ 1,054.689	$ 1,054.689
Dividends, Preferred Stock, Cash	$ 11	$ 12	$ 34	$ 34
Series F Preferred Stock [Member]
Dividends Payable [Line Items]
Preferred Stock, Dividends Per Share, Declared	$ 296.875	$ 296.875	$ 890.625	$ 890.625
Dividends, Preferred Stock, Cash	$ 12	$ 12	$ 36	$ 36
Series G Preferred Stock
Dividends Payable [Line Items]
Preferred Stock, Dividends Per Share, Declared	$ 19.250	$ 19.250	$ 38.500	$ 38.500
Dividends, Preferred Stock, Cash	$ 20	$ 20	$ 39	$ 39

Equity (Common Stock Repurchase

Equity (Common Stock Repurchase Authorization) (Details) - USD ($) $ in Millions	Sep. 30, 2024	May 01, 2024	May 25, 2023	May 03, 2023	May 04, 2022
Equity, Class of Treasury Stock [Line Items]
Stock Repurchase Program, Authorized Amount		$ 3,000	$ 1,000	$ 3,000	$ 3,000
May32023Authorization
Equity, Class of Treasury Stock [Line Items]
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 0
May252023Authorization
Equity, Class of Treasury Stock [Line Items]
Stock Repurchase Program, Remaining Authorized Repurchase Amount	0
May2022Authorization
Equity, Class of Treasury Stock [Line Items]
Stock Repurchase Program, Remaining Authorized Repurchase Amount	0
May 1 2024 Repurchase Authorization
Equity, Class of Treasury Stock [Line Items]
Stock Repurchase Program, Remaining Authorized Repurchase Amount	$ 2,301

Equity (Common Stock - Narrativ

Equity (Common Stock - Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Equity [Abstract]
Treasury Stock, Shares, Acquired					39,373,496	36,602,858
Treasury Stock, Value, Acquired, Cost Method, Net Of Excise Tax					$ 2,800	$ 2,200
Treasury Stock, Value, Acquired, Cost Method	$ 781	$ 801	$ 2,046	$ 1,465

Equity (Stock-Based Compensatio

Equity (Stock-Based Compensation Plans - Narrative) (Details) - shares	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2024	Sep. 30, 2024	Dec. 31, 2023
Minimum
Equity - Stock-based Compensation Plans [Line Items]
Future Performance Factor			0%
Maximum
Equity - Stock-based Compensation Plans [Line Items]
Future Performance Factor			175%
Performance Shares
Equity - Stock-based Compensation Plans [Line Items]
Performance Factor			147.50%
Vested in period			1,048,303
Issued in period	1,546,247
Performance Units
Equity - Stock-based Compensation Plans [Line Items]
Performance period		3 years
Vested in period			118,848
Paid in period	175,301

Equity (Dividend Restrictions -

Equity (Dividend Restrictions - Narrative) (Details) $ in Billions	9 Months Ended
	Sep. 30, 2024 USD ($)
Equity [Abstract]
Cash Dividends Paid to Parent Company by Consolidated Subsidiaries	$ 1.1

Equity (Components of Accumulat

Equity (Components of Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	$ 27,540	$ 30,492	$ 30,253	$ 30,125
Ending Balance	31,164	25,895	31,164	25,895
Accumulated Other Comprehensive Income (Loss)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(20,736)	(20,386)	(19,242)	(22,621)
OCI before reclassifications	4,627	(5,871)	2,102	(4,264)
Deferred income tax benefit (expense)	(827)	1,227	(364)	873
AOCI before reclassifications, net of income tax	(16,936)	(25,030)	(17,504)	(26,012)
Amounts reclassified from AOCI	(454)	1,011	363	2,276
Deferred income tax benefit (expense)	150	(235)	(99)	(518)
Amounts reclassified from AOCI, net of income tax	(304)	776	264	1,758
Ending Balance	(17,240)	(24,254)	(17,240)	(24,254)
Unrealized Investment Gains (Losses), Net of Related Offsets
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(19,187)	(17,979)	(14,506)	(22,646)
OCI before reclassifications	9,942	(12,599)	3,450	(8,189)
Deferred income tax benefit (expense)	(2,082)	2,871	(573)	1,882
AOCI before reclassifications, net of income tax	(11,327)	(27,707)	(11,629)	(28,953)
Amounts reclassified from AOCI	121	710	514	2,316
Deferred income tax benefit (expense)	(33)	(172)	(124)	(532)
Amounts reclassified from AOCI, net of income tax	88	538	390	1,784
Ending Balance	(11,239)	(27,169)	(11,239)	(27,169)
Unrealized Gains (Losses) on Derivatives
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	99	1,179	183	1,557
OCI before reclassifications	125	(1,004)	(376)	(1,085)
Deferred income tax benefit (expense)	(101)	232	103	249
AOCI before reclassifications, net of income tax	123	407	(90)	721
Amounts reclassified from AOCI	(607)	271	(247)	(130)
Deferred income tax benefit (expense)	192	(57)	45	30
Amounts reclassified from AOCI, net of income tax	(415)	214	(202)	(100)
Ending Balance	(292)	621	(292)	621
FPBs Discount Rate Remeasurement Gains (Losses)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	6,606	3,919	2,658	6,115
OCI before reclassifications	(5,891)	8,223	(807)	5,325
Deferred income tax benefit (expense)	1,289	(1,897)	153	(1,195)
AOCI before reclassifications, net of income tax	2,004	10,245	2,004	10,245
Amounts reclassified from AOCI	0	0	0	0
Deferred income tax benefit (expense)	0	0	0	0
Amounts reclassified from AOCI, net of income tax	0	0	0	0
Ending Balance	2,004	10,245	2,004	10,245
MRBs Instrument- Specific Credit Risk Remeasurement Gains (Losses)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(73)	108	27	107
OCI before reclassifications	99	(142)	(28)	(141)
Deferred income tax benefit (expense)	(22)	30	5	30
AOCI before reclassifications, net of income tax	4	(4)	4	(4)
Amounts reclassified from AOCI	0	0	0	0
Deferred income tax benefit (expense)	0	0	0	0
Amounts reclassified from AOCI, net of income tax	0	0	0	0
Ending Balance	4	(4)	4	(4)
Foreign Currency Translation Adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(6,785)	(6,282)	(6,158)	(6,377)
OCI before reclassifications	349	(348)	(136)	(168)
Deferred income tax benefit (expense)	90	(9)	(52)	(94)
AOCI before reclassifications, net of income tax	(6,346)	(6,639)	(6,346)	(6,639)
Amounts reclassified from AOCI	0	0	0	0
Deferred income tax benefit (expense)	0	0	0	0
Amounts reclassified from AOCI, net of income tax	0	0	0	0
Ending Balance	(6,346)	(6,639)	(6,346)	(6,639)
Defined Benefit Plans Adjustment
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(1,396)	(1,331)	(1,446)	(1,377)
OCI before reclassifications	3	(1)	(1)	(6)
Deferred income tax benefit (expense)	(1)	0	0	1
AOCI before reclassifications, net of income tax	(1,394)	(1,332)	(1,447)	(1,382)
Amounts reclassified from AOCI	32	30	96	90
Deferred income tax benefit (expense)	(9)	(6)	(20)	(16)
Amounts reclassified from AOCI, net of income tax	23	24	76	74
Ending Balance	$ (1,371)	$ (1,308)	$ (1,371)	$ (1,308)

Equity (Reclassifications Out o

Equity (Reclassifications Out of Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)	$ (77)	$ (927)			$ (873)	$ (2,650)
Net investment income	5,227	4,825			15,868	14,542
Net derivative gains (losses)	767	(1,202)			(720)	(2,289)
Other expenses	3,263	3,204			9,660	9,394
Income (loss) from continuing operations before provision for income tax	1,994	534			4,241	1,221
Income tax (expense) benefit	(653)	(39)			(1,072)	(233)
Net income (loss)	1,341	495	$ 1,828	$ 493	3,169	988
Reclassification out of Accumulated Other Comprehensive Income
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net income (loss)	304	(776)			(264)	(1,758)
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Investment Gains (Losses), Net of Related Offsets
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)	(122)	(730)			(531)	(2,420)
Net investment income	0	1			0	6
Net derivative gains (losses)	1	19			17	98
Income (loss) from continuing operations before provision for income tax	(121)	(710)			(514)	(2,316)
Income tax (expense) benefit	33	172			124	532
Net income (loss)	(88)	(538)			(390)	(1,784)
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Income (loss) from continuing operations before provision for income tax	607	(271)			247	130
Income tax (expense) benefit	(192)	57			(45)	(30)
Net income (loss)	415	(214)			202	100
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives | Interest Rate Contract
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)	(1)	17			(2)	77
Net investment income	5	11			18	38
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives | Foreign currency swaps
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)	602	(301)			226	10
Net investment income	1	1			4	3
Other expenses	0	1			0	2
Reclassification out of Accumulated Other Comprehensive Income | Unrealized Gains (Losses) on Derivatives | Credit derivatives
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Net investment gains (losses)	0	0			1	0
Reclassification out of Accumulated Other Comprehensive Income | Defined Benefit Plans Adjustment
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Amortization of net actuarial gains (losses)	(35)	(33)			(104)	(98)
Amortization of prior service (costs) credit	3	3			8	8
Income (loss) from continuing operations before provision for income tax	(32)	(30)			(96)	(90)
Income tax (expense) benefit	9	6			20	16
Net income (loss)	$ (23)	$ (24)			$ (76)	$ (74)

Other Revenues and Other Expe_3

Other Revenues and Other Expenses Other Revenues (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 554	$ 554	$ 1,689	$ 1,662
Other revenues	648	606	1,960	1,866
Vision fee for service arrangements
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	126	144	402	446
Prepaid legal plans
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	144	128	437	389
Fee-based investment management
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	99	103	295	306
Administrative services-only contracts
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	69	65	205	193
Recordkeeping and administrative services (1)
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	38	39	113	114
Other revenue from service contracts from customers
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Excluding Assessed Tax	78	75	237	214
Other Income
Disaggregation of Revenue [Line Items]
Other revenues	$ 94	$ 52	$ 271	$ 204

Other Revenues and Other Expe_4

Other Revenues and Other Expenses Other Revenues (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Revenue from Contract with Customer [Abstract]
Receivables related to revenues from service contracts from customers	$ 245	$ 243

Other Expenses (Other Expenses)

Other Expenses (Other Expenses) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Other Income and Expenses [Abstract]
Employee-related costs (1)	$ 892	$ 914	$ 2,742	$ 2,743
Third-party staffing costs	371	362	1,082	1,066
General and administrative expenses	162	209	463	539
Pension, postretirement and postemployment benefit costs	65	59	195	177
Premium taxes, other taxes, and licenses & fees	183	162	530	507
Commissions and other variable expenses	1,515	1,483	4,480	4,347
Capitalization of DAC	(691)	(742)	(2,114)	(2,189)
Amortization of DAC and VOBA	516	499	1,523	1,448
Amortization of negative VOBA	(7)	(7)	(19)	(20)
Interest expense on debt	257	265	778	776
Total other expenses	3,263	3,204	9,660	9,394
Net change in cash surrender value of investments, net of premiums paid	$ (58)	$ 12	$ (135)	$ (60)

Employee Benefit Plans (Net Per

Employee Benefit Plans (Net Periodic Benefit Costs) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pension Benefits
Net periodic benefit costs [Abstract]
Service costs	$ 41	$ 38	$ 122	$ 113
Interest costs	114	118	342	353
Expected return on plan assets	(115)	(119)	(345)	(360)
Amortization of net actuarial (gains) losses	42	40	125	118
Amortization of prior service costs (credit)	(3)	(3)	(9)	(9)
Net periodic benefit costs (credit)	79	74	235	215
Other Postretirement Benefits
Net periodic benefit costs [Abstract]
Service costs	0	1	2	2
Interest costs	10	11	30	32
Expected return on plan assets	(14)	(13)	(42)	(41)
Amortization of net actuarial (gains) losses	(7)	(7)	(21)	(22)
Amortization of prior service costs (credit)	0	0	0	0
Net periodic benefit costs (credit)	$ (11)	$ (8)	$ (31)	$ (29)

Income Tax (Narrative) (Details

Income Tax (Narrative) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, Percent	33%	7%	25%	19%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%	21%	21%	21%

Earnings Per Common Share (Earn

Earnings Per Common Share (Earnings Per Common Share) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Weighted Average Shares:
Weighted average common stock outstanding - basic	699.3	751.4			710.9	764.1
Incremental common shares from assumed exercise or issuance of stock-based awards	4.4	4.1			4.6	4.6
Weighted average common stock outstanding - diluted	703.7	755.5			715.5	768.7
Net Income (Loss):
Net income (loss)	$ 1,341	$ 495	$ 1,828	$ 493	$ 3,169	$ 988
Less: Net income (loss) attributable to noncontrolling interests	(1)	6			14	17
Less: Preferred stock dividends	67	67	$ 101	$ 98	168	165
Net income (loss) available to MetLife, Inc.’s common shareholders	$ 1,275	$ 422			$ 2,987	$ 806
Basic	$ 1.82	$ 0.56			$ 4.20	$ 1.05
Diluted	$ 1.81	$ 0.56			$ 4.17	$ 1.05

Contingencies, Commitments an_2

Contingencies, Commitments and Guarantees (Contingencies - Narrative) (Details) $ in Millions	9 Months Ended		12 Months Ended
	Sep. 30, 2024 USD ($) Claims	Sep. 30, 2023 Claims	Dec. 31, 2023 Claims
Minimum
Loss Contingencies
Loss Contingency, Range of Possible Loss, Portion Not Accrued	$ 0
Maximum
Loss Contingencies
Loss Contingency, Range of Possible Loss, Portion Not Accrued	$ 125
Asbestos Related Claims
Loss Contingencies
Asbestos-Related Claims | Claims	2,251	1,924	2,565

Contingencies, Commitments an_3

Contingencies, Commitments and Guarantees (Commitments and Guarantees - Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2024	Dec. 31, 2023
Contingencies, Commitments and Guarantees [Abstract]
Cumulative maximum indemnities and guarantees contractual limitation	$ 638
Liabilities for indemnities, guarantees and commitments	19	$ 19
Minimum
Contingencies, Commitments and Guarantees [Abstract]
Indemnities and guarantees contractual limitation range	1
Maximum
Contingencies, Commitments and Guarantees [Abstract]
Indemnities and guarantees contractual limitation range	329
Mortgage Loan Commitments
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair Value Disclosure, Off-balance Sheet Risks, Face Amount, Liability	2,400	4,000
Commitments to Fund Partnership Investments, Bank Credit Facilities, Bridge Loans and Private Corporate Bond Investments
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair Value Disclosure, Off-balance Sheet Risks, Face Amount, Liability	$ 8,300	$ 9,200